Renal Transplantation by unknown
Renal Transplantation 
Updates and Advances
Edited by Layron Long
Edited by Layron Long
Photo by sudok1 / iStock
This  book presents a nice international compilation of scholarly papers and chapters 
which address the latest advances in renal transplant surgery. These works cover a 
variety of topics; the last advance and success of renal transplant science: biochemistry, 
immunology, molecular genetics, pharmacology - pharmacogenetics, pediatric 
transplant and a few rare uropathies that warrant organ replacement.
ISBN 978-953-51-0173-4




– UPDATES AND ADVANCES 
 





– UPDATES AND ADVANCES 
 




Renal Transplantation - Updates and Advances
http://dx.doi.org/10.5772/1299
Edited by Layron Long
Contributors
Jun Wu, Ying Wang, Li Ma, Gaoxing Luo, Yong Huang, Cristian Sager, Juan Carlos Lopez, Victor Duran, Carol Burek, 
Juan Pablo Corbetta, Santiago Weller, Mohammad Amin Abbasi, Alireza R. Rezaie, Ata Abbasi, Koosha Kamali, Kei 
Ishibashi, Tatsuo Suzutani, Taigo Kato, Maria Jose Herrero, Maria Galiana, Virginia Bosó, Sergio Bea, Elia Ros, Jose Luis 
Poveda, Jaime Sánchez-Plumed, Salvador F. Aliño, Thomas Rath, Manfred Küpper, Geng Zhang, Jianlin Yuan, Marco 
Antonio Ayala-Garcia, Joel Maximo Soel Encalada, Beatriz Gonzalez Yebra, Éctor Jaime Ramírez Barba, Miguel Angel 
Pantoja-Hernández, Salwa Shabbir Sheikh, Abdul Razack Amir, Jumana Amir, Ahmad Enshaei, Hamidreza Baghani 
Aval, Samaneh Esmaeili, Gholamreza Mokhtari, Pooja Binnani, Madan Mohan Bahadur, Bhupendra Gandhi, Chang 
Qing Zhang, Yan Jie Guo
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Renal Transplantation - Updates and Advances
Edited by Layron Long
p. cm.
ISBN 978-953-51-0173-4
eBook (PDF) ISBN 978-953-51-6857-7
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
3,900+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr Layron Long (Samaritan Urology, Good Samari-
tan Regional Medical Center, Corvallis, OR, USA) is a 
board-certified urologist who earned a medical degree 
from Meharry Medical College in Nashville, Tenn. He 
completed an internship in general surgery at Vanderbilt 
University Medical Center in Nashville and a fellowship 
in molecular genetics at Howard University/Johns Hop-
kins University in Washington, D.C. Dr Long trained in urological surgery 
at TUFTS New England Medical Center in Boston and finished his training 
as a senior and chief resident at the University of Washington Medical 
Center in Seattle. After completing residency training, Dr Long was an 
acting instructor and completed an Endourological Society fellowship in 
robotic surgery, laparoscopy and endo-urology at the University of Wash-
ington. He is a member of the American Urological Association, American 
Association of Clinical Urologists, Society of Endourology, Society of Lap-











Chapter 1 Preservation of Renal Allografts for Transplantation 1 
Marco Antonio Ayala-García, Miguel Ángel Pantoja Hernández, 
Éctor Jaime Ramírez-Barba, Joel Máximo Soel Encalada 
and Beatriz González Yebra 
Chapter 2 Renal Transplantation from Expanded Criteria Donors 17 
Pooja Binnani, Madan Mohan Bahadur and Bhupendra Gandhi 
Chapter 3 Donor Nephrectomy 27 
Gholamreza Mokhtari, Ahmad Enshaei,  
Hamidreza Baghani Aval and Samaneh Esmaeili 
Chapter 4 Renal Transplantation and Urinary Proteomics 35 
Ying Wang, Li Ma, Gaoxing Luo, Yong Huang and Jun Wu 
Chapter 5 Renal Explantation Techniques 49 
Marco Antonio Ayala- García, Éctor Jaime Ramírez-Barba, 
Joel Máximo Soel Encalada, Beatriz González Yebra 
Chapter 6 Renal Transplantation in Patient with Fabry’s Disease  
Maintained by Enzyme Replacement Therapy 75 
Taigo Kato 
Chapter 7 Polymorphism of RAS in Patients with AT1-AA 
Mediated Steroid Refractory Acute Rejection 85 
Geng Zhang and Jianlin Yuan 
Chapter 8 Soluble CD30 and Acute Renal Allograft Rejection 101 
Koosha Kamali, Mohammad Amin Abbasi,  
Ata Abbasi and Alireza R. Rezaie 
Chapter 9 Role of Cytomegalovirus Reinfection in Acute Rejection 
and CMV Disease After Renal Transplantation 119 
Kei Ishibashi and Tatsuo Suzutani 
Contents 
Preface XI 
Chapter 1 Preservation of Renal Allografts for Transplantation 1 
Marco Antonio Ayala-García, Miguel Ángel Pantoja Hernández, 
Éctor Jaime Ramírez-Barba, Joel Máximo Soel Encalada 
and Beatriz González Yebra 
Chapter 2 Renal Transplantation from Expanded Criteria Donors 17 
Pooja Binnani, Madan Mohan Bahadur and Bhupendra Gandhi 
Chapter 3 Donor Nephrectomy 27 
Gholamreza Mokhtari, Ahmad Enshaei,  
Hamidreza Baghani Aval and Samaneh Esmaeili 
Chapter 4 Renal Transplantation and Urinary Proteomics 35 
Ying Wang, Li Ma, Gaoxing Luo, Yong Huang and Jun Wu 
Chapter 5 Renal Explantation Techniques 49 
Marco Antonio Ayala- García, Éctor Jaime Ramírez-Barba, 
Joel Máximo Soel Encalada, Beatriz González Yebra 
Chapter 6 Renal Transplantation in Patient with Fabry’s Disease 
Maintained by Enzyme Replacement Therapy 75 
Taigo Kato 
Chapter 7 Polymorphism of RAS in Patients with AT1-AA 
Mediated Steroid Refractory Acute Rejection 85 
Geng Zhang and Jianlin Yuan 
Chapter 8 Soluble CD30 and Acute Renal Allograft Rejection 101 
Koosha Kamali, Mohammad Amin Abbasi, 
Ata Abbasi and Alireza R. Rezaie 
Chapter 9 Role of Cytomegalovirus Reinfection in Acute Rejection 
and CMV Disease After Renal Transplantation 119 
Kei Ishibashi and Tatsuo Suzutani 
X Contents
Chapter 10 Pharmacogenetics of Immunosuppressive 
Drugs in Renal Transplantation 143 
María Galiana, María José Herrero, Virginia Bosó, 
Sergio Bea, Elia Ros, Jaime Sánchez-Plumed, 
Jose Luis Poveda and Salvador F. Aliño 
Chapter 11 Pharmacokinetics and Pharmacodynamics of 
Mycophenolate in Patients After Renal Transplantation 163 
Thomas Rath and Manfred Küpper 
Chapter 12 Malignant Neoplasms in Kidney Transplantation 179 
S. S. Sheikh, J. A. Amir and A. A. Amir 
Chapter 13 Osteonecrosis of Femoral Head (ONFH) 
After Renal Transplantation 205 
Yan Jie Guo and Chang Qing Zhang 
Chapter 14 Pediatric Kidney Transplant in Uropaties 213 
Cristian Sager, Juan Carlos López, Víctor Durán,  











Due to the advances in renal transplantation, the treatment of end stage renal disease 
has been revolutionized. The modern progression of transplant surgery, molecular 
genetics, and pharmacogenetics has led to a reduction in surgical complications, 
prolonged survival, and improvements in the coset effectiveness of renal transplants.  
This text offers a medley of international papers that address the most recent advances 
in the field. “Renal Transplantation - Updates and Advances“ provides a 
comprehensive , concise, evidence based codification of the current state of surgical 
techniques, immunology, pharmacology, and molecular science regarding the 
treatment and management of renal transplantation for  end stage renal disease. This 
book is a treasure – trop of data, providing access to vital information, providing a 
great reference to state of the art perspectives on the subject at hand.  
Dr. Layron Long 
Samaritan Urology 
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1. Introduction 
Kidney transplantation requires the availability of allografts obtained from diverse types of 
donors. Once the kidney is outside of the donor's body, it must be preserved in a state in 
which, after being transplanted, its normal operation can be quickly restored. Proper 
preservation of the renal graft is crucial, because it extends the viability of the organ, thus 
providing time for the complex preparation steps that are required for the transplantation 
procedure. These preparatory steps include the selection of the recipient, histocompatibility 
testing, transportation of the organ over long distances, and preparation of the recipient in 
the operating room.  
The first documented case of perfusion and preservation of an isolated organ was 
performed by Loebel in 1849. Other pioneers have subsequently contributed to this area: 
Langendorf in 1845 used a siphoning tube connected to the organ, while Martin created a 
method to perfuse the coronary artery in vitro in the early 1900’s. In 1905 Carrel published 
“Anastomosis and Transplant of Blood Vessels”. Around 1930, Heinz Rosenberg built a 
perfusion machine, and in 1935 Lindbergh built a pulsatory perfusion machine. 
In the early 1960’s, the only known preservation method was simple organ cooling. 
Lapchinsky in the former Soviet Union started transplanting extremities and kidneys that 
were preserved at +2°C and +4°C, preserving them for up to 28 hours. In 1963 Calne and 
Pegg demonstrated that perfusion of cold blood to an ischemic kidney could prolong its 
preservation up to 12 hours. In 1967, Belzer preserved kidneys for up to 72 hours, using a 
method of continuous perfusion “ex situ”. In 1969 Collins described the use of a preservation 
solution that resembled the composition of the intracellular fluid, and was used for 
perfusion/rinsing of the organ in cold temperature “in situ”, and also for its further 
hypothermic storage, achieving kidney preservation for up to 30 hours. In the 1980’s Belzer, 
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Southard and many other investigators started to lay the foundations for understanding the 
metabolic changes that occur in the extracted organs after explantation. 
In this chapter the techniques for kidney allograft preservation will be briefly reviewed, and 
the pathophysiological changes that occur during preservation and reperfusion of the 
allograft will be discussed. Finally, the currently used preservation solutions will be 
described. 
2. Techniques for preservation of the renal allograft 
2.1 Hypothermic perfusion techniques 
The combination of continuous perfusion and hypothermic storage used by Belzer et al. in 
1967 represented a new paradigm in regards to organ preservation, achieving successful 
canine kidney preservation for 72 hours. In this technique, after the initial washes 
performed during perfusion in the operating room, the organ is introduced in a device that 
keeps a controlled flow (continuous or pulsatory) with cold preservation solution (0-4°C). 
This flow allows complete perfusion of the organ and clearing of any micro thrombi in the 
blood stream, while facilitating the elimination of final metabolic products. Its beneficial 
effects include a lower incidence of delay in the initial functioning of the graft, the 
possibility to assess its viability in real time, and the possibility of providing metabolic 
(oxygen or substrates) or pharmacologic support during the perfusion. The hypothermic 
perfusion machine (HPM) with continuous flow has not shown advantages with respect to 
the pulsatory flow machine. Figures; 1 and 2, shows some of the perfusion machines 
currently being used. 
 
Fig. 1. Hypothermic perfusion machine: Waters RM3® Renal Preservation System from 
Waters Medical System®.  
 




Fig. 2. Hypothermic perfusion machine: Life Port Kidney Transporter® from Organ 
Recovery Systems®. 
To date, hypothermic perfusion is the approach that provides the longest possible 
preservation time for renal allografts. However, due to its complexity, high cost, and the 
need for abundant equipment, these techniques are only suitable for use in facilities highly 
specialized in renal preservation. Additionally, they require well prepared personnel with 
vast experience in the field of allograft preservation. 
The use of HPM has the following advantages and disadvantages: 
Advantages: 
1. Less incidence of delay in the re-initiation of kidney allograft function. 
2. Better preservation for longer periods of time (especially greater than 24 hours) 
3. Ability to control flow and pressure, therefore ability to monitor intrarenal resistance 
during perfusion. 
4. Decreased renal vasospasm. 
5. Ability to provide metabolic support during perfusion. 
6. Potential for pharmacological manipulation during perfusion. 
Disadvantages: 
1. Increased cost. 
2. Endothelial injury. 
3. Possibility of mechanical failure. 
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2.2 Normothermic preservation techniques 
Just recently, interest has been arising on the beneficial effects of continuous normothermic 
or subnormothermic perfusion (25-37 °C) in the preservation process, especially of kidneys 
from non-beating heart donors. The potential benefits of normothermia during perfusion are 
the decrease of vascular resistance and the increase in oxygen release. 
2.3 Oxygen insufflation technique 
This technique was first described by Isselhard et al. in 1972, in which oxygen is insufflated 
through the kidney vessels and then escapes through small perforations on the organ’s 
surface. This technique was attempted for the first time in canine kidneys, and has been the 
subject of a pilot clinical study. 
2.4 Preservation by cold storage  
This technique consists in substituting the vascular contents for a cold preservation solution, 
replacing the intracellular fluid for that of the solution. It is a very simple technique, but it 
only partially achieves its objective, because, in contrast to the continuous perfusion 
techniques, it does not maintain cellular metabolism in hypothermia. This is the technique 
that the majority of renal explantation teams utilize. The following is required for its 
application: 
1. Preservation solution. 
2. The temperature of the preservation solution should be 4°C. 
3. The perfusion fluid should be infused at a pressure greater than 60 torr, ensuring the 
complete elimination of the graft’s vascular contents. In practice, this is achieved by 
placing the perfusion fluids at 100-150 cm above the organs to be perfused. 
4. The amount of solution necessary to preserve the kidney is 1 liter, but it is standard 
practice to stop perfusion only after the effluent fluid from the graft does not contain 
any blood. 
3. Pathophysiology and basis for the preservation of a renal allograft 
The extraction, storage, and transplantation of a renal allograft from a donor significantly 
alter the kidney’s internal homeostasis. The extent of these changes influences the extent to 
which kidney function will be recovered after transplantation. Kidney injury mainly occurs 
as a result of ischemia, and the different preservation techniques serve to minimize this 
injury and improve the allograft’s function and survival. 
3.1 Basis for the preservation of the renal allograft 
Any kidney that has been extracted from the body suffers a process known as ischemia. The 
graft does not receive oxygen or nutritional support, and at the same time, products of its 
own metabolism accumulate, resulting in injury. The injury to the tissue is initially 
reversible, but after a certain interval it becomes irreversible. This phenomenon is known as 
“hot ischemia”, and under these conditions the time limit for organ viability is between 30 
and 60 minutes. 
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The deterioration caused by ischemia is mediated by chemical reactions that happen more 
or less rapidly depending on the temperature. During hypothermia, reversible ischemic 
injury also appears early on (“cold ischemia”), but differs from hot ischemia in several ways. 
The fundamental cause of ischemic injury resides in the molecular changes suffered by 
cellular membranes. Initially, the cells swell and become turgid due to the alterations in the 
functionality of the cell membrane. After 60 minutes of hot ischemia, rupture of renal cell 
membranes is observed, followed by cellular necrosis. 
Another phenomenon also observed in hot ischemia is called “absence of reflux”, which 
comprises the lack of blood flow when circulation is restored to the organ. This occurs when 
erythrocytes accumulate in the vessels. Therefore, completely eliminating erythrocytes in 
the vessels through rinsing during the ischemic period is essential. 
3.2 Effects of hypothermia (cold ischemia) 
The key to successful organ preservation is hypothermia. Cooling reduces the rate at which 
intracellular enzymes degrade the components that are essential for cellular viability. 
Hypothermia does not completely stop cellular metabolism, it only slows it down for a 
limited time, after which function ceases completely and viability is lost (cellular death). The 
length of this period is organ-specific. 
The majority of enzymes in normothermic animal cells show a decrease in their activity 
from 1.5- 2 times for each 10°C decrease in temperature, following the Van Hoff rule: 
Q10= (K₂/K1)10/(t2-t1) 
Where Q10 is the coefficient for a change of 10°C in temperature, and K1 and K₂ are the rates 
of the enzymatic reactions at temperatures t1 and t2, respectively. In a renal cell with a Q10 of 
2, a change in temperature from 37°C to 0°C decreases the rate of the metabolic reactions by 
a factor of 12 to 13. 
The majority of organs tolerate between 30 to 60 minutes of hot ischemia, without 
completely losing their function. Thus, the simple cooling of a kidney increases its 
preservation time up to 12 to 13 hours, as shown by Calne and Pegg in 1963. After 13 hours, 
ultrastructural changes can be observed in the proximal tubules and, to a lesser extent, in the 
distal tubules. 
The only methods that could in theory maintain a kidney viable for months or years are 
freezing of the organ, or its continuous aerobic perfusion. Temperatures below 0°C have 
been used to successfully preserve isolated cells and some simple tissues, but not kidneys. 
Cryopreservation is still an exciting and complex field of research. The method of 
continuous aerobic perfusion is complex, expensive and requires trained personnel with 
vast experience in organ preservation, and thus this technique is not routinely used in 
clinical practice. 
The ideal preservation temperature for kidney allografts is between 0°C and 5°C (4°C seems 
to be the ideal temperature). Higher temperatures would accelerate cellular metabolism, 
making it necessary to provide nutrients to support its metabolic requirements through 
continuous perfusion during the preservation period. 
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As previously mentioned, in cold ischemia, besides hypothermia, perfusion fluids are also 
needed. Therefore, the renal allograft is subjected to ischemia in anaerobic hypothermia, 
which is accompanied by the events described below. 
3.2.1 Cellular edema induced by ischemia and hypothermia 
Under normal conditions, the cells are in an extracellular environment rich in sodium and 
low in potassium, while the intracellular environment is poor in sodium and rich in 
potassium. This equilibrium against a gradient between both sides of the plasma membrane 
is maintained by the Na+/K+ pump which requires energy (ATP) obtained from oxidative 
phosphorylation. The pump keeps this balance by avoiding the entrance of sodium into the 
cell and counteracting the colloidal osmotic pressure derived from proteins and other 
intracellular anions. Under normal conditions, the intracellular osmotic force is 110-140 
mOsm/Kg. 
Anaerobic hypothermia (such as in the kidney stored in the cold) decreases the activity of 
the Na+/K+ pump and reduces the plasma membrane potential.  Sodium and chloride enter 
the cell following a concentration gradient, dragging with them water, which causes the cell 
to swell, causing cellular edema (Fig 3). This edema could be counteracted by adding to the 
preservation solution 110-140 mmol/l of substances that are impermeable to the cell (i.e. 
they cannot pass the plasma membrane due to their elevated molecular weight). We will 
refer to these substances as “waterproofing agents”. 
 
Fig. 3. Cellular edema. 
The problem posed by waterproofing agents is that, even though they diffuse poorly across 
the membrane, they will eventually enter the cell over time. Therefore, when implanting the 
kidney in its new environment, the cells will suddenly be exposed to a relatively hypotonic 
extracellular osmolarity. Because the Na+/K+ pump is unable to start functioning quickly 
enough, potassium cannot be easily expelled to counteract this effect. One example of such 
agents is mannitol, which can be used as a waterproofing agent in preservation solutions. 
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Mannitol accumulates intracellularly, cannot be metabolized, and is only slowly eliminated 
from the cytosol, leading to cellular edema not directly related to hypothermia. Edema in 
endothelial cells can interfere with the reestablishment of normal blood flow, which by itself 
results in hot ischemia.  Edema of parenchymal cells will also involve the mitochondria, 
with subsequent structural and functional deterioration of the tissue. The majority of 
preservation solutions contain waterproofing agents at a concentration close to 110 mmol/l. 
It seems that obtaining an adequate concentration of waterproofing agents in these solutions 
is essential to achieve adequate preservation by storage in cold. 
3.2.2 Cellular acidosis 
The cells of the organs stored in cold are under anaerobic conditions. To maintain their 
energy needs (ATP), they use anaerobic glycolysis which increases the concentration of 
lactate and hydrogen ions intracellularly. This causes acidosis that leads to lysosomal 
instability, activates lysosomal enzymes, and alters mitochondrial properties, which causes 
cell injury and death. (Fig 4). 
 
Fig. 4. Glycolysis. 
To prevent intracellular acidosis, preservation solutions that contain substances that 
counteract acidosis (buffers) are used.  Substances such as phosphate or histidine are used 
for this purpose.  On the other hand, it seems advisable to have a slightly alkaline pH (7.6 – 
8.0 at 37°C) in the solution destined for cold rinsing. 
3.2.3 Expansion of the interstitial space  
When an organ is perfused, and also later during its storage, there is an expansion of the 
interstitial space. This compresses the capillary system, causing the inadequate distribution 
of the preservation fluid across the tissue. Solutions that do not contain oncotic substances 
(such as albumin and other colloids) quickly diffuse to the interstitial space and cause 
edema when perfused. The preservation solution needs to contain substances that will 
create enough osmotic colloidal pressure to allow the free exchange of essential substances 
with the preserving solution, without expanding the interstitial space (Fig 5).  
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Fig. 5. Osmotic colloidal pressure. 
3.2.4 Decrease of cellular energy output 
Hypothermia blocks the production of energy at various levels, with cold-resistant 
enzymatic reactions remaining active, and with a limited supply of glycolytic intermediates 
and energetic reserves necessary for the maintenance of cellular integrity. These reactions 
stimulate synthesis of triglycerides from glucose. 
The main source of energy in the renal cortex during hypothermia is the metabolism of free 
fatty acids. The octanoic acids (especially caprilic acid) are degraded to acetyl-coenzyme A 
and enter the Krebs cycle. In contrast, long-chain free fatty acids, such as palmitic and 
miristic acids, cannot be degraded in energy-producing cycles but are incorporated to tissue 
triglycerides through an energy-consuming process. Furthermore, phosphorylation is 
suppressed during hypothermia due to the inability of adenosine diphosphate to penetrate 
the mitochondrial inner membrane after hypothermic inactivation of adenosine diphosphate 
translocase. The adenosine diphosphate stays in the cytosol and degrades to adenosine 
monophosphate, and finally to hypoxanthine, which easily diffuses outside of the cell. 
Recovery of the depleted adenosine diphosphate occurs through de novo synthesis, and 
could require several hours after reestablishment of normal temperatures and appropriate 
oxygen levels. Thus, the preservation solution needs to contain substances that will maintain 
or replenish ATP (for example adenosine and glutamate). 
3.2.5 Intracellular accumulation of calcium 
The calcium-calmodulin complex plays a central role in the regulation of multiple 
enzymes responsible for mitochondrial respiration, adenosine triphosphate transport and 
regulation of the ion transport and membrane potentials. These effects increase the 
chances that the control of cytosolic calcium could help restore or preserve the enzymatic 
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reactions necessary to maintain the integrity of cells subjected to hypothermic ischemia. 
Some calcium-mediated cellular reactions require maintenance of low levels of cytosolic 
calcium, together with an ability to rapidly fluctuate these levels along large ranges of 
concentration, in such a way that specific intracellular targets can be alternatively 
activated and deactivated. 
During hypothermic ischemia, the enzymatic systems primarily responsible for calcium 
efflux are deactivated at the plasma membrane (calcium-specific adenosine triphosphatase 
and calcium-sodium exchange system). The rapid depletion of the energy reserves during 
hypothermic ischemia results in deactivation of calcium-specific adenosine-triphosphatase, 
which causes a massive influx of sodium into the cytosol; as a consequence, there is failure 
of the calcium-sodium exchange system. There is also a massive influx of calcium, which 
adversely affects numerous cellular enzymes, producing deterioration of cellular function 
and eventually cellular death. 
The changes in the calcium-calmodulin complex can also generate mitochondrial and 
membrane dysfunction, damaging the phospholipid nature of these structures by activating 
the phospholipase pathway with subsequent production of prostaglandin derivatives. This 
damage primarily affects endothelial cells, and is observed prior to the damage to the 
parenchymal cells. Endothelial separation, due to cytoskeletal damage, could result in 
collagen exposure, which in turn produces platelet aggregation and intravascular 
coagulation. Although an organ in which the parenchymal cells have been damaged can be 
recovered, this is not feasible when the damage affects the endothelial cells. 
4. Pathophysiology of renal allograft reperfusion upon implantation 
Much of the injury to transplanted kidneys does not occur during ischemia, but instead 
during reperfusion at the time of implantation. This damage is a consequence of the 
following events: 
4.1 Release of accumulated toxic metabolites 
Re-establishment of blood flow allows the recovery of the oxygen supply and the 
elimination of accumulated toxic metabolites. Although reperfusion is necessary to recover 
the organ after the ischemic injury, the systemic release of these toxic metabolites into 
circulation could have metabolic consequences in distant sites, as well as produce local 
tissue damage. Additionally, some of these events can trigger inflammatory processes which 
are a direct stimulus to the immune system, significantly contributing to the risk of acute 
graft rejection. 
4.2 Reactive oxygen species 
Damage due to free radicals is less significant in the kidneys than other organs. The greatest 
source of oxygen radicals comes from the activation of the enzyme xanthine oxidase, 
although leukocyte and macrophage activation can also be involved. The end products of 
the degradation of ATP are frequently metabolized to urea by the action of xanthine 
dehydrogenase. However, in an acidic environment, xanthine dehydrogenase becomes 
xanthine oxidase. When oxygen is supplied to the cellular environment during reperfusion,  
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xanthine oxidase converts accumulated extracellular waste into xanthine and superoxide 
anion (a reactive oxygen species). This anion rapidly reacts with itself to form hydrogen 
peroxide, a potent oxidizing agent capable of injuring the cell by oxidizing lipid membranes 
and cellular proteins. Hydrogen peroxide also triggers the production of other potent 
reactive oxygen species, including hydroxyl radical and singlet oxygen. Finally, these events 
lead to alteration of mitochondrial respiration and to lipid peroxidation with subsequent 
cellular destruction. The production of reactive oxygen species also initiates production of 
prostaglandins (by direct activation of phospholipase), including Leukotriene B4 and 
Platelet Activating Factor. These substances increase leukocyte adhesion to the vascular 
endothelium. Neutrophils could contribute to local injury by blocking microcirculation and 
by degranulation, which results in proteolytic damage to the kidney. It is therefore advisable 
to add substances to the preservation solution that protect against the formation of reactive 
oxygen species (for example, allopurinol), or “radical cleansers” (superoxide dismutase, iron 
chelating agents, mannitol, dimethylnitrosamine). However, it should be noted that the 
potential benefits of these components are the subject of debate. 
4.3 Release of cytokines 
Ischemia-reperfusion is associated with strong release of Tumor Necrosis Factor alpha, 
Interferon gamma, Interleukin 1 and Interleukin 8. These cytokines cause an up-regulation 
of adhesive molecules which produce leukocyte adherence and platelet plugs after 
revascularization, resulting in graft failure and kidney rejection. 
The vascular endothelium modulates smooth muscle tone in the vessel by releasing various 
local hormones or autacoids. The production of one of them, nitric oxide, which is induced 
by inflammatory cytokines, correlates with acute rejection. 
5. Available preservation solutions 
For kidney preservation by cold storage, the Euro-Collins (EC) solution, University of 
Wisconsin (UW) solution, Histidine-Tryptophan-Ketoglutarate (HTK) solution, or Celsior 
solution can be used. The components are described in table 1. 
The UW solution seems to be associated with better results when compared to the EC 
solution, showing better initial graft function and a 10% reduction in the need for dialysis 
after transplantation (the mean need for dialysis with preservation by storage in cold is 
between 20 and 50%).  Both solutions guarantee preservation of up to 30 hours, so the 
kidney implantation surgery is completely elective (programmed). 
Continuous hypothermic perfusion reduces the incidence of initial graft failure (need for 
postransplant dialysis) to 10%. 
5.1 Euro-Collins solution 
This solution is nowadays used as a preservation solution in isolated renal explantation, 
yielding preservation times of up to 30 hours with less cost than UW solution. However, 
muticentric studies show a better initial graft function with less need for dialysis in grafts 
preserved in UW solution. 
 












Sodium 10 30 15 100 Electrolyte 
Potassium 115 120 10 15 Electrolyte 
Magnesium - 5 4 13 Electrolyte y cytoprotector 
Chloride 15 - 50 - Electrolyte 
Calcium - - 0,015 0,25 Electrolyte 
Phosphate 50 25 - - Buffer 
Sulphate - 5 - - Buffer 
Bicarbonate 10 - - - Buffer 
Histidine - - 180 30 Buffer and waterproofing 
Histidine CIH - - 18 - Buffer 
Glucose 195 - - - Waterproofing 
Mannitol - - 30 60 Waterproofing 
Raffinose - 30 - - Waterproofing 
Lactobionate - 100 - 80 Waterproofing and 
chelating Fe and Ca 
Adenosine - 5 - - Energy 
Ketoglutarate - - 1 - Energy 
Glutamate - - - 20 Energy 
Glutathione - 3 - 3, reduction Anti-free radicals 
Allopurinol - 1 - - Anti-free radicals (inhibits 
xhantine-oxidase) 
Tryptophan - - 2 - Membrane stabilizer 
Dexamethasone - 8 - - Membrane stabilizer 
Insulin - 100 U/l - - Membrane stabilizer 
HES (Hydrox-Ethyl- 
Starch), a synthetic 
starch 
- 50 g/l - - Synthetic colloid 
pH 7 7,4 7,2 7,3  
Osmolarity 355 320 310 340  
Viscosity Low High Low Low  
Table 1. Preservation solutions and their components. EC=Euro-Collins, UW=Universtiy of 
Wisconsin, HTK= Histidine-Tryptophan-Ketoglutarate. 
5.2 Belzer or University of Wisconsin solution 
Currently, this is the solution used for preservation of all abdominal organs, including the 
kidneys. Basically, it is composed of lactobionate and raffinose as waterproofing agents, 
hydroxyl-ethyl-starch (colloid), phosphate (buffer), adenosine (precursor of ATP synthesis), 
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and glutathione and allopurinol (to counteract oxygen radicals). It does not contain glucose 
and it is an “intracellular” solution (rich in potassium and low in sodium), similar to the EC 
solution. 
The disadvantages of UW are the following: 
1. High cost 
2. It has to be kept refrigerated until its use. 
3. Supplements need to be added immediately before its use (insulin, penicillin and 
dexamethasone), although this can be excluded without adverse effects. 
4. The glutathione losses efficacy with time (unstable). 
5. The solution can precipitate, requiring filtering during kidney perfusion and rinsing. 
5.3 HTK-bretschneider (Custodiol) 
It is named HTK because of its components (Hisitidine-Tryptophan-Ketoglutarate) It is an 
“extracellular solution” (low in potassium) and its components include histidine (buffer and 
osmotic effect), mannitol (waterproofing agent, osmotic effect and anti-reactive oxygen 
species), tryptophan (membrane stabilizer) and ketoglutarate (substrate for cellular 
metabolism). Its osmolarity is similar to that of the UW solution (310 vs. 320) and has a 
lower osmotic pressure (15-25 mmHg vs. 0 mmHg). It has lower viscosity, which is why a 
smaller volume of solution is used during perfusion.  
Regarding cost, HKT is comparable to the UW solution, when the specific requirements for 
the use of either solution are taken into account. HKT remains stable at room temperature, 
so it does not need to be refrigerated (unlike UW, although cooling to 4°C should be 
performed at least 2 to 3 hours before its use). HKT also does not precipitate and does not 
require filtering during perfusion. Being a low potassium solution, HKT also has the 
(theoretical) advantage of minimizing vascular injury. 
5.4 Celsior 
This is an “extracellular solution” (low in potassium). Its composition includes 
waterproofing agents like lactobionate and mannitol, antioxidants like reduced glutathione, 
metabolic substrates like glutamate, and a buffer (histidine). The solution is stable, it does 
not need refrigeration or filtering during perfusion. The volume needed to perfuse and its 
cost are similar to those of the UW solution. 
6. Conclusions 
Despite evidence that preservation techniques with perfusion machines provide better graft 
quality and longer periods of preservation, perfusion and subsequent storage at 4°C (for the 
shortest period possible) is still the standard procedure for preservation of renal grafts. A 
valid argument in favor of this practice is that it provides acceptable results with a simpler 
and cheaper method than the use of perfusion machines, which requires expensive and 
cumbersome equipment, as well as additional personnel. An important limitation of the 
preservation of organs by storage in cold is the impossibility of assessing whether the organ 
will adequately function after implantation. In this sense, machine perfusion offers a series 
of added advantages with respect to the preservation by simple cooling: a) it reduces the 
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vascular resistance induced by ischemia and facilitates the elimination of erythrocyte 
remnants from the microcirculation, which allows better reperfusion after implantation, and 
b) it allows testing of the viability or quality of the organ before implantation, by monitoring 
the flow and pressure, or by determination of biochemical markers related to organ viability 
released into the preservation solution (alpha glutathione-S-transferase, pi-glutathione-S-
transferase, alanineaminopeptidase, among others). 
Preservation with HPM is routinely used in only few centers around the world. In Europe 
its use is not extensive, but in the United States it is used in about 20% of kidney transplant 
centers. 
The most frequently used preservation fluids are Euro-Collins, University of Wisconsin and 
HTK-Custodiol, which yield preservation times between 18 and 36 hours. 
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The disadvantages of UW are the following: 
1. High cost 
2. It has to be kept refrigerated until its use. 
3. Supplements need to be added immediately before its use (insulin, penicillin and 
dexamethasone), although this can be excluded without adverse effects. 
4. The glutathione losses efficacy with time (unstable). 
5. The solution can precipitate, requiring filtering during kidney perfusion and rinsing. 
5.3 HTK-bretschneider (Custodiol) 
It is named HTK because of its components (Hisitidine-Tryptophan-Ketoglutarate) It is an 
“extracellular solution” (low in potassium) and its components include histidine (buffer and 
osmotic effect), mannitol (waterproofing agent, osmotic effect and anti-reactive oxygen 
species), tryptophan (membrane stabilizer) and ketoglutarate (substrate for cellular 
metabolism). Its osmolarity is similar to that of the UW solution (310 vs. 320) and has a 
lower osmotic pressure (15-25 mmHg vs. 0 mmHg). It has lower viscosity, which is why a 
smaller volume of solution is used during perfusion.  
Regarding cost, HKT is comparable to the UW solution, when the specific requirements for 
the use of either solution are taken into account. HKT remains stable at room temperature, 
so it does not need to be refrigerated (unlike UW, although cooling to 4°C should be 
performed at least 2 to 3 hours before its use). HKT also does not precipitate and does not 
require filtering during perfusion. Being a low potassium solution, HKT also has the 
(theoretical) advantage of minimizing vascular injury. 
5.4 Celsior 
This is an “extracellular solution” (low in potassium). Its composition includes 
waterproofing agents like lactobionate and mannitol, antioxidants like reduced glutathione, 
metabolic substrates like glutamate, and a buffer (histidine). The solution is stable, it does 
not need refrigeration or filtering during perfusion. The volume needed to perfuse and its 
cost are similar to those of the UW solution. 
6. Conclusions 
Despite evidence that preservation techniques with perfusion machines provide better graft 
quality and longer periods of preservation, perfusion and subsequent storage at 4°C (for the 
shortest period possible) is still the standard procedure for preservation of renal grafts. A 
valid argument in favor of this practice is that it provides acceptable results with a simpler 
and cheaper method than the use of perfusion machines, which requires expensive and 
cumbersome equipment, as well as additional personnel. An important limitation of the 
preservation of organs by storage in cold is the impossibility of assessing whether the organ 
will adequately function after implantation. In this sense, machine perfusion offers a series 
of added advantages with respect to the preservation by simple cooling: a) it reduces the 
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vascular resistance induced by ischemia and facilitates the elimination of erythrocyte 
remnants from the microcirculation, which allows better reperfusion after implantation, and 
b) it allows testing of the viability or quality of the organ before implantation, by monitoring 
the flow and pressure, or by determination of biochemical markers related to organ viability 
released into the preservation solution (alpha glutathione-S-transferase, pi-glutathione-S-
transferase, alanineaminopeptidase, among others). 
Preservation with HPM is routinely used in only few centers around the world. In Europe 
its use is not extensive, but in the United States it is used in about 20% of kidney transplant 
centers. 
The most frequently used preservation fluids are Euro-Collins, University of Wisconsin and 
HTK-Custodiol, which yield preservation times between 18 and 36 hours. 
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1. Introduction 
The 21st century has come as an era of chronic diseases including chronic kidney diseases. 
Treatment at the end stage of kidney failure involves replacing the lost functions of kidneys 
by dialysis or by a kidney transplant.  The end stage renal disease (ESRD) population is 
increasing worldwide. The National Kidney Foundation says that “rates of chronic kidney 
disease (CKD) in the United States have increased by more than 20% over the past decade, 
causing dramatic loss of life and sky-rocketing health care costs, according to the 2008 
annual report by the US Renal Data System”(National Kidney Foundation ,2009). 
Kidney transplantation was proven unquestionably the preferred therapy for most patients 
with ESRD. Survival, cardiovascular stability and quality of life were found superior in 
allograft recipients compared to similar patients who remained on dialysis (Wolfe et al, 
1999; Nathan et al, 2003).  
There was a large gap between the number of patients waiting for a transplant and the 
number receiving a transplant. This gap has widened over the decade, according to 2009 
OPTN/SRTR Annual report. The waiting list for a donor kidney has grown from slightly 
more than 40,000 people in 1998 to about 110,466 in 2011, as per UNOS (United Network for 
Organ Sharing) data base. Sometimes the wait is two or three years, but often it stretches to 
five or 10 years or longer. Some die while waiting. During the past few years, there has been 
renewed interest in the use of expanded criteria donors (ECD) for kidney transplantation to 
increase the numbers of deceased donor kidneys available. More kidney transplants would 
result in shorter waiting times and limit the morbidity and mortality associated with long-
term dialysis therapy.  
Performing renal transplant with a perfectly healthy kidney to all the patients with ESRD is 
an ideal scenario. But growing waiting lists and shortage of kidneys makes it necessary to 
make some compromises. Use of so-called, marginal or borderline donors can increase 
donor pool by almost 20 to 25%.  
Terms- expanded criteria donor or marginal donor simply means accepting suboptimal quality 
grafts, either from a living donor or a cadaver donor with some acceptable medical risks. 
Scientific Registry of Transplant Recipients (SRTR)/Organ Procurement and Transplantation 
Network (OPTN) data showed 41% discard rate for ECD kidneys. Common reasons for 
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1. Introduction 
The 21st century has come as an era of chronic diseases including chronic kidney diseases. 
Treatment at the end stage of kidney failure involves replacing the lost functions of kidneys 
by dialysis or by a kidney transplant.  The end stage renal disease (ESRD) population is 
increasing worldwide. The National Kidney Foundation says that “rates of chronic kidney 
disease (CKD) in the United States have increased by more than 20% over the past decade, 
causing dramatic loss of life and sky-rocketing health care costs, according to the 2008 
annual report by the US Renal Data System”(National Kidney Foundation ,2009). 
Kidney transplantation was proven unquestionably the preferred therapy for most patients 
with ESRD. Survival, cardiovascular stability and quality of life were found superior in 
allograft recipients compared to similar patients who remained on dialysis (Wolfe et al, 
1999; Nathan et al, 2003).  
There was a large gap between the number of patients waiting for a transplant and the 
number receiving a transplant. This gap has widened over the decade, according to 2009 
OPTN/SRTR Annual report. The waiting list for a donor kidney has grown from slightly 
more than 40,000 people in 1998 to about 110,466 in 2011, as per UNOS (United Network for 
Organ Sharing) data base. Sometimes the wait is two or three years, but often it stretches to 
five or 10 years or longer. Some die while waiting. During the past few years, there has been 
renewed interest in the use of expanded criteria donors (ECD) for kidney transplantation to 
increase the numbers of deceased donor kidneys available. More kidney transplants would 
result in shorter waiting times and limit the morbidity and mortality associated with long-
term dialysis therapy.  
Performing renal transplant with a perfectly healthy kidney to all the patients with ESRD is 
an ideal scenario. But growing waiting lists and shortage of kidneys makes it necessary to 
make some compromises. Use of so-called, marginal or borderline donors can increase 
donor pool by almost 20 to 25%.  
Terms- expanded criteria donor or marginal donor simply means accepting suboptimal quality 
grafts, either from a living donor or a cadaver donor with some acceptable medical risks. 
Scientific Registry of Transplant Recipients (SRTR)/Organ Procurement and Transplantation 
Network (OPTN) data showed 41% discard rate for ECD kidneys. Common reasons for 
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discard of these donor kidneys were older donors, glomerulosclerosis on biopsy and poor 
renal perfusion (Sunga et al, 2008). Current utilization is 15% of all transplanted kidneys.  
2. Marginal versus expanded criteria donor 
Some authors believe that the term ‘expanded’ be used instead of “marginal” because the 
term ‘marginal’ may be considered pejorative by the patients who receive them, as well as 
by the programs that transplant them (Kauffman, 1997). 
3. Standard donor versus expanded criteria donors 
Graft and patient survival after ECD kidney transplantation are inferior to survival rates 
with SCD kidney transplantation. The differences are initially insignificant, but increase 
over time. The half-lives of deceased-donor kidneys (ECD or SCD) are shorter than the half-
life of a living-donor kidney (Metzger, 2003). Many large retrospective database analysis 
compared outcomes of standard-criteria donor (SCD) kidney transplants with ECD kidney 
transplants. Overall, mortality in the perioperative period was greater in ECD kidney 
recipients (Merion et al, 2005; Remuzzi et al, 2006). Kidneys transplanted from expanded 
criteria donors have a higher rate of delayed graft function, more acute rejection episodes, 
and decreased long-term graft function. Several factors, including prolonged cold ischemia 
time (CIT), increased immunogenicity, impaired ability to repair tissue, and impaired 
function with decreased nephron mass may contribute to this (De Fijter et al, 2001). Despite 
these inferior results, these transplants had definitely survival advantage over patients still 
receiving dialysis (Ojo et al, 2001; Merion et al, 2005).  It was also observed that, despite an 
increased mortality risk during the initial post-transplant period, the long-term mortality 
risk was > 50% lower for patients who were 60 to 74 years of age at the time of waiting list 
registration compared with those who remained on dialysis (Wolfe et al, 1999). 
4. Optimised allocation 
The strategy proposed by Bryce Kiberd et al was to retrieve all kidneys; but visibly scarred 
kidneys should be discarded. He also proposed performing biopsy in some deceased donors 
kidneys > age 65, > age 55 and donor Creatinine clearance<60 - 70 ml/min, discarding 
advanced arteriolar sclerosis or interstitial fibrosis. Allocating these grafts to Older (>59) or 
diabetic, avoid the sensitized, minimize cold ischemic time and avoid large weight or age 
mismatches (Bryce Kiberd, 2011). Schnitzler and colleagues used a Markov model to 
determine the best timing for an individual patient to accept an offer of an ECD kidney, 
based on registry data from the United States Renal Data System (USRDS) and expected 
quality-adjusted life years (Schnitzer et al, 2003). Common practice in the United States as 
well as Europe is to place older donor kidneys in older patients (Voiculescu et al, 2002; Smits 
et al, 2002; Kasiske et al, 2002; Lee et al, 1999).  
5. Types of marginal donors 
5.1 Living marginal donor 
Living‐related kidney donation is a way out of the current dilemma of insufficient supply of 
renal allografts. The risk to the donor is minimal, but not zero. Apart from these peri‐
operative risks, are there potential long‐term risks with respect to renal function, proteinuria  
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and hypertension. Potential risks must be excluded by careful work‐up of the donor (Duraj 
et al, 1995; Natarajan et al, 1992; Foster et al, 1991). There is enough evidence to suggest that, 
standard living donors do not face risks for ESRD any higher than those of age- matched 
peers (Fehrman‐Ekholm et al, 2001). But this doesn’t hold true for marginal living donors. In 
fact, emphasis should be given to ascertain the risk of developing CKD as well as ESRD in 
these donors.  
Marginal Donors - Inclusion 
 Elderly donors 
 GFR – 60 to 70 ml/ min 
 Mild Hypertension 
 Donor with Stone Disease 
 Donors with Renal cysts 
 Donors with BMI>30 
 Other issues like tuberculosis, DM, proteinuria, hematuria, malignancy, family history 
of ESRD and CMV Infections 
5.1.1 Aged kidney donors 
Glomerulosclerosis increases with age. There is decrease in GFR of approx 1 ml/min per 
1.73 m2 per year after age 40. There is a documented acute decrease in GFR of approximately 
30% after unilateral nephrectomy; however, the impact of unilateral nephrectomy on this 
rate of decline in GFR is unknown.  
Twenty per cent glomerulosclerosis is usually considered the upper limit for accepting 
kidneys from a donor. There is higher incidence of delayed graft function with such 
kidneys. Further, there may be associated increased rate of acute rejection. Advancing age is 
associated with higher incidence of hypertension (Moreso et al, 1999). The influence of 
donor age on the outcome of living donor kidney transplantation is not very clear. Gill et al 
in their observational cohort study of 23,754 kidney transplantations performed in recipients 
60 years and older, found that old living donor transplants were associated with inferior 3-
year graft survival rates, but similar 3-year patient survival rates compared with young 
living donor transplants. Elderly deceased criteria donor transplantations were associated 
with a greater risk of graft loss. He proposed old living donors an important option for 
elderly transplantation (Gill et al, 2008). There are other few studies in the literature that 
found encouraging results with elderly living donor transplants (Kumar et al, 2000; De La 
Vega, 2004). Graft survival, patient survival, degree of hypertension and renal function were 
similar in elderly and young living donor transplant groups.  Contrary to these encouraging 
results, others noted poor patient and graft survival in elderly donor transplants (Toma et al, 
2001; Prommool et al, 2000). Long term outcome of this group is not known.  
5.1.2 Hypertensive donors 
There are no precise guidelines regarding donation from patients with arterial hypertension. 
It is now accepted that systolic blood pressure greater than 140 mmHg is a much more 
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discard of these donor kidneys were older donors, glomerulosclerosis on biopsy and poor 
renal perfusion (Sunga et al, 2008). Current utilization is 15% of all transplanted kidneys.  
2. Marginal versus expanded criteria donor 
Some authors believe that the term ‘expanded’ be used instead of “marginal” because the 
term ‘marginal’ may be considered pejorative by the patients who receive them, as well as 
by the programs that transplant them (Kauffman, 1997). 
3. Standard donor versus expanded criteria donors 
Graft and patient survival after ECD kidney transplantation are inferior to survival rates 
with SCD kidney transplantation. The differences are initially insignificant, but increase 
over time. The half-lives of deceased-donor kidneys (ECD or SCD) are shorter than the half-
life of a living-donor kidney (Metzger, 2003). Many large retrospective database analysis 
compared outcomes of standard-criteria donor (SCD) kidney transplants with ECD kidney 
transplants. Overall, mortality in the perioperative period was greater in ECD kidney 
recipients (Merion et al, 2005; Remuzzi et al, 2006). Kidneys transplanted from expanded 
criteria donors have a higher rate of delayed graft function, more acute rejection episodes, 
and decreased long-term graft function. Several factors, including prolonged cold ischemia 
time (CIT), increased immunogenicity, impaired ability to repair tissue, and impaired 
function with decreased nephron mass may contribute to this (De Fijter et al, 2001). Despite 
these inferior results, these transplants had definitely survival advantage over patients still 
receiving dialysis (Ojo et al, 2001; Merion et al, 2005).  It was also observed that, despite an 
increased mortality risk during the initial post-transplant period, the long-term mortality 
risk was > 50% lower for patients who were 60 to 74 years of age at the time of waiting list 
registration compared with those who remained on dialysis (Wolfe et al, 1999). 
4. Optimised allocation 
The strategy proposed by Bryce Kiberd et al was to retrieve all kidneys; but visibly scarred 
kidneys should be discarded. He also proposed performing biopsy in some deceased donors 
kidneys > age 65, > age 55 and donor Creatinine clearance<60 - 70 ml/min, discarding 
advanced arteriolar sclerosis or interstitial fibrosis. Allocating these grafts to Older (>59) or 
diabetic, avoid the sensitized, minimize cold ischemic time and avoid large weight or age 
mismatches (Bryce Kiberd, 2011). Schnitzler and colleagues used a Markov model to 
determine the best timing for an individual patient to accept an offer of an ECD kidney, 
based on registry data from the United States Renal Data System (USRDS) and expected 
quality-adjusted life years (Schnitzer et al, 2003). Common practice in the United States as 
well as Europe is to place older donor kidneys in older patients (Voiculescu et al, 2002; Smits 
et al, 2002; Kasiske et al, 2002; Lee et al, 1999).  
5. Types of marginal donors 
5.1 Living marginal donor 
Living‐related kidney donation is a way out of the current dilemma of insufficient supply of 
renal allografts. The risk to the donor is minimal, but not zero. Apart from these peri‐
operative risks, are there potential long‐term risks with respect to renal function, proteinuria  
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and hypertension. Potential risks must be excluded by careful work‐up of the donor (Duraj 
et al, 1995; Natarajan et al, 1992; Foster et al, 1991). There is enough evidence to suggest that, 
standard living donors do not face risks for ESRD any higher than those of age- matched 
peers (Fehrman‐Ekholm et al, 2001). But this doesn’t hold true for marginal living donors. In 
fact, emphasis should be given to ascertain the risk of developing CKD as well as ESRD in 
these donors.  
Marginal Donors - Inclusion 
 Elderly donors 
 GFR – 60 to 70 ml/ min 
 Mild Hypertension 
 Donor with Stone Disease 
 Donors with Renal cysts 
 Donors with BMI>30 
 Other issues like tuberculosis, DM, proteinuria, hematuria, malignancy, family history 
of ESRD and CMV Infections 
5.1.1 Aged kidney donors 
Glomerulosclerosis increases with age. There is decrease in GFR of approx 1 ml/min per 
1.73 m2 per year after age 40. There is a documented acute decrease in GFR of approximately 
30% after unilateral nephrectomy; however, the impact of unilateral nephrectomy on this 
rate of decline in GFR is unknown.  
Twenty per cent glomerulosclerosis is usually considered the upper limit for accepting 
kidneys from a donor. There is higher incidence of delayed graft function with such 
kidneys. Further, there may be associated increased rate of acute rejection. Advancing age is 
associated with higher incidence of hypertension (Moreso et al, 1999). The influence of 
donor age on the outcome of living donor kidney transplantation is not very clear. Gill et al 
in their observational cohort study of 23,754 kidney transplantations performed in recipients 
60 years and older, found that old living donor transplants were associated with inferior 3-
year graft survival rates, but similar 3-year patient survival rates compared with young 
living donor transplants. Elderly deceased criteria donor transplantations were associated 
with a greater risk of graft loss. He proposed old living donors an important option for 
elderly transplantation (Gill et al, 2008). There are other few studies in the literature that 
found encouraging results with elderly living donor transplants (Kumar et al, 2000; De La 
Vega, 2004). Graft survival, patient survival, degree of hypertension and renal function were 
similar in elderly and young living donor transplant groups.  Contrary to these encouraging 
results, others noted poor patient and graft survival in elderly donor transplants (Toma et al, 
2001; Prommool et al, 2000). Long term outcome of this group is not known.  
5.1.2 Hypertensive donors 
There are no precise guidelines regarding donation from patients with arterial hypertension. 
It is now accepted that systolic blood pressure greater than 140 mmHg is a much more 
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important cardiovascular risk factor than raised diastolic blood pressure. In fact, there is 
little evidence that well-controlled hypertension may lead to kidney damage in an otherwise 
healthy subject. According to a Consensus Conference held in Amsterdam (Delmonico, 
2005), there is no reason to reject as a kidney donor a subject more than 50 years of age who 
has a normal blood pressure on therapy with a GFR > 80 ml/min and proteinuria < 300 mg 
per day(Delmonico et al, 2005). Ambulatory blood pressure monitoring has been proposed 
as a more sensitive method than office blood pressure measurements in identifying 
hypertension in living donors (Ozdemir et al, 2000).  
5.1.3 Diabetic donors 
Diabetics are generally excluded because of the increased risk of postoperative 
complications in the short term and because of the potential risk of developing diabetic 
nephropathy in the long term (Delmonico et al, 2005; Kasiske et al, 1995).  Diabetic 
nephropathy occurs in familial clusters and heredity helps to determine susceptibility to 
diabetic nephropathy (Sequist et al, 1989). It was clearly stated in Consensus Conference 
held in Amsterdam, that individuals with a history of diabetes or fasting blood glucose of ≥ 
126mg/dl (7.0mmol/L) on at least two occasions (or 2-h glucose with OGTT ≥ 200mg/dl 
(11.1mmol/L)) should not donate(Delmonico et al, 2005). 
5.1.4 Patients with nephrolithiasis 
It seems reasonable to accept as donors only those subjects without stones at the time of 
evaluation and with normal values within a 24-hour urine collection of calcium, urate, and 
oxalate. According to a Consensus Conference, patients with stones caused by inherited 
disorders, inflammatory bowel disease, or systemic disease are at high risk of recurrence 
and should not be considered for donation (Delmonico et al, 2005).  In the series a cohort of 
710 renal transplant recipients from mayo clinic, evaluation was done for the risk transplant 
graft renal calculus formation over duration of 4 years. 44 donor kidneys had calculi, 
majority being <2mm. Stable stone size was seen in four patients, increase in stone size 
averaging 2.9 millimeters in four patients. No loss of the transplanted kidneys occurred due 
to stone obstruction in the patients studied (Ho et al, 2005). Whether or not kidney stone 
formers should donate a kidney is controversial. The American Society of Transplantation 
(AST) position paper proposes guidelines that a kidney stone former may donate a kidney 
if: only one stone has ever formed; stones have been multiple, but none have formed for >10 
years and none are seen on radiograph; and the donor is screened for metabolic 
abnormalities and is offered life-long follow-up that includes periodic risk reassessment, 
medical treatment, and hydration (Michelle et al, 2006). 
5.1.5 Obese donors 
There is little information on the long-term follow-up of obese donors. Of some concern, in 
patients submitted to unilateral nephrectomy for various reasons, those with a BMI > 30 had 
a significantly higher risk of developing proteinuria or renal dysfunction in the long term 
than did those with a BMI < 30 (Praga et al, 2000). The Consensus Conference held in 
Amsterdam discouraged donation from persons with a BMI higher than 35(Delmonico et al, 
2005). Dyslipidemia are associated with decreased kidney function in the general population 
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and have faster rates of progression in patients who have chronic kidney disease. However, 
isolated dyslipidemia is not a contraindication for donation.  
5.1.6 Other issues 
 Adult relatives of patients with polycystic kidney disease can be accepted for donation 
if they have a normal CT or renal ultrasound scan. 
 Donors with malignancy- a history of malignancy is in general a contraindication to 
living kidney donation, other than carcinoma in situ of the uterine cervix or treated low 
grade, non- melanotic skin carcinoma.  
 Donors with transmissible infections- HIV positive status remains a contraindication for 
donation. Cytomegalovirus (CMV) and Ebstein-barr virus (EBV) status is measured at 
some transplant centers and they delay transplant till PCR for CMV becomes negative. 
Most of the adults are EBV and CMV-positive; most of the children are negative. The 
risk of post-transplantation lymphoproliferative disorder (PTLD) is the concern in CMV 
and EBV-negative individuals receiving positive donors. However, the risk is not as 
high to prohibit renal transplantation (Delmonico et al, 2005). Renal transplantation 
should be considered using HCV-seropositive grafts for qualified patients with chronic 
kidney disease (CKD) stage 5 and HCV infection since good information indicates that 
the transplantation of kidneys from HCV-infected donors results in improved survival 
compared to wait-listed and dialysis-dependent candidates (Fabrizi et al, 2009). 
Hepatitis C Virus (HCV) positive donor may be considered for donation to a HCV 
positive recipient only if the donor PCR is negative, certain genotypes (Genotype 4) are 
treated and eradicated of the donor and there is no evidence of chronic hepatitis or 
cirrhosis on liver biopsy. However, there is no data on live kidney transplantation from 
HCV positive donors. Hepatitis B Virus (HBV) positive status currently is not accepted 
for donation. However, there are some isolated reports of transplantation by groups in 
New Zealand (Delmonico et al, 2005). Donors treated for pulmonary TB require a more 
specific and extensive examination of the urinary tract and the kidneys prior to 
donation.  
5.1.7 Ethical issues 
Ethical issues in accepting marginal criteria donors are very complex. The living kidney 
donation means giving life to a patient on dialysis but at the same time avoiding risks to the 
donor. An important problem with marginal donors is that these marginal living donors 
may themselves add up the pool of chronic kidney disease patients in the long run.    
At American Transplant Congress 2003, in cases of marginal donor transplantation, a prior 
sample consent by both donor and recipient was proposed stating expect increase in 
delayed graft function, expected decrease in graft survival, expected decrease in waiting 
time, expected increase in survival compared to waiting and benefit of transplant prior to 
increased morbidity.  
It is truly anticipated that the transplantation of ECD and DCD kidneys would result in 
higher costs. More frequent need for hemodialysis, more hospital readmissions due to poor 
or late onset graft function and more opportunistic infections in recipients of ECD and DCD 
kidneys results in higher cost for their initial medical care. 
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important cardiovascular risk factor than raised diastolic blood pressure. In fact, there is 
little evidence that well-controlled hypertension may lead to kidney damage in an otherwise 
healthy subject. According to a Consensus Conference held in Amsterdam (Delmonico, 
2005), there is no reason to reject as a kidney donor a subject more than 50 years of age who 
has a normal blood pressure on therapy with a GFR > 80 ml/min and proteinuria < 300 mg 
per day(Delmonico et al, 2005). Ambulatory blood pressure monitoring has been proposed 
as a more sensitive method than office blood pressure measurements in identifying 
hypertension in living donors (Ozdemir et al, 2000).  
5.1.3 Diabetic donors 
Diabetics are generally excluded because of the increased risk of postoperative 
complications in the short term and because of the potential risk of developing diabetic 
nephropathy in the long term (Delmonico et al, 2005; Kasiske et al, 1995).  Diabetic 
nephropathy occurs in familial clusters and heredity helps to determine susceptibility to 
diabetic nephropathy (Sequist et al, 1989). It was clearly stated in Consensus Conference 
held in Amsterdam, that individuals with a history of diabetes or fasting blood glucose of ≥ 
126mg/dl (7.0mmol/L) on at least two occasions (or 2-h glucose with OGTT ≥ 200mg/dl 
(11.1mmol/L)) should not donate(Delmonico et al, 2005). 
5.1.4 Patients with nephrolithiasis 
It seems reasonable to accept as donors only those subjects without stones at the time of 
evaluation and with normal values within a 24-hour urine collection of calcium, urate, and 
oxalate. According to a Consensus Conference, patients with stones caused by inherited 
disorders, inflammatory bowel disease, or systemic disease are at high risk of recurrence 
and should not be considered for donation (Delmonico et al, 2005).  In the series a cohort of 
710 renal transplant recipients from mayo clinic, evaluation was done for the risk transplant 
graft renal calculus formation over duration of 4 years. 44 donor kidneys had calculi, 
majority being <2mm. Stable stone size was seen in four patients, increase in stone size 
averaging 2.9 millimeters in four patients. No loss of the transplanted kidneys occurred due 
to stone obstruction in the patients studied (Ho et al, 2005). Whether or not kidney stone 
formers should donate a kidney is controversial. The American Society of Transplantation 
(AST) position paper proposes guidelines that a kidney stone former may donate a kidney 
if: only one stone has ever formed; stones have been multiple, but none have formed for >10 
years and none are seen on radiograph; and the donor is screened for metabolic 
abnormalities and is offered life-long follow-up that includes periodic risk reassessment, 
medical treatment, and hydration (Michelle et al, 2006). 
5.1.5 Obese donors 
There is little information on the long-term follow-up of obese donors. Of some concern, in 
patients submitted to unilateral nephrectomy for various reasons, those with a BMI > 30 had 
a significantly higher risk of developing proteinuria or renal dysfunction in the long term 
than did those with a BMI < 30 (Praga et al, 2000). The Consensus Conference held in 
Amsterdam discouraged donation from persons with a BMI higher than 35(Delmonico et al, 
2005). Dyslipidemia are associated with decreased kidney function in the general population 
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and have faster rates of progression in patients who have chronic kidney disease. However, 
isolated dyslipidemia is not a contraindication for donation.  
5.1.6 Other issues 
 Adult relatives of patients with polycystic kidney disease can be accepted for donation 
if they have a normal CT or renal ultrasound scan. 
 Donors with malignancy- a history of malignancy is in general a contraindication to 
living kidney donation, other than carcinoma in situ of the uterine cervix or treated low 
grade, non- melanotic skin carcinoma.  
 Donors with transmissible infections- HIV positive status remains a contraindication for 
donation. Cytomegalovirus (CMV) and Ebstein-barr virus (EBV) status is measured at 
some transplant centers and they delay transplant till PCR for CMV becomes negative. 
Most of the adults are EBV and CMV-positive; most of the children are negative. The 
risk of post-transplantation lymphoproliferative disorder (PTLD) is the concern in CMV 
and EBV-negative individuals receiving positive donors. However, the risk is not as 
high to prohibit renal transplantation (Delmonico et al, 2005). Renal transplantation 
should be considered using HCV-seropositive grafts for qualified patients with chronic 
kidney disease (CKD) stage 5 and HCV infection since good information indicates that 
the transplantation of kidneys from HCV-infected donors results in improved survival 
compared to wait-listed and dialysis-dependent candidates (Fabrizi et al, 2009). 
Hepatitis C Virus (HCV) positive donor may be considered for donation to a HCV 
positive recipient only if the donor PCR is negative, certain genotypes (Genotype 4) are 
treated and eradicated of the donor and there is no evidence of chronic hepatitis or 
cirrhosis on liver biopsy. However, there is no data on live kidney transplantation from 
HCV positive donors. Hepatitis B Virus (HBV) positive status currently is not accepted 
for donation. However, there are some isolated reports of transplantation by groups in 
New Zealand (Delmonico et al, 2005). Donors treated for pulmonary TB require a more 
specific and extensive examination of the urinary tract and the kidneys prior to 
donation.  
5.1.7 Ethical issues 
Ethical issues in accepting marginal criteria donors are very complex. The living kidney 
donation means giving life to a patient on dialysis but at the same time avoiding risks to the 
donor. An important problem with marginal donors is that these marginal living donors 
may themselves add up the pool of chronic kidney disease patients in the long run.    
At American Transplant Congress 2003, in cases of marginal donor transplantation, a prior 
sample consent by both donor and recipient was proposed stating expect increase in 
delayed graft function, expected decrease in graft survival, expected decrease in waiting 
time, expected increase in survival compared to waiting and benefit of transplant prior to 
increased morbidity.  
It is truly anticipated that the transplantation of ECD and DCD kidneys would result in 
higher costs. More frequent need for hemodialysis, more hospital readmissions due to poor 
or late onset graft function and more opportunistic infections in recipients of ECD and DCD 
kidneys results in higher cost for their initial medical care. 
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5.2 Marginal cadaveric donor  
The Organ Procurement and Transplantation Network instituted a formalized definition of 
marginal kidneys in 2002 with the advent of the Expanded Criteria Donor (ECD) (Metzger et 
al, 2003).  These deceased donor kidneys were demonstrated to convey a 70% or greater risk 
for graft loss for transplant recipients relative to an ideal donation and were characterized 
by a donor age older than 60 yr or older than 50 yr and accompanied by two additional risk 
factors, including a history of hypertension, elevated terminal donor Creatinine, and 
cerebrovascular cause of death.  
Despite expected higher rate of graft failure compared to SCD kidneys, multiple studies 
have subsequently shown that kidney transplantation using ECDs is still associated with a 
substantial reduction in morbidity and improvement in life expectancy when compared 
with suitable transplant candidates who remained on maintenance dialysis treatment 
(UNOS Policy 3.5.1, 2002; Institute of Medicine, 1997; Ojo et al, 2001).  
6. Donation after cardiac death (DCD) 
Another approach to the organ shortage has been the utilization of donors after cardiac 
death. The recovery of organs from nonheart beating donors is an important, medically 
effective and ethically acceptable approach to reducing the gap that exists now and will 
continue to exist in future between the demand for and available supply of organs for 
transplantation’. A lot of investigators have reported excellent short-term outcomes using 
these donors, and 10–15% growth in organ donation as a result of the use of DCD donors 
was demonstrated. Multiple studies have shown that the overall results of DCD (without 
ECD characteristics) and SCD kidney transplants are comparable (Institute of Medicine, 
1997; Ojo et al, 2001; Stratta et al, 2004). A main issue with NHBD is the significantly higher 
rate of delayed graft function, compared with that associated with heart-beating donor 
(Keizer et al, 2005).  
7. Role of kidney biopsy 
Outcomes of ECD kidney transplantation are improved when a pre-implantation biopsy of 
the donor kidney is evaluated using the scoring system introduced by Karpinski and 
colleagues (Karpinski et al, 1999). Using this system, donor renal pathology is scored from 0 
to 3 (none to severe disease) in 4 areas: glomerulosclerosis, interstitial fibrosis, tubular 
atrophy, and vascular disease. A donor vessel score of 3/3 is associated with a 100% 
incidence of delayed graft function and a significantly worse renal function at one year. 
8. Patient management: Immunosuppressive protocols 
Optimal management is a challenge in ECD kidney transplant recipients. These transplants 
are feared with increased rates of acute rejections and delayed graft function. Therefore, 
adequate level of Immunosuppression is desired.  Management for an ECD kidney is based 
on potential nephron-protecting strategies, including cold ischemia time minimization, 
pulsatile perfusion preservation, immunosuppression focused on nephrotoxicity 
minimization, and adequate infection prophylaxis. Although calcineurin inhibitors are 
excellent drugs, the nephrotoxicity they impart is largely responsible for postponing chronic 
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allograft dysfunction and achieve better long-term graft survival. The problem of 
calcineurin inhibitor-related nephrotoxicity is an even greater concern in older recipients of 
ECD kidneys. Various strategies of CNI withdrawal, minimization as well as avoidance 
were utilized by a number of investigators.  
 Antibody induction, MMF, steroids. 
 MMF monotherapy or MMF plus steroids. 
 Antibody induction, sirolimus, MMF, steroids. 
 Antibody induction, sirolimus, MMF, steroids. 
 Conversion from a calcineurin-inhibitor-based regimen to a sirolimus-based regimen 
The potential for CNI-free sirolimus and MMF–based therapy in ECD kidney transplant 
recipients has not been adequately studied to date. Consequently, extrapolation of the best 
results obtained with anti–interleukin 2 receptors, MMF, steroids, and moderate exposure to 
tacrolimus might constitute an advisable strategy (Ekberg et al, 2007).  
9. Conclusion 
In summary, the use of marginal donors for kidney transplantation increases the numbers of 
donor kidneys available, results in shorter waiting times, and limits the morbidity and 
mortality associated with long-term dialysis therapy. These kidneys are known to have 
worse long-term survival than standard criteria kidneys. Elderly patients with longer 
waiting times show better survival receiving such kidney than remaining on dialysis 
therapy. A management protocol for ECD kidney transplantation should be based on 
potential nephronprotecting strategies like, minimization of cold ischemia time, tailored 
immunosuppression with early CNI minimization or delayed moderate dose, CNI addition 
after induction, and adequate infection prophylaxis.  
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1. Introduction 
Donor selection for allografting of a non-paired vital organ, such as the heart, is necessarily 
limited to cadaveric or possibly xenogeneic sources. In contrast, because of the presence in 
most normal persons of two kidneys – each with a physiological reserve capable of 
providing four times the minimal required function – renal transplantation has become an 
accepted medical procedure using cadaveric and living related or unrelated volunteers as 
organ sources.  
Each of these donor categories presents unique ethical, legal and social implications (Spital, 
1991; Woo, 1992). 
That must be addressed carefully to protect not only the health and rights of the recipient 
but also those of the donor. 
Of equal importance are the medical aspects of donor evaluation and the technical features 
of the nephrectomy procedure.  
The initial functional capacity of the transplanted kidney is largely independent of 
immunological factors; however, it is highly dependent on the efficacy of donor preparation 
and procurement techniques in preventing ischemic injury.  
It has been necessary to adapt the surgical procedures to develop combination procurement 
techniques that provide equal protection for the extra renal organs as well as the kidneys.  
2. Living kidney donor 
The first successful renal transplant was performed in 1954. With the development of 
effective immunosuppressive regimens, this observation was extended to less compatible 
intrafamilial donors and eventually to unrelated donors. 
Until the early 1980s, many dialysis patients had doubt to heed cadaver donor 
transplantation because its morbidity and mortality rates were manifold. 
With the introduction of calcineurin inhibitors, monoclonal and polyclonal antibody 
immunosuppression and other new immunosuppressive agents into clinical regimens, the 
gap in graft survival between living related and cadaveric renal transplantation narrowed 
considerably.  
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Living related donor grafts still have a 10 to 12 % better survival rate at 1 year and a 
significantly higher probability of function thereafter, however (Cecka and Terasaki, 1998).  
Family members as suitable organ donors were recommended. (Delmonico et al., 1990). 
The experience of using living unrelated kidneys in transplantation has shown that these 
organs have a graft survival profile that, in fact approaches that of related donors (Terasaki 
et al., 1995).  
Even with the current widespread application of calcineurin inhibitors and monoclonal 
and polyclonal antibody immunosuppression, there is a persisting biological advantage of 
living donor kidneys (living related donor or living unrelated donor) over cadaver donor 
allograft.  
Although short – term graft survival after transplantation from both donor sources is 
excellent, the 5 year success rate of greater than 80 % that can be attained using living donor 
kidneys exceeds  by 10 to15% of any reported cadaver  donor results. 
Another justification for using living donors is that the operation can be specifically 
planned, limiting waiting time on dialysis.  
Of greater importance is the ability to perform the transplant when the recipient is in 
optimal medical condition. This ability is particularly pertinent for diabetic patients, whose 
condition may deteriorate rapidly on dialysis. Finally, there is the risk that the patient may 
develop antibody to HLA antigens during prolonged dialysis, especially if intermittent 
blood transfusions are required.  
The final reason for the continued expansion of living donor transplantation is the 
insufficient supply of cadaver donor organs required to fulfill the needs of renal failure 
victims awaiting transplantation (Cohen et al., 1998).  
For each 1 million of the population, approximately 75 to 80 renal transplants would have 
to be performed annually to keep pace with the more than 100 new patients diagnosed 
with end – stage renal disease and previous transplant recipients whose allograft 
eventually fail.  
Even in areas with outstanding cadaver donor retrieval rates or with less strict criteria for 
donor selection (Kauffman et al., 1997), the number of potential recipients greatly exceeds 
the supply of donor’s kidneys. A steadily growing population of patients is being 
maintained on dialysis in most areas of the world.  
With the extension of minimally invasive techniques to living kidney donation the potential 
adverse impact of the operation has become less significant.  
Although, it was thought that laparoscopic nephrectomy for renal transplantation might 
have some adverse effects to the donor organ because of prolonged warm ischemic interval, 
it is known that laparoscopic donor nephrectomy leads to decreases analgesic dose, 
decreased length of hospitalization, early return to normal daily activity and less surgical 
morbidity. 
Nowadays, new devices are used in laparoscopic nephrectomy, have led to shorten ischemic 
time. So that its results are now comparable to those achieved after classic open 





Laparosopic donor nephrectomy (LDN) has become the preferred technique for live donor 
nephrectomy at most transplant centers in the United States (Ratner et al, 1999; Jacobs et al, 
2004). 
Survival studies indicate that the 5 year life expectancy of a unilaterally nephrectomized 35 
year – old male donors is 99 % compared with 99.3 % normal expectation (Merrill, 1964). 
The quality of life after kidney donation has been reported in 979 patients who had donated 
a kidney for transplantation (Johnson et al., 1997). Most of the responders had an excellent 
quality of life.  
Multivariate analysis of those who did not respond favorably identified the following two 
factors for negative psychosocial outcome; relatives other than first degree and recipients 
who died within 1 year of transplantation.  
Concern has been raised that healthy human donors might develop hypertension and renal 
dysfunction years after unilateral nephrectomy. Follow – up studies of hundreds of living 
donors for 20 years have been unable, however, to identify any convincing evidence of long 
– term functional abnormalities associated with unilateral nephrectomy (Najarian et. al., 
1992). 
Regarding to these considerations, living donors continue to be the significant proportion of 
that donor pool. The proportion varies from less than 5% in some areas to 100% in areas 
where cadaver donor transplantation is unavailable. At present in U.S. about 27% of 
transplanted kidneys are obtained from living donors. 
3. Medical evaluation and selection of the living donor  
Advantages of transplant should be reasonable in comparison with its limited risks and both 
patient and donor should be justified for accepting it. 
All potential donors are first screened for emotional stability and motivation as well as 
blood group ABO typing.  
Incompatibility of ABO blood group between donor and recipient has resulted in irreversible 
rejection. Because of the extreme shortage of donor kidneys, especially for blood group O 
recipients, this requirement has been constantly reassessed. Several groups have reported 
successful results after transplantation of blood group A2 kidneys into group O recipients 
(Nelson et.al., 1998). Approximately 20% of blood group A persons are subtyped as A2. The 
highly successful transplantation of A2 kidneys into group O recipients has been explained by 
the low expression of A determinants in A2 kidneys compared with A1 kidneys.  
Potential donors remaining after initial screening process are evaluated to confirm excellent 
general health and bilateral renal function (kasiske et. al., 1996).The basic criteria for a renal 
donor are an absence of renal disease, an absence of transmissible malignancy, and an 
absence of active infection. 
Many of the studies are directed toward detection of exterarenal pathology. This medical 
evaluation may reveal significant but treatable problems of which the donor was unaware. 
(Table 1) (Ko, et al. 2001) 
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Family conference with transplant-dialysis team ABO blood group, tissue typing, 
leukocyte cross match, ± mixed lymphocyte culture 
History, physical examinations, serial blood pressure determinations 
Cell blood count, coagulation profile, BUN, serum creatinine, FBS, cytomegalovirus 
antibody, human immunodeficiency virus antibody, hepatitis B and C testing, cholesterol, 
triglycerides, calcium, phosphorus, urine analysis, urine culture, 24-hour urine protein 
Chest radiograph, intravenous pyelogram or ultrasound electrocardiogram
Aortogram or digital subtraction angiography and/or three-dimensional computed 
tomography 
Table 1. Evaluation of living donors. 
The remaining studies are concerned with the quality of renal function and the clarification 
of any anatomical abnormalities in either kidney. It must be determined that the non-
donated kidney is normal. 
Final selection of the donor, if several medically suitable relatives are available is made on 
the basis of histocompatibility testing. Selection also may be determined on the basis of age 
(avoiding elderly volunteers) or on less objective factors, such as the special social 
obligations of particular family member.  
It is now clear that living unrelated donor kidneys provide significant physiological and 
long term survival advantages and are being accepted with increasing frequency. In most 
centers donation for monetary compensation is not allowed (Childress, 1996; Quinibi 1997).  
The imaging of kidneys prior to nephrectomy performs by several methods, including: 
ultrasound (US); conventional angiography (CA); digital subtraction angiography (DSA); 
computed tomography (CT) and magnetic resonance imaging (MRI), each of which has innate 
problems. A single modality to assess vasculature, renal parenchyma and urinary drainage is 
preferred. The pre-nephrectomy anatomy which most anticipates complications during the 
transplant procedure is the presence or absence of variant arteries (Stephen Munn, 2010). 
For the living donor who has been identified by these criteria, the classic gold standard 
aortogram has been the final diagnostic study scheduled. The ability to visualize data 
obtained with CT or MRI in a three-dimensional method carefully reconstructing the 
images, isolating arteries, veins or parenchymal structures has assisted surgical planning. 
Surgical goals are to minimize warm ischemia time, to preserve renal vessels, and to 
preserve ureteral blood supply. 
Magnetic resonance imaging and angiography provide suboptimal information on renal 
vascular anatomy (Kok NF, et al., 2008). 
Arvine-Berod and et al compared the sensitivity of computed tomography angiography 
(CTA) and magnetic resonance angiography (MRA) in preoperative renal vascularisation in 
living kidney donors. They determined that MRA is less sensitive than CTA in living kidney 
donors especially in the detection of multiple renal arteries. (Arvine-Berod A, et al., 2011) 
4. Post operative care and complications 





Most of patients are ready for discharge from the hospital in 3 to 4 days and for return to 
employment by 4 weeks.  
Urine culture, renal function tests and a complete blood count are reassessed before 
discharge. The patient then has follow – up evaluations at increasing intervals.  
The perioperative mortality rate for kidney donors is estimated to be 0.30 % (kasiske et al., 
1996). Approximately 20 deaths have been reported after living donor allograft donation 
over 35 years (Jones et al., 1993). Other complications of the kidney donor procedure are 
generally minimal and easily remediable (Johnson et al., 1997).  
The current overall complication rate is approximately 2 % (Bia et al., 1995).  
Most complications occur in the perioperative period, with atelectasis, urinary infection, 
wound problems and prolonged bowel dysfunction accounting for the majority.  
One of the most dangerous complications is thrombophlebitis with possible life-threatening 
pulmonary embolus.  
Fatal cases of hepatitis, myocardial infarction and depression, leading to alcoholism have 
been reported.  
Longer term morbidity should be minimal. Endogenous creatinine clearance rates rapidly 
approach 70 to 80 % of the preoperative level, and reports of late renal failure have been 
extremely rare. An important factor is the exclusion during the selection process of 
pathology or potential pathology in the donors. 
The short and long – term morbidity of donor nephrectomy are generally considered to be 
low enough, and probability of successful graft outcome high enough, to make the risks 
acceptable for fully informed donors. 
The decrease of worsening donor and noticeable successful results of transplantation from 
unrelated living donors caused some centres became interested to donation from strangers 
(Spital, 1994). According to our experience, male donors have better prognosis and survival 
compared with females.  
5. Cadaver kidney donor 
If a suitable living donor is not available, most patients with end-stage renal failure should 
be considered for cadaveric renal transplantation, not only because transplantation is more 
cost-effective but also because true rehabilitation seldom is achieved on long-term dialysis 
(Evans et al., 1985). Although the long-term success rates remain inferior to those achieved 
with interfamilial transplantation, projections indicate that cadaver donor allograft currently 
have a 1-year graft survival rate of greater than 85% and graft half-life (time to loss of 50% of 
currently surviving grafts) has improved to at least 10 years (Cecka and Terasaki, 1998).   
Present methods of preservation may permit 72 hours maintenance of the cadaver donor 
kidney in a condition sufficiently viable to allow return of function after revascularization. 
Opportunities are present for evaluation of the physiological and bacteriological condition 
of the donor kidney and for pursuing histocompatility selection after the organ is removed 
from the cadaver. Because of these factors and increasingly widespread establishment of the 
definition of brain death guidelines that allow removal of organs that are more likely to be 
physiologically healthy, cadaver donor renal allograft continue to account for approximately 
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75% of reported transplants. The total number is limited only by the unsolved worldwide 
problem of persisting barriers to organ donation (Cohen et al., 1998). 
6. Evaluation of the potential cadaver kidney donor 
The ideal donor is a young, previously healthy individual who has sustained a fatal head 
injury or cerebrovascular accident.  
Transplantation of kidneys from small pediatric donors is possible, although the technical 
aspects are more exacting. When kidneys are obtained from a pediatric donor less than 3 
years of age, most groups recommend en bloc transplantation of both organs into a single 
adult recipient. We have reported a successful En Bloc bilateral kidney, Aorta, and Vena 
Cava Transplantation from a 3 years old deceased boy to an adult recipient in our center in 
Guilan University of Medical Sciences, Iran. (Fig. 1) (Mokhtari et al., 2010) 
 
Fig. 1. En-bloc kidneys after transplantation (recipient). After irreversibility of brain damage 
is established, maintenance of renal blood flow and function without any complication and 
adequate hydration is important. Minor terminal elevations of blood urea nitrogen and 
creatinine levels are not unusual and do not necessarily exclude the donor.  
A major concern for the donor team is the risk of transmitting infection with the allograft 
into an immunosuppressed recipient. 
Diagnosis of irreversible coma, or brain death, which has been recognized by neurologists 
and neurosurgeons, has presented a set of circumstances that of great potential benefit to 
patients needing organ allografts. The concept and definition of brain death do not depend 
in any way on transplantation.  
The discontinuation of respiratory support and other extraordinary therapy for patients 
who have been declared dead after careful assessment of brain function should be 
considered a humane and necessary act without regard to the possibility of such a person 





After extensive assessment of such patients, neurologists and neurosurgeons universally 
have agreed that once functional death of the brain stem occurs, there is no chance for 
partial recovery, and artificial support should be withdrawn.  
7. Nonhuman kidney donor 
The need for kidneys is growing steadily, whereas organ donation has leveled off or 
decreased in some regions. This situation has resulted in a rapidly escalating demand for 
medical and economic resources to support long-term peritoneal dialysis or hemodialysis 
programs. Because the supply of such resources is limited, constant efforts must be made to 
improve the efficacy and increase the number of transplants performed. The latter is 
determined primarily by the number of donor organs available.  
Nonhuman (xenogenetic) donors represent a possible alternative source of transplantable 
organs. Beginning in the earlry1900s, several isolated attempts were made on to transplant 
kidneys from various animal donors into patients with renal failure. If a successful approach 
to the use of such organs could be established, an unlimited pool of donors free of most of 
the legal and moral issues associated with the use of human organs could be made available. 
The major obstacle to such an approach has been the increased intensity of the rejection 
response elicited by the more diverse genetic relationship between donor and recipient (Ko, 
et al. 2001). 
For several reasons, there is renewed interest in the possibility that xenotransplantation 
could provide the solution for the shortage of human donor organs. The first reason for this 
enthusiasm is the increasingly successful use of genetic engineering to produce transgenic   
animals expressing recombinant molecules designed to moderate the immune response 
(Bhatti et al., 1999; Schmoeckel et al., 1998; Waterworth et al., 1998; Zaidi et al., 1998). 
Another reason for the renewed optimism regarding xenotransplantation has been the 
demonstration in preclinical primate models that tolerance of allograft can be produced 
without the need for long-term immunosuppression (Kirk et al., 1999).   
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1. Introduction 
Urine is the terminal metabolites of bloodstream which is produced by filtration of 
glomerulus, and re-absorption, secretion and excretion of the renal tubule and collecting 
tubule (Figure 1), so that proteins found in serum may also be identified in urinary proteins. 
Urinary composition and properties can reflect the status of the entire urinary system, 
especially the changes in the type and quantity of proteins in the urine that carry 
information of the occurrence and development as well as prognosis of a variety of diseases 
of the urinary system, urine can also reflect relevant situation of other organs of the body. 
The source of urine is simple, convenient and non-invasive, easily accepted by patients, with 
no discomfort and contraindications. Therefore, uroscopy is one of the most common and 
important methods used to diagnose kidney and urinary tract diseases. In this sense, 
urinary proteome analysis can be used for the diagnosis and / or prognosis indicators of 
diseases. 
 
Fig. 1. 70% of the urinary proteins and peptides originate from the kidney and the urinary 
tract, whereas the remaining 30% originates from the circulation (Davis et al, 2001). 
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2. Methods of uroscopy 
For diseases of urinary system, uroscopy is an important basis for diagnosis and is also of 
very important reference value for the diagnosis of certain systemic diseases and diseases of 
other organs of the body which affect the changes of urine, such as diabetes, blood diseases, 
liver and gallbladder diseases, epidemic hemorrhagic fever, etc. Meanwhile, the laboratory 
tests of urine can also reflect the treatment efficacy and prognosis of some diseases.  
2.1 Urine routine examination  
Uroscopy includes items of routine uroscopy, mid-stream urine culture (MSU), urinary 
three cups test, Addis count, quantitative test of urine protein and so on. The usually 
popular saying of "uroscopy" most often refers to routine uroscopy, and it is one of the 
most popular tests of routine examination. The test items included in routine uroscopy are 
visual inspection and biochemical tests, etc., wherein visual inspection refers to directly 
observation of the color and appearance of urine with naked eyes; biochemical tests refers 
to the urinary biochemical tests, which are often carried out with urine analyzer in 
hospital. The test items by urine analyzer are: urine protein, urine sugar, urine three bile 
pigments (urine bilirubin, urobilinogen and urobilin), urine volume, urine ketone, 
urobilinogen, urine specific gravity, and urine sediment. Compared with serum and other 
body fluid samples, the protein composition of urine is relatively simple, stable and easy to 
be analyzed, and can be used for the detection of many human diseases, especially diseases 
of urinary system. Therefore, regular urine examination is of great significance to detect 
urinary tract diseases. 
2.2 Special urine examination 
With the rapid development of molecular biology, the examination methods of urine 
changed from simplification to diversification. For example: 1. ELISA kits for detection of 
HIV antibodies in urine specimens, WB diagnostic kits for detection of HIV-1 antibodies in 
urine; 2. fluorescently labeled DNA probes for detection of the four kinds of chromosomal 
abnormalities associated with bladder cancer; 3. pregnancy test strip for detection of Human 
Chorionic Gonadotropin (hCG); 4. Streptococcus pneumonia antigen detection technique for 
screening of invasive pneumococcal infections; 5 K powder urine test board for detection of 
occult blood; 6 urine test kits for rapid detection of heroin. 
Uroscopy is playing an increasingly important role in the clinical application, and more and 
more attention is being paid to it in product test and product R & D. Therefore, the study on 
urine has become a popular research direction, in which study on urine proteins is 
particularly prominent, including studies on specific proteins and whole proteomics. 
3. Urinary proteomics 
At the same time of proteomics study extensively extending into various fields of the 
medical community, urinary proteomics has also made great progress, and has achieved 
important research results in finding early diagnostic markers of various diseases of urinary 
tract and other systems and exploring the mechanisms of disease development. 
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3.1 Study status of normal urinary proteomics 
In 1996, Marshall et al proposed the concept of urinary proteomics, which is to use the high-
throughput of proteomics technologies and systematically to analyze and identify all 
proteins in urine and study their biological functions. They applied proteomics technologies 
to analyze the composition of normal urinary proteins for the first time. First, normal urine 
was condensed through dye precipitation, and then analysed by 2-dimensional 
electrophoresis (2-DE), but no protein was identified.  
In 1997, Heine et al employed reversed phase chromatography (RP) and ion exchange 
chromatography to purify and separate peptides. Combining with high performance liquid 
chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS), they analyzed 
the spectra of peptides and proteins of normal urine, and 34 high-abundance proteins were 
identified, including albumin, apolipoprotein, immunoglobulin, collagen, procollagen. 
In 2001, Spahr et al identified 751 peptide sequence and 124 proteins using liquid 
chromatography–tandem mass spectrometry (LC-MS/MS). Compared with 2-DE, LC-
MS/MS is much quicker in analysis and identification, but it could not be used to 
quantitatively analyze the difference in protein content between different samples. 
In 2002, Thongboonkerd et al analyzed normal adult urinary proteins isolated by acetone 
extraction and ultracentrifugation using 2-DE, discovered 67 spots by gel imaging, and 
identified 47 proteins by matrix assisted laser desorption ionization/time of flight mass 
spectrometry (MALDI-TOF-MS), including transport proteins, adhesion molecules, 
complement components, molecular chaperones, receptors, enzymes, matrix proteins, and 
signal-related proteins using MALDI-TOF-MS. The proteins and membrane proteins 
isolated by ultracentrifugation in this experiment can not be obtained by conventional 
acetone extraction, indicating that complete urinary protein mapping could not be obtained 
by using a single separation method. 
In 2004, Pieper et al, by combining MALDI-TOF-MS with 2-D LC/ESI-MS/MS, separated 
nearly 140 protein spots and identified 150 unique urinary proteins, a third of which were 
classified as original plasma proteins in circulation. In 2004, Schaub et al analyzed normal 
urine using surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF-MS) and found that there were differences in protein composition for female 
midstream urine and first voided urine samples, while there were no such differences in 
male urine samples. 
In 2004, Weissinger et al analyzed the urinary proteomes of 57 healthy volunteers, 16 
patients with minimal change disease (MCD), 18 patients with membranous 
glomerulonephritis (MGN), and 10 patients with focal segmental glomerulosclerosis (FSGS) 
by capillary electrophoresis mass spectrometry (CE-MS). They identified 173 peptides with 
more than 90% probability, and 690 peptides with more than 50% probability from healthy 
individuals. Based on these data, they established a "normal" polypeptide pattern in healthy 
individuals. Peptides found in the urine of patients differed significantly from the normal 
controls. These differences allowed the distinction of specific protein spectra in patients with 
different primary renal diseases.  
In 2004, Oh et al carried out proteomics analysis on the urine of 40 healthy adults (equal 
number of male and female) after precipitation trichloroacetic acid. In addition to some 
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potential-dependent protein spots, the urinary protein spots on 2-DE gel of male and female 
were almost identical (Figure 2), which can be used as standard 2-DE urinary protein 
profiles, providing a foundation for analyzing and looking for novel specific biomarkers for 
diseases in the future. 
 
Fig. 2. Comparison of (A) female and (B) male urinary proteins separated on 2-D gels. Male 
and female specific proteins are indicated with circles (Oh et al,2004). 
In 2005, Sun et al identified 226 special urinary proteins in combination 1-DE with 1-D 
LC/MS/MS, 1-D LC/MS/MS, or 2-D LC/MS/MS, and discussed the proteins identified by 
different methods. In 2005, Castagna et al confirmed 383 special gene products from urinary 
proteins enriched on coating beads with hexamer peptide ligand library in combination 
with linear ion trap-Fourier transform mass spectrometry (LTQ FTMS). 
In 2006, Adachi et al employed 1-D sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and RP-HPLC for protein separation, and then used LTQ FTMS 
and LTQ Orbitrap-MS to analyze trypsin digested pepdides. Finally, 1543 proteins and their 
fragments were identified in the urine of healthy individuals. Further research showed that 
most of the proteins in the urine were membrane proteins, which may derive from external 
secretion. In 2010, Li et al identified 1310 non-redundant high-confidence proteins using 
integrated multidimensional liquid chromatography (IMDL) and multidimensional liquid 
chromatography (MDLC). 
In summary, good results have been achieved in normal urinary proteomics, the proteome 
profiles of healthy population have been gradually improved and supplemented. At the 
same time, the methods and techniques for urinary proteomics have also been further 
developed and optimized. However, the identification consistency of normal urine proteins 
by researchers is low, and the reliability of the results remains to be verified. The 
establishment of profiles of normal urinary proteomes plays an important role in screening 
different markers of urine differentiation for a variety of disease states. 
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3.2 Urinary proteomics technologies 
The commonly used technologies for protein isolation and identification in urinary 
proteomics include SDS-PAGE, 2-DE, LC-MS, SELDI-TOF-MS, CE-MS (Figure 3,Figure 4). 
Currently, proteomics technologies have been extensively used in clinical diagnosis and 
various fields of biological study. 
 
Fig. 3. Proteome analysis of urine requires fractionation to reduce complexity of the sample. 
1 Fractionation can be obtained by different chromatographic techniques or by the specific 
absorption of a set of proteins on a surface. 2 These fractions are subsequently analyzed by 
MS where the relative abundance of the different proteins and peptides is determined.  
3 Informatics treatment of the protein data in combination with the fractionation (example: 
migration time on a capillary or LC column) parameters yields protein profiles representing 
the (partial) proteincontent of samples. SELDI-TOF-MS, 2-D-PAGE (Caubet et al, 2010). 
 
Fig. 4. Schematic summary of methodologies and applications of renal and urinary 
proteomics. 2-D PAGE; LC-MS/MS, SELDI-TOF-MS; CE-MS. (Thongboonkerd , 2010) 
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3.3 Significance and problems of urinary proteomics  
Urinary proteomics related to the huge protein networks has exhibited widely application in 
many areas. The therapeutic intervention target molecules have demonstrated a valuable 
impact for the diagnosis and treatment technology, and have become a powerful weapon for 
clarifying the mechanisms, diagnosis, prevention and control of major human diseases. 
Although rapid developments have already been achieved in urinary proteomics 
technologies, some urgent problems still need to be solved, such as (1) the low amount of 
proteins in normal urine, imperfect enrichment techniques, and different urinary protein 
sample preparation methods, which can affect the isolation and identification of urinary 
proteins; (2) the determination of the best collection time of urine samples:  the available 
studies have shown that urinary proteins in urine samples collected at different times show 
significant difference; (3) the elimination of various ions and high-abundance proteins 
without losing low-abundance proteins; (4) the analysis of extremely acidic, alkaline, small, 
large, low-abundance, and highly hydrophobic proteins using proteomics technologies; (5) 
the lack of adequate standard urine profiles for different diseases, and the further 
improvement of urinary protein data and bioinformatics; (6) the establishment of standard 
urine protein preparation and analytical methodology. 
The broad prospects of urinary proteomics are beyond doubt, and urinary proteomics 
involves a large network of proteins, with the continuous development of science and 
technology of today, the above problems will gradually be resolved. 
4. Urinary proteomics and diseases 
With the development of front research in life sciences and the emergence of cutting-edge 
new technologies, proteomics has entered into a brand new era of studying functional 
proteomics in large scale and high-throughput, and could play an important role in the 
study of major diseases. Back in the late 1990s, people have begun to identify urinary 
proteins. The available studies have shown that survivin and cox2-2 proteins in urine are 
valuable for the diagnosis of early bladder cancer; transforming growth factors TGF-β1 and 
laminin (LN) have some relevance to breast cancer; the detection of podocalyxin has a very 
important diagnostic value for early renal damage in diabetic patients; AQP-2 protein plays 
a key role in water metabolism disorder in patients with liver cirrhosis; AQP-2 has 
diagnostic value in hypertension. Studies on disease biomarkers are the most popular 
hotspot in urinary proteomics. 
4.1 Developmental trend of urinary proteomics in renal diseases  
As early as the 1990s, researchers have begun urinary proteomics in renal diseases, and have 
found some special diagnostic biomarkers and characteristic spectra. Compared with 
traditional methods, diagnostic specificity was greatly improved, and these methods were 
easily accepted by patients. In renal diseases, such as renal cancer, glomerular disease, acute 
renal transplantation rejection, researchers have already begun urine diagnostic biomarker 
related study. But no significant achievement and dramatic breakthrough were reported. 
Therefore, researchers need make more efforts to actively promote the progress of research 
in this area.  
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The identification of urinary proteomes shows great potential in diagnosis and monitoring 
of renal diseases, and is the important direction of developing non-invasive diagnosis and 
monitoring for renal diseases. Another important goal for proteomic research is to apply 
newly discovered biomakers into clinical laboratory testing. This method is convenient, 
rapid, repeatable, and non-invasive. The entire process only takes 3 to 4 hours, greatly 
reducing the time for histopathologic examination, which makes great contribution to 
improve the post-operative care level after renal transplantation. Renal transplantation was 
the earliest developed and also the most mature organ transplantation currently, which 
provides a second life chance for patients with advanced renal failure. However, 
transplantation rejection is still an insurmountable obstacle in the field of transplantation. 
4.2 Renal transplantation and acute rejection  
Acute rejection (AR) is the most common form rejection in clinical. It can occur at any time 
after renal allograft transplantation, but mostly occurs in the 3 months after transplantation, 
while within the first month is the most common. AR is not only a vital factor to influence 
the long-term survival of the kidney transplanted, but also the major reason to cause the 
early graft damage, long-term graft dysfunction, and chronic graft nephropathy. Until now, 
to carry out transplantation renal biopsy and pathological histology is the only way to 
confirm definite diagnosis. However, these methods cause not only pain in patients but also 
a certain degree of renal damage. Furthermore, rejection is a continuous biological process 
occurred under the use of immunosuppressant, and the diagnosis by renal biopsy is only 
based on the tissue samples at a certain time. For some patients, immunological changes 
could not be observed in rejection even if a pathological examination has been carried out 
and it is difficult to differentiate from the damages caused by the use of 
immunosuppressant, and the diagnosis takes two to three days. Thus, it is urgently need a 
frequently used and non-invasive detection method for early detection of markers of 
allograft damages. 
4.3 Acute renal allograft rejection status of proteomics  
Clarke et al analyzed the urinary proteins from renal transplantation patients with AR (17 
recipients) and without rejection (15 recipients) using SELDI-TOF-MS. Significant 
differences were observed at 6.5KD, 6.7 KD, 6.6 KD, 7.1 KD and 13.4 KD between the two 
groups, while 10.0 KD and 3.4 KD were found to have a sensitivity of 83% and a specificity 
of 100% in diagnosing AR. It was also found that several groups of proteins specifically 
appeared in the urine of AR patients, which are likely to serve as diagnostic markers of AR. 
O’Riordan et al studied the urine of renal transplantation patients using SELDI-TOF-MS. 3 
proteins with peak value at 4.7kDa, 25.6kDa and 19.0kDa, sensitivity between 90.5 % ~ 
91.3% and specificity between 77.2 % ~ 83.3 %, were screened out, which could serve as 
important biomarkers for distinguishing of AR patients from stable renal function patients. 
For the follow-up study, two peptides, ß-defensin -1 (4.7KD) and Alpha 1-antichymotrypsin 
(4.4KD), were indentified. Compared with patients with stable renal function after 
transplantation, ß-defensin -1 decreased in the urine of AR patients while Alpha 1-
antichymotrypsin increased (P < 0.05). The study showed that the ratio of ß-defensin -1 and 
Alpha 1-antichymotrypsin in urine might be a potential new biomarker for diagnosing AR 
after renal transplantation. 
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3.3 Significance and problems of urinary proteomics  
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many areas. The therapeutic intervention target molecules have demonstrated a valuable 
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The identification of urinary proteomes shows great potential in diagnosis and monitoring 
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and it is difficult to differentiate from the damages caused by the use of 
immunosuppressant, and the diagnosis takes two to three days. Thus, it is urgently need a 
frequently used and non-invasive detection method for early detection of markers of 
allograft damages. 
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Clarke et al analyzed the urinary proteins from renal transplantation patients with AR (17 
recipients) and without rejection (15 recipients) using SELDI-TOF-MS. Significant 
differences were observed at 6.5KD, 6.7 KD, 6.6 KD, 7.1 KD and 13.4 KD between the two 
groups, while 10.0 KD and 3.4 KD were found to have a sensitivity of 83% and a specificity 
of 100% in diagnosing AR. It was also found that several groups of proteins specifically 
appeared in the urine of AR patients, which are likely to serve as diagnostic markers of AR. 
O’Riordan et al studied the urine of renal transplantation patients using SELDI-TOF-MS. 3 
proteins with peak value at 4.7kDa, 25.6kDa and 19.0kDa, sensitivity between 90.5 % ~ 
91.3% and specificity between 77.2 % ~ 83.3 %, were screened out, which could serve as 
important biomarkers for distinguishing of AR patients from stable renal function patients. 
For the follow-up study, two peptides, ß-defensin -1 (4.7KD) and Alpha 1-antichymotrypsin 
(4.4KD), were indentified. Compared with patients with stable renal function after 
transplantation, ß-defensin -1 decreased in the urine of AR patients while Alpha 1-
antichymotrypsin increased (P < 0.05). The study showed that the ratio of ß-defensin -1 and 
Alpha 1-antichymotrypsin in urine might be a potential new biomarker for diagnosing AR 
after renal transplantation. 
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To use SELDI-TOF-MS, Schaub et al found three peak clusters in 17 AR patients among 18 
renal transplant patients, four out of 22 stable transplant patients, zero out of 28 control 
patients. The follow-up study showed that theses peak clusters derived from non-trypsin 
attached from of urine ß2-micglobulin (ß2-m). Thus, ß2-m may be use as acute tubular 
injury biomarker, becoming one of the standards of non-invasive early AR diagnosis. 
Reichelt et al analyzed the urine of 13 renal biopsy confirmed AR patients and 10 renal 
transplant patients without pathological symptom of rejection by using SELDI-TOF-MS, and 
two biomarkers, 25.71kDa and 28.13kDa, were found, the diagnostic sensitivity was 90% 
and 93% respectively, and the specificity was 80% and 85% respectively. SELDI-TOF-MS 
appears to be a promising new diagnostic tool for distinguishing renal transplant patients 
with AR from those without rejection or healthy volunteers. 
Jia et al chose urine as the object to find biomarkers for AR using 2-DE-MS and Westernblot 
assay. They obtained 30 protein spots with significant decline trend by MS, and identified 16 
protein spots. Among them, three proteins, alpha-1-antichymotrypsin, tumor rejection 
antigen gp96, and Zn-Alpha-2-Glycoprotein associated with immune rejection, which may 
be candidate biomarkers for early clinical diagnosis of AR after renal transplantation.  
Freue et al studied the plasma proteome collected from 32 patients with and without renal 
biopsy confirmed AR after renal transplantation using iTRAQ-MALDI-TOF/TOF. They 
found that 18 plasma proteins to be related to inflammation could be potential plasma 
biomarkers. Plasma biomarkers may be used to monitor post-transplant and permit 
effectively therapeutic intervention to minimize graft damage. 
A large number of studies showed that some special biomarkers found in the urine of 
patients with AR after renal transplantation had a certain degree of reproducibility. 
However, above mentioned studies still need to design reasonably to improve the sensitivity 
and specificity of the results so that these potential biomarkers could be used for clinical 
screening.   
4.4 Proteomics in AR in renal transplantation and current problems  
Renal transplantation is the main way to treat end-stage renal diseases. With the application 
of immunosuppressant, the survival rate for renal transplantation has been increased step 
by step. However, there is still rejection after renal transplantation. Currently, renal biopsy 
is still the main basis for diagnosis, but mostly biopsy is only carried out when symptoms 
occur to the patients, diagnosis can not be made in advance, and there are some risks for 
renal biopsy itself. The ideal way is to find some specific indicators in urine or blood to 
make diagnosis. The advantage of this kind of diagnosis is that it is non-invasive, and the 
change of some biological indicators in body fluid appeared earlier than clinical symptoms, 
so diagnosis can be made in advance by taking advantage of these indicators. Even if 
urinary proteomics can not completely replace renal biopsy to become a “golden standard”, 
it may still be used as an early screening tool so that renal biopsy will be minimized and 
unnecessary renal biopsy will be avoided. Taking into consideration of the high cost of 
protein analysis, the proteins identified in different laboratories still need to be further 
confirmed. Thus, the use of urinary proteins to monitor patients of renal transplantation is 
difficult to be carried out clinically within a short period of time. 
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5. Developmental direction of proteomics  
With the rapid development of proteomics and its extensive application in many areas, 
proteomics technologies have been applied to a variety of life sciences. Proteomic research 
subjects include prokaryotic microorganisms, eukaryotic microorganisms, plant, animals, 
and human being, involving many important biological phenomena, such as signal 
transformation, cell differentiation, and protein folding. Therefore, the new research 
direction is the inexorable development trend of proteomics. 
5.1 Quantitative proteomics 
At present, life sciences have entered the post-genomic era. The research focuses have 
shifted from the discovery of genetic information to functional analysis, attempting to 
qualitatively and quantitatively study the full set of proteins of a certain biological sample 
expressed under specific conditions. It is a research hotspot in post-genomic era. With the 
continuous deepening of research and development of experimental techniques, 
quantitative proteomics has become hot research topics. The focus of quantitative 
proteomics is the accurate quantitation of the complex proteins from biological samples. For 
special proteomes, their physical and chemical properties are highly complicated because 
the dynamic range of protein expression is large. Thus high-throughput and high sensitivity 
experimental platform, represented by biological mass spectrometry, is the effective means 
and key technology for proteomics research. 
The performance indicators of biological mass spectrometry, such as resolution, sensitivity, 
speed, accuracy, reproducibility, and dynamic range, have continuously improved as the 
development of proteomics. However, technological advances could not solve all the 
problems. Furthermore, complex steps are used from sample preparation to data analysis, 
which will introduce not ignorable system errors, and as well as seriously affect the accuracy 
of quantitative analysis. Currently, the analysis strategies of quantitative proteomics based on 
biological mass spectrometry are as follows: fluorescent two-dimensional difference gel 
electrophoresis (2-D DIGE), isotope coded affinity tagging (ICAT), isobaric tags for relative 
and absolute quantitation ( iTRAQ), stable isotope labeling with amino acids in cell culture 
(SILAC), chemical labeling with amino acids, and comparison of the difference of peptide 
mass spectra. Quantitative methods include relative and absolute quantitation. Relative 
quantitative proteomics, also known as comparative proteomics, refers to the comparative 
analysis of relative changes of protein expression in cells, tissues or body fluids under different 
physiological and pathological conditions. Absolute quantitative proteomics is to determine 
the quantity or concentration of each protein in cells, tissues or body fluids. Absolute 
quantitation of proteins is a method to compare particular peptide elements of a sample 
against a spiked in isotopic labeled synthetic analogue.  
Proteomics quantitative information can be used to understand the functions of proteins in 
interaction network. The analysis of the absolute amount of clinical biomarkers could help 
us determine the occurrence and development of diseases, and this provides practical 
guidance for the clinical diagnosis and treatment of diseases. 
5.2 Phosphoproteomics 
Recently, protein post-translational modification has gradually become one of research 
hotspots in proteomics. Protein phosphorylation is a reversible post-translational  
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by step. However, there is still rejection after renal transplantation. Currently, renal biopsy 
is still the main basis for diagnosis, but mostly biopsy is only carried out when symptoms 
occur to the patients, diagnosis can not be made in advance, and there are some risks for 
renal biopsy itself. The ideal way is to find some specific indicators in urine or blood to 
make diagnosis. The advantage of this kind of diagnosis is that it is non-invasive, and the 
change of some biological indicators in body fluid appeared earlier than clinical symptoms, 
so diagnosis can be made in advance by taking advantage of these indicators. Even if 
urinary proteomics can not completely replace renal biopsy to become a “golden standard”, 
it may still be used as an early screening tool so that renal biopsy will be minimized and 
unnecessary renal biopsy will be avoided. Taking into consideration of the high cost of 
protein analysis, the proteins identified in different laboratories still need to be further 
confirmed. Thus, the use of urinary proteins to monitor patients of renal transplantation is 
difficult to be carried out clinically within a short period of time. 
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and human being, involving many important biological phenomena, such as signal 
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modification which plays an important role in cell proliferation, cell differentiation, cell signal 
transduction, regulation, transcription and translation, protein complex formation, and 
protein degradation. Therefore, the identification of phosphorylated proteins is an important 
part of research on post-translational modification. However, it is difficult to use mass 
spectrometry to directly detect phosphorylated proteins because of their low abundance. To 
solve this problem and enhance the signal response of phosphorylated peptides/proteins in 
mass spectra, we need to enrich phosphorylated peptides/proteins. The widely used and 
newly established isolation and enrichment methods of phosphoproteomics mainly include: 
antibody enrichment, kinase-specific enrichment, affinity enrichment, chemical modification, 
multi-chromatography separation and enrichment. 
Li et al identified 31 phosphorylated proteins and 51 specific peptides from normal urine 
using proteomics methods. The rapid development of quantitative phosphoproteomics 
methods and technologies has laid a solid foundation for the study of spatial and temporal 
dynamics of protein phosphorylation and better understanding of biological functional of 
regulatory networks. As an important part of proteomics research, quantitative 
phosphoproteomics will meet great challenges in technologies and methods because of the 
unique characteristics of phosphorylated proteins. Phosphoproteomics will become an 
important study direction in the future. 
5.3 Glycoproteomics 
Glycosylation is one of the most common and important post-translational modification of 
proteins. It is currently known that at least one half of mammal proteins are glycoprotein, 
which widely distributed in various cells and tissues, especially abundant in the cell surface 
and body fluids. Protein glycosylation has important biological functions, such as 
participation in cell adhesion and signal transformation, influence on the secretion and 
stability of proteins, elimination of the aging proteins in plasma, immune and inflammatory 
response, and recognition of egg and sperm. Protein glycosylation is of great significance in 
diseases, especially in the occurrence, development and metastasis of tumors. In a particular 
state, the amount of glycoprotein and /or the change of sugar chain structure of 
glycoprotein reflect the change of physiological or pathological states, such as the 
autoimmune diseases caused by sugar chain abnormity of immunoglobulin (Ig), rheumatoid 
arthritis, IgA nephropathy, thyroiditis, systemic lupus erythematosus, and AIDS. 
In 2006, Wang et al identified 225 glycoprotein enriched by ConA lectin from the urine of 
normal young volunteers using LTQ. Currently the discovered biomarkers of a variety of 
known diseases are glycoprotein, such as prostate specific antigen which could serve as 
suggestive biomarker for prostate cancer, tumor antigen CA125 etc.  
Hence, researches on glycoprotein have great biological significance and application 
prospect. Glycoproteomics has begun to attract more and more attention. In recent years, 
with the rapid development of proteomics technologies, glycoproteomics has also gained 
considerable progress. At current stage, researches on glycoproteome are mainly focused on 
the development and utilization of methodology. The existing enrichment methods, such as 
lectin affinity chromatography, solid phase capture based on chemical reaction, are 
relatively mature, and are currently the most widely applied methods for glycoprotein 
enrichment. Although the research methods of glycosylation sites have been improved 
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gradually, to solve the main problems existed still depends on the further development of 
mass spectrometry. We believe that, as the development of technologies, glycoproteome will 
play a greater role in further improvement of proteome expression, the discovery of 
biological markers in disease proteomics, and the research of drug targets. 
6. Conclusion 
For many patients with end-stage renal failure, renal transplantation is their first choice, the 
prognosis is good, but long-term survival rate has not yet achieved great improvement. 
Each patient should insist on taking immunosuppressant after renal transplantation, which 
is essential for the long-term prognosis of renal transplantation. Therefore, it is urgently 
needed for a non-invasive testing method to be used repeatedly for the early detection of 
biomarkers of allograft injury. Although current diagnostic methods have made some 
progress, none of them is absolutely reliable for clinical application. The combined 
application of many methods may lead to the increase of the diagnostic sensitivity and 
specificity. Its exact clinical application value needs to be further confirmed. In short, new 
diagnostic methods will continue to emerge as the development of technologies. Timely and 
accurate detection of AR through non-invasive or low-invasive methods is the future 
research direction. Although some progress has already made in this area, there is still no 
reliable, less invasive, and costless method that can be applied to clinical practice.  Urinary 
proteomics technologies have the potential to reveal the complex pathophysiology, and are 
expected to become a powerful tool to solve this problem. Researches based on large scale 
samples are expected to provide proof for clinical application. 
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progress, none of them is absolutely reliable for clinical application. The combined 
application of many methods may lead to the increase of the diagnostic sensitivity and 
specificity. Its exact clinical application value needs to be further confirmed. In short, new 
diagnostic methods will continue to emerge as the development of technologies. Timely and 
accurate detection of AR through non-invasive or low-invasive methods is the future 
research direction. Although some progress has already made in this area, there is still no 
reliable, less invasive, and costless method that can be applied to clinical practice.  Urinary 
proteomics technologies have the potential to reveal the complex pathophysiology, and are 
expected to become a powerful tool to solve this problem. Researches based on large scale 
samples are expected to provide proof for clinical application. 
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1. Introduction 
The demand for kidneys for transplantation has increased significantly in recent years. This 
increase is, at least in part, due to improvements in therapies that minimize tissue rejection, 
as well as to more inclusive selection criteria for kidney recipients. The high demand for 
organs also places challenges on surgeons, requiring them to be familiar with more diverse 
sources of organ donors. Currently, there are three main sources of kidneys for explantation: 
cadaveric donors with brain death, non-heart-beating donors, and live donors. 
Kidney explantation from a cadaveric donor with brain death can be performed following 
one of two main approaches: 1) multi-organ explantation using the classic technique or with 
total abdominal evisceration, or 2) by explanting the kidneys only.  
In renal explantation from non-heart-beating donors two techniques can be applied: in situ 
perfusion or cooling of the body with cardiopulmonary bypass.  
To obtain a kidney from a live donor, either traditional open surgery or laparoscopy is 
performed. The latter can be carried out in a transperitoneal or retroperitoneal fashion, with 
endless variations that take advantage of recent technological improvements. 
Surgical transplantation teams within medical institutions should be capable of performing 
renal explantation from both cadaveric and live donors, and should have in place 
organizational strategies that are most appropriate for each particular case, complying with 
the following: 
1. Simplicity; the procedures should be easy to perform. 
2. Effectiveness; the procedures should best preserve the integrity of the organs. 
3. Efficiency; the procedures are carried out using only those resources that are strictly 
necessary. 
This chapter describes each one of the renal explantation techniques, as well as the back-
table procedures, i.e. preparation of the renal graft after explantation for further 
implantation of the organ in the recipient. 
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1. Introduction 
The demand for kidneys for transplantation has increased significantly in recent years. This 
increase is, at least in part, due to improvements in therapies that minimize tissue rejection, 
as well as to more inclusive selection criteria for kidney recipients. The high demand for 
organs also places challenges on surgeons, requiring them to be familiar with more diverse 
sources of organ donors. Currently, there are three main sources of kidneys for explantation: 
cadaveric donors with brain death, non-heart-beating donors, and live donors. 
Kidney explantation from a cadaveric donor with brain death can be performed following 
one of two main approaches: 1) multi-organ explantation using the classic technique or with 
total abdominal evisceration, or 2) by explanting the kidneys only.  
In renal explantation from non-heart-beating donors two techniques can be applied: in situ 
perfusion or cooling of the body with cardiopulmonary bypass.  
To obtain a kidney from a live donor, either traditional open surgery or laparoscopy is 
performed. The latter can be carried out in a transperitoneal or retroperitoneal fashion, with 
endless variations that take advantage of recent technological improvements. 
Surgical transplantation teams within medical institutions should be capable of performing 
renal explantation from both cadaveric and live donors, and should have in place 
organizational strategies that are most appropriate for each particular case, complying with 
the following: 
1. Simplicity; the procedures should be easy to perform. 
2. Effectiveness; the procedures should best preserve the integrity of the organs. 
3. Efficiency; the procedures are carried out using only those resources that are strictly 
necessary. 
This chapter describes each one of the renal explantation techniques, as well as the back-
table procedures, i.e. preparation of the renal graft after explantation for further 
implantation of the organ in the recipient. 
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2. Renal explantation from cadaveric donor with brain death 
Renal explantation from a cadaveric donor with brain death may be performed during 
multi-organ extraction using the traditional technique or with total abdominal evisceration. 
Modifications to these techniques, such as quick removal or combined liver-pancreas 
explantation do exist, but their detailed description is beyond the scope of this chapter.  
Exclusive renal explantation from a cadaveric donor with brain death can also be 
performed, if necessary, when limitations exist due to special circumstances, including: 
1. The quality of the facilities available 
2. The specific guidelines of different organ transplant programs. 
3. The viability of other organs in the cadaveric donor. 
4. The need for further approval procedures for the removal of certain organs. 
All surgical organ explantation procedures on cadaver must meet the following basic 
principles: 
1. Adequate exploration and dissection to detect anomalies. 
2. Cannulation and perfusion with preservation fluids in situ. 
3. Extraction without damage to organs and with unscathed vascular pedicles. 
2.1 Classic multi-organ explantation 
This technique was described in 1984 by Starzl, and is based on the dissection of all of the 
organ vascular pedicles, prior to their perfusion, such that explantation takes place shortly 
after perfusion. In general, this technique is carried out by independent surgical teams, with 
one team per organ. It is essential that all surgeons adhere to the pre-approved procedures, 
with the following order of participation: 
Cardiac Surgery Team 
Lung Surgery Team 
Liver Surgery Team 
Pancreatic Surgery Team 
Renal Surgery Team 
Corneal Team 
Musculoskeletal Team 
2.1.1 Description of the classical multi-organ extraction technique 
The donor is placed in the supine position with arms in forced abduction. A nasogastric tube 
and a Foley catheter in urethra are placed. Body hair shaving and antisepsis are performed 
from chin to mid-thigh. Sterile drapes are placed, and two suction devices are installed, one 
for the thoraxic phase and a second one for the abdominal phase. Six thousand (6000) cc of 
preservation fluid should be available, at a temperature of 0 to 4 º C, as well as sterile 
crushed ice. The cardiac or hepatic team starts the surgery by performing a sternotomy and 
an incision from the xiphoid process to the pubis, with or without bilateral subcostal 
extension (Fig. 1), allowing access to all thoracic and abdominal organs. After opening the 
peritoneum, the round ligament is transected and ligated, and the falciform ligament is 
sectioned with electrocautery until the origin of the right and left triangular ligaments is 
reached. 
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In the thoracic phase, a perfect hemostasis of the sternal branches should be accomplished 
when performing the sternotomy. A Finochietto sternal retractor is put in place before 
sectioning both pleurae vertically. A short right and left frenectomy improves thoracic and 
abdominal removal. This is done with electric scalpel, while the lung, pericardium and liver 
are protected by the hands of the assistant. The opening of the pleura is useful for correction 
of a possible hypoventilation. 
 
Fig. 1. (A) Sternotomy and midline laparotomy with (I) or without (II) bilateral subcostal 
extension. (B) Exposure of the thoracoabdominal organs. 
The cardiac team opens the pericardium and inspects the heart for vascular or contractility 
abnormalities. If the organ is deemed adequate for transplantation the team informs the 
transplant coordinator, such that logistic arrangements related to transplantation 
procedures can be followed. 
The hepatic team inspects the liver, assessing its consistency, color, presence of trauma or 
other pathology, and the presence of possible vascular abnormalities, especially arterial 
abnormalities. When applying digital pressure on the parenchyma, a healthy liver rapidly 
regains its color; when this does not happen, a biopsy will be needed to evaluate steatosis. 
Injury in more than 60% of the hepatocytes indicates a greatly increased risk of primary 
dysfunction of the organ, and thus it is rejected for explantation. If after performing this 
inspection the liver is considered viable for transplantation, the procedure continues and the 
transplant coordinator is informed. The ascending colon is greatly mobilized by sectioning 
the right parietocolic and a Kocher maneuver is performed to access the abdominal aorta 
and inferior vena cava, both of which are dissected and controlled with a thick ligation on 
their caudal origins (Fig. 2). The inferior mesenteric artery is tied and sectioned. 
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The pancreatic team sections the gastrocolic ligament and obtains hemostasis by successive 
ligations, from the right to the left colic flexures, along the greater curvature of the stomach. 
To the left this maneuver is continued with section of the gastrosplenic ligament and of the 
short vessels. This allows uncovering of the omentum and exposure of the tail of the 
pancreas, which can be explored. A normal pancreas has a yellow-orange coloration, is 
flexible and presents little or no edema. A significant peripancreatic edema that dissects the 
glandular lobes points to an initial acute pancreatitis, which rules out the explantation of the 
pancreas. After hanging down the right and left colonic flexures, the vascular pedicles of the 
mesocolon are dissected and sectioned at their origin, between two ligatures. This maneuver 
allows the lowering of the colonic frame and exposure of the entire pancreas (Fig. 3). 
 
Fig. 2. Kocher maneuver, access to the abdominal aorta and inferior vena cava. 
 




Fig. 3. Downward displacement of the colon, exposing all of the subdiaphragmatic organs. 
The hepatic team intervenes further; it identifies and dissects the superior mesenteric artery 
from its aortic origin to about 3-4 cm distally, to check for the possible presence of an 
anomalous right hepatic artery. The elements of the hepatic hilum are dissected and the left 
gastric artery is dissected in search of a left hepatic artery. The left triangular ligament is 
transected with electrocautery and the left lobe of the liver is moved to the right. A 
dissection of the supraceliac abdominal aorta is performed, sectioning the right crus of the 
diaphragm. Once it has been surrounded, the aorta is controlled with a tourniquet, for its 
subsequent clamping. The gallbladder is opened and rinsed with saline solution. 
After the dissection of all of the vascular elements described above, heparinization of the 
cadaver takes place, by the administration of 300 U/kg of intravenous heparin. Cannulation 
of the inferior mesenteric vein is performed just below the inferior edge of the pancreas, at 
about 2 cm, using a probe of 18 to 20 Frens. The end of this probe is placed at the origin of 
the portal vein, firmly fixing it to the vein above and below its point of entry. Cannulation of 
the abdominal aorta is performed just above the iliac bifurcation, with a 24 Frens probe in 
adults and a 16 Frens probe in children. Similarly, cannulation of the vena cava is 
performed, to allow for venous drainage, thus preventing edema of various organs and 
facilitating their cooling. 
The cardiac team simultaneously cannulates the ascending aorta and the pulmonary artery, 
through cardioplegia and pulmoplegia needles, respectively. The cardiac team then clamps 
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the thoracic aorta, while the supraceliac aorta is clamped by the hepatic team. The perfusion 
of the abdominal organs is initiated by means of the cannulas located in the aorta and 
inferior mesenteric vein, while the cardioplegic perfusion starts through the ascending aorta, 
and the pulmoplegic perfusion through the pulmonary artery (Fig. 4). Six thousand (6000) cc 
of preserving solution is commonly used: 1000 cc in the ascending aorta, 1000 cc in the 
pulmonary artery, 2000 cc in the abdominal aorta, and 2000 cc in the inferior mesenteric 
vein. 
 
Fig. 4. In situ hypothermic perfusion. 
At this point the mechanical ventilator is disconnected from the endotracheal tube. Once the 
thoracic aorta is occluded, the decompression of the heart chambers is performed via the 
inferior vena cava, by partially severing the left atrial appendage. The lack of a "universal" 
preservation solution makes it necessary to separate the cooling territories of heart, lungs 
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and abdominal organs. The thoracic and abdominal cavities are simultaneously irrigated 
with crushed ice to further accelerate the cooling. 
The cardiac team removes the heart, severing the pulmonary veins, the superior and inferior 
vena cava, the aorta, and the pulmonary arteries. Special care should be taken with the 
section of the pulmonary artery, as there should be enough tissue left in both the lung and 
heart grafts. 
The pulmonary team sections the pericardium up to the pulmonary hilum, leaving wide 
margins. The trachea is clamped as proximally as possible, and a staple line is placed above 
the 5th tracheal ring (6-8 cm). The trachea is then sectioned between the clamp and the staple 
line. The triangular ligaments are severed on both hemithorax, as well as the posterior 
mediastinal soft tissue, allowing the explantation of the lungs as a block. 
After removing the heart and lungs, the hepatic team waits until the liver is adequately 
perfused. This is apparent by the discoloration of the organ, and should take approximately 
10 to 15 minutes. The removal of the liver depends intimately on that of the pancreas, 
because the arteries of these organs originate from a common celiac trunk. Additionally, 
when a right hepatic artery originates from the superior mesenteric artery, the latter is also a 
common origin for both hepatic and pancreatic vessels. The issue that arises is whether the 
celiac trunk should accompany the liver or the pancreas. It all depends on the distribution of 
the arteries of the liver. If one right and one left hepatic arteries do exist, taking the celiac 
trunk with the liver may allow taking of the gastrohepatic trunk to the potential 
implantation site for the right hepatic artery (gastroduodenal stump or splenic ostium). 
The gastroduodenal artery and the common bile duct are transected at the level of the 
duodenum, so that the portal vein is exposed. The perfusion of the inferior mesenteric vein 
is stopped, the cannula is withdrawn and the vein is tied along the bottom edge of the 
pancreas. The portal vein is transected. If the celiac trunk accompanies the liver, the aorta is 
transected between the origin of the celiac trunk and the superior mesenteric artery; the axis 
of the section should be very oblique, upwards and backwards, to avoid the risk of injury to 
a renal artery. The infrahepatic vena cava is transected just above the confluency of the renal 
veins. The right diaphragm and retrocaval tissue are sectioned, which exposes the whole 
liver and allows its extraction. 
The pancreatic team rejoins the surgical field and transects the duodenum between two 
rows of surgical staples (TA55) immediately below the pylorus and then at the angle of 
Treitz. The superior mesenteric pedicle is tied and severed at the bottom edge of the third 
duodenal portion. The origin of the superior mesenteric artery is freed from its lymphatic 
surroundings and is meticulously tied because it can be the source of considerable 
lymphatic leakage on the revascularized graft. The superior mesenteric artery is sectioned at 
the level of the aorta, becoming free of the pancreas. 
Once the heart, lungs, liver and pancreas are explanted from the cadaver, the renal team 
gets involved. The perfusion of preservation solution to the kidneys can be maintained 
throughout the previous phase, to avoid heating and thereby injury. Both ureters are 
dissected and sectioned at their distal end, close to the bladder. The aorta and inferior vena 
cava are sectioned distally to the insertion of the perfusion cannulas. All lumbar vessels and 
retroaortic tissue are sectioned in a cranial direction. Finally, the adhesions of the kidneys to 
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throughout the previous phase, to avoid heating and thereby injury. Both ureters are 
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the retroperitoneum are sectioned. This fully releases the kidneys, which can then be 
extracted for subsequent packaging in preservation solution and back-table preparation. 
After all useful organs have been explanted, the following tissues are also recovered: iliac 
vessels that may be needed for vascular reconstruction of both the liver and kidneys, and 
spleen material for Human Leukocyte Antigen (HLA) system studies. At this time the 
corneal team intervenes, and finally the musculoskeletal team. At some facilities skin is also 
removed, and this is the last explantation procedure to be performed. 
The reconstruction of the cadaver must be very careful. This step is as important as any of 
the above, as it is essential to preserve the dignity and integrity of the cadaver (Fig. 5). This 
procedure should allow delivering of the body of the donor in the following fashion: 1) all 
incisions performed for the removal of organs and tissues should be sutured, 2) no tubes or 
catheters should remain, 3) the body should be clean, with particular care in removing all 
blood stains, 4) the eyes should be closed, 5) limbs from where skeletal or muscle tissue was 
explanted should be properly covered, 6) a sign should be placed indicating whether 
skeletal or muscle tissue was obtained, and that prostheses were placed accordingly, 7) the 
body should be covered with a sheet or placed inside a bag. 
 
Fig. 5. Dignity of the cadaver. 
2.2 Total abdominal evisceration  
Developed by Nakazato in 1992, this technique is based on the minimal possible 
manipulation of the donor body, which is limited to the insertion of cannulas for infusion of 
preservation fluids. The organs are then dissected out and most of the surgical procedures 
on the organs are performed at the bench “ex vivo”. Two surgical teams are involved in this 
method, a thoracic team and an abdominal team, and they each operate in two distinct 
phases: the dissection of the corpse and the dissection of organs ex vivo. 
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2.2.1 Dissection on the cadaver 
The donor is placed in the supine position as in the classical technique, catheters are placed 
and antisepsis and shaving are performed. With preservation fluid and sterile crushed ice 
available, a sternotomy and midline laparotomy are performed with bilateral subcostal 
extension (Fig. 1). Both the thoracic and abdominal organs are approached and inspected, 
and their potential viability or any contraindications are communicated. 
Once the decision to proceed has been made both the thoracic and abdominal teams work 
simultaneously. The thoracic team performs the opening of the pericardium, dissection of 
large vessels, and identification of ascending aorta and pulmonary artery, if lung 
explantation is going to be performed. The abdominal team identifies the superior 
mesenteric vein at the root of the mesocolon, identifies the infrarenal aorta just above the 
origin of the iliac arteries and dissects the descending thoracic aorta before widely opening 
the left diaphragm. At this level the aorta is covered by only the pleura and has no branches. 
Once these maneuvers have been performed, which should take approximately 15 to 30 
minutes, heparin is administered intravenously at a dose of 300 U/kg. The perfusion 
cannulas are then put in place. 
In the thorax, the cardioplegic cannula is inserted into the aortic root. When the lungs are to 
be removed, the insertion of the cannula is performed at the level of the pulmonary artery. 
In the abdomen, the insertion of the cannula (18 to 20 Frens in adults, 14 to 16 Frens in 
children) is performed at the level of the inferior mesenteric vein. There is also insertion of a 
cannula into the distal aorta (20 to 24 Frens for adults and 14 to 16 Frens for children). Also, 
the inferior vena cava is cannulated for venous drainage. 
After performing the maneuvers described above both teams are ready to start the infusion 
and coordinated extraction of the respective organs, in the following order: First, 
simultaneous clamping of thoracic and abdominal aorta, and establishment of large venous 
drainage through the cannula placed in the vena cava, with sectioning of the infracardiac 
vena cava. Perfusion of the preservation fluids is started, at the following ratios: 1000 cc for 
the heart, 1000 cc for the lung, and 4000 cc for the abdomen. After the organs have been 
perfused, the removal of the heart and lungs is performed, just as in the classical technique. 
In the abdomen all of the mesocolon is sectioned, and the colon is mobilized. The jejunum is 
transected at the level of the ligament of Treitz with a stapling device (GIATM or PLCTM) and 
the small intestine mesentery is sectioned, after which the small bowel and colon are 
externalized from the abdomen. Both ureters are identified and distally sectioned. The left 
diaphragm insertion and left parietocolic are transected. The stomach, spleen, pancreas and 
left kidney are moved toward the midline. The right diaphragm insertion and right 
parietocolic are then transected, following mobilization toward the midline of the liver, 
pancreas and right kidney. The distal thoracic esophagus is identified and sectioned with a 
stapling device and the thoracic aorta is transected just above the clamp placed at that level, 
which remains in the closed position to allow the continuous perfusion of the abdominal 
organs. The posterior diaphragm and all retroperitoneal tissue posterior to the aorta are then 
sectioned. The infrarenal aorta and vena cava are sectioned distally to the insertion site of 
the perfusion cannula. 
The organ complex consisting of the liver, stomach, duodenum-pancreas-spleen, and 
kidneys is introduced into a pan with saline solution and crushed ice. The explantation is 
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the retroperitoneum are sectioned. This fully releases the kidneys, which can then be 
extracted for subsequent packaging in preservation solution and back-table preparation. 
After all useful organs have been explanted, the following tissues are also recovered: iliac 
vessels that may be needed for vascular reconstruction of both the liver and kidneys, and 
spleen material for Human Leukocyte Antigen (HLA) system studies. At this time the 
corneal team intervenes, and finally the musculoskeletal team. At some facilities skin is also 
removed, and this is the last explantation procedure to be performed. 
The reconstruction of the cadaver must be very careful. This step is as important as any of 
the above, as it is essential to preserve the dignity and integrity of the cadaver (Fig. 5). This 
procedure should allow delivering of the body of the donor in the following fashion: 1) all 
incisions performed for the removal of organs and tissues should be sutured, 2) no tubes or 
catheters should remain, 3) the body should be clean, with particular care in removing all 
blood stains, 4) the eyes should be closed, 5) limbs from where skeletal or muscle tissue was 
explanted should be properly covered, 6) a sign should be placed indicating whether 
skeletal or muscle tissue was obtained, and that prostheses were placed accordingly, 7) the 
body should be covered with a sheet or placed inside a bag. 
 
Fig. 5. Dignity of the cadaver. 
2.2 Total abdominal evisceration  
Developed by Nakazato in 1992, this technique is based on the minimal possible 
manipulation of the donor body, which is limited to the insertion of cannulas for infusion of 
preservation fluids. The organs are then dissected out and most of the surgical procedures 
on the organs are performed at the bench “ex vivo”. Two surgical teams are involved in this 
method, a thoracic team and an abdominal team, and they each operate in two distinct 
phases: the dissection of the corpse and the dissection of organs ex vivo. 
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2.2.1 Dissection on the cadaver 
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and their potential viability or any contraindications are communicated. 
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large vessels, and identification of ascending aorta and pulmonary artery, if lung 
explantation is going to be performed. The abdominal team identifies the superior 
mesenteric vein at the root of the mesocolon, identifies the infrarenal aorta just above the 
origin of the iliac arteries and dissects the descending thoracic aorta before widely opening 
the left diaphragm. At this level the aorta is covered by only the pleura and has no branches. 
Once these maneuvers have been performed, which should take approximately 15 to 30 
minutes, heparin is administered intravenously at a dose of 300 U/kg. The perfusion 
cannulas are then put in place. 
In the thorax, the cardioplegic cannula is inserted into the aortic root. When the lungs are to 
be removed, the insertion of the cannula is performed at the level of the pulmonary artery. 
In the abdomen, the insertion of the cannula (18 to 20 Frens in adults, 14 to 16 Frens in 
children) is performed at the level of the inferior mesenteric vein. There is also insertion of a 
cannula into the distal aorta (20 to 24 Frens for adults and 14 to 16 Frens for children). Also, 
the inferior vena cava is cannulated for venous drainage. 
After performing the maneuvers described above both teams are ready to start the infusion 
and coordinated extraction of the respective organs, in the following order: First, 
simultaneous clamping of thoracic and abdominal aorta, and establishment of large venous 
drainage through the cannula placed in the vena cava, with sectioning of the infracardiac 
vena cava. Perfusion of the preservation fluids is started, at the following ratios: 1000 cc for 
the heart, 1000 cc for the lung, and 4000 cc for the abdomen. After the organs have been 
perfused, the removal of the heart and lungs is performed, just as in the classical technique. 
In the abdomen all of the mesocolon is sectioned, and the colon is mobilized. The jejunum is 
transected at the level of the ligament of Treitz with a stapling device (GIATM or PLCTM) and 
the small intestine mesentery is sectioned, after which the small bowel and colon are 
externalized from the abdomen. Both ureters are identified and distally sectioned. The left 
diaphragm insertion and left parietocolic are transected. The stomach, spleen, pancreas and 
left kidney are moved toward the midline. The right diaphragm insertion and right 
parietocolic are then transected, following mobilization toward the midline of the liver, 
pancreas and right kidney. The distal thoracic esophagus is identified and sectioned with a 
stapling device and the thoracic aorta is transected just above the clamp placed at that level, 
which remains in the closed position to allow the continuous perfusion of the abdominal 
organs. The posterior diaphragm and all retroperitoneal tissue posterior to the aorta are then 
sectioned. The infrarenal aorta and vena cava are sectioned distally to the insertion site of 
the perfusion cannula. 
The organ complex consisting of the liver, stomach, duodenum-pancreas-spleen, and 
kidneys is introduced into a pan with saline solution and crushed ice. The explantation is 
 
Renal Transplantation – Updates and Advances 
 
58
now completed, and as in the classical technique, additional tissues are recovered and the 
final preparation of the corpse is secured. This explantation technique takes about 15 to 30 
minutes, such that the overall duration of surgical procedures in the donor will be no longer 
than 45 to 60 minutes. This relatively short time significantly simplifies logistics and makes 
total abdominal evisceration particularly advisable in cases where the maintenance of the 
donor body is complicated. 
2.2.2 Dissection ex vivo 
2.2.2.1 Separation of renal block 
The abdominal specimen is dissected from its posterior face. The aorta is sectioned 
throughout its entire length, thereby identifying the origins of all visceral arteries and their 
possible anomalies. The anterior side of the aorta is sectioned between the orifices of the 
renal arteries and superior mesenteric artery. The hepatorenal ligament is sectioned, 
followed by identification of the infrahepatic vena cava, which is sectioned just above the 
outlet of the renal vessels. The pancreatorenal ligament is transected. The kidneys are then 
ready for back-table surgery. 
2.2.2.2 Separation of the liver from the pancreas-duodenum-spleen complex 
The superior mesenteric artery is identified and dissected to check for the presence of a right 
hepatic artery which, if present, is preserved as part of the hepatic specimen. The celiac 
trunk is identified and dissected, after which the splenic and left gastric arteries are 
identified and sectioned, provided that there are no anomalies in the left hepatic artery. The 
specimen is turned over, in order to dissect it by its anterior or ventral face. When the 
pancreas is to be explanted, the common bile duct, gastroduodenal artery and portal vein 
are distally sectioned from right to left, just above the outlet of the coronary vein. Otherwise, 
the sectioning is performed at the junction with the superior mesenteric vein. The stomach is 
separated by cutting the gastrohepatic ligament, and the duodenum is sectioned with a 
stapling device when the pancreas is to be explanted. Otherwise, the liver can be separated 
from the rest of the specimen at this point. 
2.3 Exclusive renal explantation from cadaveric donor 
This technique follows the principles of the classical multi-organ explantation described by 
Starzl, and kidney transplant surgeons are invariably well versed in this approach. It is used 
when limitations are imposed on the surgical team by outside factors, such as the hospital, 
the specific organ transplantation programs that may be active in the facility, the quality of 
the other organs in the donor, or the unavailability of the authorizations necessary to 
explant organs other than the kidneys. 
2.3.1 Description of the exclusively renal explantation technique 
The cadaveric donor is placed on the operating table in the supine position, with the arms in 
forced abduction, and a Foley catheter is placed in the urethra. Shaving and antisepsis of the 
abdominal wall is performed, sterile fields are placed and the abdominal cavity is accessed 
by means of a medial xifopubic laparotomy with bilateral subcostal extension. The right 
colon is greatly mobilized by cutting the right parietocolic, and a Kocher maneuver is 
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performed, the small bowel is mobilized superiorly until it is only held together by the 
mesenteric vessels. Following these maneuvers the abdominal aorta and inferior vena cava 
can be accessed, dissected, and controlled with a thick ligature in its caudal origins (Fig. 2). 
The inferior mesenteric artery is ligated and sectioned. The right kidney is identified and is 
freed from the fascia of Gerota. The same dissection is done with the left kidney, ending 
with the creation of a window on the left sided colonic mesentery. At this point there is no 
attempt to identify and dissect the renal arteries or veins. The hilum is left untouched. 
During this dissection, the surgeons look for several anomalies that might be present, such 
as: 
1. Congenital malformations and anatomical variations of the kidneys, such as horseshoe 
kidney. 
2. Iliac arterial branches to the lower kidney poles. 
3. Precava branches of the lower pole of right kidney. 
4. Postaortic left renal vein. 
The superior mesenteric artery is sectioned. The lymph nodes near the stump of the superior 
mesenteric artery are sectioned in order to place the vascular clamp 1 cm above the origin of 
said artery. The hepatic hilum is dissected and the portal vein is ligated. The donor is 
heparinized intravenously at a dose of 300 U/kg. The aorta and the cava are ligated distally 
and are proximally cannulated, and the perfusion of preservation fluids through the aorta is 
started. The aorta is clamped above the superior mesenteric artery, while the drainage of 
blood is allowed from the cannula in the abdominal vena cava. It is often necessary to open 
the diaphragm and cut the infracardiac vena cava, allowing abundant venous drainage. As a 
consequence of this maneuver blood contaminates the abdominal cavity, and thus constant 
suction will be required within the cavity. Should it be desirable to keep blood away from 
the abdominal cavity, a sternotomy could be performed as part of the initial approach (Fig. 
1), thus preserving the integrity of the diaphragm and restricting blood to the thoracic 
cavity, where constant suction with two sets of aspiration equipment should be ensured. 
The abdominal cavity is irrigated with crushed ice prepared with normal saline to further 
accelerate cooling, while 4 liters of preservation solution is infused through the aorta (Fig. 6). 
Subsequently the ureters are clipped in their more distal portion using Kelly forceps, near 
the bladder, are cut at this level, and dissected in the distal to proximal direction. The 
abdominal aorta and inferior vena cava are sectioned, above the site of their initial ligation, 
and are sectioned below the diaphragm. The complete specimen including aorta and vena 
cava is extracted, together with the kidneys and ureters. The iliac vessels are removed, as 
they may be required for vascular reconstructions, and splenic tissue is obtained for studies 
of the HLA system. Everything is placed in cold solution with crushed ice. The specimen 
consisting of both kidneys will subsequently be subjected to back-table surgery. The 
abdominal cavity is then sutured, and the cadaver is left clean, removing any catheters and 
tubes. The corpse is treated as described previously. 
3. Renal explantation from non-heart-beating donor 
In recent years, the possibility of obtaining organs for transplantation from donors in 
asystole has been reconsidered. Following the work of García-Rinaldi in 1975, in situ 
perfusion of cadaveric kidneys by cold infusion made directly through a catheter via the 
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now completed, and as in the classical technique, additional tissues are recovered and the 
final preparation of the corpse is secured. This explantation technique takes about 15 to 30 
minutes, such that the overall duration of surgical procedures in the donor will be no longer 
than 45 to 60 minutes. This relatively short time significantly simplifies logistics and makes 
total abdominal evisceration particularly advisable in cases where the maintenance of the 
donor body is complicated. 
2.2.2 Dissection ex vivo 
2.2.2.1 Separation of renal block 
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throughout its entire length, thereby identifying the origins of all visceral arteries and their 
possible anomalies. The anterior side of the aorta is sectioned between the orifices of the 
renal arteries and superior mesenteric artery. The hepatorenal ligament is sectioned, 
followed by identification of the infrahepatic vena cava, which is sectioned just above the 
outlet of the renal vessels. The pancreatorenal ligament is transected. The kidneys are then 
ready for back-table surgery. 
2.2.2.2 Separation of the liver from the pancreas-duodenum-spleen complex 
The superior mesenteric artery is identified and dissected to check for the presence of a right 
hepatic artery which, if present, is preserved as part of the hepatic specimen. The celiac 
trunk is identified and dissected, after which the splenic and left gastric arteries are 
identified and sectioned, provided that there are no anomalies in the left hepatic artery. The 
specimen is turned over, in order to dissect it by its anterior or ventral face. When the 
pancreas is to be explanted, the common bile duct, gastroduodenal artery and portal vein 
are distally sectioned from right to left, just above the outlet of the coronary vein. Otherwise, 
the sectioning is performed at the junction with the superior mesenteric vein. The stomach is 
separated by cutting the gastrohepatic ligament, and the duodenum is sectioned with a 
stapling device when the pancreas is to be explanted. Otherwise, the liver can be separated 
from the rest of the specimen at this point. 
2.3 Exclusive renal explantation from cadaveric donor 
This technique follows the principles of the classical multi-organ explantation described by 
Starzl, and kidney transplant surgeons are invariably well versed in this approach. It is used 
when limitations are imposed on the surgical team by outside factors, such as the hospital, 
the specific organ transplantation programs that may be active in the facility, the quality of 
the other organs in the donor, or the unavailability of the authorizations necessary to 
explant organs other than the kidneys. 
2.3.1 Description of the exclusively renal explantation technique 
The cadaveric donor is placed on the operating table in the supine position, with the arms in 
forced abduction, and a Foley catheter is placed in the urethra. Shaving and antisepsis of the 
abdominal wall is performed, sterile fields are placed and the abdominal cavity is accessed 
by means of a medial xifopubic laparotomy with bilateral subcostal extension. The right 
colon is greatly mobilized by cutting the right parietocolic, and a Kocher maneuver is 
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performed, the small bowel is mobilized superiorly until it is only held together by the 
mesenteric vessels. Following these maneuvers the abdominal aorta and inferior vena cava 
can be accessed, dissected, and controlled with a thick ligature in its caudal origins (Fig. 2). 
The inferior mesenteric artery is ligated and sectioned. The right kidney is identified and is 
freed from the fascia of Gerota. The same dissection is done with the left kidney, ending 
with the creation of a window on the left sided colonic mesentery. At this point there is no 
attempt to identify and dissect the renal arteries or veins. The hilum is left untouched. 
During this dissection, the surgeons look for several anomalies that might be present, such 
as: 
1. Congenital malformations and anatomical variations of the kidneys, such as horseshoe 
kidney. 
2. Iliac arterial branches to the lower kidney poles. 
3. Precava branches of the lower pole of right kidney. 
4. Postaortic left renal vein. 
The superior mesenteric artery is sectioned. The lymph nodes near the stump of the superior 
mesenteric artery are sectioned in order to place the vascular clamp 1 cm above the origin of 
said artery. The hepatic hilum is dissected and the portal vein is ligated. The donor is 
heparinized intravenously at a dose of 300 U/kg. The aorta and the cava are ligated distally 
and are proximally cannulated, and the perfusion of preservation fluids through the aorta is 
started. The aorta is clamped above the superior mesenteric artery, while the drainage of 
blood is allowed from the cannula in the abdominal vena cava. It is often necessary to open 
the diaphragm and cut the infracardiac vena cava, allowing abundant venous drainage. As a 
consequence of this maneuver blood contaminates the abdominal cavity, and thus constant 
suction will be required within the cavity. Should it be desirable to keep blood away from 
the abdominal cavity, a sternotomy could be performed as part of the initial approach (Fig. 
1), thus preserving the integrity of the diaphragm and restricting blood to the thoracic 
cavity, where constant suction with two sets of aspiration equipment should be ensured. 
The abdominal cavity is irrigated with crushed ice prepared with normal saline to further 
accelerate cooling, while 4 liters of preservation solution is infused through the aorta (Fig. 6). 
Subsequently the ureters are clipped in their more distal portion using Kelly forceps, near 
the bladder, are cut at this level, and dissected in the distal to proximal direction. The 
abdominal aorta and inferior vena cava are sectioned, above the site of their initial ligation, 
and are sectioned below the diaphragm. The complete specimen including aorta and vena 
cava is extracted, together with the kidneys and ureters. The iliac vessels are removed, as 
they may be required for vascular reconstructions, and splenic tissue is obtained for studies 
of the HLA system. Everything is placed in cold solution with crushed ice. The specimen 
consisting of both kidneys will subsequently be subjected to back-table surgery. The 
abdominal cavity is then sutured, and the cadaver is left clean, removing any catheters and 
tubes. The corpse is treated as described previously. 
3. Renal explantation from non-heart-beating donor 
In recent years, the possibility of obtaining organs for transplantation from donors in 
asystole has been reconsidered. Following the work of García-Rinaldi in 1975, in situ 
perfusion of cadaveric kidneys by cold infusion made directly through a catheter via the 
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femoral artery into the aorta has successfully been applied. This approach has allowed a 
significant reduction in the time of warm ischemia, thus overcoming the main limitation of 
non-heart-beating donors, i.e. the poor preservation of the organs, which are often subjected 
to long periods of warm ischemia. "Warm ischemic time" is defined as the time elapsed from 
the moment of circulatory arrest until the cooling of the organ, and includes the time 
elapsed both with and without effective cardiopulmonary resuscitation maneuvers. In 
contrast, "cold ischemic time" involves the time elapsed from the moment of cold perfusion 
until revascularization is achieved, once the organ is implanted in the recipient. 
Following García-Rinaldi, many authors have implemented these methods with good 
results, and the inclusion of this group of donors in organ procurement programs is 
increasingly being recommended.  Other variations to this protocol have also emerged, such 
as that of Koyama, who has used body hypothermia by cardiopulmonary bypass with good 
results in non-heart-beating donors. 
The sources of non-heart-beating donors are diverse, and after the Maastricht workshop in 
1995 four categories have been defined: 
Category 1: Donors that reach the hospital as cadavers (after traffic accidents or other 
causes, patients have cardiac arrest during transport to the hospital, without application of 
cardiopulmonary resuscitation maneuvers. These donors are considered cadavers upon 
arrival to the hospital). 
Category 2: Recipients of ineffective cardiopulmonary resuscitation (CPR, includes most 
non-heart-beating donors, and can originate from within the hospital or from outside 
sources). 
Category 3: Donors where cardiac arrest is expected (patients with irreversible brain 
damage, but that do not meet the criteria for brain death donors. The donors are taken to the 
operating room, where the life support measures are interrupted, and cardiac arrest is 
expected). This group raises many ethical considerations and is not accepted in many 
countries. 
Category 4: Donors with brain death that are part of organ donation programs, and who 
suffer cardiac arrest in the course of the diagnostic procedures or while awaiting for 
explantation equipment to become available. 
3.1 Selection criteria for donors 
Selection criteria for potential non-heart-beating organ donors include: 
1. Age between 7 and 55. 
2. Cause of death should be known or suspected, ruling out those donors who have died 
as a consequence of personal violent acts (due to potential interference with judicial 
investigations) 
3. Thoracic or abdominal injuries with massive bleeding should be absent 
4. Ischemic time without effective CPR of less than 30 minutes. 
5. Ischemic time with effective CPR of up to 2 hours. 
6. A total warm ischemic time, including the time with and without cardiopulmonary 
resuscitation maneuvers, of up to 2 and a half hours. 
7. The criteria applicable to donors with brain death 
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3.2 Initial procedures  
The procedure for removal of organs from non-heart-beating donors begins after the 
diagnosis of death by the medical team that has treated the patient, at which point the 
cadaver is considered as a potential donor. At this point it is necessary to accurately assess 
the length of warm ischemia suffered by the organs, from the time of cardiac arrest until the 
beginning of cardiopulmonary resuscitation, and from the beginning of these maneuvers 
until the onset of cold recirculation. Initially, mechanical ventilation and cardiac massage on 
the body is continued, in order to maintain the best possible perfusion of the organs, and the 
heparinization of the donor begins (300 U/kg body weight). Simultaneously, blood samples 
are obtained to perform laboratory measurements, with emphasis on the plasma serology 
information that will be necessary for the selection of the recipient. Some authors (Booster 
MH et al, 1993) recommend the use of phentolamine (0.125 mg/kg) to induce vasodilatation 
of the renal vessels prior to the infusion, and thus facilitate the rapid decrease in 
temperature. The femoral artery and vein are catheterized by surgical dissection and cold 
perfusion of organs is started. Some groups (González MM et al, 1994; Szostek M et al, 1995) 
have reported good results using mechanical ventilation and cardiac massage for the 
maintenance of the donor until the moment of explantation. 
3.3 Techniques for perfusion in situ 
Renal perfusion was traditionally achieved by gravity, with perfusion of cold preservation 
solution through the femoral artery (in situ perfusion), and exsanguination via the femoral 
vein. García Rinaldi et al. used a catheter with a double balloon and triple lumen, placed in 
the aorta via the femoral artery, thus achieving isolation of renal circulation. Surface cooling 
of the kidneys has been added to this methodology, by continuous hypothermic peritoneal 
infusion, which reduces the temperature in the kidney and protects renal microvasculature 
in case of ineffective cold perfusion. This is especially important in cases when perfusion 
lasts a relatively long time. Improvements have also been made by adding pressure to the 
preservation fluid. Anaise has shown that when 70 mmHg of pressure is used, the drop in 
temperature is faster and more effective (up to 15 degrees Celsius in 5 minutes). Lower 
pressure would increase the release of renin-angiotensin, which could cause an increase in 
renal vascular resistance, thus promoting a decrease in renal blood flow and poor 
hypothermia. 
3.4 Body cooling with cardiopulmonary bypass 
In this procedure, cannulation of the femoral artery and vein is performed, allowing 
connection to an extracorporeal circulation system with a membrane oxygenator and heat 
exchanger (Fig. 6). A Fogarty balloon is placed through the contralateral femoral artery to 
interrupt blood flow above the level of the superior mesenteric artery. This prevents the 
flow of blood from the donor and of preservation solution above this level, ensuring a 
temperature differential between both chambers. Priming and premedication of the 
extracorporeal circulation system is achieved with 2 g fosfomycin, 8 mg pancuronium, 300 
mg hydrocortisone, 2000 cc of Ringer-Lactate, 500 cc hydroxyethyl starch, 200 cc of molar 
bicarbonate serum, and 30,000 U of heparin. 
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femoral artery into the aorta has successfully been applied. This approach has allowed a 
significant reduction in the time of warm ischemia, thus overcoming the main limitation of 
non-heart-beating donors, i.e. the poor preservation of the organs, which are often subjected 
to long periods of warm ischemia. "Warm ischemic time" is defined as the time elapsed from 
the moment of circulatory arrest until the cooling of the organ, and includes the time 
elapsed both with and without effective cardiopulmonary resuscitation maneuvers. In 
contrast, "cold ischemic time" involves the time elapsed from the moment of cold perfusion 
until revascularization is achieved, once the organ is implanted in the recipient. 
Following García-Rinaldi, many authors have implemented these methods with good 
results, and the inclusion of this group of donors in organ procurement programs is 
increasingly being recommended.  Other variations to this protocol have also emerged, such 
as that of Koyama, who has used body hypothermia by cardiopulmonary bypass with good 
results in non-heart-beating donors. 
The sources of non-heart-beating donors are diverse, and after the Maastricht workshop in 
1995 four categories have been defined: 
Category 1: Donors that reach the hospital as cadavers (after traffic accidents or other 
causes, patients have cardiac arrest during transport to the hospital, without application of 
cardiopulmonary resuscitation maneuvers. These donors are considered cadavers upon 
arrival to the hospital). 
Category 2: Recipients of ineffective cardiopulmonary resuscitation (CPR, includes most 
non-heart-beating donors, and can originate from within the hospital or from outside 
sources). 
Category 3: Donors where cardiac arrest is expected (patients with irreversible brain 
damage, but that do not meet the criteria for brain death donors. The donors are taken to the 
operating room, where the life support measures are interrupted, and cardiac arrest is 
expected). This group raises many ethical considerations and is not accepted in many 
countries. 
Category 4: Donors with brain death that are part of organ donation programs, and who 
suffer cardiac arrest in the course of the diagnostic procedures or while awaiting for 
explantation equipment to become available. 
3.1 Selection criteria for donors 
Selection criteria for potential non-heart-beating organ donors include: 
1. Age between 7 and 55. 
2. Cause of death should be known or suspected, ruling out those donors who have died 
as a consequence of personal violent acts (due to potential interference with judicial 
investigations) 
3. Thoracic or abdominal injuries with massive bleeding should be absent 
4. Ischemic time without effective CPR of less than 30 minutes. 
5. Ischemic time with effective CPR of up to 2 hours. 
6. A total warm ischemic time, including the time with and without cardiopulmonary 
resuscitation maneuvers, of up to 2 and a half hours. 
7. The criteria applicable to donors with brain death 
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3.2 Initial procedures  
The procedure for removal of organs from non-heart-beating donors begins after the 
diagnosis of death by the medical team that has treated the patient, at which point the 
cadaver is considered as a potential donor. At this point it is necessary to accurately assess 
the length of warm ischemia suffered by the organs, from the time of cardiac arrest until the 
beginning of cardiopulmonary resuscitation, and from the beginning of these maneuvers 
until the onset of cold recirculation. Initially, mechanical ventilation and cardiac massage on 
the body is continued, in order to maintain the best possible perfusion of the organs, and the 
heparinization of the donor begins (300 U/kg body weight). Simultaneously, blood samples 
are obtained to perform laboratory measurements, with emphasis on the plasma serology 
information that will be necessary for the selection of the recipient. Some authors (Booster 
MH et al, 1993) recommend the use of phentolamine (0.125 mg/kg) to induce vasodilatation 
of the renal vessels prior to the infusion, and thus facilitate the rapid decrease in 
temperature. The femoral artery and vein are catheterized by surgical dissection and cold 
perfusion of organs is started. Some groups (González MM et al, 1994; Szostek M et al, 1995) 
have reported good results using mechanical ventilation and cardiac massage for the 
maintenance of the donor until the moment of explantation. 
3.3 Techniques for perfusion in situ 
Renal perfusion was traditionally achieved by gravity, with perfusion of cold preservation 
solution through the femoral artery (in situ perfusion), and exsanguination via the femoral 
vein. García Rinaldi et al. used a catheter with a double balloon and triple lumen, placed in 
the aorta via the femoral artery, thus achieving isolation of renal circulation. Surface cooling 
of the kidneys has been added to this methodology, by continuous hypothermic peritoneal 
infusion, which reduces the temperature in the kidney and protects renal microvasculature 
in case of ineffective cold perfusion. This is especially important in cases when perfusion 
lasts a relatively long time. Improvements have also been made by adding pressure to the 
preservation fluid. Anaise has shown that when 70 mmHg of pressure is used, the drop in 
temperature is faster and more effective (up to 15 degrees Celsius in 5 minutes). Lower 
pressure would increase the release of renin-angiotensin, which could cause an increase in 
renal vascular resistance, thus promoting a decrease in renal blood flow and poor 
hypothermia. 
3.4 Body cooling with cardiopulmonary bypass 
In this procedure, cannulation of the femoral artery and vein is performed, allowing 
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Fig. 6. Cannulation of the femoral artery and vein in the non-heart-beating donor. 
The main difference between the in situ perfusion technique and body cooling with 
cardiopulmonary bypass is that in the latter the blood volume of the donor is maintained, 
without exsanguination. This ensures the reversibility of the process, and therefore its 
universal applicability, including in cases where it is necessary to wait for further 
authorization before confirming the deceased as an organ donor. In the two techniques used 
(in situ perfusion and body cooling with cardiopulmonary bypass), the donor is transferred 
to the operating room after obtaining court approval, and the kidney explantation is 
performed and, where appropriate, that of the liver and other tissues. The techniques used 
are the same previously described in this chapter for brain-dead cadaver donors. 
3.5 Final procedures 
More so than for other types of donor, in the non-heart-beating donor, the assessment of 
organ viability is crucial. This is achieved through macroscopic examination, and through 
biopsies. Biochemical determinations after death will provide very little guidance regarding 
kidney function, due to post-mortem cytolysis. Research in this area is currently focused on 
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the metabolism of adenine nucleotides. Through these studies, the correlation between 
cellular energy status (adenine nucleotides) and post-transplant functionality has been 
established, both in renal and hepatic transplants obtained from non-heart-beating donors. 
4. Explantation of kidneys from living donors 
Because of the large numbers of patients awaiting kidneys worldwide, public health systems 
have invested more effort in promoting donation from living individuals. One of the factors 
that traditionally have discouraged potential living donors is the need to undergo an open 
nephrectomy, which can cause significant pain and scarring. Open nephrectomy was the 
first to be applied to living donors, starting in the mid twentieth century. 
The advent of laparoscopic procedures in almost all branches of surgery, including urology, 
opened new possibilities for increasing the number of living kidney donors. Patients are 
able to return to work sooner, suffer less pain, and find the minimal scarring more 
aesthetically acceptable. In 1991 Clayman et al. introduced the use of laparoscopic urological 
procedures for curative nephrectomy. Later, in 1995, Ratner et al. described laparoscopic 
nephrectomy, initially transperitoneal, for the purposes of transplantation. Also in 1995 
Yang et al. published the retroperitoneal procedure, and thereafter a host of variations to 
these techniques have emerged, increasingly taking advantage of the significant 
technological advances in surgery. The currently used surgical techniques for kidney 
explantation from living donors are described below. 
4.1 Open nephrectomy with classic lumbar sectioning 
This technique is safe for the donor and for the kidney graft; and is used as the “gold 
standard” for the evaluation of new techniques. The live donor is placed in the lateral 
position, and the operating table is flexed at the level of the umbilicus to achieve complete 
flank exposure (Fig. 7). A 15 to 20 cm incision is made on the flank below the 12th rib, and a 
retroperitoneal dissection is performed. After ligation of the renal vessels the kidney can be 
removed and placed in cold preservation solution, so that back-table surgery can be 
performed. This procedure allows for a very short time of warm ischemia. The main 
disadvantages of this approach are related to the significant surgical wounding of the 
abdominal wall, which causes pain, prolonged hospital stays, poor aesthetics of the wound, 
and a slow convalescence. 
4.2 Minimally invasive open donor nephrectomy 
After the introduction of the laparoscopic donor nephrectomy, there was increasing interest 
in developing a minimally invasive modification of the classical open donor nephrectomy, 
and subsequently the muscle-sparing mini-incision donor nephrectomy was developed. 
This operation can be performed via an anterior, flank or posterior approach with an 
incision of approximately 7 cm. With the donor placed in a lateral decubitus position and 
the operation table maximally flexed, a horizontal skin incision is made anterior to the 11th 
rib toward the umbilicus. The fascia and muscles of the abdominal wall are carefully split 
between the muscle fibres avoiding harm to the intercostal nerves between the internal 
oblique and transverse abdominal muscles. The peritoneum is displaced medially and 
Gerota’s fascia is opened on the lateral side of the kidney. The working space is limited, 
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therefore long instruments are used. The kidney is meticulously dissected and arterial and 
venous structures are identified. After dissection, the ureter is divided and sutured distally. 
The renal artery and vein are clamped and ligated. This approach provides the safety of the 
conventional open technique. This minimally invasive open donor nephrectomy results in 
reduced blood loss, hospital stay and incision-related complications compared with the 
classical open donor nephrectomy. There is only a marginal increase in operation time 
without compromising graft and recipient survival. 
 
Fig. 7. Living donor position in the open nephrectomy. 
4.3 Laparoscopic nephrectomy 
With the donor in the lateral position and the operating table maximally flexed, 4 trocars are 
inserted in the following fashion (Fig. 8): 1) a 12 mm port at the umbilical level in the 
midclavicular line, 2) a 10 or 12 mm port at the umbilical level, 3) a 5 mm  port between the 
umbilicus and the xiphoid process, and 4) a 12 mm port, 2 cm away from the symphysis 
pubis (the wound for this port will be incorporated into the Pfannenstiel incision, through 
which the kidney will be removed from the abdominal cavity). The abdomen is insufflated 
to 12 mmHg. The colon is mobilised and displaced medially. Gerota’s fascia is opened and 
the renal vein and ureter, with sufficient periureteral tissue, are identified and dissected. 
The renal artery is identified. Branches of the adrenal, gonadal and lumbar veins are clipped 
and divided. The ureter is clipped distally and divided. Then, a low transverse suprapubic 
(Pfannenstiel) incision or midline incision is made creating a gate for extraction of the 
kidney. The renal artery and vein are divided using an endoscopic stapler or clips. The 
kidney is extracted through the extraction incision, and flushed with preservation fluid and 
stored on ice. Extraction of the kidney can be performed directly through the incision or by 
using a special endoscopic specimen retrieval bag. 
Disadvantages of this technique include the steep and long learning curve, the risk of bowel 
injury from trocar insertion or during instrumentation, internal hernias or hernia through 
trocar sites and intestinal adhesions. Injuries to the lumbar vein, renal artery and aorta, 
pneumomediastinum, splenic injury, and adrenal/retroperitoneal haematomas have been 
reported. 
Conversion rate from laparoscopic to open surgery is 1.8% (range 0 to 13.3%). 
Approximately half of the conversions to open surgery are due to bleeding or vascular  
 




Fig. 8. Living donor position and placement of trocars for laparoscopic nephrectomy. 
injury. The laparoscopic technique results in a shorter vascular pedicle when compared with 
the open donor nephrectomy. The warm ischaemia time and operating time for laparoscopic 
donor nephrectomy are substantially longer than those achieved in open donor 
nephrectomy. 
4.4 Hand-assisted laparoscopic nephrectomy  
This technique incorporates one port for the hand. Hand-assisted laparoscopic donor 
nephrectomy was first utilized in order to minimize the learning curve of the total 
laparoscopic donor nephrectomy (Fig. 9). In addition, the hand port provides increased 
safety to laparoscopic donor nephrectomy, because rapid control of eventual massive blood 
loss from major blood vessels is possible.  
Different incisions for hand introduction have been described, such as a Pfannenstiel 
incision, a midline supraumbilical, periumbilical, or infraumbilical incision. The hand port 
can be used partly or totally during the operation. 
The hand-assisted laparoscopic donor nephrectomy is done transperitoneally. After open 
dissection of the distal ureter and gonadal vein through a 7 to 8 cm Pfannenstiel incision the 
nondominant operator’s hand is introduced through a hand port and two trocars are placed. 
The insufflation pressure is maximally 12 mmHg. The right or left colon is then mobilized. 
The renal vein and artery are identified and the kidney is mobilized from the surrounding 
tissue. After transecting the ureter distally, the renal artery is transected with metal clips or 
an endoscopic stapler which is used to transect the renal vein. The kidney is extracted 
through the Pfannenstiel incision and flushed and preserved with cold preservation fluid. 
Potential disadvantages are higher costs because of the hand port, a worse ergonomic  
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Fig. 9. Hand-assisted laparoscopic donor nephrectomy. 
position for the surgeon during operation, a higher rate of wound infections and increased 
traumatic injury to the transplant as a consequence of manipulation. Conversion to open 
surgery is 2.97% in the hand-assisted group. The most common causes for conversion to 
open surgery include intraoperative haemorrhage or vascular injury, difficult kidney 
exposure or an obese donor, vascular staple malfunction, adhesions and loss of 
pneumoperitoneum. Potential advantages of hand-assisted laparoscopic donor 
nephrectomy over conventional laparoscopy include the ability to use tactile feedback, less 
kidney traction, rapid control of bleeding, fast kidney removal and shorter warm ischaemic 
periods.  
4.5 Laparo-endoscopic single-site (LESS) donor nephrectomy  
In this technique a single port is used (Fig. 10). There are two variants, the transperitoneal, 
which involves a 7 cm periumbilical incision, and the retroperitoneal, which utilizes a 6 cm 
incision in the groin, below the "bikini line". The instruments and lens for dissection and 
sectioning of renal hilar vessels and the ureter are introduced through the single port. The 
same port is later used to remove the kidney. 
4.6 Robotic-assisted donor nephrectomy 
Robotic-assisted donor nephrectomy can be performed with or without hand assistance. The 
Da Vinci robotic system has three components: a console, a control tower and the surgical  
 




Fig. 10. Laparoendoscopic single-site (LESS) donor nephrectomy. 
arm cart (Fig. 11). The donor nephrectomy is performed with the patient placed in a 
decubitus position. The operating table is flexed to maximize the exposure of the kidney 
during the procedure. Four trocars are placed in the left or right side of the abdomen to 
allow placement of three articulated robotic arms, the robotic camera, and the standard 
laparoscopic instrument used for retraction and dissection during the procedure. The left or 
right colon is mobilized medially to expose the kidney. Dissection of Gerota’s fascia, 
perirenal tissue and vascular structures are performed as described above. 
The advantage of this technique is that the movement of the articulated arm of the robot 
reproduces the action of the human wrist, which provides more mobility. A potential 
disadvantage is the costs. 
4.7 Use of natural orifices 
An innovative approach to spare the donors of some of the surgical consequences of the 
donation, and thus increase the pool of living donors, relies on avoiding sectioning of the 
abdominal wall altogether, by removing the kidney through the vagina. This technique has 
been used before for the purpose of treating a diseased kidney, and has subsequently been 
proposed as an option for explantation from living donors. This method represents, at this 
point, just a preliminary proposal, and several objections have been raised, but it is worth 
mentioning it as one more possible alternative. 
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Fig. 11. Da Vinci robotic system. 
5. Back-table preparation 
The purpose of back-table on the explanted kidney is to examine the organ and prepare, 
under hypothermic conditions (4 ° C), the vascular ends for the subsequent vascular 
anastomosis. Perinephric fat is removed, without damaging the renal vessels or ureter. It is 
best not to dissect close to the hilum. The vessels that do not lead to or from the kidney are 
ligated. Arterial branches are completely dissected and, before being ligated, lack of flow to 
the kidney and ureter must be ensured. If the specimen was obtained from a cadaveric 
donor, it is placed such that its posterior face is visible. The aorta and the vena cava are 
opened (Fig. 12), the emergence of both renal vessels is identified, and through them, proper 
perfusion of the kidney with preservation solution is ensured. The emergence of both renal 
vessels is dissected and separated from the aorta, leaving behind an ample Carrel patch. 
There is a difference in the length of the vein and the artery in the right kidney (the vein 
being shorter). Many surgeons use the vena cava to extend the right renal vein, thus 
compensating for this difference in length, in order to prevent bending of the renal artery 
after transplantation. An alternative approach used by some surgeons is to cut the artery 
and perform an end-to-side anastomosis in the transplant, without a Carrel patch. The 
kidneys are subsequently packaged in sterile plastic bags (doubly bagged), with 
preservation solution, and then placed on ice for transport or preservation until the time of 
transplantation. 
 




Fig. 12. Posterior view of the kidneys. The aorta is divided in the posterior midline. 
6. Conclusions 
There are multiple techniques and approaches to renal explantation, whose application will 
depend on, among other factors: 
1. Type of donor. 
2. Preferences and experience of the surgical team that will perform the explantation. 
Some general guidelines to be considered in choosing the most appropriate renal 
explantation procedure are shown in Table 2. 
Studies that have compared the evolution of transplanted organs and documented the 
outcomes of both the classical explantation approach and the total abdominal evisceration 
have found no differences between these two methods. 
The kidney-only explantation procedure from cadaveric donor, and the back-table 
preparation are the two basic techniques that must be mastered by all renal transplant 
surgeons, because they are the basis on which all other renal explantation techniques for 
cadaveric donors are based. 
Successful kidney explantation from non-heart-beating donors requires perfect organization 
and coordination between different disciplines, both within and outside the hospital unit, to 
ensure the quality of the process and therefore the usefulness of the organs procured for 
transplantation. 
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extraction   
Requires coordination with 
different surgical teams. 
Total abdominal 
evisceration  
Indicated when time for extraction 
is limited (unstable donor)  
Kidney-only 
extraction  
Used when explantation of other 




Perfusion in situ 
With or without continuous 
hypothermic peritoneal 
perfusion  
Requires a perfect organization 
and coordination between 
different disciplines inside and 
outside the hospital 





Classic lumbar opening  
The gold standard for evaluation 
of other kidney explantation 




Reduced blood loss, hospital stay 
and incision-related complications 
Laparoscopy  
Laparoscopic nephrectomy 
Shortens hospitalization time, 
requires less analgesia, improves 
the aesthetics of the wound and 




There is less kidney traction, 
better bleeding control, the kidney 
is removed faster, reduces the 




(LESS) donor nephrectomy 
Technically complex procedures 
Robotic-assisted donor 
nephrectomy High costs 
Use of natural orifices 
It would only be applicable to 
female patients (vaginal route). 
Risk of infections 
Table 2. Techniques for explantation of kidneys for transplantation. 
In selecting techniques for kidney explantation from living donors, the following factors are 
to be considered: operating time, postoperative complications, postoperative pain, warm 
ischemic time, surgical aesthetics and prognosis of renal function in the recipient. 
Any newly proposed approach or technique for renal explantation must: 
1. Be technically feasible. 
2. Prove to be as safe as the technique that it seeks to replace. 
3. Be demonstrably innocuous to the graft and to the recipient. 
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extraction   
Requires coordination with 
different surgical teams. 
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Indicated when time for extraction 
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Reduced blood loss, hospital stay 
and incision-related complications 
Laparoscopy  
Laparoscopic nephrectomy 
Shortens hospitalization time, 
requires less analgesia, improves 
the aesthetics of the wound and 




There is less kidney traction, 
better bleeding control, the kidney 
is removed faster, reduces the 




(LESS) donor nephrectomy 
Technically complex procedures 
Robotic-assisted donor 
nephrectomy High costs 
Use of natural orifices 
It would only be applicable to 
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Risk of infections 
Table 2. Techniques for explantation of kidneys for transplantation. 
In selecting techniques for kidney explantation from living donors, the following factors are 
to be considered: operating time, postoperative complications, postoperative pain, warm 
ischemic time, surgical aesthetics and prognosis of renal function in the recipient. 
Any newly proposed approach or technique for renal explantation must: 
1. Be technically feasible. 
2. Prove to be as safe as the technique that it seeks to replace. 
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1. Introduction 
Fabry’s disease (FD) is a rare inborn error of glycosphingolipid catabolism can lead to renal 
failure. The life expectancy is reduced for both genders, and the major causes of death 
include cardiac death, stroke, or the consequences of end stage of renal disease. This article 
summarizes the current knowledge about FD and the treatment of kidney transplantation 
and enzyme replacement therapy in FD. 
2. About Fabry’s disease  
FD is a rare sphingolipidosis related and X-linked disorder of glycosphingolipid catabolism 
caused by deficient lysosomal α-galactosidase A activity(Fig.1). Deficiency of the enzyme 
leads to progressive accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in 
vascular endothelia, heart tissue, connective tissue, peripheral nerves, and the kidneys 
(Table.1, Fig.2). Male patients typically develop painful acroparesthesia followed by 
proteinuria, renal failure, cardiac hypertrophy and cerebral white matter lesions. Females 
are carriers and may present a wider range of symptoms(Fig.3,4). The incidence has been 
estimated to be 1:117,000 live births and 1:50,000 males. Registries of dialysis patients from 
the United States and Europe indicate that FD is the cause of end-stage renal disease (ESRD) 
for approximately 0.2% of patients on dialysis(Fig.5). Renal disease of some form occurs in 
most patients, with ESRD a common manifestation in hemizygous males that may develop 
by the fourth to fifth decade of life. The clinical course in heterozygous female patients 
involves a delayed onset of symptoms and milder progression, although some female 
patients present with symptoms similar to those seen in classically affected male patients. 
The analysis of 197 kidney transplant recipients with FD indicates that they have superior 
graft survival and similar patient survival compared with patients with other causes of 
ESRD. However, Fabry patients had a higher risk of death compared with a matched cohort 
of patients with other causes of ESRD. The median lifespan is 50 years for affected male 
patients and 70 years for female patients. Current therapy for ESRD in patients with FD 
involves renal transplantation and enzyme replacement therapy (ERT). 
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Fabry’s disease (FD) is a rare inborn error of glycosphingolipid catabolism can lead to renal 
failure. The life expectancy is reduced for both genders, and the major causes of death 
include cardiac death, stroke, or the consequences of end stage of renal disease. This article 
summarizes the current knowledge about FD and the treatment of kidney transplantation 
and enzyme replacement therapy in FD. 
2. About Fabry’s disease  
FD is a rare sphingolipidosis related and X-linked disorder of glycosphingolipid catabolism 
caused by deficient lysosomal α-galactosidase A activity(Fig.1). Deficiency of the enzyme 
leads to progressive accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in 
vascular endothelia, heart tissue, connective tissue, peripheral nerves, and the kidneys 
(Table.1, Fig.2). Male patients typically develop painful acroparesthesia followed by 
proteinuria, renal failure, cardiac hypertrophy and cerebral white matter lesions. Females 
are carriers and may present a wider range of symptoms(Fig.3,4). The incidence has been 
estimated to be 1:117,000 live births and 1:50,000 males. Registries of dialysis patients from 
the United States and Europe indicate that FD is the cause of end-stage renal disease (ESRD) 
for approximately 0.2% of patients on dialysis(Fig.5). Renal disease of some form occurs in 
most patients, with ESRD a common manifestation in hemizygous males that may develop 
by the fourth to fifth decade of life. The clinical course in heterozygous female patients 
involves a delayed onset of symptoms and milder progression, although some female 
patients present with symptoms similar to those seen in classically affected male patients. 
The analysis of 197 kidney transplant recipients with FD indicates that they have superior 
graft survival and similar patient survival compared with patients with other causes of 
ESRD. However, Fabry patients had a higher risk of death compared with a matched cohort 
of patients with other causes of ESRD. The median lifespan is 50 years for affected male 
patients and 70 years for female patients. Current therapy for ESRD in patients with FD 
involves renal transplantation and enzyme replacement therapy (ERT). 
 




Fig. 1. If a male with Fabry disease and an unaffected (non-carrier) female have children, all 
of their daughters will be Fabry carriers and none of their sons will be affected with Fabry 
disease. 
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Fig. 2. The classification of sphingolipidosis. 
 
 
      
Fig. 3. Clinical features of Fabry’s disease; angiokeratomas. 
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Fig. 4. Clinical features of Fabry’s disease; corneal and lenticular opacities. 
 
 
Fig. 5. Ultra structural changes in glomerulus with FD with myelin-like inclusions and 
subendothelial deposits. 
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3. Renal transplantation in patient with Fabry’s disease 
Renal transplantation was known to be effective for FD, as previous reports demonstrated 
that the procedure provided equivalent 5-year patient and graft survivals, as well as 
improvement of overall prognosis in patients with ESRD due to FD. In contrast, another 
study found that a renal allograft could not repair the deficient enzyme activity of α-
galactosidase A and noted that the accumulation of Gb3 impaired renal function, which 
might signify the possibility of recurrence of FD in the renal allograft. According to a 
previous study from the European Dialysis and Transplant Association/European Renal 
Association Registry, graft survival at 3 years in 33 patients with FD was not considered as 
inferior to that of patients with other nephropathies (72% vs. 69%), and patient survival after 
transplantation was comparable to that of patients aged under 55 years with non-Fabry 
nephropathies. Excellent graft and patient survival were also reported from the US Renal 
Data System Registry. FD is therefore not considered a contraindication for renal 
transplantation. Although a case study has shown that the disease may recur in the 
transplanted organ, another case study has shown no evidence of disease recurrence in a 
renal biopsy 8 years after transplantation. A further case study showed extensive Fabry-
related renal changes in a renal biopsy from a patient who had received a graft from his 
sister who was heterozygous for the disease. 
4. The efficacy of enzyme replacement therapy (ERT) 
Enzyme replacement therapy (ERT) for the treatment of Fabry’s disease was first performed 
in the 1970s, however, open-label phase 2 trials were not performed until the 2000s. ERT 
using recombinant human alpha-galactocidase A (generic names agalsidase alpha and 
agalsidase beta) was approved for use in Europe in 2001 and in the United States in 2003. 
Initial randomised controlled trials (RCT) showed that 69% of the treatment group was free 
of renal microvascular endothelial deposits of globotriaosylceramide (primary endpoint) 
versus no change in the placebo group after 20 weeks (p < 0.001). Although there did not 
appear to be a difference in quality of life as assessed by the SF-36, another RCT showed a 
statistically significant decrease in pain severity and improvement in quality of life (primary 
outcome). This study also showed improvement in renal architectural distortion (mesangial 
diameter) (p = 0.01) and increase in creatinine clearance (p = 0.02). In a more recent, larger 
RCT, 42% of placebo patients versus 27% of treated patients had clinical events (defined as 
renal, cardiac or cerebrovascular event or death); the time to first clinical event adjusted for 
baseline proteinuria favoured agalsidase beta but included the null (hazard ratio 0.47, CI: 
0.21–1.03; p< 0.06). Although overall the results were less than overwhelming, treatment 
effect was greater in patients with preserved renal function. There are no data currently 
regarding ERT and affect on mortality. 
Moreover, a purified recombinant α-galactosidase A enzyme (Fabrazyme®) was synthesized 
and administration in non-transplanted FD patients was reported to markedly reduce serum 
ceramide levels. A detailed report revealed few serious adverse events in a total of 401 
patients receiving long-term treatment; as in this study, most adverse events consisted of 
mild infusion reactions. Patients given recombinant α-GalA at 1 mg/kg once every two 
weeks showed decreased microvascular endothelial deposits of Gb3 in skin over a period of 
20 weeks and plasma Gb3 also decreased. In addition, in patients who received ERT for 30-
36 months, serum creatinine and estimated glomerular filtration rate values remained stable, 
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while the level of plasma Gb3 remained in a normal range after ERT. More recently, Cybulla 
et al. explored the effects of agalsidase alfa in transplant patients with FD. Allograft function 
of 20 patients from the Fabry Outcome Survey registry was analyzed after approximately 3.5 
years (median) of agalsidase alfa therapy at the standard dose of 0.2 mg/kg every other 
week. After 2 years of ERT, there was a slight but nonsignificant increase in serum 
creatinine (1.4 mg/dl at baseline versus 1.6 mg/dl) and a decrease in eGFR (59.2 
ml/min/1.73 m2 at baseline versus 51.1 ml/min/1.73 m2 at 2 years). Similar to the 
previously mentioned study, proteinuria remained stable during this time period. In 
contrast, ERT may be less effective to improve renal or cardiac function in cases with 
progressive damage to tissue, as it would likely be difficult to recover the function. 
Therefore, renal transplantation in conjunction with ERT might achieve better improvement 
of the graft and overall survival of FD patients. 
Mignani et al. reported that plasma Gb3 was decreased by 23-50% after ERT in renal 
transplant patients with FD. In addition, Inderbitzin et al. treated a patient with persistent 
FD-related acroparesthesia and found that ERT for 100 months after renal transplantation 
resulted in an excellent clinical course. In another study, Mignani et al. also reported 3 
patients who underwent ERT after renal transplantation, who had maintained renal 
function and improved cardiac function. In each of those cases, ERT was performed after 
renal transplantation, whereas we previously reported a rare case of successful cadaveric 
renal transplantation in patient with FD maintained by ERT with an excellent clinical course. 
We treated a 48-year-old male patient with a typical clinical history of FD from childhood 
(intermittent fever, cutaneous angiokeratoma, pain attacks in arms and legs). At the age of 
25, renal function disorder with proteinuria was pointed out and hemodialysis started at 26 
years old. He was diagnosed with FD based on deficient lysosomal α- galactosidase A 
activity at the age of 46 and began ERT by injection of recombinant α-galactosidase e.g. 
Agalsidase beta at 1mg per kg bodyweight once every two weeks in August 2004. After the 
induction of ERT, he still had diffuse angiokeratoma of the body and intermittent abdominal 
pain. Echocardiographic evaluation suggested hypertrophic obstructive cardiomyopathy 
with left ventricular hypertrophy. 
On December 17, 2005, cadaveric renal transplantation was performed (Fig.6) for the patient. 
The initial immunosuppressive agents were cyclosporine, mycophenolate mofetil, steroids, 
and basiliximab, with the cyclosporine trough levels kept at 100-150 ng/ml. No rejection or 
other complications appeared during the immediate follow-up period, and he withdrew 
from hemodialysis 23 days after transplantation. At discharge, serum creatinine was 
reduced to about 1.9 mg/ml and was at a steady-state level. At the same time, the 
disappearance of the skin lesions and abdominal pain was noticed. At 12 and 24 months 
after transplantation, graft biopsies were performed, as the serum creatinine level increased 
to 2.2～2.3 mg/dl. Histological results demonstrated acute cellular rejection, however, there 
were no abnormal deposits of accumulated glycosphingolipids in the glomerular podocytes 
or tubular epithelial cells. Electron microscopy revealed normal glomerular cells with a 
slight increase in the mesangial matrix (Fig.7). 
There were no dense deposits. The acute rejection responded to intravenous 
deoxyspergualin and serum creatinine decreased to 2.0 mg/dl. Since transplantation, ERT 
has been continued once every two weeks and no complications as a result of that therapy 
have been recognized. 
Renal Transplantation in Patient with  




Fig. 6. Clinical course of the patient. Cr creatinine; CsA, cyclosporine; HD, hemodialysis; 
MMF, mycofenolate mophetil; PSL, predonisolone. 
 
Fig. 7. Electron microscopy of normal glomerulus from kidney graft. Occasional foci of 
podocyte fusion are present. 
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The recurrence of FD in patients with a transplanted kidney has rarely been reported. 
Findings of small amounts of Gb3 deposits in renal grafts have been limited to vascular 
endothelial cells and tubular epithelial cells. We consider that renal transplantation 
combined with ERT reduces the risk of recurrence of FD in a transplanted kidney. However, 
further data are required to confirm whether such treatment will confer long-term 
renoprotective effects on renal transplantation. 
An important problem facing FD patients is that a successful kidney graft survives for 10-15 
years, however, cardiovascular complications related to metabolic disease may occur during 
that time. FD generally progresses systemically after renal transplantation and cardiac 
ceramide deposition ultimately determines the fate of these patients in the second decade 
after renal transplantation. Since ERT improves cardiac involvement in FD patients, renal 
transplantation combined with ERT may be the best therapy for ESRD at the present time. 
Additional clinical studies are needed to determine the effects of this combination on the 
overall prognosis of FD. 
5. Conclusion  
Renal transplantation is effective for FD and improves patient and graft survivals as well as 
overall prognosis in patients with ESRD due to FD. And ERT is well tolerated in patients 
with FD who have undergone renal transplantation. 
In summary, some studies indicate that kidney transplantation and ERT are viable option 
for patients with ESRD due to FD. Although ERT appears to stabilize renal function, further 
data are required to confirm whether such treatment will confer long-term renoprotective 
effects on kidney transplant patients. 
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1. Introduction 
Acute rejection is one major reason of the graft loss in renal transplantation. Most of the 
allograft rejections are due to the existence of the antibodies. The importance of the series 
tests of HLA and HLA antibodies associated with transplantation has been widely 
recognized. Although considerable rejection episodes can be explained by the appearance of 
the donor specific anti-HLA antibodies (DSA), it is reported that even in the case of ‘ideal’ 
HLA identical donor grafts transplanted into ‘ideal’ recipients, 23% are rejected within 10 
years [1]. So effect of HLA antibodies accounts for only some of the immunological failures 
of allograft and there must be large fraction of undetected antibodies against non-HLA 
mismatches. 
Despite various ways were used in the prevention of acute rejection, pulse steroid treatment 
remains the first-line therapy of all immumosuppresion projects and has a 60 to 70% success 
rate [2]. There are still recipients suffered from steroid refractory acute rejection (SRAR) and 
get worse. These rejections typically have an aggressive clinical course and are associated 
with graft loss [3]. Some of the patients would have to return to blood dialysis immediately 
and part of them die from complications. We detected antibodies in these patients and 
found that some of them do not have HLA antibodies and one of their marked 
characteristics is malignant hypertension. We presumed this is a special type of rejection. 
Thus, both immunologic and non-immunologic mechanisms for this specific type of rapid 
renal allograft dysfunction have to be considered. 
In case of the SRAR is appeared in a small part of the renal transplantation recipients, we 
presume that the genetic factors are involved it. It is reported that single nucleotide 
polymorphism (SNP) of some immune response related genes is involved in the 
development the acute rejection. The SNP of some genes can affect their functions by the 
changing either cytokine production or amino acid sequence. And the structure and 
function of some critical components would be altered concomitantly. The characteristic 
change of related proteins would finally induce the immune response and then trigger the 
rejection process. 
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Hypertension has been found to be an independent contributor in the progression of renal 
allograft failure in some studies [4, 5]. The presence of genetic abnormalities in blood 
pressure regulation could promote post-transplant hypertension and by that contribute to a 
more rapid loss of renal allograft function. The recipients’ blood pressure levels may depend 
on several factors, such as graft function, type, and dosage of immunosuppressive agents 
applied, previous rejection episodes, recurrence of the underlying nephropathy, and a 
previous history of hypertension [6]. The renin– angiotensin–aldosterone system (RAS) is a 
proteolytic cascade with an important role in blood pressure regulation and maintenance of 
fluid and electrolyte balance [7]. It was also reported that over activation of the RAS is 
linked to poor long-term renal transplant function and decreased graft survival times [8]. 
RAS polymorphisms associated with hypertension in certain groups have been identified 
[9]. We hypothesis that the occurrence of SRAR may be due to the over activating of RAS in 
a special group of recipients. And therefore, genes of the RAS deserve consideration. 
Among these the angiotensinogen (AGT), angiotensin-converting enzyme (ACE), 
angiotensin type 1 receptor (AT1R), and aldosterone synthase (CYP11B2) genes are of 
particular interest. Yet the prevalence and distribution, alone or combined, of the M235T-
AGT, I/D-ACE, A1166C-AT1R, or -344C/T-CYP11B2 polymorphisms and their relation 
with SRAR has not been well studied. 
In the studies of immunologic mechanism of acute vascular rejection, some data suggested 
that agonistic angiotensin type 1 (AT1) receptor autoantibodies (AT1-AA) may contribute to 
the pathogenesis of the rejection [10]. Some experiments implicated the role of renin-
angiotensin system in the regulation of specific immune responses and immune-mediated 
renal injuries [11]. And AT1 receptor blockade appeared to effectively attenuate the 
agonistic activity of the antibodies. 
So the SRAR may be a kind of specific rejection, whose origin, mechanism and results and 
treatment are all different from other types of rejections. Therefore, this study tried to 
determine whether or not gene polymorphisms of RAS are associated with steroid 
refractory acute rejection. Further more, by studying the gene-gene interaction, we searched 
the association of the occurrence of SRAR with the appearance of AT1-AA. 
2. Subjects and methods  
2.1 Study patients and biopsies 
A total 206 renal transplant recipients were included: 116 males and 90 females, mean age 
29.6±10.2 years range 22–55 years transplanted at Department of Urology of Xi Jing hospital, 
4th Military Medical University from January 1st, 2001, through December 31st, 2005. The 
transplants were first grafts in all cases. Serum samples obtained during rejection episodes 
were screened for donor specific anti-HLA antibodies and also agonistic antibodies 
targeting the AT1 receptor. This study was approved by the Ethics Committee of the 
Hospital, and all patients gave their oral informed consent while he or she was awaiting 
transplantation. 
Allograft-biopsy specimens were processed by standard techniques and graded according to 
the Banff97 criteria. C4d staining on paraffin-embedded sections was made according to a 
protocol described previously [12, 13]. 
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2.2 Immunosuppressive treatment 
Initial immunosuppressive therapy consisted of a calcineurin inhibitor, mycophenolate 
mofetil, methylprednisolone, and antibody against interleukin- 2 receptor for induction. All 
the recipients were treated with high dose pulse of methylprednisolone for 3 days with the 
dose of 0.5g, 0.5g, 0.25g in each day after the operation and a dose of 0.75g 
methylprednisolone was used on the operation day. Cyclosporine A or tacrolimus were 
introduced when serum creatinine levels were below 300μmol/L. Anti-proliferative agents, 
mycophenolate mofetil (1.5 g/day) or azathioprine (1–2 mg/kg/ day) were started on the 
day of transplantation. Prednisolone was reduced to 20mg daily after 7 days. Daily doses of 
CsA and tacrolimus were adjusted according to peak and trough blood levels respectively. 
High dose of methylprednisolone was utilized when the subject developed acute rejection 
after renal transplantation.  
Patients resistant to steroid were experienced further treatments. The further therapy 
includes protein A immunoadsorption (IA) and intravenous immune globulin. Patients who 
were positive for AT1-AA were added with angiotensin II Receptor Blockers (ARB). Patients 
initially treated with cyclosporine were switched to high dose tacrolimus when refractory 
rejection was detected. 
2.3 DNA extraction, PCR analysis and genotyping 
Genomic DNA prepared from blood cells using a standard column extraction technique. 
ACE I/D polymorphism in intron 16 of the ACE gene was determined as described 
previously [14]. In order to exclude mistyping of heterozygotes, all DD individuals were 
also examined using primers specific for the insertion variant. PCR products were resolved 
on a 2% agarose gel by ethidium bromide staining. 
AGT M 235 T was determined by PCR amplification according to a method described 
previously [15].The 165 bp PCR product was digested with TthIII at 37℃ for 3h and resolved 
on a 2.5% agarose gel by ethidium bromide staining. 
For the analysis of the AT1R (A1166C) polymorphism [16], a 410bp PCR product was 
digested with DdeI enzyme at 37℃for 3h and separated by electrophoresis in 2% agarose 
gel.  
CYP11B2 gene polymorphism was performed according to method described by Brand et al 
[17]. The PCR product was restricted with 5 U of the restriction endonuclease HaeIII over 2 
h at 37℃ and final product was electrophoresed in 2% agarose gel and visualized directly by 
ethidium bromide staining. The -344T allele lacks the HaeIII site that is present in the -344C 
allele and gives rise to a fragment of 273 bp rather than 202 bp.  
2.4 Antibody assays 
The detection of AT1-AA The peptides corresponding to the sequence of the second 
extracellular loop of the human AT1 receptor positions 165aa-191aa (I-H-R-N-V-F-F-I-E-N-
T-N-I-T-V-C-A-F-HY- E-S-Q-N-S-T-L) were synthesized by a peptide synthesis system [18]. 
The peptide was evaluated by HPLC analysis on a Vydac C-18 column, and 95% purity was 
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achieved. The ELISA assay of antibodies was performed according to the described 
previously [19].  
2.5 Statistics  
All statistical analyses were performed with the help of the SPSS 10.0 statistical software 
package. Categorical variables were assessed by the chi-square test. Survival curves for each 
group were calculated by the Kaplan-Meier method. Differences in genotype and allele 
distributions between groups were tested by the χ2 test. To compare the prevalence of SRAR 
among the genotypes of each polymorphism, genotypic odds ratios (OR) and 95% 
confidence intervals (CI) for SRAR were estimated using logistic regression analysis. Data 
are given as means with SD. In all statistical analysis the significance was considered 
significant when level (P) values were lower than 0.05. Test of Hardy–Weinberg equilibrium 
was performed in the subjects.  
3. Results  
All patients were classified into three groups according to the occurrence of SRAR. Two hundred 
and six renal transplant recipients were concerned by this study. Posttransplant 
hypertension was found in 102 cases (49.5%) of all patients. According to the presence of 
SRAR, patients were classified into two groups: group I (G I ), 19 patients (9.2%) underwent 
SRAR (10 men and 9 women), among them 14 had malignant hypertension. Group II (GII ) 
was the rest 187 patients who did not suffer from SRAR (104 men and 83 women), 16 of 
them had malignant hypertension, the difference between the two groups is significant. And 
150 normal people were set as control group (GIII). Baseline characteristics of the GI and GII 
were compared. No difference was observed in terms of age and sex in the donors. 
Moreover, no statistically significant differences were found between the GI and GII in 
terms of sex distribution, percentage of first kidney transplantation and cause of end-stage 
renal disease And there were no significant differences between the GI and GII for total 
number of HLA-mismatches, ischemia times (Table 1). 
The DD genotype of ACE and CC genotype of AT1R were risk factors for the development 
and progression of the SRAR. The genotype distributions of four key genes ACE I/D, AGT 
M235T, AT1R A1166C and CYP11B2 -344C/T of the RAS polymorphisms exhibited a 
nonsignificant difference with that predicted by the Hardy–Weinberg equilibrium in all 
cases. The significant differences of gene frequencies between all patients and control group 
were not observed. 
Differences between GI and GII and controls in genotype distributions were observed for 
both ACE gene polymorphisms with DD genotype and CC genotype of AT1R 
polymorphism being more prevalent in GI than in other two groups. Genotype distributions 
of other polymorphisms investigated in AGT and CYP11B2 genes did not differ between 
these three groups. The difference in allele distributions was only observed for AT1R 
A1166C with the C allele being more frequent in G I than G II and controls (42.1% v 29.9% 
and 30.1%) (Table 2). To test the association of ACE and AT1R gene polymorphisms with 
SRAR, genotypic ORs were calculated. Taking the II genotype of the ACE I/D 
polymorphism as a reference, the OR for SRAR associated with the ID genotype was 1.53  
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 Non-SRAR SRAR 
 (n=187) (n=19) 
Age (years) 36.5±11.6 37.7±12.5 
Male (%) 53 47 
IgG 9.3±2 10.4±2.8 
No. of HLA MM 3.6±1.2 3.2±1.8 
PRA positive (%) 7.6±1.2 7.5±1.5 
Duration of dialysis before NTx (mon) 20.3±16.2 23.6±18.6 
CIT(h) 10.6±7.1 11.6±7.3 
Cause of ESRD   
Chronic glomerulonephritis 56.9 50.6 
Hereditary 16.1 17.6 
High blood pressure 6.5 10.6 
IgA nephropathy 3.2 4.5 
Unknown 17.1 16.7 
CIT = Cold ischemia time; NTx=renal transplantation; HLA MM = HLA mismatch 
Table 1. Characteristics of patients involved in the study. 
   Genotypes  Alleles 
AGT M235T MM (%) MT(%) TT(%) M(%) 
GI  6 (31.6) 9 (47.3) 4(21.1) 21(55.3) 
GII  61 (32.6) 87(46.5) 39(20.9) 209(55.9) 
GIII 44 (29.3) 70 (46.7) 36(24) 158(52.7) 
ACE I/D + II (%) ID (%) DD (%) D (%) 
GI 3 (15.8) 9 (47.3) 7 (36.8) 19 (50) 
GII  55 (29.4) 108 (57.8) 24 (12.8) 156 (42.9) 
GIII  43 (28.7) 85 (56.7) 22 (14.6) 129 (43) 
AT1R A1166C* AA (%) AC (%) CC (%) C (%) 
GI 6 (31.6) 6 (31.6) 7 (36.8) 16 (42.1) 
G II  92 (49.2) 82 (43.9) 13 (8.0) 112 (29.9)  
G III  72 (48.0) 64 (42.7) 14 (9.3) 92 (30.1) 
CYP11B2 CC (%) TC (%) TT (%) C (%) 
GI 3 (15.8) 8 (42.1) 8 (42.1) 14 (36.8) 
GII  25 (13.3) 84 (44.9) 78 (41.8) 134 (35.8) 
GIII  19 (12.7) 67 (44.7) 64 (42.6) 105 (35.0)  
* : Significant difference in genotype and allele frequencies of GIversus both G II and G III (P＜0.01);  
+ : Significant difference in genotype frequencies of G I versus both G II and G III (P＜0.01). 
Table 2. Distributions of genotype and allele frequencies in each group. 
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Chronic glomerulonephritis 56.9 50.6 
Hereditary 16.1 17.6 
High blood pressure 6.5 10.6 
IgA nephropathy 3.2 4.5 
Unknown 17.1 16.7 
CIT = Cold ischemia time; NTx=renal transplantation; HLA MM = HLA mismatch 
Table 1. Characteristics of patients involved in the study. 
   Genotypes  Alleles 
AGT M235T MM (%) MT(%) TT(%) M(%) 
GI  6 (31.6) 9 (47.3) 4(21.1) 21(55.3) 
GII  61 (32.6) 87(46.5) 39(20.9) 209(55.9) 
GIII 44 (29.3) 70 (46.7) 36(24) 158(52.7) 
ACE I/D + II (%) ID (%) DD (%) D (%) 
GI 3 (15.8) 9 (47.3) 7 (36.8) 19 (50) 
GII  55 (29.4) 108 (57.8) 24 (12.8) 156 (42.9) 
GIII  43 (28.7) 85 (56.7) 22 (14.6) 129 (43) 
AT1R A1166C* AA (%) AC (%) CC (%) C (%) 
GI 6 (31.6) 6 (31.6) 7 (36.8) 16 (42.1) 
G II  92 (49.2) 82 (43.9) 13 (8.0) 112 (29.9)  
G III  72 (48.0) 64 (42.7) 14 (9.3) 92 (30.1) 
CYP11B2 CC (%) TC (%) TT (%) C (%) 
GI 3 (15.8) 8 (42.1) 8 (42.1) 14 (36.8) 
GII  25 (13.3) 84 (44.9) 78 (41.8) 134 (35.8) 
GIII  19 (12.7) 67 (44.7) 64 (42.6) 105 (35.0)  
* : Significant difference in genotype and allele frequencies of GIversus both G II and G III (P＜0.01);  
+ : Significant difference in genotype frequencies of G I versus both G II and G III (P＜0.01). 
Table 2. Distributions of genotype and allele frequencies in each group. 
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(95% confidence interval [CI] 0.40-5.86) and the OR associated with the DD genotype was 
5.34 (95% CI 1.27-22.42), indicating a recessive effect of the D allele on risk (Table 3). A 
similar situation was observed for the A1166C polymorphism in the AT1R gene. Taking AA 
genotype as a reference, the OR for SRAR associated with the AC genotype was 1.15 (95% CI 
0.36-3.70) and that associated with the CC genotype was 8.34 (95% CI 2.43-28.69).  
The OR associated with the combination of DD and CC genotypes versus all other 
combinations was 5.92 (95% CI 2.85-12.37), that is, very similar to the one observed in the 
separate analyses of these two polymorphisms (Table 3).  
  OR 95% CI 
ACE I/D ID versus II 1.53 0.40-5.86 
 DD versus II 5.34 1.27-22.42* 
AT1R A1166C CC versus AA 8.34 2.43-28.69*  
 AC versus AA 1.15 0.36-3.70 
ACE I/D and DD+CC versus all other 5.92 2.85-12.37* 
AT1R A1166C genotypes on two loci   
CI = confidence interval; OR = odds ratio. * : P＜0.05. 
Table 3. Odds rations for the presence of SRAR by ACE I/D and AT1R A1166C. 
Malignant hypertension was companied with the AT1-AA mediated SRAR. We performed 
univariate analysis of the factors affecting SRAR to the overall group. The factors 
significantly associated with graft transplant failure were HLA mismatch >1 (P >0.05). 
Among the nineteen recipients suffered SRAR, fourteen patients occurred malignant 
hypertension. In the detection of AT1R antibodies and DSA, the former were invariably 
positive in the malignant hypertension recipients and the DSA negative in their peripheral 
blood. While the rest 4 cases of SRAR recipients have the peripheral DSA and 1 case with 
neither AT1-AA nor DSA. 
The demographic data from the 14 patients who were positive for AT1-receptor 
antibodies were compared with those for the 4 patients with donor-specific anti-HLA 
antibodies. As shown in Table 4, patients with anti-HLA antibodies were more likely to 
have staining for C4d in their renal biopsy specimens and had less rapid allograft loss. 
Otherwise, there were no significant differences in clinical or demographic characteristics 
between the two groups. 
The biopsy specimens from patients with malignant hypertension and refractory rejection 
who had no donor-specific anti-HLA antibodies (stained with hematoxylin and eosin) 
showed the evidence of tubulitis and intravascular inflammatory cells. Interlobular arteries 
were obstructed by swollen endothelial cells which underwent necrosis and vacuolation. 
The smooth muscle cells proliferated and the intima thickened greatly. Inflammatory cells 
can be seen inside the vascular and segmental veinlets. The atrophied glomcrulus were 
divided into subsections. Tubules were expanded with red cell cast inside it. The peritubular 
capillaries were aggregated with polymorph nuclear leukocytes. Interstitium was infiltrated 
with inflammatory cells. The renal shows multiple perfusion defects and cortical infarctions 
(Figure 1). 
 











Male sex (n) 8 2 
Cold-ischemia (h)   
Median 6.7 6.5 
Range 2.4-18.5 2.2-19.1 
No. of HLA mismatches   
Median 3 3 
Range 0-3 1-5 
PRA at transplantation (%)   
Median 5 6 
Range 0-7 0-9 
Age at transplantation (yr)   
Median 36.5 37.2 
Range 19-49 20-48 
Time from transplantation to rejections(days)   
Median 3 6 
Range 2-360 3-351 
C4d-positive (No.)* 3 4 
* : P<0.01. 
Table 4. Characteristics of patients with AT1-Receptor antibodies and patients with donor-
specific anti-HLA antibodies but without AT1R-Receptor antibodies. 
AT1-AA mediated SRAR was markedly associated with the prognosis of the renal transplant 
recipients. The occurrence of SRAR was analyzed for an association with the susceptibility to 
worsening renal graft function. A stable renal function was more often observed in 
recipients who did not suffered from SRAR than in GI. There was a striking effect of the 
SRAR and long-term stable graft function (Figure 2A), with more patients suffering from 
worsening renal function with the occurrence of SRAR (Kaplan-Meier, P<0.05). The analysis 
also discovered that the occurrence of SRAR is strongly associated with the appearance of 
the antibodies of AT1R. The χ2 analysis revealed that the positive of AT1-AA is strongly 
related to the appearance of SRAR. We also noticed that the frequency of the AT1R-C allele 
and ACE D-allele is comparable in SRAR group. Patients with anti-HLA antibodies had 
substantially better graft survival than did those who had malignant hypertension but did 
not have anti-HLA antibodies (Figure 2B). 
Treatment consisting of protein A immunoadsorption (IA), intravenous immune globulin, 
and 100 mg of losartan daily in nine patients with AT1R antibodies resulted in significantly 
improved allograft survival, as compared with that in patients receiving standard anti-
rejection treatment (Figure 2C). Serum from four patients with the longest rejection-free 
follow-up (who are still receiving losartan) became negative for AT1-receptor antibodies. 
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Fig. 1. Features of Refractory Rejection in Patients without Donor-Specific Anti-HLA 
Antibodies The biopsy specimens from representative patients showed the evidence of 
tubulitis and intravascular inflammatory cells. The atrophied glomcrulus were divided into 
subsections. Tubules were expanded with red cell cast inside it (Panel A). Inflammatory cells 
can be seen inside the vascular and segmental veinlets (Panel B). Interlobular arteries were 
obstructed by swollen endothelial cells which underwent necrosis and vacuolation. The 
smooth muscle cells proliferated and the intima thickened greatly. The peritubular 
capillaries were aggregated with polymorph nuclear leukocytes. Interstitium was infiltrated 
with inflammatory cells (Panel C and D).  
 




Fig. 2. Graft survival in the Kaplan–Meier analysis was significantly decreased in the 
patients with SRAR compared with those who did not suffered from it (Panel A). The graph 
in Panel B demonstrates accelerated allograft loss in patients who had refractory vascular 
rejection with non-HLA antibodies, compared with patients who had vascular rejection and 
donor-specific anti-HLA antibodies. Graft survival in the Kaplan–Meier analysis was 
significantly increased in the patients with AT1-receptor antibodies who received losartan 
and IA, as compared with those who received nonspecific treatment (Panel C).  
4. Discussion 
The factors leading to SRAR are not fully understood, but they consist of humoral immune 
response and genetic factors [20]. We studied the SNP of RAS and AT1R antibodies and 
DSA in patients, and tested C4d on their biopsy specimens. The findings of this study 
suggest an association of RAS polymorphism and the occurrence of SRAR in renal 
transplantation recipients. The single nucleotide polymorphism of RAS may be one of the 
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non-immunologic mechanisms of the SRAR. Yet the appearance of autoantibody of AT1R 
may be one of the immunologic mechanisms of the occurrence of this type rejection. Our 
results support the hypothesis that there is an association between the occurrence of the 
SRAR and the appearance of the AT1-AA in recipients whose genotype of RAS performed 
certain polymorphism. The recipients with the DD genotype of ACE and CC genotype of 
AT1R may trend to suffer the AT1-AA mediated rejection. The process of the rejection may 
be improved by the application of ARB, coupled with protein A immunoadsorption and 
high dose intravenous immunoglobulin.  
The outcome of the renal transplantation was improved obviously with the use of CsA and 
FK506. Methylprednisolone was widely used in preventing and treatment of acute rejection 
and most recipients benefit from it. But there are still some patients who are refractory to the 
steroid treatment. Most of them have the similar characteristics including anuria after 
transplantation, malignant hypertension and graft function loss. It has been proved that 
many diseases have their own genotype polymorphism backgrounds. Genes that affect 
blood pressure regulation, mesangial or vascular proliferation or aspects of inflammatory 
response may play important roles in this complex syndrome. Genes determining the 
activity of a recipient’s renin–angiotensin system (RAS) may be alloantigen-independent 
factors that influence the kidney allograft function. 
Investigation of the genetics, physiology, and pharmacotherapeutics of RAS and its 
regulators has made it one of the most intensely studied molecular pathways of human 
diseases. The RAS is implicated in the development of a variety of human disorders, 
including cardiovascular diseases [21]. Inhibition of this system has had proven benefits in 
reducing the risk of cardiovascular endpoints [22], diabetes, and end stage renal disease 
(ESRD) [23]. Genetic variability in the RAS may modify renal responses to injury and 
disease progression. It seems some differential group of recipients is destined to lose their 
grafts faster. Our study was designed to elucidate the relationship between genetic RAS 
polymorphisms namely ACE I/ D, AGT M235T, AT1R A1166C and CYP11B2 and SRAR in 
Chinese renal transplant recipients. 
The angiotensin converting enzyme (ACE) gene displays an insertion/deletion 
polymorphism in intron 16, and homozygosity of the deletion allele is known to be 
associated with higher serum ACE levels [24]. The DD genotype of ACE gene is a risk factor 
for the progression of chronic renal failure in IgA nephropathy [25]. It has also been 
reported that patients with ACE (DD) and angiotensinogen AGT (TT) genotypes are linked 
to poorer long-term renal transplant function [26, 27]. Demonstrated survival benefits may 
be a result, in large measure, of the salutary effects of angiotensin converting enzyme (ACE) 
inhibition on the endothelium [28] and vascular smooth muscle cells [29]. A beneficial 
association of CAD progression in Caucasian pediatric renal transplant recipients with the II 
genotype and/or the presence of the I allele is also found [26, 30, 31]. Current evidence on 
the nature of the renal risk is associated with the D-allele, as also apparent from a large 
meta-analysis that addressed cardiovascular risk, indicates that the D-allele acts as a course-
modifying gene rather than as a disease-inducing gene [32].  
In the present study, the D allele of ACE is a risk factor for the development and progression 
of the SRAR while no significant relationship was found between ACE I/D polymorphism 
and CAD [33]. The result is in line with other studies that examined the effect of the ACE 
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I/D polymorphism on the progression of diabetic nephropathy [34], and the progression of 
chronic renal failure in immunoglobulin A nephropathy [35] and in adult polycystic kidney 
disease [36]. This effect of the D allele of ACE is also similar with the findings reported by 
Abdi et al [30] and Akc¸ay et al. [37] which found that ACE DD genotype was associated 
with poorer chronic transplant function and more rapid chronic progression. Some related 
results also have been reported by Barocci et al. [38] in pediatric transplant recipients and 
Gaciong et al. [39] in adult transplant recipients. Our data are consistent with these views. 
Thus, the presence of a D-allele does not appear to enhance renal risk in itself, but once a 
sequence of events leading to progressive renal function loss is initiated by whatever cause, 
its course is more rapid in presence of the D allele [40]. 
Angiotensin II has been proven to have growth factor-like and angiogenic activities [41] 
and these activities are mediated through the activation of the angiotensin type 1 receptor 
[42]. The AGT1R A1166C polymorphism was found to predict the systemic and renal 
response to angiotensin receptor antagonism and angiotensin II infusion in healthy 
subjects [43]. In the present study patients with the AGT1R C allele tended to have a 
worse preservation of graft function than patient homozygous for the A allele. Yet 
patients with the C allele exhibited a stronger response to losartan, showed a faster serum 
creatinine degression, and had a better response of the decent of the mean blood pressure 
compared with subjects homozygous for the AA allele, suggesting an increase in 
intrarenal angiotensin II activity with the AC/CC genotype. However, the treatment was 
neither randomly assigned nor blinded, and the numbers of patients are too small to 
permit us to draw firm conclusions. This would indicate that recipient AGT1R C allele 
may adversely affect renal outcome after kidney transplantation. Moreover, our data are 
in contrast with another report in which the C allele of AT1R dose not adversely affect 
renal response after transplantation [44]. However, we do not know the genotype of the 
donors because they were not genotyped. As the frequency of the A allele in the general 
population is high (71% in our patients), the probability of a recipient with the C allele 
receiving a kidney with the C allele is low. In the analysis of the results, the incidence of 
SRAR is very low (9.2%), the recipients with AT1-AA is even lower (6.8%). We suppose 
that the occurrence of SRAR may be based on the condition when the C recipient meets 
the C donor coincidently, and then the autoantibody of AT1-AA would be created in this 
group. Of course this is only an imagination need to be tested.  
There are many polymorphisms in the AGT gene located on chromosome 1q42–q43. In 
exon 2, a nonsynonymous substitution of T by C in codon 235 of the AGT gene, leads to a 
change from Methionine to Threonine. In Caucasians, African and Japanese populations, 
the T235 variant of this M235T polymorphism of this gene has been consistently 
associated with higher levels of angiotensinogen in plasma and an increased risk for 
hypertension [45, 46, 47]. 
The primary regulation of aldosterone synthesis is via the renin-angiotensin system, which 
is responsive to the state of the electrolyte balance and plasma volume. The -344T/C 
polymorphism in the CYP11B2 promoter region, the steroidogenic factor-1 binding site, was 
reported to be associated with blood pressure or aldosterone secretion. Some investigators 
found a positive association between the -344T polymorphism in the CYP11B2 gene and 
essential hypertension. Our study suggests that the CYP11B2 gene promoter region 
polymorphism and AGT M235T is not directly associated with SRAR. Therefore, this 
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polymorphism may not be a risk factor for the rejection or the malignant hypertension, at 
least not in the Chinese population. The lack of relationship between these two genotypes 
and early graft function in our study may indicate that other factors have major impacts in 
the setting of kidney transplantation. 
We also examine the relationship between the given RAS polymorphism and the emergency 
of peripheral AT1-AA of the recipients. Draun et al reported that AT1-receptor–mediated 
pathway may contribute to refractory vascular rejection [48]. Our results revealed that the 
recipients with D allele of the ACE and the C allele of the AT1R are inclined to have the 
AT1-AA. This phenomenon can partly explain the fact that only small percent of recipients 
have SRAR.  
Our report suggests that a SNP of the RAS component may contribute to the development 
of the steroid refractory acute rejection of kidney grafts. Individuals bearing D allele of ACE 
and C allele of AT1R may be sensitive to suffer steroid resistant acute rejection after renal 
transplantation. And the patients subjected to SRAR always produce AT1-AA. There is 
some statistical association between the appearance of AT1-AA and the D allele of ACE and 
C allele of AT1R. Patients with these types of antibodies have a less favorable prognosis, 
greater graft loss, and poorer long-term function as compared with patients with DSA alone. 
The treatment against such antibody mediated immune response is necessary and effective. 
We speculate the AT1-AA may have been produced when the subjects experienced 
preeclampsia or renal transplantation before or for other reasons. The importance of the 
detection of the genotype of ACE and AT1R and AT1-receptor antibodies in patients on a 
waiting list for a transplant might be comparable with the detection of PRA in identifying 
risk factors for refractory rejection. 
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recipients with D allele of the ACE and the C allele of the AT1R are inclined to have the 
AT1-AA. This phenomenon can partly explain the fact that only small percent of recipients 
have SRAR.  
Our report suggests that a SNP of the RAS component may contribute to the development 
of the steroid refractory acute rejection of kidney grafts. Individuals bearing D allele of ACE 
and C allele of AT1R may be sensitive to suffer steroid resistant acute rejection after renal 
transplantation. And the patients subjected to SRAR always produce AT1-AA. There is 
some statistical association between the appearance of AT1-AA and the D allele of ACE and 
C allele of AT1R. Patients with these types of antibodies have a less favorable prognosis, 
greater graft loss, and poorer long-term function as compared with patients with DSA alone. 
The treatment against such antibody mediated immune response is necessary and effective. 
We speculate the AT1-AA may have been produced when the subjects experienced 
preeclampsia or renal transplantation before or for other reasons. The importance of the 
detection of the genotype of ACE and AT1R and AT1-receptor antibodies in patients on a 
waiting list for a transplant might be comparable with the detection of PRA in identifying 
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1. Introduction 
1.1 Renal transplantation 
Renal transplantation is the treatment of choice for most patients with end-stage renal 
diseases (ESRD). Patients usually undergo transplantation after a variable period of dialysis. 
Recently, due to development of standard surgical techniques and improvement in post 
transplantation care such as organ preservation, immunosuppressive and antimicrobial 
agents graft and patient outcome has significantly improved. The recognition of anti-donor-
HLA antibodies in a renal allograft recipient’s serum, at the time of or after transplantation, 
is usually correlated with specific antibody-mediated clinical syndromes which can be 
categorized into three groups such as hyperacute rejection, acute humoral rejection and 
chronic humoral rejection. Allograft rejection is caused by several component of the immune 
system; consist of antibody, complement, T cells and other cell types. The mechanisms of 
pathways of acute rejection are being determined and the consequences of immune rejection 
are identified by graft dysfunction and classified by histological features of allograft biopsy 
specimens (Solez et al., 2008).  
1.2 Hyperacute rejection 
Hyperacute rejection occurs within 24 hours of reperfusion and is characterized by immediate 
loss of graft function resulting abrupt cessation of urine flow. Hyperacute rejection might be 
either diagnosed clinically by the surgeon with mottling cyanosis and reduced turgor in the 
graft or by a histopathologic feature of interstitial hemorrhage, microthrombosis and 
inflammation (neutrophils and fibrin infiltration) of the failed allografts which might be 
qualitatively similar to those seen in acute antibody mediated rejection (AMR). Hyperacute  
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1. Introduction 
1.1 Renal transplantation 
Renal transplantation is the treatment of choice for most patients with end-stage renal 
diseases (ESRD). Patients usually undergo transplantation after a variable period of dialysis. 
Recently, due to development of standard surgical techniques and improvement in post 
transplantation care such as organ preservation, immunosuppressive and antimicrobial 
agents graft and patient outcome has significantly improved. The recognition of anti-donor-
HLA antibodies in a renal allograft recipient’s serum, at the time of or after transplantation, 
is usually correlated with specific antibody-mediated clinical syndromes which can be 
categorized into three groups such as hyperacute rejection, acute humoral rejection and 
chronic humoral rejection. Allograft rejection is caused by several component of the immune 
system; consist of antibody, complement, T cells and other cell types. The mechanisms of 
pathways of acute rejection are being determined and the consequences of immune rejection 
are identified by graft dysfunction and classified by histological features of allograft biopsy 
specimens (Solez et al., 2008).  
1.2 Hyperacute rejection 
Hyperacute rejection occurs within 24 hours of reperfusion and is characterized by immediate 
loss of graft function resulting abrupt cessation of urine flow. Hyperacute rejection might be 
either diagnosed clinically by the surgeon with mottling cyanosis and reduced turgor in the 
graft or by a histopathologic feature of interstitial hemorrhage, microthrombosis and 
inflammation (neutrophils and fibrin infiltration) of the failed allografts which might be 
qualitatively similar to those seen in acute antibody mediated rejection (AMR). Hyperacute  
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rejection is generally considered to be mediated by humoral immutnity (Baid S e al., 2001). 
Immunofluorescence (IF) studies demonstrated IgG (but not IgM) in glomerular and 
peritubular capillaries The pathogenesis of hyperacute rejection depends on the activation of 
complement activated through any pathway (classical, alternative, or lectin) can initiate 
hyperacute rejection regardless of how complement is activated (Chang A.T and Platt J.L. 
2009). Hyperacute rejection of clinical allografts is most often caused by anti-HLA antibodies 
which bind to blood vessels and activate the complement system in a newly transplanted 
organ. Hyperacute rejection is observed in up to 80% of the kidneys transplanted into 
recipients with cytotoxic antibodies detected by cytotoxic cross match (Patel R and Terasaki PI, 
1969). Hyperacute rejection is more common in allogarfts with these antibodies compared with 
ABO-incompatible renal transplants. Hyperacute rejection can also occur independent of anti-
donor antibodies and these cases may reflect activation of the alternative or lectin pathways as 
might occur with ischemic injury (Chang A.T and Platt J.L, 2009). 
Hyperacute rejection may occur in some recipients appearing to lack anti-donor antibodies. 
In some cases antibody capable of binding to and injuring the graft may be present but is 
not detected by assays in which leukocytes are used as the target. Fortunately, with the 
serologic technologies and expertise now available, hyperacute rejection has become an 
extremely rare occurrence. 
1.3 Acute rejection 
Acute rejection episodes (ARE) typically develop after transplantation at any time after 
organ transplantation and are divided histopathologically in to two categories: interstitial 
and vascular (Fig 1). A key clinical sign of acute rejection is a baseline rise in serum 
creatinine of 25% in the asymptomatic patient with no other apparent explanation.  Novel 
immunosuppressive drugs and regimens have decreased the incidence of acute rejection 
occurrence, however, acute rejection (AR) is still a major risk of early graft dysfunction and 
late kidney graft loss (kamali et al., 2009). Despite the introduction of successful 
immunosuppressive drug therapies, acute renal allograft rejection still occurs in 10–20% of 
patients after cadaveric renal transplantation and causes graft loss in up to 6% in the first 
year after transplantation (Magee, Pascual., 2004). The early phase of diagnosis of acute 
allograft rejection might help clinicians to perform required procedures to prevent 
undesirable posttransplant complications (kamali et al., 2009). 
1.3.1 Acute interstitial allograft rejection 
Also termed acute cellular rejection or acute reversible rejection is characterized by an 
infiltration of inflammatory cells (mainly of CD8 T lymphocytes) in the interstitium, and 
tubular epithelium involvement named tubulitis (Racusen LC et al. 1999).  Tubulitis has 
been regarded as a reliable marker for acute rejection even though it can be seen in other 
forms of interstitial nephritis (Colvin., 1996). The infiltrate is more concentrated in the cortex 
than in the renal medulla. Rejection that is predominantly cellular is considered to be readily 
reversible with therapy. 
1.3.2 Acute vascular rejection  
Acute vascular rejection is called as acute humoral rejection contains the most severe 
changes in the small arteries, veins, and arterioles. Humoral antibodies may cause tissue 
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injury or organ dysfunction by themselves or in collaboration with immunocompotent cells 
(Fig2) (Lederer S.R et al, 2001). The diagnostic criteria for acute humoral rejection are given 
in Table 1. 
1. Morphologic evidence of acute tissue injury 
acute tubular injury 
neutrophils and/or mononuclear cells in PTC 
and/or glomeruli and/or capillary thrombosis 
fibrinoid necrosis/intramural or transmural 
inflammation in arteries 
2. Immunopathologic evidence for antibody action 
C4d and/or (rarely) immunoglobulin in PTC 
Ig and complement in arterial fibrinoid necrosis 
3. Serologic evidence of circulating antibodies to 
donor HLA or other anti-donor endothelial antigen 
*Cases that meet only two of the three numbered criteria are considered suspicious for acute humeral 
rejection (AHR). Acute cellular rejection may also be present.  
Table 1. Diagnostic criteria for acute antibody-mediated rejection (adapted from Lorraine et 
al., 2006)* 
It is emphasized that humoral immune reactions soon after transplantation had a much 
stronger impact than alloreactivity during later periods. Occurrence of delayed graft function 
(DGF) was assumed as long-term consequences of alloreactivity events early after 
transplantation (Ojo et a.l, 1997). Humoral reactions late after transplantation that are clearly 
detectable in serum and biopsy samples obviously do not significantly reduce graft survival 
(Lederer et al., 2001).  In renal allograft recipients who experienced acute humoral rejection, 
donor-specific circulating alloantibody showed a sensitivity and specificity of 95% and 96% 
respectively (Feucht HE et al, 1991). Crespo and colleagues reported an acute rejection 
prevalence of 6.3% among 232 transplanted patients, two thirds of whom were steroid 
resistant (Crespo et a.l, 1999). Acute humoral rejection refractory to steroids and polyclonal 
antibodies leads to a 70% to 80% rate of graft loss (Watschinger B, Pascual M, 2002). The 
earliest morphologic characteristics of acute vascular rejection are swelling and vacuolization 
of the endothelial cells with areas of ulceration.  Graft survival among patients with acute 
humoral rejection and without specific therapy is poor but novel treatment modalities of acute 
humoral rejection has saved some grafts (Watschinger B, Pascual M, 2002). Acute humoral 
rejection therapy seeks to remove circulating antibodies through plasmapheresis or 
immunabsorption and to inhibit B-cell proliferation using mycophenolate. Acute humoral 
rejection requires different therapy than cell-mediated rejection. Therapy for Acute humoral 
rejection is plasmapheresis and intravenous Ig combined with intense immunosuppression 
(typically tacrolimus and mycophenolate mofetil). In analysis of 113 renal allograft recipients 
by Péfaur J. et al, the recipients received high doses of IVIG (2 g/kg in five doses; two also 
received plasmapheresis or thymoglobulin). Mycophenolate, tacrolimus, and steroids were 
used as maintenance immunosuppressive therapy. Patient and graft survivals were 100% 
(abapted from Péfaur J. et al, 2008). 
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Fig. 1. (A) Acute cellular rejection (ACR): no staining for C4d is seen in peritubular 
capillaries. (B) Acute humoral rejection (AHR): widespread and bright staining for C4d is 
present in the peritubular capillaries that are interspersed in between the silhouettes of 
tubules. (C) ACR: mononuclear cells are present in the interstitium (*) and in peritubular 
capillaries (arrows). (D) AHR: abundant neutrophils are present in dilated peritubular 
capillaries (arrows). (E) ACR: scattered mononuclear cells are present in glomerular 
capillaries (arrows). (F) AHR: neutrophils are present in glomerular capillaries (arrows). 
Staining: C4d-FITC in A and B; Hematoxylin and eosin (H&E) in C, D, and F; and periodic 
acid-Schiff (PAS) in E. Magnifications: _400 in A through D; _450 in E and F. (adapted from 
Saadi et al. 2004) 
1.4 Antibody-mediated rejection 
As novel immunosuppressive protocols had effective control of T cell mediated acute 
rejection, antibody-mediated rejection (AMR) of renal allograft has re-emerged as an 
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important post-transplant complication.The complement system plays an important role in 
antibody mediated rejection (AMR) via classical pathway activation. Antibody-mediated 
rejection is characterized pathologically by focal ischemia, severe injury to the endothelial 
cells lining blood vessels in the graft and diffuse intravascular coagulation . 
Expression of anticoagulant molecules (thrombomodulin and heparan sulfate) from normal 
endothelial cells inhibit coagulation process (Miyata Y and Platt JL). Activated endothelial 
cells promote coagulation and inflammation which induce expression of cell adhesion 
molecules and cytokines (Saadi et al. 2004) 
1.5 Delayed graft function (DGF)  
Delayed graft function (DGF) and acute rejection are the two main early adverse events in 
renal transplantation. Historically, DGF was defined by the requirement for dialysis within 
the first week of renal transplantation. The rate of DGF varies between among different 
centers from 20 to 40% (Koning OH et al ,1997). The incidence of DGF was 20% to 29% 
among deceased donor kidneys and 6% among living donor kidneys (Halloran and 
Hunsicker, 2001). Investigation of 689 allograft renal transplants form HLA-mismatched 
unrelated living donors revealed the incidence of DGF was 7.7%, which was higher than 
reports with HLA-matched living related donors (Ghods AJ et al, 2007). Many pathological 
findings are associated with DGF, the most common being acute tubular necrosis. Typical 
histological findings of DGF are dilatation of tubules, loss of proximal epithelial cell brush 
border, epithelial cell necrosis/apoptosis, and cellular casts (Smith KD et al , 2003). The 
impact of DGF on long-term graft survival is controversial. Some, though not all, evidence 
suggests that DGF may increase the frequency of acute rejection and thus reduce long-term 
survival. Univariate and multivariate analyses showed that DGF significantly reduced the 
survival rate and half-life of renal grafts. Troppmann et al.  Found that only if DGF and early 
acute rejection co-existed would DGF be one of the risk factors that reduced the long-term 
survival rate of recipient kidney (Troppmann C et al. 1996).  The early inflammatory 
response is initiated by ischemia/reperfusion, activation of innate immunity and 
subsequent alloantigen-primed T cell recruitment, activation and proliferative expansion. 
DGF is also thought to up-regulate MHC class II antigens, thus predisposing the 
transplanted graft to an increased incidence of acute rejection, which can be recognized 
histologically by the presence of tubulitis and infiltration of leukocytes into the tubular 
epithelium (Daily P et al, 2005). However, there are also reports showing that DGF played a 
greater role as a risk factor than acute rejection and HLA mismatch, and that DGF affected 
renal graft survival by increasing acute rejection and the chronic rejection rate, and 
decreased the survival rate of renal graft independent of acute rejection (Geddes CC et al. 
2002). Aquino-Dias and associations have extended the diagnostic accuracy of mRNA 
profiles in recipients with DGF (Aquino-Dias EC. et al, 2008). Peripheral blood cell levels of 
TIM-3 mRNA are suspected to predict acute rejection in renal allograft recipients with DGF 
with a sensitivity of 100% and a specificity of 100% (Manfro RC et al, 2008).  The main 
modality in management of DGF is to support the patient with dialysis and to monitor for 
rejection with serial biopsies. 
At engraftment, ischemia-reperfusion injury occurs with activation of Toll-like receptors of 
the innate immune system and subsequent cytokine release. These pro-inflammatory 
mediators induce tubular epithelial cells to attract neutrophils and T cells by production of  
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Fig. 2. Diagram of postulated events leading to graft damage during kidney transplantation 
(Adapted from Womer K.L. and Kaplan B, 2009). 
chemokines. Innate immune system activation induces maturation of dendritic cells, leading 
the transition to the adaptive or antigen-specific phase of transplantation immunity. 
Dendritic cells activate CD4+ T helper cells through presentation of alloantigen in the 
context of major histocompatibility complex (MHC) molecules and ligation of appropriate T 
cell surface costimulatory molecules. After activation, CD4+ T helper cells induce further T 
cell proliferation, the production of alloantibodies from B cells, activation of macrophages, 
and differentiation of naïve CD8+ T cells into cytotoxic T lymphocytes. Mononuclear cells, 
especially cytotoxic T lymphocytes, enter between tubular cells and induce apoptosis by 
releasing cytolytic granules containing perforin and granzyme or by exposure to FasL on the 
T cell surface. Tubular cells chronically exposed to transforming growth factor β (TGFβ) 
may undergo epithelial-mesenchymal transition, an aberrant phenotype evidenced by 
epithelial cell expression of α-smooth muscle actin and loss of E-cadherin expression. These 
cells then may migrate to the interstitium and contribute to fibrosis. Both T cells and 
antibody likely recognize alloantigen on target endothelium. While T cells may cause 
cytotoxicity directly, alloantibody is usually directed against the MHC molecule, followed 
by activation of complement. Antigen recognition leads to endothelial secretion of factors 
that activate the immune and coagulation systems. These activities promote rejection and 
chronic changes of the endothelium and underlying smooth muscle layer, resulting in the 
characteristic histopathologic findings of transplant arteriopathy. Alloantigen-independent 
factors also contribute to tubular and endothelial cell damage.  
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2. HLA matching  
The human leukocyte antigen system (HLA) is the name of the major histocompatibility 
complex (MHC) which contains a large number of genes related to immune system function 
in humans. This group of genes resides on chromosome 6 and encodes cell-surface antigen-
presenting proteins and many other proteins. HLA antigens on the cell membrane play an 
important role in the immune response to foreign tissue (Muczynski KA et al. 2003). HLA 
complex is highly polymorphous (Marsh SG et al. 2002). Thus it is difficult to identify none-
mismatched donors with only limited samples. In order to increase the matching rates, HLA 
typing has been recommended supported by the public epitope theory. MHC molecules are 
divided into 2 main classes: HLA class I antigens (HLA-A, HLA-B, HLA-C) are presented on 
the surface of all nucleated cells and platelets and HLA class II antigens (HLA-DR, HLA-
DQ, HLA-DP, HLA-DM, HLA-DO) are expressed on professional antigen-presenting cells, 
but also on the surface of endothelial vascular cells and renal tubular epithelial cells 
(Muczynski KA et al. 2003). Human capillary endothelial cells, in contrast to rodents, 
express both human lymphocyte antigen (HLA) class I and class II molecules with high 
density even under normal physiological conditions (McDouall RM. et al, 1997). Cytotoxic 
antibodies (anti-HLA) are not detectable normally but after the blood/plasma transfusion, 
in pregnancy or after a previous transplant. When these antibodies are directed against HLA 
system of transplanted organ, their targets are represented by the graft endothelial cells 
which is followed by activation of complement, coagulation cascade and other inflammation 
factors. This mechanism mediated by anti-HLA antibodies is called humoral rejection 
(hyperacute rejection) that results in severe injury of endothelial cells and dysfunction of the 
transplanted organ (Moise A et al 2010). The first clinical importance of anti-HLA antibodies 
was demonstrated in 1969 (Patel R and Terasaki PI. 1969). Now it is known that the 
recipients who present preformed cytotoxic antibodies have a high rate of graft rejection. 
Production of antibodies after transplantation remains the main factor of acute and chronic 
rejections. Sometimes, antibody-mediated rejection (AMR) is still inevitable in human 
leukocyte antigen (HLA)-identical donor-recipient transplants (Zou Y and Stastny P, 2009). 
Antibody sensitization to alloantigens of the HLA system is one of the greatest barriers in 
successful renal transplantation (Zou YZ et al. 2007). Moise and colleagues reported that in 
both, compatible and incompatible subjects, post-renal transplantation could develop de 
novo anti-HLA antibodies especially those had an HLA mismatch with donor predictable 
for acute graft rejection (Moise A et al 2010). HLA-I antigens can be identified on nucleated 
cells, including on the endothelia of small renal vessels. Anti-HLA-I Ig G antibodies can 
injure the small vascular endothelia of the graft and induce serious rejections such as HR 
(Halloran PF et al 1990, 1992). HLA-II antigens are mainly expressed by immune cells. It is 
previously accepted that HLA-II antibodies have a relatively minor impact on the early graft 
outcome, despite a few cases reported with a higher rejection rate and humoral rejections 
occurrence due to HLA-II antibodies. A large-scale multi-center clinical study illustrated 
that graft survival rate at two or three years was decreased in recipients with both HLA-I 
and HLA-II antibodies, this was lower in recipients with more than three mismatched HLA 
alleles (Susal C and Opelz G. 2004). However, no significant difference was found in 
recipients with HLA-II antibodies compared with unsensitized patients. It is suggested that 
ELISA detected development of HLA antibodies, especially HLA-I antibodies, in the post-
transplant period may provide a good predictor of acute rejection and of graft survival. 
Besides according to tissue inflammation and repair mechanisms inflicted by anti-HLA 
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antibodies results in exposure of self antigens which lead to post-transplant autoimmunity. 
Detection of immune responses to self-antigens will provide new strategies to monitor and 
prevent development of late graft dysfunction (Natha DS. et al, 2010).  
3. Immunologic factors in renal transplantation 
A major challenge for the field of transplantation is the lack of understanding of molecular 
mechanisms of immune response early after transplantation. The association between the 
presence of donor specific antibodies (DSA) and acute rejection has been noted in the late 
1970s (Hartono C et al. 2010). Complement proteins have been described to play a significant 
role in organ damage following transplantation both in the process of ischemia reperfusion 
and in modulating the activation of the adaptive immune response. Based on the knowledge 
alloreactive T cells are key mediators of transplant injury (Dinavahi R. et al, 2008). It has 
become clear that the type of specific immune response to offending agents is largely 
dependent on the preferential activation of peculiar CD4 T helper (Th) cells able to secrete 
defined patterns of cytokines. Two distinct CD4 T helper cell subsets, coded as Th1 and Th2, 
showing distinct and mutually exclusive patterns of cytokine secretion, have been identified in 
both mice and humans (Romagnani S. et al, 1995). Significant efforts have been carried out to 
demonstrate methodologies that reliably measure cellular alloimmunity, and in determining 
the utility of these approaches as biomarkers for acute rejection, biopsy proven fibrosis and 
impaired allograft function. Traditional methods of measuring T cell alloreactivity include 
proliferation and cytotoxicity assays, performed either on bulk cultures (mixed lymphocyte 
responses) or as limiting dilution assays. While these methods are accepted as useful research 
tools, their intensive labor requirements and limited reproducibility have prevented them 
from becoming standardized clinical tests (Dinavahi R. et al, 2008). 
4. Serum markers of allograft dysfunction 
Identification of serum markers or parameters before and after transplantation of recipients 
assuming increased risk of allograft rejection helps clinicians for a successful performance in 
individualization of immunosuppression therapeutic regimens and ensures a more 
adequate follow-up of these patients (Rouschop KM et al, 2005). High dose 
immunosuppression should be avoided at least for low-risk recipients due to the massive 
side effects such as cancer development, infection and toxicity. For example, Aggressive 
immunosuppression may reactivate polyoma BK virus, which is usually latent in the 
urinary tract.  Few biologic assays that might be potentially useful for monitoring the 
immune status of renal graft recipients have been reported (Susal C et al. 2003). Some 
reports have elucidated that a number of acute-phase reactants, such as C-reactive protein 
(Oyen O et al, 2001) and pro-inflammatory cytokinesn (IL-6), have been associated with 
allograft rejection (Waiser J et al, 1997), although their usefulness also has been debated 
(Cueto-Manzano et al, 2005). It is noted that IL-17 may be involved early alloimmune 
response during the course of acute rejection. IL-17 may play the role of an early initiator of 
the T cell-dependent inflammatory reaction. Human IL-17, a new cytokine secreted from 
CD4+ activated memory T cells, can stimulate the production of proinflammatory and 
haematopoietic cytokines by macrophages and stromal cells (Fossiez F et al, 1996). 
Immunofluorescence has shown the expression of IL-17 in kidney biopsies from patients 
suffering from graft rejection, while pretransplant biopsies and normal kidneys were  
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negative. Recently, monocyte-associated IL-18 has been suggested to be a pertinent 
biomarker in keeping with growing interest in monocyte infiltration during rejection.  Striz 
et al. also observed a significant increase in serum IL-18 levels in patients with acute renal 
allograft rejection, compared with patients with uncomplicated transplantation, and further 
showed that IL-18 mRNA was released in response to increased TNF-_ and IFN-_ 
production (Striz I et al, 2005). Another complement component which has important role in 
organ transplantation is CD55, which is also called  Decay Accelerating Factor (DAF). This 
molecule is present on the cell surface e where it accelerates the decay of C3 and C5 
convertases from the classic and alternative pathway of complement to prevent their 
amplification and self-damaging effect on cells (Medof ME. et al, 1984).  Early post-
transplant acute rejection and infection are major causes of morbidity and mortality, 
whereas, lack of full rehabilitation, drug toxicity, chronic rejection and malignancies 
constitute debilitating the long-term complications. All problems described above may be 
(directly or indirectly) related to the lack of easy and feasible immunological tests for 
predicting the risk of rejection and recognizing ongoing rejections after transplantation as 
early as possible. (Truong DQ. et al, 2007). It has long been a goal of transplant 
immunologists to develop tests for assessing the pretransplant risk of patients for 
immunologic rejection and for recognizing impending rejections after transplantation as 
early as possible (Susal C. al, 2004).  
5. Soluble CD30 (sCD30) 
In addition to cytokines, other relevant proteins have been studied. Soluble CD30 (sCD30), a 
member of the TNF receptor superfamily that is a 120 kD membrane glycoprotein and 
expressed on Th2 cells, may be useful. (Serum levels of sCD30 are associated with disease 
activity of Th2-type cells and with disease remission in Th1-mediated disease states. Although 
the role of Th1 versus Th2 responses in allograft rejection has been strongly debated, CD30_ T 
cells are implicated in the alloimmune response (Martinez OM et al, 1998).  
Recent reports have proposed sCD30 as a noninvasive serological marker to predict 
immunological risk and graft failure among kidney transplant recipients (Pelzl S. et al, 
2003). Both CD4 and CD8 T cells expressed CD30 after primary alloantigenic stimulation 
(Martinez OM. et al, 1998). Th1 cytokines including IL-2, TNF-α, and IFN-γ mediate cellular 
immune responses and are pro-inflammatory, whereas, Th2-type cytokines IL-4 and IL-10 
have been shown to inhibit the development and function of Th1-cells, to suppress 
inflammation, and to enhance humoral pathways of the immune response (Warle Mc. et al, 
2001). Some studies suggested that CD30 may serve as a marker for human T lymphocytes 
that produce Th2 cytokines (Manetti R. et al, 2007), while others demonstrated a strict 
association between CD30 expression and Th1 cytokine production (Martinez OM. et al, 
1998). However, Pellegrini et al. found that CD30 may be an important co-stimulatory 
molecule and marker for the physiological balance between Th1/Th2 immune response 
(Pellegrini P. et al, 2003). After activation of CD30+ T cells, a soluble form of CD30 (sCD30) 
is released proteolytically, however, the biological significance of this process is still not 
clearly defined (Dong W. et al, 2006). Th1-cytokines are mainly involved in allograft 
rejection, while Th2-type immune response may be graft protective by blocking the graft 
damaging Th1-type anti-donor response (Reding R. et al, 2006). A soluble form of CD30 
(sCD30) is released into the bloodstream after activation of CD30+ T cells (Romagnani S. et 
al, 1995). 
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5.1 Pre transplant CD30 
Several reports from the Collaborative Transplant Study (CTS) have suggested that elevated 
pre and post-transplantation levels of the soluble CD30 (sCD30) molecule might be 
predictive for an increased incidence of rejection and worse kidney graft prognosis (Sengul 
S et al 2006). 
Many reports have supported a role for sCD30 in the immune response associated with 
renal allograft rejection. The presence of increased pretransplantation concentrations of 
sCD30 has been associated with the development of acute rejection (Langan LL et al. 2007) 
and with humoral rejection and graft loss. While some reports demonstrated that T-cell 
activation marker soluble CD30 (sCD30) was an independent predictor of immunologic risk 
in renal transplant recipients without preformed alloantibodies (Vaidya S et al. 2006). It was 
reported that high sCD30 levels measured before transplantation, which might be a sign of 
activation of Th2 responses and, consequently, antibody production, could correlate with 
the risk of vascular rejection and production of DSA (Weimer R. et al, 2006). However lower 
levels of sCD30 was determined to be a helpful marker to distinguish patients with a low 
risk for development of DSA and antibody-mediated rejection (Slavcev A. et al, 2007). Study 
by Vaidya et al. recognized that estimation of sCD30 before transplantation might be a 
better predictive factor than PRA for the evaluation of the risk for occurrence of DSA and 
development of vascular rejection (Vaidya S et al. 2006). Some authors described an 
increased sCD30 level only during a rejection episode of the vascular type, while the more 
common tubulointerstitial type showed decreased sCD30 levels even lower than those of 
healthy volunteers (Rajakariar R. et al, 2005). According to some studies the sCD30 
concentration was also high in both groups of patients before transplantation and levels of 
sCD30 decreased during the first 3 to 5 posttransplant days, increasing significantly between 
5 and 15 days following transplantation among recipients who developed acute rejection 
episodes (Ayed K et al. 2006). Measurements of serial changes in soluble CD30 levels after 
transplantation have revealed a decrease of sCD30 in stable transplant recipients (Sengul S 
et al 2006).  Kamali and colleagues have measured Pre and post-operative sCD30 levels of 3 
groups (acute rejection, delayed graft function, and uncomplicated course group). It has 
been described significant decreases in sCD30 plasma levels on 14th day after transplant. 
Despite a significant decrease, groups of patients with acute rejection had higher CD30 
concentrations on the 14th day after the transplants, compared with delayed graft function 
and uncomplicated course groups (Kamali K. et al, 2009). Based on published results pre-
transplant sCD30 serum levels higher than 100 U/ml have been classified as a risk factor for 
the survival of kidney allografts (Cinti P. et al, 2005).  In a large series of nearly 3900 kidney 
transplants performed at 29 centers in 15 countries, it was demonstrated that pretransplant 
determination of the Th2-type activation marker sCD30 is a powerful indicator for 
estimating the risk of graft rejection not only in presensitized but also in nonsensitized 
recipients (Susal et al. 2002). Patients with history of renal transplantation had higher levels 
of s CD30 than first kidney graft recipients (Susal et al. 2002). Investigation of pretransplant 
serum sCD30 content in 2998 recipients with a low sCD30 of <100 U/ml demonstrated a 
higher a 5-yr graft survival rate compared with 901 recipients with a high sCD30 of >100 
U/ml. Determination of the sensitivity and specifity sCD30 testing based on positive 
(≥100U/ml) and negative (<100 U/ml) levels has revealed that with a specificity of sCD30 
>80%, negative sCD30 levels might be a useful marker for identifying patients with a low 
risk for development of donor specific  antibody (DSA) and antibody-mediated rejection 
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(Slavcev A. et al, 2007). Spiridon C and associates found  no statistically significant difference 
among patients with 3–6 HLA-A, B, DR mismatches and 0–2 HLA-A, B, DR mismatches when 
pre-transplant level of sCD30 was below 90 U/mL. It is indicated that the effect of HLA 
mismatches can only be seen among patients with high level of sCD30 (Spiridon C. et al, 2008). 
Correlation between serum levels of sCD30 and Neopterin, which is a known activation 
marker of the T-cell/monocyte system and plays an important role in the chronic allograft 
nephropathy (CAN) process, demonstrated that up-regulation of 1-year sCD30 levels was 
associated with decreased 2-year GFR (. It was observed that increased 1-year sCD30 as well as 
Neopterin/CR are significantly associated with impaired 2-year graft function and serve as 
indicators of graft deterioration by chronic allograft nephropathy (Weimer R. et al, 2006). 
Association of sCD30 levels and immunosuppressive regimen has also been investigated. 
Pretransplant sCD30 assessment may serve as a useful parameter because high pretransplant 
sCD30 levels were shown to be associated with impaired kidney graft survival in 
Cyclosporine-A treated recipients (Susal C. et al, 2002). The current prospective randomized 
study shows that both cyclosporine-A and Tacrolimus based immunosuppressive regimens, 
used either in combination with  Azathioprine or mycophenolate mofetil (CellCept), were 
associated with down-regulation of pretransplant sCD30 levels 4 months post-transplant, 
without a further significant change from 4 months to 1 and 2 years. It was demonstrated that 
Tacrolimus based regimens are more effective in suppressing sCD30 levels and thus might be 
the appropriate treatment in patients with pretransplant elevated sCD30. It was found an 
association between CD4 helper function and sCD30 2 years post-transplant, both in 
Cyclosporine-A and Tacrolimus treated patients, which might be the result of diminished 
suppression of CD4 helper activity due to reduced Calcineurin inhibitor drug exposure 
(Weimer R. et al, 2000). This evidence suggests that the measurement of sCD30 levels offers 
relevant clinical information regarding rejection risk and can contribute to the selection of the 
appropriate immunosuppressive regimen in high-risk recipients for the prevention of acute 
rejection and chronic allograft nephropathy (Kim MS et al. 2006). 
5.2 Post transplant CD30 
To prevent irreversible graft damage, it is important to diagnose and treat acute rejection in 
its earliest phase. Serial measurement of sCD30 levels after transplantation could become a 
feasible and non invasive method to predict acute graft rejection and might allow 
identifying patients prone to acute rejection during the first days after transplantation; 
before an acute rejection was occurred and diagnosed by conventional methods. 
Importantly, at this early time point, detection of acute rejection in the kidney with DGF is 
made difficult because conventional noninvasive rejection parameters, such as rising serum 
creatinine and oliguria cannot be used to make the diagnosis, however, sCD30 allowed a 
differentiation of group acute rejection from group DGF patients (Dong W. et al, 2006). In 
contrast to patients with an uncomplicated course or acute tubular necrosis (ATN) in the 
absence of rejection, plasma sCD30 levels remained high during the first 3 to 5 
posttransplant days in recipients who subsequently developed acute allograft rejection 
(Susal C. et al, 2004). Now it is clear that the sCD30 levels decrease significantly after renal 
transplantation. It was reported that even in patients developed kidney rejection sCD30 
levels decreased up to 55% at day 7 post-transplantation (Truong DQ. et al, 2007). In a 
similar study, showed that an important decrease of sCD30 was detected 2 weeks after renal 
transplantation and patients without rejection had lower sCD30 value compared to patient 
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Importantly, at this early time point, detection of acute rejection in the kidney with DGF is 
made difficult because conventional noninvasive rejection parameters, such as rising serum 
creatinine and oliguria cannot be used to make the diagnosis, however, sCD30 allowed a 
differentiation of group acute rejection from group DGF patients (Dong W. et al, 2006). In 
contrast to patients with an uncomplicated course or acute tubular necrosis (ATN) in the 
absence of rejection, plasma sCD30 levels remained high during the first 3 to 5 
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who experienced rejection episodes (Slavcev A. et al, 2005). Comparison of CD30 
concentrations on the 14th day after transplantation, within acute rejection, delayed graft 
function (DGF) and uncomplicated course groups revealed that a higher soluble CD30 
concentration on day 14 after transplant is associated with acute rejection (Kamali K. et al, 
2009). In sera of 231 patients average sCD30 level before transplantation was much higher 
than that of healthy individuals. Most important, the decrease of sCD30 levels after 
transplantation varied in different groups. Compared with Group UC and DGF, patients of 
Group acute rejection had higher sCD30 levels on day 5 posttransplantation. Data also show 
that there was no association between rejection time and sCD30 levels (Dong W. et al, 2007). 
It is demonstrated that patients free of rejection in the first month post-transplant had lower 
sCD30 concentrations 2 weeks after transplantation compared to rejecting patients (Slavcev 
A. et al, 2005). Thus, an integration of the individualized evaluation of posttransplant sCD30 
serum level as one biomarker, together with accompanying diseases which affect the 
immunological reactivity post-transplantation, may be a feasible approach for the non-
invasive post-transplant prediction of acute kidney allograft rejection. 
6. Panel-reactive antibody (PRA) 
Renal transplantation in sensitized patients remains a highly significant challenge 
worldwide. However, highly sensitized candidates should not be eliminated from 
transplant waiting lists, as post-transplant survival rate and life quality can be greatly 
improved with transplantation, despite the risks. The level of sensitization in a kidney 
transplant recipient can be monitored before and after renal transplantation via PRA (panel-
reactive antibody) test. Highly sensitized recipients usually refer to those with antibodies 
against HLA, who are defined as panel reactive antibody (PRA) >10%, or >20%. The 
humoral immune system is an important determinant of outcome: hypersensitized patients 
show reduced long term graft survival and 10% panel reactive antibodies (PRA) is a risk 
factor (Davis CL, 2004 and Opelz G, 2001). Thus elevated panel reactive antibody (PRA) 
levels, produced against HLA and induced by transfusions, pregnancies and prior 
transplants for HLA allo-immunization are linked to hyper-acute rejections, delayed graft 
functions and poor graft survival rates. Measurement of anti-HLA antibodies before and 
after transplantation is important, as their presence increases the risk and severity of 
rejection episodes and is a significant risk factor for allograft loss (Zhou YC. et al, 1996). 
During past years, transplant surgeons usually focused on the results of PRA levels and 
lymphocyte toxicity test in the treatment of sensitized patients, but sometimes serious 
antibody mediated rejections also happened in HLA-identical donor-recipient transplants. 
Although we have not yet confirmed whether there are any anti-HLA antibodies not well 
detected with existing technologies, the concept of non-HLA antibodies bring the transplant 
surgeons and researchers with great inspiration. Following the more recent development of 
ELISA methodology for detecting HLA antibodies, several reports showed that patients 
with pretransplant HLA-I antibodies (>10% PRA) had greater risk for acute or chronic 
rejection, or an increase in post-transplant reactivity (Van Kampen CA. et al, 2001). It was 
observed a higher incidence of post-transplant donor specific HLA antibodies in patients 
having 3–50% PRA compared with patients having 0% PRA at the time of transplantation 
(Supon P. et al, 2001). The determination of panel reactive antibodies, which at present are 
exclusively used as indicators for an increased risk of graft rejection, is currently being 
critically discussed. It is illustrated that combination of positive PRA and elevated sCD30 
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levels have an additional diagnostic value,  as well as independent factors, to predict  acute 
rejection risk and subsequent graft outcome (Langan L L. et al, 2007). For this reason novel 
markers are recommended for proper monitoring of pre- and post-transplant risks. Using 
the modalities described, immunosuppressive therapies in transplant recipients can now be 
selected on the basis of individual demand, with anti-B-cell directed immunosuppression 
being most promising during the early postoperative period.  
7. Immunosuppressive therapy 
The influence of immunosuppressive regimens on sCD30 levels was provoked in many 
studies. Presensitized (PRA >5%) patients had a higher serum sCD30 content than 
nonsensitized (5% >PRA) patients. whereas, as shown in Figure 3, the effects of the two 
parameters on graft outcome were additive. Therefore presensitized patients are 
preferentially transplanted with HLA well-matched kidneys and receive stronger 
posttransplant immunosuppression, including prophylactic treatment with antilymphocyte 
antibodies (susal et at. 2002). Immunosuppressive treatment in recipients usually contains 
either with a triple drug regimen (Cyclosporine, Steroids and Azathioprine) or, in 
Presensitized patients with immunologic risk factors (presence of panel-reactive antibodies 
or history of graft rejection), a quadruple regimen, including polyvalent or monoclonal 
antilymphocyte antibodies. When patients were divided into well-matched group (with 
three or less mismatches) and poor-matched group (with more than three mismatches), no 
significant difference of sCD30 levels was shown between two groups. Soluble CD30 levels  
 
(Adapted from susal et at. 2002) 
Fig. 3. Combined effect  of serum sCD30 content and lymphocytotoxic panel reactivity 
(PRA) on kidney graft survival. sCD30- positive and PRA-positive recipients 
(sCD30+/PRA+) had a significantly impaired graft outcome, compared with sCD30-negative 
and PRA-negative (sCD30_/PRA_), sCD30-negative and PRA-positive (sCD30_/PRA+), or 
sCD30-positive and PRA negative recipients (sCD30+/PRA_) (P < 0.0001, P = 0.0003, and  
P = 0.0048, respectively). 
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were also independently evaluated in patients receiving cyclosporine A and FK506. There 
was also no significant difference of sCD30 levels between two groups. Significant 
difference of sCD30 levels was only observed between patients with acute rejection episodes 
and those without acute rejection on day 5 post-transplantation (Dong W. et al, 2006). 
Antithymocyte globulin (ATG) is recommended for desensitization of kidney transplant 
recipients with high panel-reactive antibody (PRA) and ABO-incompatibility as main 
modality for the treatment of AMR (Akalin E. et al, 2003 and Gloor JM. et al, 2003).  But 
antilymphocyte antibodies did not improve graft outcome in patients with high sCD30. 
Graft survival of recipients with a high pretransplant sCD30 treated with prophylactic 
antilymphocyte antibodies (ATG, ALG, or OKT3), was significantly worse than the rate in 
recipients with low sCD30 levels.  It is suggested that a single dose of Rituximab (50 mg/m2 
BSA) is as effective as higher doses (150 and 375 mg/m2 BSA) in depleting Bcells and 
reducing PRA levels, While the standard dose of Rituximab in AMR is 375 mg/m2 BSA 
(Vieira CA. et al, 2004). Thus, to improve graft outcome in patients with high sCD30 levels, 
other strategies seem to be necessary, possibly immunosuppressive regimens that 
specifically inhibit CD30+ T cells. 
8. Conclusion 
It is illustrated that combination of positive PRA and elevated sCD30 levels have an 
additional diagnostic value,  as well as independent factors, to predict  acute rejection risk 
and subsequent graft outcome. For this reason novel markers are recommended for proper 
monitoring of pre- and post-transplant risks. This evidence suggests that the measurement 
of sCD30 levels offers relevant clinical information regarding rejection risk and can 
contribute to the selection of the appropriate immunosuppressive regimen in high-risk 
recipients for the prevention of acute rejection and also chronic allograft nephropathy.  
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CMV Disease After Renal Transplantation 
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Fukushima Medical University 
Japan 
1. Introduction 
Renal transplantation is a most valuable treatment for patients with end-stage renal disease 
as it offers improved survival and quality-of-life benefits compared with dialysis (Evans, 
Manninen et al. 1985; Port, Wolfe et al. 1993). However, there has been no satisfactory 
increase in long-term graft survival despite significant advances in the field of renal 
transplantation (Meier-Kriesche, Schold et al. 2004). Long-term graft failure is generally due 
to death despite a functioning graft, chronic rejection, or recurrent kidney disease (Valente, 
Hariharan et al. 1997). Among these, chronic rejection is the most important cause of long-
term graft failure (Jindal and Hariharan 1999). Graft failure owing to chronic rejection is a 
common reason for retransplantation, and the most important predictor of chronic rejection 
is a previous episode of acute rejection (Almond, Matas et al. 1993; Hariharan, Alexander et 
al. 1996; Cosio, Pelletier et al. 1997). Clinical acute rejection within the first year after 
transplantation has been reported to have a detrimental effect on long-term graft survival 
(Hariharan, Johnson et al. 2000). The projected half-life for cadaveric transplants in patients 
who did not have an episode of clinical acute rejection in the first year after transplantation 
was 17.9 years in 1995, compared with that of 8.8 years for patients who had an episode of 
clinical acute rejection (Hariharan, Johnson et al. 2000). This reduction in the relative risk of 
graft failure was significant among patients without acute rejection, whereas no reduction in 
the relative risk of graft failure was observed among those with acute rejection. Thus, the 
main issue asociated with renal transplantation is the suppression of allograft rejection.  
Cytomegalovirus (CMV) infection, which is the most common infection following renal 
transplanation, continues to be a potential contributor to graft loss and a cause of severe 
mortality and morbidity. Several studies have suggested that CMV infection can lead to 
allograft rejection (Lautenschlager, Soots et al. 1997; Humar, Gillingham et al. 1999; 
McLaughlin, Wu et al. 2002; Meier-Kriesche, Schold et al. 2004; Nett, Heisey et al. 2004). 
Although the role of CMV infection in acute rejection after renal transplantation remains 
controversial, many reports have demonstrated that CMV serostatus, as defined by 
conventional classifications, influences clinical outcome in renal transplantation (Humar, 
Gillingham et al. 1999; McLaughlin, Wu et al. 2002). The combination of CMV-seronegative 
recipients (R-) with CMV-seropositive donors (D+) led to the highest risk of CMV disease.  
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Historically, concern has focused on avoiding CMV infection in D+/R- settings. However, 
some transplant recipients in the D+/R+ group experience severe CMV disease and/or 
acute rejection despite their pre-existing immunity. For example, in D+R+ cases, 
approximately 20% of recipients experienced CMV disease in the absence of any 
prophylaxis (Sagedal, Nordal et al. 2000). Analysis of the data from the United States Renal 
Data System and United Network of Organ Sharing revealed that the D+/R+, not the D+/R- 
group, had the worst graft and patient survival by 3 years (Schnitzler, Woodward et al. 1997; 
Schnitzler, Woodward et al. 1997). This may reflect the prevalence of multiple CMV 
virotypes, and that D+/R+ recipients may have double exposure to different CMV strains.  
This article addresses the impact of CMV reinfection with different CMV strains on the 
clinical course after renal transplantation.  
2. Background  
2.1 Cytomegalovirus virology 
CMV is the fifth member of the 8 known human herpes viruses (HHVs). HHVs are classified 
into three subgroups, alpha herpesvirinae, beta herpesvirinae and gamma herpesvirinae. 
CMV, a member of the beta herpes virus family together with HHV-6 and HHV-7, is a 
widespread opportunistic pathogen. Primary CMV infection usually occurs during the first 
decades of life. CMV is transmitted via salvia, body fluids, cells and tissues (Egli, Binggeli et 
al. 2007). Primary infection is followed by a latent infection that can persist throughout the 
entire life of the host. The principal reservoirs of latent CMV are the white blood cells and 
CD13-positive cells (Larsson, Soderberg-Naucler et al. 1998) and the latent virus has been 
detected in most tissues in the body. CMV can infect most renal cell types, including 
glomerular, tubular, and endothelial cells (Heieren, Kim et al. 1988; Heieren, van der Woude 
et al. 1988; Ustinov, Loginov et al. 1991). 
CMV is a DNA virus containing 230-kb double-strand DNA. CMV has a typical herpes 
virion structure consisting of viral DNA, capsid, tegument and envelope. The envelope 
contains structural proteins including glycoproteins. The glycoproteins are used for cellular 
entry by the virus. CMV initially tethers itself to cell-surface heparan sulfate proteoglycans 
(HSPGs) via viral envelope glycoproteins (Kari and Gehrz 1992; Compton, Nowlin et al. 
1993), although HSPGs alone are not sufficient to mediate viral entry. The ability of CMV to 
enter a wide variety of cell types indicates multiple receptors for entry, and many cell-
surface components have been identified as virus receptors. It is reported that CMV uses 
epidermal growth factor receptor (EGFR), platelet-derived growth factor- receptor 
(PDGFR-) and cellular integrins for cellular entry (Wang, Huong et al. 2003; Feire, Koss et 
al. 2004; Soroceanu, Akhavan et al. 2008), although these findings remain controversial 
(Isaacson, Feire et al. 2007). The entry of CMV into host cells requires interactions between 
cellular and viral molecules, and glycoproteins. Pretreatment of CMV with glycoprotein-
specific antibodies could disrupt interaction between CMV and cellular molecules (Wang, 
Huang et al. 2005; Soroceanu, Akhavan et al. 2008).  
The complete genome of the laboratory strain of CMV AD169 has been sequenced (Chee, 
Bankier et al. 1990), however, genetic differences among CMV strains have been observed in 
multiple genes. Those polymorphisms may be implicated in immunopathogenesis as well as 
CMV strain-specific behavior and cell tropism.  
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2.2 Glycoproteins of Cytomegalovirus  
The initial events associated with CMV infection require interactions between the host cell-
surface molecules and the CMV envelope. The early steps of virion attachment, fusion and 
penetration of the host cell have been assumed to be functions of the viral envelope 
glycoproteins. To date, at least 57 potential glycoproteins are known to be encoded by the 
laboratory strain of CMV (AD169), and several envelope glycoproteins have been 
characterized (Chee, Bankier et al. 1990; Britt and Mach 1996; Cha, Tom et al. 1996). These 
glycoproteins associate in high molecular weight complexes and the mature complexes are 
referred to as glycoprotein complex I (gC-I), glycoprotein complex II (gC-II) and 
glycoprotein complex III (gC-III). The genes encoding glycoproteins often show genetic 
polymorphism. Because the envelope glycoproteins elicit strong host immune responses, 
including the production of neutralizing antibodies, understanding of the genetic 
polymorphism of the glycoproteins will have an impact on strategies to protect against 
CMV infection as well as clinical studies.  
2.2.1 Glycoprotein H (gH) 
The disulphide-bond tripartite gC-III envelope complex consists of gH, gL and gO (Huber 
and Compton 1999). Glycoprotein H is one of the immunologically dominant 
glycoproteins in the CMV envelope, and is encoded by open reading frame (ORF) unique 
long (UL) region 75 (Pachl, Probert et al. 1989). The gH gene of the AD169 strain is 2,229 
nucleotides long and that of the Towne strain is 2,226 in length. The gH product of AD169 
UL75 comprises 743 amino acids (aa) and that of Towne is 742 aa, with a deletion of 
proline 36 (Pachl, Probert et al. 1989; Britt and Mach 1996). Although the UL75 is highly 
conserved among multiple CMV strains, sequence variations were found in the first 37 aa 
(Chou 1992). Based on the sequence analysis of UL75 from multiple strains, it was 
estimated that CMV gH has two genotypes (Chou 1992). gH mediates viral/host cell 
membrane fusion in the initial step of infectivity, and monoclonal anti-gH antibodies can 
inhibit virus infectivity (Keay and Baldwin 1991). Antibodies against gH can be detected 
after natural infection with CMV (Rasmussen, Matkin et al. 1991). Anti-CMV gH 
antibodies exhibit virus neutralizing activity and gH is considered a major antigen for the 
humoral immune response (Urban, Klein et al. 1996). A linear antibody binding site is 
located within the amino-terminal region of gH (aa 34-43), which shows sequence 
heterogeneity between the AD169 and Towne strains (Urban, Britt et al. 1992). This 
heterogeneity is characterized by the deletion of a proline residue at position 36 and the 
substitution of lysine for histidine at position 37 in the Towne strain as compared with the 
AD169 strain. This antibody binding site is recognized as strain-specific epitope(Urban, 
Britt et al. 1992), and the heterogeneity influences CMV susceptibility to host neutralizing 
antibodies. A recent report on congenital CMV infection has provided clear evidence that 
exposure to CMV with a different genotype causes congenital infection, even in 
seropositive mothers (Boppana, Rivera et al. 2001).  
2.2.2 Glycoprotein B (gB) 
Glycoprotein B, a component of the envelope complex gC-I, is the most abundant 
glycoprotein in the CMV envelope. gB is one of the most highly conserved components 
among all members of the herpesvirus family. It is encoded by UL55 and exhibits genetic 
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Historically, concern has focused on avoiding CMV infection in D+/R- settings. However, 
some transplant recipients in the D+/R+ group experience severe CMV disease and/or 
acute rejection despite their pre-existing immunity. For example, in D+R+ cases, 
approximately 20% of recipients experienced CMV disease in the absence of any 
prophylaxis (Sagedal, Nordal et al. 2000). Analysis of the data from the United States Renal 
Data System and United Network of Organ Sharing revealed that the D+/R+, not the D+/R- 
group, had the worst graft and patient survival by 3 years (Schnitzler, Woodward et al. 1997; 
Schnitzler, Woodward et al. 1997). This may reflect the prevalence of multiple CMV 
virotypes, and that D+/R+ recipients may have double exposure to different CMV strains.  
This article addresses the impact of CMV reinfection with different CMV strains on the 
clinical course after renal transplantation.  
2. Background  
2.1 Cytomegalovirus virology 
CMV is the fifth member of the 8 known human herpes viruses (HHVs). HHVs are classified 
into three subgroups, alpha herpesvirinae, beta herpesvirinae and gamma herpesvirinae. 
CMV, a member of the beta herpes virus family together with HHV-6 and HHV-7, is a 
widespread opportunistic pathogen. Primary CMV infection usually occurs during the first 
decades of life. CMV is transmitted via salvia, body fluids, cells and tissues (Egli, Binggeli et 
al. 2007). Primary infection is followed by a latent infection that can persist throughout the 
entire life of the host. The principal reservoirs of latent CMV are the white blood cells and 
CD13-positive cells (Larsson, Soderberg-Naucler et al. 1998) and the latent virus has been 
detected in most tissues in the body. CMV can infect most renal cell types, including 
glomerular, tubular, and endothelial cells (Heieren, Kim et al. 1988; Heieren, van der Woude 
et al. 1988; Ustinov, Loginov et al. 1991). 
CMV is a DNA virus containing 230-kb double-strand DNA. CMV has a typical herpes 
virion structure consisting of viral DNA, capsid, tegument and envelope. The envelope 
contains structural proteins including glycoproteins. The glycoproteins are used for cellular 
entry by the virus. CMV initially tethers itself to cell-surface heparan sulfate proteoglycans 
(HSPGs) via viral envelope glycoproteins (Kari and Gehrz 1992; Compton, Nowlin et al. 
1993), although HSPGs alone are not sufficient to mediate viral entry. The ability of CMV to 
enter a wide variety of cell types indicates multiple receptors for entry, and many cell-
surface components have been identified as virus receptors. It is reported that CMV uses 
epidermal growth factor receptor (EGFR), platelet-derived growth factor- receptor 
(PDGFR-) and cellular integrins for cellular entry (Wang, Huong et al. 2003; Feire, Koss et 
al. 2004; Soroceanu, Akhavan et al. 2008), although these findings remain controversial 
(Isaacson, Feire et al. 2007). The entry of CMV into host cells requires interactions between 
cellular and viral molecules, and glycoproteins. Pretreatment of CMV with glycoprotein-
specific antibodies could disrupt interaction between CMV and cellular molecules (Wang, 
Huang et al. 2005; Soroceanu, Akhavan et al. 2008).  
The complete genome of the laboratory strain of CMV AD169 has been sequenced (Chee, 
Bankier et al. 1990), however, genetic differences among CMV strains have been observed in 
multiple genes. Those polymorphisms may be implicated in immunopathogenesis as well as 
CMV strain-specific behavior and cell tropism.  
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2.2 Glycoproteins of Cytomegalovirus  
The initial events associated with CMV infection require interactions between the host cell-
surface molecules and the CMV envelope. The early steps of virion attachment, fusion and 
penetration of the host cell have been assumed to be functions of the viral envelope 
glycoproteins. To date, at least 57 potential glycoproteins are known to be encoded by the 
laboratory strain of CMV (AD169), and several envelope glycoproteins have been 
characterized (Chee, Bankier et al. 1990; Britt and Mach 1996; Cha, Tom et al. 1996). These 
glycoproteins associate in high molecular weight complexes and the mature complexes are 
referred to as glycoprotein complex I (gC-I), glycoprotein complex II (gC-II) and 
glycoprotein complex III (gC-III). The genes encoding glycoproteins often show genetic 
polymorphism. Because the envelope glycoproteins elicit strong host immune responses, 
including the production of neutralizing antibodies, understanding of the genetic 
polymorphism of the glycoproteins will have an impact on strategies to protect against 
CMV infection as well as clinical studies.  
2.2.1 Glycoprotein H (gH) 
The disulphide-bond tripartite gC-III envelope complex consists of gH, gL and gO (Huber 
and Compton 1999). Glycoprotein H is one of the immunologically dominant 
glycoproteins in the CMV envelope, and is encoded by open reading frame (ORF) unique 
long (UL) region 75 (Pachl, Probert et al. 1989). The gH gene of the AD169 strain is 2,229 
nucleotides long and that of the Towne strain is 2,226 in length. The gH product of AD169 
UL75 comprises 743 amino acids (aa) and that of Towne is 742 aa, with a deletion of 
proline 36 (Pachl, Probert et al. 1989; Britt and Mach 1996). Although the UL75 is highly 
conserved among multiple CMV strains, sequence variations were found in the first 37 aa 
(Chou 1992). Based on the sequence analysis of UL75 from multiple strains, it was 
estimated that CMV gH has two genotypes (Chou 1992). gH mediates viral/host cell 
membrane fusion in the initial step of infectivity, and monoclonal anti-gH antibodies can 
inhibit virus infectivity (Keay and Baldwin 1991). Antibodies against gH can be detected 
after natural infection with CMV (Rasmussen, Matkin et al. 1991). Anti-CMV gH 
antibodies exhibit virus neutralizing activity and gH is considered a major antigen for the 
humoral immune response (Urban, Klein et al. 1996). A linear antibody binding site is 
located within the amino-terminal region of gH (aa 34-43), which shows sequence 
heterogeneity between the AD169 and Towne strains (Urban, Britt et al. 1992). This 
heterogeneity is characterized by the deletion of a proline residue at position 36 and the 
substitution of lysine for histidine at position 37 in the Towne strain as compared with the 
AD169 strain. This antibody binding site is recognized as strain-specific epitope(Urban, 
Britt et al. 1992), and the heterogeneity influences CMV susceptibility to host neutralizing 
antibodies. A recent report on congenital CMV infection has provided clear evidence that 
exposure to CMV with a different genotype causes congenital infection, even in 
seropositive mothers (Boppana, Rivera et al. 2001).  
2.2.2 Glycoprotein B (gB) 
Glycoprotein B, a component of the envelope complex gC-I, is the most abundant 
glycoprotein in the CMV envelope. gB is one of the most highly conserved components 
among all members of the herpesvirus family. It is encoded by UL55 and exhibits genetic 
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polymorphism. The 906 aa polypeptide of the AD169 strain gB is cleaved at position 460 by 
a cellular endoprotease. Nucleotide and peptide sequence analysis revealed that variations 
were most frequent between positions 448 and 480, which includes the cleavage site (Chou 
and Dennison 1991). Restriction enzyme analysis has identified four main gB groups (gB-1, 
gB-2, gB-3 and gB-4). While variations were found in gB, substantial conservation of the 
peptide sequence is observed in this region. The closely regulated variations in gB may 
suggest its important role in the viral life cycle (Chou and Dennison 1991). Although little is 
known of the effect of gB variations on biologic function, genetic variations have been used 
for epidemiologic purpose.  
gB has a role in binding to cell surface receptors, and neutralizing gB-specific antibodies can 
inhibit the binding (Ohizumi, Suzuki et al. 1992). CMV interacts with cellular integrins, EGFR 
and PDGFR- through gB, and these compounds are considered as potential cellular 
receptors of CMV (Wang, Huong et al. 2003; Feire, Koss et al. 2004; Soroceanu, Akhavan et 
al. 2008).  
The antigenicity of gB has been well studied and linear neutralizing and non-neutralizing 
antibody-binding sites have been defined (Britt and Mach 1996). The antigen domain 1 
(AD1), which is located between positions 560 and 640 of gB, is a major neutralizing 
epitope (Schoppel, Hassfurther et al. 1996) and is the most highly conserved region 
among viral strains. The second antibody binding site on gB is the antigen domain 2 
(AD2), which is located between aa 28 and 84 of gB (Meyer, Sundqvist et al. 1992). Within 
the AD2 domain, two antigenic sites have been identified. Site I is located between aa 68 
and 77, and this region is conserved among CMV wild-type strains and is the target of 
neutralizing antibodies. Site II, another binding sequence in the AD2, is located between 
aa 50 and 54. Site II binds non-neutralizing antibodies and is strain-specific (Meyer, 
Sundqvist et al. 1992).  
2.2.3 Glycoprotein N (gN) 
Glycoprotein N is a component of the envelope complex gC-II (Mach, Kropff et al. 2000; Dal 
Monte, Pignatelli et al. 2001). gN has been identified as one of the major antigens together 
with gH and gB (Shimamura, Mach et al. 2006). It is encoded by the ORF UL73, and 
antibodies against gN neutralize virus infectivity. The immunogenic gC-II is also the major 
heparin binding complex (Kari and Gehrz 1992).  
UL73 has four main genomic variants, denoted gN-1, gN-2, gN-3 and gN-4 (Pignatelli, Dal 
Monte et al. 2001). The worldwide geographical distribution of identified variants of the 
gN was investigated and it was found that the variants do not necessarily exhibit the 
same frequency distribution (Pignatelli, Dal Monte et al. 2003). The gN genomic variants 
are related to the immunopathogenesis of CMV in immunocompromised hosts and in 
congenitally infected infants (Pignatelli, Dal Monte et al. 2003; Pignatelli, Rossini et al. 
2003).  
2.2.4 Other Glycoproteins 
Other than gH, gB and gN, the large CMV genome encodes many additional glycoproteins. 
UL100 encodes glycoprotein M (gM), which, together with gN, is a component of gC-II. gM 
is essential for viral replication (Hobom, Brune et al. 2000), and seems to be highly 
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conserved (Lehner, Stamminger et al. 1991). It was shown that most sera failed to react with 
either gM or gN alone (Mach, Kropff et al. 2000). Virus neutralizing antibodies were shown 
to be directed at the gN component of the gM–gN complex.  
In addition to gH, the gC-III envelope complex contains glycoprotein O (gO) and 
glycoprotein L (gL) (Huber and Compton 1999). gO is encoded by the UL74 ORF. The 
sequence analysis of UL74 showed a high degree of variability at the N-terminal end 
(Paterson, Dyer et al. 2002). The analysis of clinical isolates identified four major 
phylogenetic groups, denoted gO-1, gO-2, gO-3 and gO-4 (Mattick, Dewin et al. 2004). gL is 
encoded by the UL115 ORF. Four major phylogenetic groups were again identified and 
denoted gL-1, gL-2, gL-3 and gL-4 (Rasmussen, Geissler et al. 2002). gL is essential for the 
transport of the gH glycoprotein to the cell surface (Kaye, Gompels et al. 1992; Spaete, 
Perot et al. 1993).  
The large number of gH-gO-gL combinations suggests that gC-III has an immunological 
potential, and has implications for viral tropism and spread (Rasmussen, Geissler et al. 
2002).  
2.3 CMV genpotype and renal transplantation 
Transplantation in a D+/R+ setting is usually accompanied by multiple CMV strains in 
recipients after transplantation (Manuel, Pang et al. 2009), with mixtures of gB and gH 
genptypes were commonly observed in organ transplant recipients (Zhou, Fan et al. 2007). 
As CMV displays genetic polymorphism among glycoproteins thought to be implicated in 
tissue tropism and immunopathogenesis, an association betweenf glycoprotein genotype 
with CMV infection in organ transplantation has been reported (Woo, Lo et al. 1997) 
(Humar, Kumar et al. 2003; Retiere, Lesimple et al. 2003; Coaquette, Bourgeois et al. 2004; 
Rossini, Pignatelli et al. 2005; Zhou, Fan et al. 2007; Manuel, Asberg et al. 2009). It is known 
that gB plays an important role in virus entry and is also a target of neutralizing antibodies 
(Cranage, Kouzarides et al. 1986; Ohizumi, Suzuki et al. 1992; Navarro, Paz et al. 1993; 
Hopkins, Fiander et al. 1996; Lantto, Fletcher et al. 2003). Therefore, many studies have 
attempted to find a correlation between gB genotype and the occurrence of CMV infection 
or disease in organ transplant recipients. In a study involving 50 transplant recipients, the 
gB genotype was found not to effect viral load or clinical response to therapy (Humar, 
Kumar et al. 2003). Although another study also found no significant differences among gB 
genotypes with regard to the development of symptomatic disease, acute graft rejection, or 
CMV load, immunocompromised patients infected with multiple gB genotypes showed a 
progression to CMV disease, had an increased rate of graft rejection and had higher CMV 
loads (Coaquette, Bourgeois et al. 2004). Recent large, prospective cohort studies of organ 
transplantation have shown mixed infection to be associated with higher viral loads and 
delayed virologic clearance according on the basis of gB distribution analysis (Manuel, 
Asberg et al. 2009). Mixed genotype infection was more likely when both donor and 
recipient were CMV seropositive.  
In addition to gB, associations between gN genotype and clinical features in organ 
transplant recipients were investigated (Rossini, Pignatelli et al. 2005). This study involving 
74 solid organ transplant recipients showed a difference in virulance between those with the 
gN-1 and gN-4 strains. The gN-4 strain was associated with higher levels of antigenemia-
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polymorphism. The 906 aa polypeptide of the AD169 strain gB is cleaved at position 460 by 
a cellular endoprotease. Nucleotide and peptide sequence analysis revealed that variations 
were most frequent between positions 448 and 480, which includes the cleavage site (Chou 
and Dennison 1991). Restriction enzyme analysis has identified four main gB groups (gB-1, 
gB-2, gB-3 and gB-4). While variations were found in gB, substantial conservation of the 
peptide sequence is observed in this region. The closely regulated variations in gB may 
suggest its important role in the viral life cycle (Chou and Dennison 1991). Although little is 
known of the effect of gB variations on biologic function, genetic variations have been used 
for epidemiologic purpose.  
gB has a role in binding to cell surface receptors, and neutralizing gB-specific antibodies can 
inhibit the binding (Ohizumi, Suzuki et al. 1992). CMV interacts with cellular integrins, EGFR 
and PDGFR- through gB, and these compounds are considered as potential cellular 
receptors of CMV (Wang, Huong et al. 2003; Feire, Koss et al. 2004; Soroceanu, Akhavan et 
al. 2008).  
The antigenicity of gB has been well studied and linear neutralizing and non-neutralizing 
antibody-binding sites have been defined (Britt and Mach 1996). The antigen domain 1 
(AD1), which is located between positions 560 and 640 of gB, is a major neutralizing 
epitope (Schoppel, Hassfurther et al. 1996) and is the most highly conserved region 
among viral strains. The second antibody binding site on gB is the antigen domain 2 
(AD2), which is located between aa 28 and 84 of gB (Meyer, Sundqvist et al. 1992). Within 
the AD2 domain, two antigenic sites have been identified. Site I is located between aa 68 
and 77, and this region is conserved among CMV wild-type strains and is the target of 
neutralizing antibodies. Site II, another binding sequence in the AD2, is located between 
aa 50 and 54. Site II binds non-neutralizing antibodies and is strain-specific (Meyer, 
Sundqvist et al. 1992).  
2.2.3 Glycoprotein N (gN) 
Glycoprotein N is a component of the envelope complex gC-II (Mach, Kropff et al. 2000; Dal 
Monte, Pignatelli et al. 2001). gN has been identified as one of the major antigens together 
with gH and gB (Shimamura, Mach et al. 2006). It is encoded by the ORF UL73, and 
antibodies against gN neutralize virus infectivity. The immunogenic gC-II is also the major 
heparin binding complex (Kari and Gehrz 1992).  
UL73 has four main genomic variants, denoted gN-1, gN-2, gN-3 and gN-4 (Pignatelli, Dal 
Monte et al. 2001). The worldwide geographical distribution of identified variants of the 
gN was investigated and it was found that the variants do not necessarily exhibit the 
same frequency distribution (Pignatelli, Dal Monte et al. 2003). The gN genomic variants 
are related to the immunopathogenesis of CMV in immunocompromised hosts and in 
congenitally infected infants (Pignatelli, Dal Monte et al. 2003; Pignatelli, Rossini et al. 
2003).  
2.2.4 Other Glycoproteins 
Other than gH, gB and gN, the large CMV genome encodes many additional glycoproteins. 
UL100 encodes glycoprotein M (gM), which, together with gN, is a component of gC-II. gM 
is essential for viral replication (Hobom, Brune et al. 2000), and seems to be highly 
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conserved (Lehner, Stamminger et al. 1991). It was shown that most sera failed to react with 
either gM or gN alone (Mach, Kropff et al. 2000). Virus neutralizing antibodies were shown 
to be directed at the gN component of the gM–gN complex.  
In addition to gH, the gC-III envelope complex contains glycoprotein O (gO) and 
glycoprotein L (gL) (Huber and Compton 1999). gO is encoded by the UL74 ORF. The 
sequence analysis of UL74 showed a high degree of variability at the N-terminal end 
(Paterson, Dyer et al. 2002). The analysis of clinical isolates identified four major 
phylogenetic groups, denoted gO-1, gO-2, gO-3 and gO-4 (Mattick, Dewin et al. 2004). gL is 
encoded by the UL115 ORF. Four major phylogenetic groups were again identified and 
denoted gL-1, gL-2, gL-3 and gL-4 (Rasmussen, Geissler et al. 2002). gL is essential for the 
transport of the gH glycoprotein to the cell surface (Kaye, Gompels et al. 1992; Spaete, 
Perot et al. 1993).  
The large number of gH-gO-gL combinations suggests that gC-III has an immunological 
potential, and has implications for viral tropism and spread (Rasmussen, Geissler et al. 
2002).  
2.3 CMV genpotype and renal transplantation 
Transplantation in a D+/R+ setting is usually accompanied by multiple CMV strains in 
recipients after transplantation (Manuel, Pang et al. 2009), with mixtures of gB and gH 
genptypes were commonly observed in organ transplant recipients (Zhou, Fan et al. 2007). 
As CMV displays genetic polymorphism among glycoproteins thought to be implicated in 
tissue tropism and immunopathogenesis, an association betweenf glycoprotein genotype 
with CMV infection in organ transplantation has been reported (Woo, Lo et al. 1997) 
(Humar, Kumar et al. 2003; Retiere, Lesimple et al. 2003; Coaquette, Bourgeois et al. 2004; 
Rossini, Pignatelli et al. 2005; Zhou, Fan et al. 2007; Manuel, Asberg et al. 2009). It is known 
that gB plays an important role in virus entry and is also a target of neutralizing antibodies 
(Cranage, Kouzarides et al. 1986; Ohizumi, Suzuki et al. 1992; Navarro, Paz et al. 1993; 
Hopkins, Fiander et al. 1996; Lantto, Fletcher et al. 2003). Therefore, many studies have 
attempted to find a correlation between gB genotype and the occurrence of CMV infection 
or disease in organ transplant recipients. In a study involving 50 transplant recipients, the 
gB genotype was found not to effect viral load or clinical response to therapy (Humar, 
Kumar et al. 2003). Although another study also found no significant differences among gB 
genotypes with regard to the development of symptomatic disease, acute graft rejection, or 
CMV load, immunocompromised patients infected with multiple gB genotypes showed a 
progression to CMV disease, had an increased rate of graft rejection and had higher CMV 
loads (Coaquette, Bourgeois et al. 2004). Recent large, prospective cohort studies of organ 
transplantation have shown mixed infection to be associated with higher viral loads and 
delayed virologic clearance according on the basis of gB distribution analysis (Manuel, 
Asberg et al. 2009). Mixed genotype infection was more likely when both donor and 
recipient were CMV seropositive.  
In addition to gB, associations between gN genotype and clinical features in organ 
transplant recipients were investigated (Rossini, Pignatelli et al. 2005). This study involving 
74 solid organ transplant recipients showed a difference in virulance between those with the 
gN-1 and gN-4 strains. The gN-4 strain was associated with higher levels of antigenemia-
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positive cells. However, in this study, no mixed gentype infection was found and only 19 of 
the 74 recipients underwent kidney transplantation. Thus the influence of infection with 
multiple gN genotypes in cases of renal transplantation remains unclear.  
These studies of glycoprotein genotypes may have some implications for the immunity of 
recipients as well as viral pathogenesis. gB has been implicated in host cell entry, cell-to-cell 
transmission of virus and fusion of infected cells, and is an important target for humoral and 
cellular immune responses (Cranage, Kouzarides et al. 1986; Navarro, Paz et al. 1993; 
Hopkins, Fiander et al. 1996; Lantto, Fletcher et al. 2003). Although polymorphisms in the 
cleavage site of the gB gene allow classification into of 4 distinct genotypes, the sequence of 
the antigenic site is well conserved (Roy, Grundy et al. 1993). The linear antibody binding 
sites include AD-1 and AD-2, which induce neutralizing antibodies and are highly 
conserved (Roy, Grundy et al. 1993). It seems that gB genotypes based on the cleavage site 
don't affect CMV infection in transplant recipients (Humar, Kumar et al. 2003). However, 
mixed gB genotype infections are associated with severe clinical manifestations (Coaquette, 
Bourgeois et al. 2004; Manuel, Asberg et al. 2009). In contrast to gB, the linear neutralizing 
antibody binding sites on gH and gN exhibit variations and form strain-specific epitopes 
(Urban, Britt et al. 1992; Burkhardt, Himmelein et al. 2009). These variations in the antibody 
binding epitopes of glycoproteins influence viral infection as they allow the virus to evade 
humoral immune responses.  
3. CMV gH strain-specific antibody epidemiology of cytomegalovirus  
3.1 ELISA for glycoproteins 
The induction of an effective antibody response against CMV is an important defense 
mechanism as it is capable of neutralizing infectious viruses. An analysis of transplant 
patients revealed that during primary infection strain-specific and strain-common 
antibodies are produced asynchronously (Klein, Schoppel et al. 1999). The strain-specific 
neutralizing antibodies are induced during infection with CMV. Because CMV can persist 
throughout the entire life of the host after primary infection, we hypothesized that detection 
of strain-specific antibodies can be used to identify the CMV strain latent in the host. To 
evaluate CMV glycoprotein strain-specific antibodies, we analyzed for strain-specific 
immunoglobulin G (IgG) antibodies against the polymorphic epitopes on the envelope gH 
glycoproteins of CMV by means of an enzyme-linked immunosorbent assay (ELISA) 
method (Ishibashi, Tokumoto et al. 2007; Ishibashi, Tokumoto et al. 2008).  
CMV strain-specific antibody responses were determined on the basis of polymorphisms in 
the antibody binding epitopes within gH between the 2 prototypical laboratory strains of 
CMV, AD169 and Towne. In addition to gH, we employed AD2 site I, which is conserved 
among CMV isolates and is the target of neutralizing antibodies, as well as AD2 site II, 
which binds non-neutralizing antibodies and is strain specific, for the detection of antibodies 
against gB (Figure 1).  
3.2 Strain-specific seroepidemiology of CMV 
The prevalence of CMV seropositivity varies around the world with seroprevalence ranging 
from 45 to 100% (Cannon, Schmid et al. 2010). For example, the CMV seroprevalence is  
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Fig. 1. Cloning and expression of recombinant antigens of CMV glycoproteins for ELISA. 
A, Oligonucleotides containing CMV gH epitopes, gB AD2 site I and site II from the AD169 
and Towne strains, were used for the expression of gH epitopes as GST fusion proteins. 
DNA fragments encoding the epitopes were prepared by annealing two synthetic 
oligonucleotides. The DNA strand for the AD2 site I region was synthesized by Taq DNA  
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positive cells. However, in this study, no mixed gentype infection was found and only 19 of 
the 74 recipients underwent kidney transplantation. Thus the influence of infection with 
multiple gN genotypes in cases of renal transplantation remains unclear.  
These studies of glycoprotein genotypes may have some implications for the immunity of 
recipients as well as viral pathogenesis. gB has been implicated in host cell entry, cell-to-cell 
transmission of virus and fusion of infected cells, and is an important target for humoral and 
cellular immune responses (Cranage, Kouzarides et al. 1986; Navarro, Paz et al. 1993; 
Hopkins, Fiander et al. 1996; Lantto, Fletcher et al. 2003). Although polymorphisms in the 
cleavage site of the gB gene allow classification into of 4 distinct genotypes, the sequence of 
the antigenic site is well conserved (Roy, Grundy et al. 1993). The linear antibody binding 
sites include AD-1 and AD-2, which induce neutralizing antibodies and are highly 
conserved (Roy, Grundy et al. 1993). It seems that gB genotypes based on the cleavage site 
don't affect CMV infection in transplant recipients (Humar, Kumar et al. 2003). However, 
mixed gB genotype infections are associated with severe clinical manifestations (Coaquette, 
Bourgeois et al. 2004; Manuel, Asberg et al. 2009). In contrast to gB, the linear neutralizing 
antibody binding sites on gH and gN exhibit variations and form strain-specific epitopes 
(Urban, Britt et al. 1992; Burkhardt, Himmelein et al. 2009). These variations in the antibody 
binding epitopes of glycoproteins influence viral infection as they allow the virus to evade 
humoral immune responses.  
3. CMV gH strain-specific antibody epidemiology of cytomegalovirus  
3.1 ELISA for glycoproteins 
The induction of an effective antibody response against CMV is an important defense 
mechanism as it is capable of neutralizing infectious viruses. An analysis of transplant 
patients revealed that during primary infection strain-specific and strain-common 
antibodies are produced asynchronously (Klein, Schoppel et al. 1999). The strain-specific 
neutralizing antibodies are induced during infection with CMV. Because CMV can persist 
throughout the entire life of the host after primary infection, we hypothesized that detection 
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immunoglobulin G (IgG) antibodies against the polymorphic epitopes on the envelope gH 
glycoproteins of CMV by means of an enzyme-linked immunosorbent assay (ELISA) 
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CMV strain-specific antibody responses were determined on the basis of polymorphisms in 
the antibody binding epitopes within gH between the 2 prototypical laboratory strains of 
CMV, AD169 and Towne. In addition to gH, we employed AD2 site I, which is conserved 
among CMV isolates and is the target of neutralizing antibodies, as well as AD2 site II, 
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3.2 Strain-specific seroepidemiology of CMV 
The prevalence of CMV seropositivity varies around the world with seroprevalence ranging 
from 45 to 100% (Cannon, Schmid et al. 2010). For example, the CMV seroprevalence is  
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Fig. 1. Cloning and expression of recombinant antigens of CMV glycoproteins for ELISA. 
A, Oligonucleotides containing CMV gH epitopes, gB AD2 site I and site II from the AD169 
and Towne strains, were used for the expression of gH epitopes as GST fusion proteins. 
DNA fragments encoding the epitopes were prepared by annealing two synthetic 
oligonucleotides. The DNA strand for the AD2 site I region was synthesized by Taq DNA  
 
Renal Transplantation – Updates and Advances 
 
126 
polymerase after annealing the two oligonucleotides. Each cassette has BamHI and EcoRI 
sites at the ends for cloning. These DNA cassettes were cloned into the EcoRI and BamHI 
sites of expression vector pGEX-5x. B, SDS-PAGE of the purified GST fusion proteins 
containing the AD169-gH (lane 1), Towne-gH (lane 2), AD2 site I epitope (lane 3), AD169-
AD2 site II (lane 4) and Towne-AD2 site II epitopes (lane 5). Each epitope was expressed in 
E. coli strain DH5α as a fusion protein with GST, and purified using GSTrap FF (Amersham 
Bioscience). Size standards are shown on the left side of the gel. C, ELISA using purified 
GST fusion proteins containing AD169- and Towne-specific gH epitopes. Reactivity of 
CMV-seronegative sera (closed triangles) and CMV-seropositive sera reacting with the gH 
epitopes specific to AD169 (closed circles) and Towne (open circles) were plotted. A dashed 
horizontal line indicates the cut-off OD. Optical density (OD) values specific to each strain-
specific gH antigen were obtained by subtracting the OD values for GST. An arbitrary cutoff 
for the ELISA (OD=0.25) was defined as the mean plus two standard deviations (SD) of OD 
values obtained from a panel of 23 healthy CMV seronegative volunteers. Figures were 
modified from our recent papers (Ishibashi, Tokumoto et al. 2007; Ishibashi, Tokumoto et al. 
2008). 
93.8% in Japan, 86.7% in Chile (Lagasse, Dhooge et al. 2000), 82.5% in the United States 
(Fowler, Stagno et al. 2003) and 49.5% in France (Lepage, Leroyer et al. 2011). CMV 
antibodies reflect prior exposure and existing immunity. However, it has been reported that 
the protection conferred by pre-existing immunity is limited because of the strain-
dependence of the immune responses(Boppana, Rivera et al. 2001). CMV exists as a variety 
of different strains according to the genotype of its envelope glycoproteins. The analysis of 
CMV reinfection or of mixed infections has become increasingly important. Reinfection may 
occur when a subsequent CMV infection evades the pre-existing humoral immunity of the 
host. In this study, which was approved by the institutional ethics committee, blood 
samples were obtained from a total of 352 subjects (aged 15 to 75), consisting of healthy 
volunteers and consecutive potential donors and recipients for renal transplantation. We 
employed ELISA using GST-fusion proteins containing the strain-specific gH epitopes from 
AD169 and Towne strains as well as gB AD2 site I and AD2 site II to detect preexisting 
strain-specific antibodies in transplant recipients and healthy blood donors. The distribution 
of antibody responses against glycoproteins is summarized in Figure 2.  
A panel of sera obtained from 352 blood donors was evaluated using the GST fusion 
proteins. Among the 255 serum samples with antibodies against gH and/or gB, 207(81.2%) 
were reactive with the gH ELISA and 178(69.8%) with the gB AD2 site I ELISA, with 132 
samples reactive with both gB and gH. The CMV seropositive rate was lower in subjects 
aged in their teens (50%) and 20s (62%), and the rate increased significantly with increases in 
age, reaching 80-90% in subjects aged 30 years or over. Strain-specific antibody responses 
among the 207 gH seropositive samples showed that 44 samples were reactive with the gH 
of both AD169 and Towne. Of the 44 donors whose serum contained antibodies against both 
AD169 and Towne, 27 (61%) were aged 50 years or over (Figure 2B). This dual-positive rate 
was significantly higher than that for donors under 50 years (p<0.01). This result indicates 
that organ transplantation from older donors to younger recipients; for example, from a 
father or mother to one of their children, as is common in living-related transplantation, can 
increase the risk of reinfection with CMV. 
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Fig. 2. Distribution of gH and gB-specific antibodies and their seroprevalence. 
A: Summary of the number and distribution of serum samples according to antibody 
responses against gH epitopes and gB AD2.  
B: Seroprevalence of CMV. Closed yellow triangles indicate CMV serostatus analyzed using 
a conventional ELISA kit. Rate of positive antibodies against gH and rate of positive strain-
specific antibodies against both AD169 and Towne strains according to age. Age group and 
number of serum samples are shown on the horizontal axis. Figures were modified from our 
recent paper (Ishibashi, Tokumoto et al. 2008). 
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of both AD169 and Towne. Of the 44 donors whose serum contained antibodies against both 
AD169 and Towne, 27 (61%) were aged 50 years or over (Figure 2B). This dual-positive rate 
was significantly higher than that for donors under 50 years (p<0.01). This result indicates 
that organ transplantation from older donors to younger recipients; for example, from a 
father or mother to one of their children, as is common in living-related transplantation, can 
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3.3 Association of HLA-DR with strain-specific antibodies  
Several reports have described the association between the occurrence of viral infection and 
disease and the presence of certain HLA antigens in the host (Stewart, Kelsall et al. 1981; 
Baldwin, Claas et al. 1983; Roenhorst, Tegzess et al. 1985; Kraat, Christiaans et al. 1994; 
Varga, Rajczy et al. 2008). Many HLA antigens, including HLA-A2, HLA-A24, HLA-A32, 
HLA-B52, HLA-Bw4, HLA-DR6, HLA-DR11, HLA-DR15 and HLA-DQ3, were reported 
to increase the risk of CMV infection (Roenhorst, Tegzess et al. 1985; Chen, Rocha et al. 2001; 
Hodge, Boivin et al. 2004; Fan, Meng et al. 2006), although there were some conflict among 
the results (Gomez, Aguado et al. 1993). Major histocompatibility complex (MHC) molecules 
are critical for the presentation of antigens. The association between HLA alleles and CMV 
infection may be due to the differential presentation of CMV peptides by HLA molecules 
and/or the differential recognition by host lymphocytes. Studies in animals showed a 
genetic susceptibility to CMV infection which is controlled by the MHC (Chalmer, 
Mackenzie et al. 1977; Grundy, Mackenzie et al. 1981). Although the immune responses to 
CMV infection could be linked to CMV infection, polymorphism of CMV antigenic proteins 
may constitute an immune evasion mechanism. The differential presentation of 
polymorphic gB or Immediate Early-1 peptide by HLA molecules was suggested by the data 
from renal transplant recipients (Retiere, Lesimple et al. 2003). Another possible association 
between HLA and CMV infection is in the production of antibodies. It has been reported 
that deficiencies in the production of neutralizing antibodies against CMV gB in certain 
HLA types may lead to increased susceptibility (Wada, Mizuno et al. 1997). In this report, 
subjects with HLA-DR9 had a higher positive rate against CMV gB and subjects with HLA-
DR15 had a lower positive rate against gB. Production of antibodies against another major 
epitope of CMV, gH, may correlate with certain HLA types. We investigated HLA-DR type 
and strain-specific antibody responses against gH in potential donors and recipients for 
renal transplantation (Ishibashi, Tokumoto et al. 2009). Our results showed that subjects 
with HLA-DR10 showed a significantly lower response rate against CMV gH and subjects 
with HLA-DR11 had a lower response rate. It is of interest that there have been some reports 
that HLA-DR11 alleles are more susceptible to active CMV infection in the case of solid 
organ transplantation (Retiere, Lesimple et al. 2003; Fan, Meng et al. 2006). However, the 
percentages of subjects with HLA-DR10 and HLA-DR11 were very small in our study 
population. Geographical analysis of the distribution of antibodies against CMV 
glycoproteins and HLA types would be of interest. 
4. Differences in adverse events between CMV primary infections and 
reinfections  
4.1 Pattern of infection and clinical impact of CMV 
CMV infection and disease are crucial causes of morbidity and mortality among transplant 
recipients. The term “CMV infection” applies to a condition in which there is evidence of 
CMV replication whether or not symptoms are present. There are three main patterns of 
CMV infection, primary infection, reactivation and reinfection (Ljungman, Griffiths et al. 
2002). Primary infection is defined as a new-onset infection in recipients who had been 
found to be seronegative. The recipients acquire CMV from their donors for the first time. If 
the latent infected recipient’s original CMV is reactivated in recipients who were 
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seropositive, it is understood as reactivation. Reinfection is defined as infection of new CMV 
strain in recipients who were previously seropositive. Reinfection is diagnosed if the 
detected CMV strain was different from that of their donor’s by using a variety of molecular 
techniques or inferred if the recipients acquire new antibodies against strain-specific 
epitopes.  
CMV infections in solid organ transplant recipients induce serious direct and indirect 
consequences. The direct clinical effects of CMV include CMV infection, CMV disease and 
end-organ diseases; i.e., gastrointestinal disease, hepatitis, retinitis, nephritis, cystitis, 
myocarditis, encephalitis and pancreatitis. In addition to the directly effects, CMV is 
associated with graft rejection, allograft dysfunction and failure, cardiovascular 
complications, and fungal, viral or bacterial superinfection, all of which are known as the 
“indirect effects” of CMV (Ljungman, Griffiths et al. 2002).  
Classically, because of its high rate of CMV primary infection, concern was mainly focused 
on CMV in D+/R- settings. However, in D+/R+ transplantation, the presence of antibodies 
against matched CMV gH epitopes influence the outcome of transplantation. More adverse 
events were observed in the case of reinfection with different CMV strains.  
4.2 Classification of transplant pairings according to CMV strain-specific antibody 
responses 
To identify potential CMV reinfections before renal transplantation, genotypes of the 
CMVs latently infecting donors and recipients should be detected. One of the methods 
considered for the genotyping of CMV is the detection of CMV DNA directly from blood 
donors using PCR. However, CMV DNA during the latency phase is seldom detected in 
healthy blood donors with validated PCR (Roback, Drew et al. 2003). The low copy 
number of latency infected cells is a major limitation to PCR. It is estimated that 0.004 to 
0.12 percent of CMV-positive peripheral blood mononuclear cells harbor 2 to 13 genomes 
per cell (Slobedman and Mocarski 1999; Soderberg-Naucler, Streblow et al. 2001). The 
highest detection rate obtained with PCR to date was approximately 39% (Pignatelli, Dal 
Monte et al. 2006).  
Instead of PCR methods, we employed a serologic assay using E. coli-expressed strain-
specific epitopes (Ishibashi, Tokumoto et al. 2007). This serologic assay can estimate the 
CMV strain previously and latently infecting the blood donors. From the combination of 
antibody responses against the strain-specific gH epitopes, the conventional CMV 
D+/R+ pairings can be classified into two groups. When a recipient receives an organ 
graft from a donor who has the same strain-specific gH antibody of CMV as the 
recipient, the pairing is classified as a “matched gH” pairing. The pairings in which the 
recipients do not have  strain-specific gH antibodies matching their donor’s are classified 
as “mismatched gH” pairings. The “mismatched gH” pairings indicate that the recipients 
can not neutralize the CMV from donors. It is considered that this pairing in a D+/R+ 
setting can cause CMV reinfection. We distinguished 114 renal transplantation pairings 
according to the strain-specific responses and analyzed the data (Figure 3). We found 
differences in the clinical course after transplantation among the D+/R-, matched gH 
and mismatched gH pairings.  
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Fig. 3. Classification of transplant pairings according to strain-specific gH antibody responses.  
Classifications of the donors (D) and recipients (R) according to the conventional CMV 
serostatus (+ or -) and CMV strain-specific antibodies (Ab) against gH epitopes. Details of 
the combinations based on strain-specific Ab against gH epitopes (AD: AD169, TW: Towne, 
mix: both AD169 and Towne, and -: undetectable) are also shown. The 84 D+/R+ pairs were 
classified into three subgroups, "matched gH", "mismatched gH" and "D-negative". As 
antibodies against gH were undetectable in 7 donors, they were excluded from the analysis. 
The figure was slightly modified from our recent paper (Ishibashi, Tokumoto et al. 2007).  
4.3 Acute rejection after renal transplantation 
In this study, which was approved by the institutional ethics committee, 114 pairs of 
consecutive donors and recipients undergoing living-related renal transplantation were 
included. Immunosuppression for recipients consisted of triple-drug therapy (tacrolimus or 
cyclosporine, mycophenolate mofetile, and predonisolone). Among the 114 transplants, 
cyclosporin was used in 7 recipients who had chest pain or hyperglycemia. Rejection was 
suspected when serum creatinine level increased more than 25% from the basal level in the 
absence of urinary tract obstruction or renal graft artery stenosis. During the follow up after 
transplantation, the first rejection episode was confirmed histologically by biopsy samples 
from the grafts.  
Five recipients (21%) among the 24 D+/R- pairs and 31 recipients (37%) among the 84 
D+/R+ pairs experienced biopsy-proven acute rejection. There was no statistically 
significant difference in the acute rejection rate between the D+/R- and D+/R+ settings 
(p=0.14). Among the 27 D+/R+ patients with acute rejection whose matching of strain-
specific gH antibodies were known, 17 (53%) did not have matched strain-specific 
antibodies and was categorized as “mismatched gH”(Figure 4). The rate of acute rejection 
after renal transplantation was significantly higher in recipients in “mismatched gH” groups 
than in those of “matched gH” groups (22%; p=0.0051) and of the D+/R- groups (21%;, 
p=0.014). The average number of days after transplantation to diagnosis of acute rejection 
was 25 days for all cases with acute rejection, and there were no statistical differences in 
incubation period for acute rejection among the three groups. 
Role of Cytomegalovirus Reinfection in Acute  


























































































Fig. 4. Incidences of acute rejection. 
A, Among the 101 transplant recipients with the three types of settings, the D+/R- (n=24), 
D+/R+ matched gH (n=45) and D+/R+ mismatched gH (n=32) groups, 32 (32%) 
experienced biopsy-proven acute rejection after transplantation. The acute rejection rate in 
the gH mismatch group was significantly higher than those of the D+/R- (p=0.0051) and gH 
match (p=0.014) groups.  
B, Kaplan-Meier curves for the cumulative probability of freedom from biopsy-proven acute 
rejection. The incidence of acute rejection in the gH mismatched group was significantly 
higher than those in the D+/R- and gH matched groups (p=0.002). Figures were modified 
from our recent paper (Ishibashi, Tokumoto et al. 2007).  
4.4 CMV infection and disease in gH mismatch settings 
Incidences of CMV infection and CMV disease were monitored in the  D+/R-, gH matched 
and gH mismatched groups of transplant recipients (Figure 5). Antigenemia using pp65 
antibodies was routinely evaluated weekly for six months after transplantation. CMV 
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after renal transplantation was significantly higher in recipients in “mismatched gH” groups 
than in those of “matched gH” groups (22%; p=0.0051) and of the D+/R- groups (21%;, 
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Fig. 4. Incidences of acute rejection. 
A, Among the 101 transplant recipients with the three types of settings, the D+/R- (n=24), 
D+/R+ matched gH (n=45) and D+/R+ mismatched gH (n=32) groups, 32 (32%) 
experienced biopsy-proven acute rejection after transplantation. The acute rejection rate in 
the gH mismatch group was significantly higher than those of the D+/R- (p=0.0051) and gH 
match (p=0.014) groups.  
B, Kaplan-Meier curves for the cumulative probability of freedom from biopsy-proven acute 
rejection. The incidence of acute rejection in the gH mismatched group was significantly 
higher than those in the D+/R- and gH matched groups (p=0.002). Figures were modified 
from our recent paper (Ishibashi, Tokumoto et al. 2007).  
4.4 CMV infection and disease in gH mismatch settings 
Incidences of CMV infection and CMV disease were monitored in the  D+/R-, gH matched 
and gH mismatched groups of transplant recipients (Figure 5). Antigenemia using pp65 
antibodies was routinely evaluated weekly for six months after transplantation. CMV 
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infection was defined as the occurence of antigenemia  (> 1 pp65-positive cells/300,000 
leukocytes) during the monitoring period irrespective of clinical manifestations. Patients 
with a low level of antigenemia (1 to 9 pp65-positive cells per 3.0x105 leukocytes) were 
monitored frequently and preemptive therapy was initiated once 10 or more pp65-positive 
cells per 3.0x105 leukocytes were detected. Irrespective of antigenemia results, patients with 
CMV-related manifestations were treated immediately. The CMV-related manifestations 
include unexplained fever (temperature > 38°C with no other source to account for it) for 2 
or more days, arthralgia, leucopenia (leukocyte count of < 4000/mm3), atypical lymphocytes 
of > 3% or thrombocytopenia (platelet count of < 100,000/mm3), a rise in liver enzyme level, 
gastrointestinal ulceration or hemorrhage, and pneumonitis (Singh, Yu et al. 1994; Tanabe, 
Tokumoto et al. 1997).  
Sixteen of 24 recipients (67%) among the D+/R- group had CMV infection, and 13 (54%) of 
them developed CMV disease (Figure 5A). Among the 84 D+/R+ transplant pairings, 77 
pairings were classified as gH-matched pairings or gH-mismatched pairings. During the 6-
month follow up after renal transplantation, 37 (48%) of the 77 recipients in the D+/R+ 
group were found to be positive for CMV infection by the pp65-antigenemia assay, and 13 
recipients (17%) were diagnosed with CMV disease. The incidence of CMV disease in the 
recipients in the D+/R- group was statistically higher than in those in the D+/R+ group 
(p=0.0003). When the 13 recipients in the D+/R+ group who experienced CMV disease were 
classified by antibody response against CMV gH, 9 (9/32, 28%) were in the gH mismatch 
group and 4 were in the gH matched group (4/45, 9% Figure 5 B). Consequently, CMV 
disease was significantly more prevalent in the gH mismatched group than in the gH 
matched group. The proportion of cases with CMV infection that progressed to CMV 
disease in the gH mismatched and gH match groups were 64% and 17%, respectively 
(p=0.0038, Figure 5 C).  
4.5 CMV pp65 antigenemia and antibodies against gB and gH matching 
We performed antigenemia assays weekly during the 6-month follow up. The medians 
(ranges) of the maximum number of positive cells in the recipients from the D+/R+ gH 
mismatched and gH matched groups were 38 (1-818) and 2 (1-142), respectively. The 
maximum number of pp65-positive cells differed significantly between these two groups. 
The medians (ranges) of the maximum number of positive cells in the recipients from the 
D+/R- group was 113 (1-3128), and there was no significant difference between the D+/R- 
group and the gH mismatched group (Ishibashi, Tokumoto et al. 2007). These results reflect 
the incidence of CMV disease among each group. Matching of antibody responses against 
strain-specific CMV gH could reduce the risk of CMV disease. The gH sequences of the 
CMV strains from the recipients who showed the highest level of antigenemia after 
transplantation were found to match the antibodies present in their donors (Ishibashi, 
Tokumoto et al. 2008).  
In addition to gH, gB is considered to be one of the major target molecules for neutralizing 
antibodies as well as for cellular immune response (Gyulai, Endresz et al. 2000). We also 
evaluated the correlation between the maximum number of pp65-positive cells during the 6 
months after transplantation and antibody responses against the gB AD2 site I epitope, as 
well as the matching of antibodies against gH. Seventy-seven recipients in the D+/R+ 
matched gH or mismatched gH groups, were classified into 4 subgroups based on the  
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Fig. 5. CMV infection and CMV disease after renal transplantation. 
A, The rate of recipients diagnosed with CMV infection. If recipients showed at least 1 pp65-
positive cell during the follow up, they were diagnosed with CMV infection. There was no 
significant difference among the groups. B, The rate of CMV disease among the three 
groups. In the D+/R+ gH matched group, the rate of CMV disease was significantly lower 
than those in the other groups (*p=0.006, **p=0.013). C, The rate of recipients with CMV 
infection who progressed to CMV disease. Among the 53 recipients diagnosed with CMV 
infection, 26 patients progressed to CMV disease. Among them, 13 were D+/R- and 9 were 
gH mismatched. These rates were significantly higher than that in the gH matched group 
(*p=0.0001, **p=0.0038). Figures were modified from our recent paper (Ishibashi, Tokumoto 
et al. 2007).  
combinations of antibody responses against both gH and gB (matched gH/gB-, matched 
gH/gB+, mismatched gH/gB-, mismatched gH/gB+). Significant differences in the 
maximum numbers of pp65-positive cells obtained during the 6 months in the patients with 
CMV infection were observed. The medians of the maximum number of positive cells were 
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combinations of antibody responses against both gH and gB (matched gH/gB-, matched 
gH/gB+, mismatched gH/gB-, mismatched gH/gB+). Significant differences in the 
maximum numbers of pp65-positive cells obtained during the 6 months in the patients with 
CMV infection were observed. The medians of the maximum number of positive cells were 
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1 (range, 1–9), 20 (range, 1-142), 26 (range 1-254), and 45 (range 2-818) for the matched 
gH/gB-, matched gH/gB+, mismatched gH/gB- and mismatched gH/gB+ groups, 
respectively (Figure 6). These differences resulted from differences in the number of patients 
who diagnosed with CMV disease and given preemptive therapy. Consequently, the 
introduction of preemptive therapy was significantly more prevalent in the subgroups 
lacking antibodies against gH and/or gB than in the matched gH/gB+ subgroup.  




































Fig. 6. Maximum number of pp65-positive cells. 
Antigenemia in the 5 subgroups of transplant recipients classified based on seroimmunity 
against the particular epitopes of CMV gH and gB. The maximum number of pp65-positive 
cells during the monitoring period for each recipient with CMV infection was plotted. Each 
closed circle indicates one recipient. The broken bars in the box plot indicate the median of 
pp65-positive cells. Closed red circles indicate recipients who had given preemptive therapy 
for CMV disease. Figures were modified from our recent paper (Ishibashi, Tokumoto et al. 
2011).  
Previous studies have demonstrated that the antibody titers against AD2 measured in 
ELISA had a good correlation with neutralizing antibody titers (Rothe, Pepperl-Klindworth 
et al. 2001). However, the role of neutralizing antibodies in the control of CMV infection in 
transplantation recipients has been a matter of discussion (Schoppel, Schmidt et al. 1998; 
Volpi, Pica et al. 1999; Munoz, Gutierrez et al. 2001). Alternatively, positive anti-gB AD2 
antibodies may indicate the presence of sufficient anti-CMV cellular immune responses as a 
consequence of the natural course of CMV infection. Among the viral proteins in CMV, gB 
has been identified as a potential target for CMV-specific CD8+ and CD4+ T-cell immunity 
(Gyulai, Endresz et al. 2000; Elkington, Walker et al. 2003). Deficiencies in the response of 
cytotoxic T lymphocytes specific for CMV are important in the pathogenesis of CMV disease 
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in immunocompromised recipients (Reusser, Riddell et al. 1991). It would be interesting to 
see whether the CMV specific T-cell activity against CMV-gB correlates with the outcome of 
our ELISA against gB AD2.  
However, CMV infection was not completely prevented in spite of the presence of 
antibodies against matched gH and gB. A recent report on bacterial artificial chromosome-
derived recombinant viruses that differed only in the expression of the gN genotype on the 
background of the AD169 strain showed that 30% of human sera showed strain-specific 
neutralization (Burkhardt, Himmelein et al. 2009). It suggested that gN constituted a major 
determinant for the induction of strain-specific neutralizing antibodies as well as gH and gB. 
The antigenic variations in a single envelope protein of CMV were shown to be sufficient to 
escape neutralization. It would be interesting to see the matching of antibodies against 
strain-specific gN in addition to the matching of gH      
5. Association of CMV reinfection and acute rejection  
Many reports indicate a relationship between CMV infection and allograft rejection in renal 
transplantation (Lautenschlager, Soots et al. 1997; Humar, Gillingham et al. 1999; 
McLaughlin, Wu et al. 2002; Sagedal, Nordal et al. 2002; Nett, Heisey et al. 2004). According 
to a prospective study of 477 consecutive renal transplant patients, CMV infection and 
disease are independent risk factors for clinical acute rejection (Sagedal, Nordal et al. 2002). 
In another study of 106 consecutive renal transplants, CMV disease, but not asymptomatic 
infection, was shown to be an independent risk factor for biopsy-proven acute rejection 
(Reischig, Jindra et al. 2006). Control of CMV infection has the potential to reduce the 
prevalence of acute rejection. Even one episode of acute rejection of renal allografts 
substantially shortens overall graft survival (Ferguson 1994), and prophylaxis could offer 
greater benefits compared with pre-emptive therapy. Patients provided with prophylaxis 
showed a significantly lower incidence of biopsy-proven acute rejection compared with 
those undergoing pre-emptive therapy (Reischig, Jindra et al. 2008). Prophylaxis has been 
shown to improve long-term graft survival in renal transplant patients (Pachl, Probert et al. 
1989; Kliem, Fricke et al. 2008).  
In our study, which applied pre-emptive therapy, acute rejection was observed in 32 (32%) of 
101 renal transplant recipients. Among them, patients in the mismatched gH group, which 
indicates reinfection with a different gH strain of CMV, showed a higher rate of acute 
rejection (Figure 4). It is unclear why reinfection with CMV increased the risk of acute 
rejection while there were no significant differences in the incidence of CMV infection or 
disease from those in patients with a D+/R- setting (Figure 5). Considered from the 
perspective of immunity against CMV, escape from humoral responses, especially from 
antibodies against gH and/or gB, can induce a local inflammatory response through Toll-like 
receptors (TLRs). Inflammatory cytokine stimulation by CMV is mediated by interaction 
between the glycoproteins and TLR2 (Compton, Kurt-Jones et al. 2003). Neutralizing 
antibodies against gB and gH inhibit inflammatory cytokine responses of TLR2 to CMV 
infection (Boehme, Guerrero et al. 2006). However, this lack of efficient neutralizing 
antibodies against glycoproteins is shared by patients in a mismatched gH setting and those 
in a D+/R- setting. Differences in immunity against CMV between the mismatched gH and 
D+/R- groups could be due to the presence of memory T cells. Abate et al. reported that R+ 
recipients treated with preemptive therapy displayed a steady and constant CMV-specific 
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immune reconstitution with a highly heterogeneous pattern 60–360 days after 
transplantation, when evaluated by interferon (IFN)- enzyme-linked immunospot 
(ELISPOT) assay (Abate, Saldan et al. 2010). Indeed, the R- recipients treated with 
prophylaxis presented a very different scenario of immune reconstitution: none of the 
recipients analyzed showed evident immune reconstitution up to day 180 after 
transplantation. In this report, which analyzed 85 renal transplant recipients, 10 (IA:7, IB:3) of 
70 R+ patients(14%) and 1 (IA) of 13 R- patients (8%) experienced acute rejection (Abate, 
Saldan et al. 2010). Another report indicated that there were no differences in the frequency of 
CMV-specific T-cell frequencies between patients with and without acute rejection (Nickel, 
Bold et al. 2009). In cardiac transplantation, recipients with early detectable levels of CMV-
specific CD4 T-cells were protected from high viral loads and acute rejection (Tu, Potena et al. 
2006). To date, CMV-specific cellular responses seem to be favorable to prevent adverse 
events after transplantation. However, IFN- is a proinflammatory Th1 type 1 that regulates 
cell-mediated responses and favors allograft rejection (Crispim, Wastowski et al. 2010; 
Sementilli and Franco 2010; Tellides and Pober 2007). The excessive reconstitution of IFN-–
secreting effector cells might contribute to allograft rejection because circulating virus-specific 
T cells synthesize type 1 cytokines such as IFN-. In addition, the correlation of viral load 
with the development of CMV-specific T-cell responses remains unclear. We speculate that in 
a mismatched gH setting, a high viral load and IFN- from prompt cell-mediated responses 
induce acute rejection, whereas recipients in a matched gH setting were protected from high 
viral loads and those in a D+/R-setting lacked prompt cellular immune responses.  
6. Conclusion  
We would like to propose a working hypothesis that the mismatch of gH types, probably 
due to reinfection with a strain different from the original strain, is the major risk factor for 
CMV disease and acute rejection after renal transplantation. Pre-existing immunity against 
CMV glycoproteins has a critical role in the prevention of CMV infection, and it might allow 
recipients to avoid acute rejection. Measuring antibodies against CMV glycoproteins for 
both transplant donors and recipients can provide crucial information on CMV infection, 
particularly CMV reinfection, and the possibility of acute rejection after transplantation.  
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immune reconstitution with a highly heterogeneous pattern 60–360 days after 
transplantation, when evaluated by interferon (IFN)- enzyme-linked immunospot 
(ELISPOT) assay (Abate, Saldan et al. 2010). Indeed, the R- recipients treated with 
prophylaxis presented a very different scenario of immune reconstitution: none of the 
recipients analyzed showed evident immune reconstitution up to day 180 after 
transplantation. In this report, which analyzed 85 renal transplant recipients, 10 (IA:7, IB:3) of 
70 R+ patients(14%) and 1 (IA) of 13 R- patients (8%) experienced acute rejection (Abate, 
Saldan et al. 2010). Another report indicated that there were no differences in the frequency of 
CMV-specific T-cell frequencies between patients with and without acute rejection (Nickel, 
Bold et al. 2009). In cardiac transplantation, recipients with early detectable levels of CMV-
specific CD4 T-cells were protected from high viral loads and acute rejection (Tu, Potena et al. 
2006). To date, CMV-specific cellular responses seem to be favorable to prevent adverse 
events after transplantation. However, IFN- is a proinflammatory Th1 type 1 that regulates 
cell-mediated responses and favors allograft rejection (Crispim, Wastowski et al. 2010; 
Sementilli and Franco 2010; Tellides and Pober 2007). The excessive reconstitution of IFN-–
secreting effector cells might contribute to allograft rejection because circulating virus-specific 
T cells synthesize type 1 cytokines such as IFN-. In addition, the correlation of viral load 
with the development of CMV-specific T-cell responses remains unclear. We speculate that in 
a mismatched gH setting, a high viral load and IFN- from prompt cell-mediated responses 
induce acute rejection, whereas recipients in a matched gH setting were protected from high 
viral loads and those in a D+/R-setting lacked prompt cellular immune responses.  
6. Conclusion  
We would like to propose a working hypothesis that the mismatch of gH types, probably 
due to reinfection with a strain different from the original strain, is the major risk factor for 
CMV disease and acute rejection after renal transplantation. Pre-existing immunity against 
CMV glycoproteins has a critical role in the prevention of CMV infection, and it might allow 
recipients to avoid acute rejection. Measuring antibodies against CMV glycoproteins for 
both transplant donors and recipients can provide crucial information on CMV infection, 
particularly CMV reinfection, and the possibility of acute rejection after transplantation.  
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1. Introduction 
Facing the demand of obtaining the best cost-efficacy treatments, we are always searching 
for new alternatives to the existing therapies. The incorporation of new diagnostic 
techniques and screening, along with the continued development of safer and more effective 
drugs has improved considerably the expectations and the quality of life of patients. 
Still, there is no ideal solution to many of the diseases faced by health professionals in daily 
clinical practice, so we still have to look for alternatives to the established treatments. The 
idea of a targeted and personalized therapy to achieve therapeutic success is a goal that is 
getting more and more important every day. In this context there arises the concept of 
personalized medicine which is related in our case to the genetic variability associated with 
different individual response to the same treatment. That is, there is a difference in the 
response to the same drug in different patients that appears to be related to the different 
versions of each patient's genes coding for transport proteins, for enzymes involved in 
metabolism and those genes responsible for the drug mechanism of action, all necessary for 
the drug to perform its therapeutic effect. This kind of research is developed by two 
disciplines: pharmacogenetics and pharmacogenomics. These two terms are often mixed 
and difficult to distinguish, so the international regulatory organizations have tried to fix the 
proper definitions of both terms. The European Medicines Agency shows the definitions on 
its web site (www.ema.europa.eu, EMEA/CHMP/ICH/437986/2006) where according to 
the the International Conference on Harmonisation (ICH), Pharmacogenomics is defined as 
the study of variations of DNA and RNA characteristics as related to drug response, while 
Pharmacogenetics is a subset of pharmacogenomics and is defined as the study of variations 
in DNA sequence as related to drug response.  
So, in practice Pharmacogenetics studies the influence of genetic factors in transport, 
metabolism and drug action. The examples of pharmacogenetic tests employed in the 
clinical practice are increasing day by day, as for instance when establishing first treatment 
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in HIV patients, before employing Cetuximab in colorectal cancer and before Warfarin 
treatment. In these cases, where it has been demonstrated that it exists a correlation 
between some known genetic variants and low or no response to treatment, or even 
occurrence of adverse effects, the clinician needs the genetic test tool in order to settle the 
correct therapy to each patient. The increase of this genetic testing need is reflected also by 
the United States Food and Drug Administration (FDA) that publishes on its web site the 
list containing those drugs with a genetic test, recommended or compulsory, in their drug 
label. Table 1 shows some examples of drugs with pharmacogenomic/genetic marker 
published in FDA website. 
 
Pharmacogenetic Biomarkers in Drug Labels 
 Theraputic Area Biomarker   Label Sections   
Aripiprazole  Psychiatry  CYP2D6  Clinical Pharmacology  
Azathioprine Rheumatology  TPMT  
Dosage and Administration, 
Warnings and Precautions, 
Drug Interactions, Adverse 
Reactions, Clinical 
Pharmacology  
Carvedilol Cardiovascular  CYP2D6  Drug Interactions, Clinical Pharmacology  
Celecoxib Analgesics  CYP2C9  
Dosage and Administration, 
Drug Interactions, Use in 
Specific Populations, 
Clinical Pharmacology  
Cetuximab Oncology  EGFR  
Indications and Usage, 




Cetuximab  Oncology  KRAS  
Indications and Usage, 
Clinical Pharmacology, 
Clinical Studies  
Maraviroc Antivirals  CCR5  
Indications and Usage, 
Warnings and Precautions, 
Clinical Pharmacology, 
Clinical Studies, Patient 
Counseling Information  
Table 1. Examples of pharmacogenetic biomarkers in drug labels in FDA website 
(www.fda.gov, accession date: (24/06/2011). 
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On the other hand, Pharmacogenomics is responsible for discovering the relationships 
between genes and disease by means of the molecular etiology and pathways of each illness. 
The identification of these new associations opens a window to search for new drugs for 
novel therapeutic targets. 
The aim of both disciplines is to obtain the highest therapeutic effect with the lowest risk, 
minimizing the adverse effects of the treatments. This should lead to a better control of the 
disease through personalized medicine. 
In order to start explaining the main findings of Pharmacogenetics in the renal 
transplantation field, we need first to understand some basic concepts. The first one is 
Polymorphism, which is a monogenic mendelian character that is normally present in the 
population at least in 1% frequency. It is characterized by the presence of more than one 
allele in a same gene locus, and consequently, more than one phenotype. The 
polymorphisms that have a meaning in pharmacogenetics are those who represent different 
alleles in a gene related to the interaction of a drug with the organism. There are different 
types of polymorphisms: those were the change from one allele to the variant is only one 
nucleotide are called SNPs, Single Nucleotide Polymorphisms, and these will be the subject 
of most part of the research in the field, including our own work. But there are also other 
kind of polymorphisms as RFLPs, Restriction Fragment Lenght Polymorphisms, and VNTR, 
Variable Number Tandem Repeats. SNPs are the most common ones, representing 90% of 
the whole genetic variability. It is important not to mix this concept up with the term 
“mutation”, although actually they are sometimes mixed. A mutation is usually less 
frequent than a polymorphism, being present in less than 1% of the population but also a 
mutation represents a very little part of the whole genetic variability and is mostly 
associated with the pathology concept: a mutation is most always the cause of a 
missfunction or disease, while a polymorphism will only show some biological effect under 
some concrete circumstances. For instance, if we are carriers of a variant in a polymorphic 
site, related to a better efficacy of a given drug, we will only notice this effect if we take that 
drug, but if we never take it, we will probably not find any biological effect in our body due 
to carrying that variant.  
Another important concept to consider is the Haplotype. We refer to haplotype when we 
talk about alleles which tend to be inherited together because they are close to each other 
on the chromosomes. The haplotypes have been extensively studied by the HapMap 
project (www.hapmap.org). Currently, the investigations are more and more directed to 
the study of the effect of several combined SNPs, instead of aisled SNPs, especially those 
that form an haplotype. The reason for this is that most probably the biological effects that 
we could find are the result of the sum of the effect of several SNPs in different genes 
affecting several parts of the pathway of the drug. Moreover, the effect of a single SNP 
can be, in turn, enhanced, reduced or silenced by compensation by the effect of other 
SNPs. Related to the term haplotype we can also hear about Linkage Disequilibrium, LD, 
which is the occurrence of some combinations of alleles or genetic markers in a population 
more often or less often than would be expected from a random formation of haplotypes 
from alleles based on their frequencies. This aspect is also important in the study of SNPs, 
since in many cases, a SNP that apparently seems to have no clear biological meaning may 
be in disequilibrium with another SNP with a known effect and taking this into account, 
this property could help us infer the genotype of a patient in several SNPs, by only 
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in HIV patients, before employing Cetuximab in colorectal cancer and before Warfarin 
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Pharmacogenetic Biomarkers in Drug Labels 
 Theraputic Area Biomarker   Label Sections   
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Dosage and Administration, 
Warnings and Precautions, 
Drug Interactions, Adverse 
Reactions, Clinical 
Pharmacology  
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Celecoxib Analgesics  CYP2C9  
Dosage and Administration, 
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Cetuximab  Oncology  KRAS  
Indications and Usage, 
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Clinical Studies  
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Table 1. Examples of pharmacogenetic biomarkers in drug labels in FDA website 
(www.fda.gov, accession date: (24/06/2011). 
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studying one or two of them if they are linked, and also it makes sense to study not only 
the SNPs with a clear direct effect, but those apparently non-functional but linked to the 
functional ones. 
The application of these skills and expertise in the field of transplantation could be one of 
the great advances in current immunosupressive therapy. In the transplantation field, there 
are still many unanswered questions, its success depends on the fragile equilibrium between 
the risks and benefits of immunosuppression. Therapeutic drug monitoring helps to 
determine suitable immunosuppressant dose adjustments but usually the work is done by 
assay-error method so the challenge now is to combine pharmacokinetic with 
pharmacogenetic information to provide patients with the most suitable treatment. Many 
papers have been written about genetic variability based on SNPs influencing 
immunosuppressant blood levels but the results are still contradictory in many cases, 
probably due to the hidden effects of other SNPs not included in the study, the number of 
patients included, their ethnicity (SNP frequencies can be very different from one ethnicity 
to another) and so on. 
Just focusing our review of the state of the art in tacrolimus and cyclosporine, two genes 
seem to be the most relevant on having pharmacogentic effects on these drugs: the ABCB1 
gene, coding for the transporter P-glycoprotein, and the CYP3A5 gene, coding for an 
extensive drug-metabolizing enzyme of cytochrome P450 family. 
Tacrolimus and cyclosporine are calcineurin inhibitors indicated for prophylaxis of renal, 
liver and heart transplant rejection. Cyclosporine has a broader use as immunosuppressive 
agent, as apart from preventing transplant rejection (kidney, liver, heart, lung and bone 
marrow) it is also employed in autoimmune diseases (uveitis endogenous, psoriasis, 
nephrotic syndrome, rheumatoid arthritis and atopic dermatitis). In the metabolism of both 
drugs, cytochrome P-450 plays an important role, specifically the CYP3A5 isoform, but also 
CYP3A4 in the case of cyclosporine. On the other hand, they are both transported out of 
cells by P-glycoprotein, encoded by the gene ABCB1. Changes in expression or function of 
these proteins will cause changes in the absorption, metabolism and distribution of both 
drugs and, therefore, can lead to changes in the response and toxicity of the treatment. The 
characterization of genetic variants, as for instance SNPs, that cause variations in expression 
or function can help in establishing effective doses and in minimizing adverse reactions 
(Astellas Pharma, S.A., 2010; Staatz et al., 2010).  
The good correlation between these two drugs blood levels and their tissue concentration, 
makes them suitable for pharmacokinetic monitoring to prevent graft rejection or toxicity. If 
we add the inter- and intra-individual variability, a narrow therapeutic range and a clear 
correlation between high blood levels and appearance of toxicity, then we have two perfect 
candidates for the need of dose optimization. Other factors affecting tacrolimus and 
cyclosporine dosage/concentration after renal transplantation are consistent with the 
features of the patients (renal and hepatic function, age, race). Liver function, albumin, 
hematocrit, gastrointestinal disturbances and the effects of food are also important factors 
responsible for the variation of dosage/concentrations (Marqués et al., 2009). 
The final goal of pharmacogenetics in transplantation is to find a clear link between genetic 
variations and pharmacokinetics/pharmacodynamics of the drugs employed, to allow us to 
find the optimal doses of both initial and maintenance periods, ensuring the success of the 
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graft and reducing treatment toxicity. Amongst all the SNPs described in the literature 
included in genes related to these drugs, we need to validate those that really have an 
impact on actual clinical practice, those that really alter drug levels/efficacy/toxicity and we 
can only achieve that through research, in order to obtain individualized therapies as 
effective as possible. Contradictory results in the published studies seem to tarnish the 
utility of pharmacogenetics, but there are also many encouraging works, where clear 
correlations are found. Probably a good experimental design, without alteration of the real 
clinical setting could help to discriminate whether these studies will be useful or not in the 
therapeutic decisions, but certainly we need multiple approaches correlating genetics with 
kinetics and with safety/efficacy; good and accurate informatic tools to process such a great 
quantity of information; and finally, we do not have to forget other important factors 
involving the patient as concomitant drugs and donor genotype. In this chapter we are 
presenting a summary of some relevant published works and some of our own group's 
results in this area. 
2. Tacrolimus 
2.1 Absorption 
Tacrolimus has a mean oral bioavailability ranging from 20 to 25%. After oral 
administration, peak concentrations (Cmax) are reached in an interval of 1 to 3 hours. Co-
administration with food leads to a decrease in the speed and extent of absorption, being 
more accentuated in the case of fat rich food. Once in blood, it is highly found bound to 
erythrocytes and plasma proteins (> 98.8%), with preference for serum albumin and α-1 acid 
glycoprotein (Astellas Pharma, S.A., 2010). 
2.2 Distribution 
It is widely distributed throughout the body reaching a volume of distribution around 1,300 
liters. It has a low clearance that, as with its half-life, differs depending on the type of 
transplantation performed and the age of the patients (total clearance in pediatric patients 
undergoing liver transplantation is twice that of adult patients with the same 
transplantation type). Generally, it has a long half-life that is affected by variations in 
clearance rates observed in transplantation patients (Astellas Pharma, S.A., 2010). 
2.3 Metabolism 
Tacrolimus is extensively metabolized in the liver but also has a minimal metabolism in the 
intestine. The primary responsible is the cytochrome P450. Several products of metabolism 
have been identified, but there is only one metabolite with immunosuppressive activity 
similar to that of tacrolimus, however, it does not contribute to the pharmacological activity, 
since it has not been detected in systemic circulation (Astellas Pharma, S.A., 2010). 
2.4 Elimination 
The main route of elimination of tacrolimus is the faeces. Only 2% is excreted in urine. Only 
1% of the administered tacrolimus appears unchanged in feces and urine (Astellas Pharma, 
S.A., 2010). 
 
Renal Transplantation – Updates and Advances 
 
146 
studying one or two of them if they are linked, and also it makes sense to study not only 
the SNPs with a clear direct effect, but those apparently non-functional but linked to the 
functional ones. 
The application of these skills and expertise in the field of transplantation could be one of 
the great advances in current immunosupressive therapy. In the transplantation field, there 
are still many unanswered questions, its success depends on the fragile equilibrium between 
the risks and benefits of immunosuppression. Therapeutic drug monitoring helps to 
determine suitable immunosuppressant dose adjustments but usually the work is done by 
assay-error method so the challenge now is to combine pharmacokinetic with 
pharmacogenetic information to provide patients with the most suitable treatment. Many 
papers have been written about genetic variability based on SNPs influencing 
immunosuppressant blood levels but the results are still contradictory in many cases, 
probably due to the hidden effects of other SNPs not included in the study, the number of 
patients included, their ethnicity (SNP frequencies can be very different from one ethnicity 
to another) and so on. 
Just focusing our review of the state of the art in tacrolimus and cyclosporine, two genes 
seem to be the most relevant on having pharmacogentic effects on these drugs: the ABCB1 
gene, coding for the transporter P-glycoprotein, and the CYP3A5 gene, coding for an 
extensive drug-metabolizing enzyme of cytochrome P450 family. 
Tacrolimus and cyclosporine are calcineurin inhibitors indicated for prophylaxis of renal, 
liver and heart transplant rejection. Cyclosporine has a broader use as immunosuppressive 
agent, as apart from preventing transplant rejection (kidney, liver, heart, lung and bone 
marrow) it is also employed in autoimmune diseases (uveitis endogenous, psoriasis, 
nephrotic syndrome, rheumatoid arthritis and atopic dermatitis). In the metabolism of both 
drugs, cytochrome P-450 plays an important role, specifically the CYP3A5 isoform, but also 
CYP3A4 in the case of cyclosporine. On the other hand, they are both transported out of 
cells by P-glycoprotein, encoded by the gene ABCB1. Changes in expression or function of 
these proteins will cause changes in the absorption, metabolism and distribution of both 
drugs and, therefore, can lead to changes in the response and toxicity of the treatment. The 
characterization of genetic variants, as for instance SNPs, that cause variations in expression 
or function can help in establishing effective doses and in minimizing adverse reactions 
(Astellas Pharma, S.A., 2010; Staatz et al., 2010).  
The good correlation between these two drugs blood levels and their tissue concentration, 
makes them suitable for pharmacokinetic monitoring to prevent graft rejection or toxicity. If 
we add the inter- and intra-individual variability, a narrow therapeutic range and a clear 
correlation between high blood levels and appearance of toxicity, then we have two perfect 
candidates for the need of dose optimization. Other factors affecting tacrolimus and 
cyclosporine dosage/concentration after renal transplantation are consistent with the 
features of the patients (renal and hepatic function, age, race). Liver function, albumin, 
hematocrit, gastrointestinal disturbances and the effects of food are also important factors 
responsible for the variation of dosage/concentrations (Marqués et al., 2009). 
The final goal of pharmacogenetics in transplantation is to find a clear link between genetic 
variations and pharmacokinetics/pharmacodynamics of the drugs employed, to allow us to 
find the optimal doses of both initial and maintenance periods, ensuring the success of the 
 
Pharmacogenetics of Immunosuppressive Drugs in Renal Transplantation 
 
147 
graft and reducing treatment toxicity. Amongst all the SNPs described in the literature 
included in genes related to these drugs, we need to validate those that really have an 
impact on actual clinical practice, those that really alter drug levels/efficacy/toxicity and we 
can only achieve that through research, in order to obtain individualized therapies as 
effective as possible. Contradictory results in the published studies seem to tarnish the 
utility of pharmacogenetics, but there are also many encouraging works, where clear 
correlations are found. Probably a good experimental design, without alteration of the real 
clinical setting could help to discriminate whether these studies will be useful or not in the 
therapeutic decisions, but certainly we need multiple approaches correlating genetics with 
kinetics and with safety/efficacy; good and accurate informatic tools to process such a great 
quantity of information; and finally, we do not have to forget other important factors 
involving the patient as concomitant drugs and donor genotype. In this chapter we are 
presenting a summary of some relevant published works and some of our own group's 
results in this area. 
2. Tacrolimus 
2.1 Absorption 
Tacrolimus has a mean oral bioavailability ranging from 20 to 25%. After oral 
administration, peak concentrations (Cmax) are reached in an interval of 1 to 3 hours. Co-
administration with food leads to a decrease in the speed and extent of absorption, being 
more accentuated in the case of fat rich food. Once in blood, it is highly found bound to 
erythrocytes and plasma proteins (> 98.8%), with preference for serum albumin and α-1 acid 
glycoprotein (Astellas Pharma, S.A., 2010). 
2.2 Distribution 
It is widely distributed throughout the body reaching a volume of distribution around 1,300 
liters. It has a low clearance that, as with its half-life, differs depending on the type of 
transplantation performed and the age of the patients (total clearance in pediatric patients 
undergoing liver transplantation is twice that of adult patients with the same 
transplantation type). Generally, it has a long half-life that is affected by variations in 
clearance rates observed in transplantation patients (Astellas Pharma, S.A., 2010). 
2.3 Metabolism 
Tacrolimus is extensively metabolized in the liver but also has a minimal metabolism in the 
intestine. The primary responsible is the cytochrome P450. Several products of metabolism 
have been identified, but there is only one metabolite with immunosuppressive activity 
similar to that of tacrolimus, however, it does not contribute to the pharmacological activity, 
since it has not been detected in systemic circulation (Astellas Pharma, S.A., 2010). 
2.4 Elimination 
The main route of elimination of tacrolimus is the faeces. Only 2% is excreted in urine. Only 
1% of the administered tacrolimus appears unchanged in feces and urine (Astellas Pharma, 
S.A., 2010). 
 





The new current formulation of cyclosporine microemulsion compared to conventional 
forms, has a faster absorption, leading to a reduction of 1 hour in the t max and Cmax 
increased by 59%, with an increase of 29% in AUC (Novartis Farmacéutica, S.A., 2010). 
3.2 Distribution 
Most of the cyclosporine is outside the blood compartment. In the blood it is preferently 
distributed in plasma (33 - 47%) and erythrocytes (41-58%). 90% is fixed to plasma proteins, 
primarily lipoproteins (Novartis Farmacéutica, S.A., 2010). 
3.3 Metabolism 
Biotransformation of cyclosporin is broad and leads to the formation of about 15 
metabolites. There is not a main metabolic pathway and it suffers enterohepatic cycle 
(Novartis Farmacéutica, S.A., 2010). 
3.4 Elimination 
It is mainly performed via the bile. Only 6% of the oral dose is excreted in the urine (0.1% as 
unchanged drug) (Novartis Farmacéutica, S.A., 2010). 
4. Genetic polymorphisms 
A great number of genes are thought to be involved in different effects of 
immunosuppressive therapy (www.fda.gov; www. pharmgkb.org). Two genes in particular 
have demonstrated clear correlations in several studies: ABCB1 (or MDR1), which codes for 
the transporter P-glycoprotein and CYP3A5, which codes for an extensive drug 
metabolizing enzyme of the cytochrome P450 family. 
4.1 ABCB1 genetic polymorphisms 
P-glycoprotein is encoded by the multidrug resistance gene (MDR1), also known as the 
ABCB1 gene. The protein encoded by this gene is an ATP-dependent drug efflux pump for 
xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug 
accumulation in multidrug-resistant cells and often mediates the development of resistance 
to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. 
ABCB1 is polymorphically expressed, with at least 50 SNPs identified to date 
(http://www.ncbi.nlm.nih.gov). 
4.1.1 Influence on tacrolimus pharmacokinetics. 
The results of the influence of ABCB1 on the pharmacokinetics of tacrolimus are 
controversial. Some studies talk about an increase in the ratio Co/dose and lower dose 
requirement in those individuals expressing variant ABCB1 3435 TT regarding the CC 
variant, related to a possible lower functional activity of P-glycoprotein in the carriers of TT 
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variant (Staatz et al, 2010). This “3435 C>T” is the common nomenclature for the SNP 
cataloged as rs1045642 in the SNP database of NCBI website (http://www.ncbi.nlm. nih.gov), 
where C is the ancestral allele (also “wild type”) and most frequent and T the less frequent one 
and they lead to three different genotypes: CC, CT and TT. In contrast, some other studies 
have failed to find an association between the ABCB1 3435C>T and changes in tacrolimus 
blood levels. In a prospective study with 96 renal transplant recipients, the effect of genetic 
polymorphisms of ABCB1 on tacrolimus whole blood levels was analyzed, concluding that 
ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs (rs2229109, 1045642, 2032582, respectively), 
appeared to reduce the activity of P-glycoprotein towards tacrolimus, increasing tacrolimus 
peripheral blood mononuclear cell concentrations. Nevertheless, the impact of ABCB1 genetic 
polymorphisms on tacrolimus blood concentrations was negligible (Capron et al., 2010). In 
another study on Chinese renal transplant recipients, MDR1 3435C>T polymorphism was not 
an important factor in tacrolimus pharmacokinetics (Rong et al., 2010). In a retrospective study 
of 81 renal transplant recipients the effect on tacrolimus dosages and concentration/dose ratio 
of four frequent MDR1 SNP possibly associated with P-gp function (T-129C in exon 1b, 
1236C>T in exon 12, 2677G>T,A in exon 21, and 3435C>T in exon 26; corresponding to 
rs3213619, 1128503, 2032582 and 1045642, respectively). In the general caucasian population, 
the SNP in exons 12, 21, and 26 exhibited incomplete linkage disequilibrium, which means that 
the different variants of each SNP tend to be displayed together, but not in the 100% of the  
 
Fig. 1. Influence of the functional activity of glycoprotein-P (transporter in apical membrane) in 
the transport of tacrolimus (stars) in the intestine epithelium. The diagram shows the different 
degree of drug absorption due to variations in ABCB1/MDR1 polymorphic site rs1045642. 
Individuals with TT variant have a decreased transporter activity and hence greater absorption 
efficiency. CC variant causes more expulsion out of the cell, which decreases absorption. 
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individuals. One month after tacrolimus introduction, exon 21 SNP correlated significantly 
with the daily tacrolimus dose (P < or = 0.05) and the concentration/dose ratio (P < or = 
0.02). Tacrolimus dose requirements were 40% higher in homozygous TT than in wild-type 
patients GG for this SNP. The concentration/dose ratio was 36% lower in the wild-type GG 
patients, suggesting that, for a given dose, their tacrolimus blood concentration is lower. 
Haplotype analysis substained these results and suggested that exons 26 and 21 SNPs may 
be associated with tacrolimus dose requirements (Anglicheau et al., 2003). 
4.1.2 Influence on cyclosporine pharmacokinetics 
Nowadays the data about ABCB1 influence on cyclosporine pharmacokinetics are not 
conclusive, either. Many studies have tried to find correlations with ABCB1 SNPs 3434C>T, 
2677G>T/A and 1236C>T without significant findings. A recent meta-analysis that included 
1036 renal transplantation recipients, concluded that there were no significant differences in 
the influence of ABCB1 3435C>T on cyclosporine pharmacokinetics (AUC4/Dose, CL/F, 
Cmax/Dose or C0/Dose). However, it was indicated in this meta-analysis that CC carriers 
had lower cyclosporine exposure presented as AUC 0–12 than those with at least one T 
allele (CT or TT). In a recent study that included 225 renal transplant recipients treated with 
cyclosporine, ABCB1 2677G>T SNP correlated significantly with dose-adjusted levels in 
patients, at 1, 3 and 6 months after renal transplantation. Recipients with the wild-type 
genotype of this SNP were associated with significantly lower dose-adjusted values and 
consequently required higher cyclosporine daily dose to attain the therapeutic level. ABCB1 
1236C>T also had a minor influence on dose-adjusted C2/T0 levels (Singh et al, 2010). 
4.2 CYP450 genetic polymorphisms 
The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved 
in drug metabolism and synthesis of cholesterol, steroids and other lipids. This proteins are 
localized in the endoplasmic reticulum and their expression is induced by glucocorticoids 
and some pharmacological agents (http://www.ncbi.nlm.nih.gov). 
CYP3A5 is found in the liver, small intestine and kidney. One of the most relevants SNPs in 
this gene is rs776746, also know as 6986 A>G, being G the most frequent allele. Allele *3 is 
the wild type genotype, GG, while *1 is the variant homozygous AA and heterozygote A/G 
is known as *1/*3. There are clear ethnic differences in the prevalence of the CYP3A5*3 
genotype. At the molecular level, the SNP is located in intron 3, and the change of base 
produces a splicing defect. The result is a nonfunctional protein (allele *3). The patients that 
show the allelic variant *3 in homozygosis G/G, also called non-expressors, are slow 
metabolizers of the immunosuppressant. In contrast, heterozygote A/G alleles *1/*3 are 
intermediate metabolizers, whereas those carriers of allele *1 in homozygosis A/A are 
normal metabolizers (Glowacki et al, 2011; Macphee et al, 2005; www.pharmgkb.org) 
4.2.1 Influence on tacrolimus pharmacokinetics 
CYP3A5 may play a more important role than CYP3A4 in the metabolism of tacrolimus in 
individuals who are CYP3A5 expressors, so we will focus on this enzyme. The intrinsic 
clearance of tacrolimus is approximately 2-fold higher for CYP3A5 than for CYP3A4 
(Hesselink et al., 2008). This plasmatic clearance is higher in those individuals with genotype 
CYP3A5*1/*3 regarding those CYP3A5*3/*3 (Haufroid et al., 2006). In fact, CYP3A5*1 is 
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responsible from about 60% of tacrolimus hepatic metabolism (Dai et al., 2006; Thervet et al., 
2010), so it is of great interest studying it in order to establish optimal doses that reach 
quickly the efficient blood concentrations, avoiding toxicity but also assuring the necessary 
concentrations to avoid rejection. The studies performed so far indicate the need to 
administrate higher tacrolimus doses in patients CYP3A5*1/*1. In fact, in some of those 
studies there is even a recommendation of an initial double dose for those patients (Haufroid 
et al, 2006). In a study with forty kidney recipients, CYP3A5*1 variant was associated with 
significant lower tacrolimus dose adjusted concentration at 3, 6, 12 and 36 months after 
transplantation, concluding that CYP3A5*1 carriers need higher tacrolimus dose than 
CYP3A5*3 homozygotes to achieve the target blood concentration (Katsakiori et al., 2010). 
Similarly, in a study with 28 chinese renal transplant recipients, the patients with *1/*3 
showed significantly lower tacrolimus blood levels than those with the *3/*3 in the first and 
second week after transplantation (Zhang et al., 2010). In another similar study, on Chinese 
renal transplant recipients, individuals who were CYP3A5*1 carriers required a higher dose 
of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted AUC(0-12) of 
tacrolimus (Rong et al., 2010). The last reviewed work, with 200 patients objectifies that 
patients who were CYP3A5*3/*3 received significantly higher tacrolimus dose at 1 week, 6 
months, and 1 year (Tavira et al., 2011). Some studies found that the weighted mean apparent 
oral clearance was 48% lower in CYP3A5 nonexpressors than CYP3A5 expressors (range, 
26%-65%) (Barry & Levine, 2010). Recently, a study with 280 transplant recipients concludes 
that patients receiving a pharmacogenetic adaption of the daily dose of tacrolimus were 
associated with improved achievement of the target C0 (Thervet et al, 2010). 
4.2.2 Influence on cyclosporine pharmacokinetics 
Unlike tacrolimus, CYP3A4 may play a more dominant role than CYP3A5 in the metabolism 
of cyclosporine. The intrinsic clearance of cyclosporine, calculated from total metabolite 
formation, is approximately 2.3-fold higher for CYP3A4 than for CYP3A5 (Dai et al., 2006). 
Still, the results of studies conducted so far do not indicate a clear relationship (Anglicheau 
et al., 2007) with 3A4 isoform. However, many papers continue studying the effect of both 
on the metabolism of cyclosporine. A recent meta-analysis with twelve studies includes the 
effects of CYP3A5 during cyclosporine dose adjustment. This meta-analysis showed that 
CYP3A5*3/*3 polymorphism is associated with cyclosporine dose-adjusted concentration 
(dose-adjusted trough and dose-adjusted peak concentrations) in renal transplant recipients 
and patients carrying the CYP3A5*3/*3 genotype will require a lower dose of cyclosporine 
to reach targets levels compared with the CYP3A5*1/*1 or 1*/*3 carriers (Zhu et al., 2011). 
5. Our results 
5.1 Objective 
The aim of our studies was to evaluate the effect of the most relevant SNPs in ABCB1 and 
CYP3A5 genes, in renal transplant recipients and their donors, regarding blood 
concentrations of tacrolimus in the first two weeks post-transplantation. 
5.2 Materials and methods 
One blood sample, collected in anticoagulation tubes at routine extraction, was obtained in 
each of 97 renal transplant recipients and their donors (caucasians). The DNA was extracted  
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individuals. One month after tacrolimus introduction, exon 21 SNP correlated significantly 
with the daily tacrolimus dose (P < or = 0.05) and the concentration/dose ratio (P < or = 
0.02). Tacrolimus dose requirements were 40% higher in homozygous TT than in wild-type 
patients GG for this SNP. The concentration/dose ratio was 36% lower in the wild-type GG 
patients, suggesting that, for a given dose, their tacrolimus blood concentration is lower. 
Haplotype analysis substained these results and suggested that exons 26 and 21 SNPs may 
be associated with tacrolimus dose requirements (Anglicheau et al., 2003). 
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1236C>T also had a minor influence on dose-adjusted C2/T0 levels (Singh et al, 2010). 
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localized in the endoplasmic reticulum and their expression is induced by glucocorticoids 
and some pharmacological agents (http://www.ncbi.nlm.nih.gov). 
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this gene is rs776746, also know as 6986 A>G, being G the most frequent allele. Allele *3 is 
the wild type genotype, GG, while *1 is the variant homozygous AA and heterozygote A/G 
is known as *1/*3. There are clear ethnic differences in the prevalence of the CYP3A5*3 
genotype. At the molecular level, the SNP is located in intron 3, and the change of base 
produces a splicing defect. The result is a nonfunctional protein (allele *3). The patients that 
show the allelic variant *3 in homozygosis G/G, also called non-expressors, are slow 
metabolizers of the immunosuppressant. In contrast, heterozygote A/G alleles *1/*3 are 
intermediate metabolizers, whereas those carriers of allele *1 in homozygosis A/A are 
normal metabolizers (Glowacki et al, 2011; Macphee et al, 2005; www.pharmgkb.org) 
4.2.1 Influence on tacrolimus pharmacokinetics 
CYP3A5 may play a more important role than CYP3A4 in the metabolism of tacrolimus in 
individuals who are CYP3A5 expressors, so we will focus on this enzyme. The intrinsic 
clearance of tacrolimus is approximately 2-fold higher for CYP3A5 than for CYP3A4 
(Hesselink et al., 2008). This plasmatic clearance is higher in those individuals with genotype 
CYP3A5*1/*3 regarding those CYP3A5*3/*3 (Haufroid et al., 2006). In fact, CYP3A5*1 is 
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responsible from about 60% of tacrolimus hepatic metabolism (Dai et al., 2006; Thervet et al., 
2010), so it is of great interest studying it in order to establish optimal doses that reach 
quickly the efficient blood concentrations, avoiding toxicity but also assuring the necessary 
concentrations to avoid rejection. The studies performed so far indicate the need to 
administrate higher tacrolimus doses in patients CYP3A5*1/*1. In fact, in some of those 
studies there is even a recommendation of an initial double dose for those patients (Haufroid 
et al, 2006). In a study with forty kidney recipients, CYP3A5*1 variant was associated with 
significant lower tacrolimus dose adjusted concentration at 3, 6, 12 and 36 months after 
transplantation, concluding that CYP3A5*1 carriers need higher tacrolimus dose than 
CYP3A5*3 homozygotes to achieve the target blood concentration (Katsakiori et al., 2010). 
Similarly, in a study with 28 chinese renal transplant recipients, the patients with *1/*3 
showed significantly lower tacrolimus blood levels than those with the *3/*3 in the first and 
second week after transplantation (Zhang et al., 2010). In another similar study, on Chinese 
renal transplant recipients, individuals who were CYP3A5*1 carriers required a higher dose 
of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted AUC(0-12) of 
tacrolimus (Rong et al., 2010). The last reviewed work, with 200 patients objectifies that 
patients who were CYP3A5*3/*3 received significantly higher tacrolimus dose at 1 week, 6 
months, and 1 year (Tavira et al., 2011). Some studies found that the weighted mean apparent 
oral clearance was 48% lower in CYP3A5 nonexpressors than CYP3A5 expressors (range, 
26%-65%) (Barry & Levine, 2010). Recently, a study with 280 transplant recipients concludes 
that patients receiving a pharmacogenetic adaption of the daily dose of tacrolimus were 
associated with improved achievement of the target C0 (Thervet et al, 2010). 
4.2.2 Influence on cyclosporine pharmacokinetics 
Unlike tacrolimus, CYP3A4 may play a more dominant role than CYP3A5 in the metabolism 
of cyclosporine. The intrinsic clearance of cyclosporine, calculated from total metabolite 
formation, is approximately 2.3-fold higher for CYP3A4 than for CYP3A5 (Dai et al., 2006). 
Still, the results of studies conducted so far do not indicate a clear relationship (Anglicheau 
et al., 2007) with 3A4 isoform. However, many papers continue studying the effect of both 
on the metabolism of cyclosporine. A recent meta-analysis with twelve studies includes the 
effects of CYP3A5 during cyclosporine dose adjustment. This meta-analysis showed that 
CYP3A5*3/*3 polymorphism is associated with cyclosporine dose-adjusted concentration 
(dose-adjusted trough and dose-adjusted peak concentrations) in renal transplant recipients 
and patients carrying the CYP3A5*3/*3 genotype will require a lower dose of cyclosporine 
to reach targets levels compared with the CYP3A5*1/*1 or 1*/*3 carriers (Zhu et al., 2011). 
5. Our results 
5.1 Objective 
The aim of our studies was to evaluate the effect of the most relevant SNPs in ABCB1 and 
CYP3A5 genes, in renal transplant recipients and their donors, regarding blood 
concentrations of tacrolimus in the first two weeks post-transplantation. 
5.2 Materials and methods 
One blood sample, collected in anticoagulation tubes at routine extraction, was obtained in 
each of 97 renal transplant recipients and their donors (caucasians). The DNA was extracted  
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from 200 µL of blood using a commercially available kit based on centrifugation in 
microcolumns (UltraClean BloodSpin DNA Isolation Kit; MoBioLaboratories, Inc, Carlsbad, 
California). After quantification using a spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, Delaware) to determine the concentration and purity, DNA was stored at -20°C 
until use. A genetic analysis platform (MassARRAY; Sequenom, Inc, San Diego, California) 
was used to obtain the genotypes of each sample in the SNPs rs1045642 (3435C>T), 
rs2032582 (2677G>T/A), and rs1128503 (1236C>T) of the ABCB1 gene, and in the SNPs 
rs776746 (6986A>G, CYP3A5*3) and rs10264272 (267871G>A, CYP3A5*6) of the CYP3A5 
gene. All the 97 patients received tacrolimus as the primary immunosuppression drug, at an 
initial dose of 0.2 to 0.3 mg/kg/24 h. Blood concentration of tacrolimus was measured 
routinely using a clinical chemistry system (Dimension; Siemens Healthcare, Deerfield, 
Illinois) to determine the trough level (C0 , in nanograms per milliliter). Drug blood 
concentrations from the first and second weeks were determined, and all of the measured 
levels in the patients during that period were considered. The resulting values were plotted 
in the form of median and quartile range, 1 for each week in each group of recipients or 
recipient with their donors, according to genotypes. Normality tests of Kolmogorov-Smirnof 
and Shapiro-Wilk were performed and then differences between groups were evaluated 
using the Mann-Whitney test (nonparametric test that compares two groups) 
5.3 Results 
The SNP genotyping of the 167 samples showed similar frequencies to those expected for 
Caucasian population in public databases (SNP Database in NCBI site). Tables 2 to 4 show 
the relationship between the frequencies observed in recipients in our study regarding the 
expected ones according to the data from public data bases of the ABCB1 and CYP3A5 
genes, in the most relevant genotyping assays in caucasian population. Tables 5 to 7 show 
the same information but regarding the donors of the transplanted kidneys. The data related 
to donors is a little bit outside the expected range, while there is a better fit in recipient's 
data. We associate these findings to the lower number of donors, thus we can appreciate 
that in recipients, having a larger number of samples, the frequencies fit better. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
CC CT TT CC CT TT 
ABCB1 rs 1045642 12.5-15.5 50-60.3 37.5-24.1 22.68 52.28 24.74 
 rs 1128503 32 41 27 34.02 46.39 24.05 
Table 2. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
AA AG GG GT TT AA AG GG GT TT 






1.03 1.03 32.99 50.52 14.43 
Table 3. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
 




EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
GG GA GG GA 
CYP3A5 rs 776746 88.3-95.5 11.7-4.5 81.44 18.55 
rs 1026427 100 0 97.94 2.06 
Table 4. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
GENE POLYMORFISMS 
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
CC CT TT CC CT TT 
ABCB1 rs 1045642 12.5-15.5 50-60.3 37.5-24.1 30.07 49.18 14.75 
 rs 1128503 32 41 27 39.06 50 9.38 
Table 5. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
AA AG GG GT TT AA AG GG GT TT 






0 0 42.37 54.24 3.39 
Table 6. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
GG GA GG GA 
CYP3A5 rs 776746 88.6-95.5 11.4-4.5 79.10 19.4 
rs 1026427 99 1 98.5 1.43 
Table 7. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
5.3.1 ABCB1 
According to the literature, rs1045642 seems to be the most relevant SNP in ABCB1 gene 
regarding its correlation with tacrolimus or cyclosporine blood levels. 
Figure 2 shows tacrolimus levels as trough concentration, corrected by administered dose 
and weight of the patient (C0/Dc= C0/(Dose/weight)) during the first two weeks after renal 
transplantation, grouped in a way that we represent the data of those recipients whose 
donor has the same genotype as them (eg. CC/CC, means recipients CC whose donors were 
also CC). The data are represented as median inside the whole data range, remarking the 
interquartilic range which includes the 50% of the data. The statistical test applycated was 
Mann-Whitney two-tailed test. Statistically significant differences (p<0,05) were found 
between CC/CC vs TT/TT and also between CT/CT vs TT/TT in the second week after 
transplantation. With this kind of analysis we evaluate the global effect of the variant, C or 
T, without taking into account if the effect is greater in recipients or in donors. 
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Fig. 2. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 genotype recipient/donor. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the 
patient and donor genotype, grouped so that both genotypes match, in SNP rs1045642 of 
ABCB1 gene, in the first (1w) and second week (2w) after transplantation. The horizontal 
line inside each bar is the median of the data, the bar is the interquartilic range, including 
50% of the data, and the lines up and down the bars cover the whole data range for each set. 
A significant difference (*= p<0,05)was achieved in the second week between CC/CC and 
TT/TT, and also between CT/CT and TT/TT employing Mann-Whitney two-tailed test. 
Figures 3, 4 and 5 show the same kind of analysis as in Figure 2 but with patients grouped 
by a single recipient variant comparing the three possible donors’ genotype.  
We could not find any statistically significant differences in Fig.3, applying Mann-Whitney 
non-parametric test, most probably because we only had one value for CC/TT in the first 
week, and two for the second. However, those three values show the expected trend of 
higher tacrolimus levels than the rest of the groups. 
 




Fig. 3. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in CC recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients CC divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. No significant differences were found. 
 
Fig. 4. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in CT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients CT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. Significant differences were found between CT/CC and 
CT/TT at week two (p<0,05) employing Mann-Whitney two-tailed test. 
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Fig. 4. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in CT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients CT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
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Fig. 5. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in TT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients TT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. Significant differences were found between TT/CC and 
TT/TT at week two (p<0,05) employing Mann-Whitney one-tailed test. 
There is a clear trend of CC genotype in SNP rs1045642 to normalize tacrolimus levels, while 
there is always an increase related with T allele, especially in TT genotype, where most of 
the times, statistically significant differences are reached at week two post-transplantation. 
With these data, we can calculate an increase in the value of the median up to 286.53% when 
comparing the difference between the median in group CC/TT and the median in group 
CC/CC (fig. 2, second week) Table 8 shows the differences in percentage of the medians 
from figures 2, 3, 4 and 5, and also the quantity of recipients and tacrolimus level values 
included in each of the figures. 
But we have not only studied rs1045642, also two other relevant SNPs in ABCB1 that have 
been described to be in linkage disequilibrium with the first: rs1128503 and rs2032582. With 
the genotype data for these three SNPs in our renal transplantation recipients, we constructed 
haplotype groups, being “Normal” those recipients carrying CC in rs1045642, CC in rs1128503 
and GG in rs2032582, and “Variant” those carrying the rest of the possible combinations, 
containing at least one T allele in any of the three SNPs. The results correlating these genotypes 
with tacrolimus corrected trough level are shown in figures 6 and 7. In figure 6 the data are 
represented according to the donors’ haplotype, with n=23 values for “normal”group in the 
first week and 29 in the second, and for “variant”, 77 in the first week and 93 in the second. 
Figure 7 shows the data arranged according to the haplotype of the recipients, with 21, 19, 86 
and 110 values, respectively. In both figures we find significant differences of p<0,05 between 
the two groups with Mann-Whitney two-tailed test. 
 


















CC/CC 6 12 141.4 
CT/CT 15 33 94.6 
TT/CC 5 8 44.53 
TT/CT 9 20 71.88 
CC/TT 
1 2 
CC/CC 6 12 286.53 
CC/CT 8 14 196.52 
CT/TT 
2 4 
CT/CC 14 29 107.52 
CT/CT 15 33 71.29 
Table 8. Percent increase (Δ%) of the median in the second week after transplantation, 
comparing different groups according to their genotype recipient/donor, as shown in 
figures 2-5. Columns 2 and 5 show the number of recipients in each group, and columns 3 
and 6 show the number of tacrolimus levels included. *Recipient/Donor. 
 
Fig. 6. Tacrolimus corrected trough concentration in renal recipients regarding SNPs 
rs1045642, rs1128503 and rs2032582 haplotype in their donors. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the 
patient’s donor genotype, showing the data from recipients divided in two groups 
according to their donor’s genotype being Normal those whose donors are CC/CC/GG in 
the three SNPs respectively, and Variant those with any of the other possible combinations. 
The results displayed correspond to the first (1w) and second week (2w) after 
transplantation. The horizontal line inside each bar is the median of the data, the bar is the 
interquartilic range, including 50% of the data, and the lines up and down the bars cover the 
whole data range for each set. Significant differences were found between the two groups at 
the first week (p<0,05) employing Mann-Whitney two-tailed test. 
 




Fig. 5. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in TT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients TT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. Significant differences were found between TT/CC and 
TT/TT at week two (p<0,05) employing Mann-Whitney one-tailed test. 
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Fig. 6. Tacrolimus corrected trough concentration in renal recipients regarding SNPs 
rs1045642, rs1128503 and rs2032582 haplotype in their donors. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the 
patient’s donor genotype, showing the data from recipients divided in two groups 
according to their donor’s genotype being Normal those whose donors are CC/CC/GG in 
the three SNPs respectively, and Variant those with any of the other possible combinations. 
The results displayed correspond to the first (1w) and second week (2w) after 
transplantation. The horizontal line inside each bar is the median of the data, the bar is the 
interquartilic range, including 50% of the data, and the lines up and down the bars cover the 
whole data range for each set. Significant differences were found between the two groups at 
the first week (p<0,05) employing Mann-Whitney two-tailed test. 
 




Fig. 7. Tacrolimus corrected trough concentration in renal recipients regarding SNPs 
rs1045642, rs1128503 and rs2032582 haplotype in the patients. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding 
the recipients’ genotype, showing the data from recipients divided in two groups 
according to their haplotype being Normal those CC/CC/GG in the three SNPs 
respectively, and Variant those with any of the other possible combinations. The results 
displayed correspond to the first (1w) and second week (2w) after transplantation. The 
horizontal line inside each bar is the median of the data, the bar is the interquartilic range, 
including 50% of the data, and the lines up and down the bars cover the whole data range 
for each set. Significant differences were found between the two groups at the second 
week (p<0,05) employing Mann-Whitney two-tailed test. 
5.3.2 CYP3A5 
The corresponding data for the analysis of SNPs rs776746 and rs10264272 of CYP3A5 
showed the expected behavior, already described in the literature. In figure 8, we find a 
significant increase in tacrolimus concentration in patients GG, the non-expressors, 
regarding GA. We failed to have AA patients, which we would expect to have even lower 
concentrations than GA. Regarding SNP rs102642272, we only had one GA patient, so we 
could not perform any statistical analysis, however the only three values that we have 
from that recipient are consistent with the expected results of higher tacrolimus 
concentrations. 
 




Fig. 8. Tacrolimus corrected trough concentration in renal recipients regarding SNP rs776746 
genotype. Tacrolimus corrected trough concentration (C0/Dc (dose/weight)) (C0 ng/mL; 
dose mg/Kg/24 hours; weight Kg) is shown regarding recipient’s genotype GG or GA, in 
the first (1w) and second (2w) week after transplantation. P<0,05 statistically significant 
difference was found between groups at both weeks by Mann-Whitney one-tailed test. 
 
Fig 9. Tacrolimus corrected trough concentration in renal recipients regarding SNP 
rs10264272 genotype. Tacrolimus corrected trough concentration (C0/Dc (dose/weight)) (C0 
ng/mL; dose mg/Kg/24 hours; weight Kg) is shown regarding recipient’s genotype GG or 
GA, in the first (1w) and second (2w) week after transplantation. No statistical difference 
was found between groups. 
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The importance of obtaining the best results in terms of efficacy and safety, but also in terms 
of economic saving is out of discussion. With the personalized medicine we search for 
formulas that help us decide wich is the perfect treatment in drug and dose for each patient. 
This is actually possible nowadays with the help of tools as pharmacogenetics, but there is 
still a lot of work to do before this tool would really be useful in all the therapeutic areas in 
the daily work with the patient. There are a lot of published works about many genes and 
SNPs, but when we look deeply for the usefulness, not all of them pass the test. In this work 
we have confirmed with real patients’ data, the expected effect of five different SNPs in 
ABCB1 and CYP3A5 genes. We have also demonstrated that there is an additional effect of 
the donor’s genotype translated into the received organ, which is also playing a role in the 
transport (ABCB1) of tacrolimus (Herrero et al., 2010).  
But there are still many other genes related to tacrolimus, and also to other 
immunosuppressants as cyclosporine and micophenolic acid, which have to be explored 
and validated in the real clinical setting. 
Interdisciplinar groups are also necessary for a complete approach to the scenario, only 
summing the work of different professionals could we achieve the success. The results in 
other kinds of transplantation must also be taken in consideration (Jordán et al, 2011). 
The effects of many other factors need also to be considered, as they may overlap or disguise 
a genotype effect. 
With the data in our hands, we have found a clear effect of increased tacrolimus trough 
concentration associated with TT genotype in SNPs rs1045642, rs1128503 and rs2032582 in 
ABCB1 gene. And regarding CYP3A5, we have also found an increase of the mentioned 
levels in the non-expressor genotype GG. These data, in agreement with more published 
works by other groups (Haufroid et al. 2006, Thervet et al., 2010), makes us consider 
conducting an analysis to any patient before initiating an immunosuppressive therapy, 
before the transplantation is performed in order to know in advance the optimal dose based 
on the polymorphisms found.  
Further studies with a higher number of patients, also in long term responses, relating 
several SNPs at the same time, building haplotypes and taking also into consideration the 
correlation with adverse effects are required to establish this “new” and promising 
Pharmacogenetic Tool.  
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1. Introduction 
Mycophenolic-acid (MPA) is a selective, non-competitive inhibitor of Inosine-
Monophosphate-Dyhydrogenase (IMPDH) leading to the inhibition of the de-novo 
synthesis of guanosine-nucleotides. In human lymphocytes inhibition of IMPDH results in 
altered cellular proliferation with arrest in the S-phase of the cell cycle. Due to the absence of 
a salvage pathway, proliferating activated t-cells are severely affected by the inhibitory 
effects of MPA (1-3). For patients after renal transplantation MPA is used either as 
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1. Introduction 
Mycophenolic-acid (MPA) is a selective, non-competitive inhibitor of Inosine-
Monophosphate-Dyhydrogenase (IMPDH) leading to the inhibition of the de-novo 
synthesis of guanosine-nucleotides. In human lymphocytes inhibition of IMPDH results in 
altered cellular proliferation with arrest in the S-phase of the cell cycle. Due to the absence of 
a salvage pathway, proliferating activated t-cells are severely affected by the inhibitory 
effects of MPA (1-3). For patients after renal transplantation MPA is used either as 
mycophenolate-mofetil (MMF, Cellcept) or as enteric-coated mycophenolate-Sodium (EC-
MPS, Myfortic) in daily doses of 2000 mg respectively 1440 mg per day. 
Since its introduction in immunosuppressive therapy more than ten years ago, 
Mycophenolate-Mofetil (MMF) is an established part of immunosuppressive therapy after 
renal transplantation. Still in the first publication of the landmark Tricontinental trial 
because of possibly dose-related side effects of the drug (CMV-infection, gastrointestinal 
disturbances, and increased cancer risk) the need for individualization depending on clinical 
course or other factors was mentioned (4).  
The usefulness of pharmacokinetic measurements of MMF was shown in early studies 
stating that the Area-under the curve (AUC) of MMF is predictive of the likelihood of 
allograft rejection after renal transplantation in patients receiving mycophenolate mofetil (5). 
To facilitate therapeutic drug monitoring different limited sampling strategies for adult and 
pediatric patients after renal transplantation were established (6-13). 
The two available preparations of MPA (MMF, EC-MPS) showed equivalent drug exposure 
measured by MPA-AUC when applied to the patients in equimolar doses. Therefore, both 
preparations are seen as equipotent (14-16).  
2. Pharmacokinetics of MPA 
MPA trough levels show relevant inter- and intraindividual variability especially in patients 
with elevated serum creatinine and proteinuria (17-19). Clinically important, low trough  
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levels are associated with an increased frequency of rejection (20), whereas elevated MPA 
trough levels are related to an increased risk for infections (21). Nevertheless, relevant 
correlations between MPA trough levels and MPA-AUC values could not be detected, 
therefore the usefulness of measuring trough levels in routine care of renal transplant 
recipients is doubted (22-24). 
2.1 Effect of immunosuppressive therapy on MPA pharmacokinetics 
Concomitant immunosuppressive therapy has major influence on MPA pharmacokinetics. For 
patients on Cyclosporine (CsA)  therapy lower MPA trough levels are observed (25). In 
addition, MPA trough levels increased after discontinuation of CsA resulting in almost a 
doubling of MPA trough concentrations (26). In general, the variability of MPA-AUC in 
patients with concomitant cyclosporine and steroid therapy seems to be low (27). However, in 
154 patients with an immunosuppressive therapy consisting of CsA, prednisone and MMF the 
mean MPA AUC increased after 21 days although mean MMF dose was reduced (28).  
For patients treated with tacrolimus (TAC) increased MPA trough levels are reported (29). 
Additionally, a randomized trial with 150 participants, patients receiving TAC and MMF 
displayed significantly higher MPA trough levels and higher MPA exposure measured by 
MPA-AUC than those receiving CsA and the same dose of MMF. Equivalent MPA levels 
could only be attained in patients receiving CsA by increasing the MMF dose by 50% (30). 
Similar results were obtained for pediatric renal transplantation (31). Interestingly, at least in 
japanese renal transplant patients, a difference for MPA-AUC in patients with different 
tacrolimus-trough levels could not be detected (32). At least, for renal transplant recipients  
limited sample strategies for MPA-AUC with concomitant medication of tacrolimus are 
established (33). 
In patients with Sirolimus (SRL) MPA exposure in the presence of SRL is higher than MPA 
exposure with CsA. Therefore it was recommended, that the MMF dose should be reduced 
to 0.75 g twice a day in patients receiving SRL to obtain MPA-AUC levels comparable to that 
in patients treated with CsA and MMF 1 g twice a day (8). These results were confirmed in a 
pharmacokinetic study in 31 renal transplant patients (34). It was also shown, that although 
MPA peak concentration and time to peak concentration was comparable, the MPA-AUC 
was higher in patients receiving SRL instead of CsA (35).  
Steroids have been shown to induce the hepatic glucuronyltransferase (GT) expression 
enhancing the activity of uridine diphosphate-GT, the enzyme responsible for mycophenolic 
acid (MPA) metabolism. Therefore, also for steroids interactions with MPA are reported. 
During a steroid tapering and withdrawal phase in 26 patients MPA trough levels 
progressively increased and plasma MPA clearance declined (36). 
2.2 Effect of concomitant therapy on MPA pharmacokinetics 
For patients in the maintenance phase after transplantation it is known, that MPA-AUC 
increases with declining transplant function (37). This effect may be modulated by 
concomitant medication. Beside immunosuppression, patients after renal transplantation 
have to use antiviral prophylaxis. At least for Ganciclovir no effect on MPA clearance in 
kidney transplant recipients was reported (38).  
With respect to the use of proton pump inhibitors the published results are unequivocally. 
In japanese patients, the peak MPA-concentrations were lower with 30 mg lansoprazole 
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than with 10 mg rabeprazole or without PPI. For patients with cytochrome (CYP) 2C19, and 
multidrug resistance (MDR)1 C3435T polymorphisms this was also seen for the MPA-AUC  
(39). 
Patients after heart transplantation with PPI co-medication show significantly lower MPA 
plasma concentrations resulting in lower drug exposure exposing the patients at a higher 
risk for acute rejection (40). Also in patients with autoimmune diseases the co-medication of 
pantoprazole with MMF significantly influences the drug exposure and immunosuppressive 
potency of MMF (41). In contrast, the recently published sub-analysis of the CLEAR-study 
reported no difference in MPA-AUC in patients with or without PPI-therapy when a 3g/d 
loading dose of MMF for 5 days used. However, MPA concentrations   2 h and 12 h after 
MMF intake were reduced (42).  
At least for heart transplant recipients no influence of pantoprazole on EC-MPS 
pharmacokinetics could be disclosed (43). 
Own results in 74 patients in the early and maintenance phase after renal transplantation 
showed a relevant reduction in normalized MPA-AUC (40,9 +/- 19,7 vs. 26,1 +/- 11,7 
mg/l*h; p<0,01) in patients with PPI co-medication. A difference between patients using 
either omeprazole or pantoprazole in MPA-AUC could not be detected.  (Rath et al., 
Congress of the German Transplantation Society, 2009) 
3. Clinical relevance of MPA-AUC 
3.1 MPA-AUC and acute rejection 
In different clinical trials, MPA drug exposure was correlated with the occurrence of biopsy 
proven acute rejection (BPAR). In a double blind trial aiming for three predefined target 
MPA AUC values the incidence of BPAR was lower in patients with MPA AUC values 
between 30 and 60 µg x h/ml (28). Similar results were reported for a group of 46 stable 
patients after renal transplantation, with better graft function in patients with a MPA AUC > 
40 µg/ml*h and for pediatric renal transplantation (20;44;45).  
Three randomized trials, the OPTICEPT study, the APOMYGRE-trial (Adaption de 
Posologie du MMF en Greffe Renale) and the FDCC study (fixed-dose versus concentration 
controlled) investigated the benefit of therapeutic drug monitoring for MMF in renal 
transplant recipients.  
The APOMYGRE Trial was a study in 137 allograft recipients treated with basiliximab, 
cyclosporine A, corticosteroids and MMF. Patients were randomized to receive either 
concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA 
AUC based on three-point sampling was used to individualize MMF doses. At month 12, 
the concentration-controlled group had fewer treatment failures and acute rejection 
episodes. Therefore, the authors conclude, that therapeutic MPA monitoring using a limited 
sampling strategy can reduce the risk of treatment failure and acute rejection in renal 
allograft recipients 12 months post-transplant with no increase in adverse events (46). 
The FDCC study  was a randomized trial in 901 patients after renal transplantation allocating 
patients to receive MMF either in a fix dose or in a concentration controlled manner aiming at 
a predefined MPA AUC of 45 mg*h/L. In general, there was no difference in the incidence of 
primary treatment failure or biopsy proved rejection. However, MPA-AUC levels at day 3 
after transplantation predicts the incidence of BPAR in the first year (47). 
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exposure with CsA. Therefore it was recommended, that the MMF dose should be reduced 
to 0.75 g twice a day in patients receiving SRL to obtain MPA-AUC levels comparable to that 
in patients treated with CsA and MMF 1 g twice a day (8). These results were confirmed in a 
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was higher in patients receiving SRL instead of CsA (35).  
Steroids have been shown to induce the hepatic glucuronyltransferase (GT) expression 
enhancing the activity of uridine diphosphate-GT, the enzyme responsible for mycophenolic 
acid (MPA) metabolism. Therefore, also for steroids interactions with MPA are reported. 
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For patients in the maintenance phase after transplantation it is known, that MPA-AUC 
increases with declining transplant function (37). This effect may be modulated by 
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The OPTICEPT study was a 2-year, open-label, randomized, multicenter trial comparing the 
efficacy and safety of concentration-controlled MMF dosing with a fixed-dose regimen in 
720 kidney recipients. In patients with Tacrolimus, those with higher MMF exposure had 
less rejection episodes (48). 
Similarly, a recently published substudy of the FDCC-trial in patients with delayed graft 
function disclosed significantly lower dose-corrected MPA AUC on Day 3 and Day 10 in this 
patient group (49). 
3.2 MPA-pharmacokinetics and gastro-intestinal side effects 
It is known, that side effects of MMF are causing dose reductions in approximately 60% of 
the patients leading to a cumulative and increasing risk for acute rejection (50). In addition, 
gastrointestinal (GIT) side effects affect medical adherence of the patients with consecutive 
risk for graft failure (51). In addition, dose reductions of MMF are related to increased costs, 
mainly due to frequent hospitalization of the patients (52). 
USRDS data of 3589 patients with MMF prescription and GIT complaints revealed that 
dosage reduction or discontinuation of mycophenolate mofetil in the first 6 months after 
diagnosis of GI complications was associated with significantly increased risk of graft failure 
and increased healthcare costs in adult renal transplant recipients (53). Another report from 
USRDS data of 3675 patients with gastrointestinal complications under MMF and 
subsequent dose reduction also disclosed an increased risk for graft loss after dose reduction 
or discontinuation of MMF (54).  
The enteric coated preparation of mycophenolate (EC-MPS) is attributed to a lower rate of 
gastrointestinal side effects, but in a prospective study based on patient questionnaires the 
rate of gastrointestinal side effects was nearly identical between the two formulations (55). 
In addition, a double-blind study comparing MMF and the newly developed enteric-coated 
formulation of MPA (EC-MPS) showed no advantage for either of the drugs (56). In contrast, 
a large, prospective study in more than 700 renal transplant recipients disclosed a significant 
improvement in gastrointestinal adverse events after conversion from MMF to EC-MPS (57).  
A study in patients with GIT complaints under MMF switching to EC-MPS indicates that 
converting patients with mild, moderate or severe GI complaints from MMF to EC-MPS 
significantly reduces GI-related symptom burden and improves patient functioning and 
well-being (58). 
Also in liver transplant patients results are reported that converting patients with 
gastrointestinal complaints from MMF to equimolar doses of EC-MMF leads to a reduction 
of gastrointestinal-related symptom burden and frequency of stools (59). 
There is some evidence from pharmacokinetic studies that elevated MPA exposure 
correlates with the occurrence of gastrointestinal side effects. Some authors suggest that 
gastrointestinal side effects are related to exposure of the active substance MPA (60). Others 
report, that the occurrence of possibly MMF-related side effects corresponds with MPA-
AUC and MPA concentration 30 minutes after oral dose of 1000 mg (61). Also, a 
longitudinal study in 37 patients with 357 MPA measurements revealed higher trough levels 
in patients with MMF associated side effects(62). It is known that MPA trough levels >3 
mg/l, peak levels >8.09 mg/l and MPA-AUC > 37.6 mg*h/l may lead to adverse effects (63). 
Also in 31 patients after renal transplantation higher MPA-AUC (>60 mg*h/l) was 
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associated with side effects (64). Nevertheless, in a small pharmacokinetic study with 11 
hispanic renal transplant patients treated with EC-MPS the MPA-AUC does not correlate 
with overall Gastrointestinal Symptom Rating Scale scores or subscale scores (65). 
Also, a 5-year clinical follow-up study in 100 renal allograft recipients in whom MPA 
exposure was measured at 7 days, 6 weeks, 3 months, 1, 3, and 5 years post transplantation 
using abbreviated AUC measurements reported more episodes of leucopenia and  anemia 
with MPA AUC(0-12h) ranges >60 mg/L x h(-1). However, no association between incident 
episodes of diarrhea or infection and target MPA AUC (0-12 h) ranges (66). 
4. Pharmacodynamics of MPA 
4.1 Inhibition of IMPDH-activity 
Recently, pharmacodynamic measurement of MPA was introduced into clinical practice. 
Especially with the use of reversed-phase HPLC, it is possible to monitor the 
immunosuppressive effect of MPA in its target cell population by quantifying the activity of 
IMPDH. This nonradioactive method for specific measurement of IMPDH activity in 
isolated peripheral mononuclear cells was developed by direct chromatographic 
determination of produced xanthosine 5'-monophosphate (XMP). In the canine model MPA 
in therapeutic doses leads to an 50% inhibition of IMPDH-activity (67) . Application of a 
single dose of 1 g MMF in dialysis patients resulted in a significant inhibition of IMPDH 
activity in lysed mononuclear cells. IMPDH activity is inversely correlated to MPA blood 
concentrations and the IC (50) for in vitro inhibition of IMPDH activity was about 2 to 3 
µg/l. (68). In addition, others report, that IMPDH-activity on peak concentration of MPA is 
approximately 40% and could be suppressed for 8 hours (69). In general, it is assumed, that 
IMPDH activity has a substantial interindividual, but low intraindividual variability (70). 
This was also shown in pediatric patients (71). 
In addition, in renal allograft recipients an inverse relationship between plasma MPA and 
IMPDH activity within the dose interval was demonstrated and minimum IMPDH activity 
was a median 8 % of values pre-MMF dose, coinciding with the MPA peak. Six hours post-
dose, IMPDH activity had returned to pre-dose values. Patients receiving MMF had a 4.5-
fold higher pre-dose enzyme activity than transplanted patients without MMF (72).  Long-
term treatment with mycophenolate was associated with an induction of IMPDH activity 
(73). Also a study with 12 patients over two years showed an increase of type 1 IMPDH 
mRNA during the first 3 months following transplantation and reaching its maximal level 
during acute rejection episodes, whereas type2 IMPDH mRNA was stable (74). Interestingly, 
in 30 patients transplantation and the initiation of immunosuppressive therapy was 
associated with increased IMPDH1 and decreased IMPDH2 expression. In addition, patients 
with acute rejection during follow-up demonstrated higher IMPDH2 expression in 
pretransplant CD4+ cells than nonrejecting patients (75). Later, the same group described in 
detail the MMF concentration dependent modulation of IMPDH1 expression in renal 
allograft recipients (76). 
4.2 IMPDH-activity and acute rejection 
Measurement of IMPDH activity may be useful in estimating the degree of 
immunosuppression in individual patients in addition to applied MMF dose. When 
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The OPTICEPT study was a 2-year, open-label, randomized, multicenter trial comparing the 
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well-being (58). 
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report, that the occurrence of possibly MMF-related side effects corresponds with MPA-
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comparing three patients groups with MMF doses of 1.0, 1.5 and 2.0 g/d there was no 
correlation between MPA-AUC (0-12) values and MMF dose detectable.  Also, the degree of 
inhibition of IMPDH activity was comparable in the three groups, indicating considerable 
interindividual pharmacodynamic variability (77). In a cross-sectional analysis patients 
experiencing acute rejection episodes had increased IMPDH activity during rejection 
episodes (78). Additional information was gained in a genotyping study in 191 kidney 
transplant patients. There, seventeen genetic variants were identified in the IMPDH1 gene 
with allele frequencies ranging from 0.2 to 42.7%. Two single-nucleotide polymorphisms, 
rs2278293 and rs2278294, were significantly associated with the incidence of biopsy-proven 
acute rejection in the first year post-transplantation (79). A similar study in 82 japanese 
transplant recipients found no difference in the incidence of subclinical acute rejection 
between IMPDH1 rs2278293 or rs2278294 polymorphisms (p = 0.243 and 0.735, 
respectively). However, the authors report that the risk of subclinical acute rejection for 
recipients who cannot adapt in therapeutic drug monitoring (TDM) of MPA seems to be 
influenced by IMPDH1 rs2278293 polymorphism (80). Also, in patients after renal 
transplantation high pre-transplant IMPDH-activity predisposes to subsequent MPA dose-
reductions and increases the risk for acute rejection (81). 
4.3 IMPDH activity and MMF or EC-MPS  
There is some discussion about the degree of IMPDH suppression with either MMF or EC-
MPS.  In a single-center, crossover study in patients treated with MMF and EC-MPS IMPDH 
activity inversely followed MPA concentrations and was inhibited to a similar degree 
(approximately 85%) by both formulations. In addition, the calculated value for 50% IMPDH 
inhibition was identical for both drugs (16). However, when comparing the 
pharmacodynamic activity of MMF and EC-MPS a series of 260 measurements in 110 
patients disclosed lower median IMPDH activity in the EC-MPS patients than in the MMF 
patients. This was especially pronounced in patients on 1440 mg/d EC-MPS compared with 
2000 mg/d MMF (82). 
Nevertheless, for EC-MPS a recently published pharmacokinetic study in 75 de-novo kidney 
transplant recipients randomly assigning the patients either to receive EC-MPS as standard 
dose  or as intensified dose revealed in an exploratory analysis of IMPDH activity that the 
intensified regimen resulted in significantly lower IMPDH activity on day 3 after 
transplantation (83). 
There is ongoing discussion about the effect of PPI therapy on pharmacokinetics of MMF 
and EC-MPS. In a cross-sectional analysis in 153 renal transplant recipients, we measured 
IMPDH-activity before the first daily dose of MMF or EC-MPS. We could not detect any 
statistical with respect to PPI intake, type or dosing of either MMF or EC-MPS (Congress of 
the German Transplant Society, 2009).  
5. Measuring IMPDH-activity 
5.1 Sample preparation 
Peripheral blood is collected in 5ml tubes with Li-heparin as anti-coagulant and stored at 
room temperature. Heparin is superior to EDTA as anti-coagulant since it maintains cell 
viability for longer time. Within four hours after arrival of the sample to the lab, and within 
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no more than two days of collection, the peripheral mononuclear cell fraction is isolated by 
density centrifugation according to a modified protocol from Glander et al. (2001). Li-
heparinized blood (2.5ml) is mixed with an equal volume of phosphate-buffered saline 
(PBS), carefully layered on 4ml Lymphodex (InnoTrain, Germany) density gradient 
centrifugation medium in a 15ml screw-cap polypropylene tube, and centrifuged at 1200 x g 
for 15 min without brake at room temperature.  
The mononuclear cell fraction is collected from the interphase and transferred into a fresh 
15ml screw-cap tube with 5ml PBS for washing. The cells are washed only once with PBS 
since repeated washing steps might cause diffusion of mycophenolate from the cells, 
resulting in over-estimation of the residual IMPDH activity. After centrifugation at 1200 x g 
for 10 min at room temperature, the supernatant is removed quantitatively. This step is 
crucial with respect to the assay validity, since only a minute fraction of the total 
mycophenolate is contained within the cells, while the vast majority (estimated 99%) is 
present in the plasma. Any trace of the supernatant might therefore still contain 
considerable amounts of mycophenolate, hence leading to a vast underestimation of the 
residual IMPDH activity. The cell pellet is resuspended in 250µl ice-cold HPLC-grade water, 
and 125µl of the sample are transferred into each of two 2ml screw-cap vials, one designated 
as working sample, the second as back-up. The vials are deep frozen at -80°C until assayed. 
In the same way, control cells from healthy probands are prepared; these cells will be 
included in each assay as an incubation control.  
5.2 IMPDH activity assay 
The residual IMPDH activity is assayed in a cell-free system. The patient samples and 
control cells are thawed at room temperature and vigorously vortexed for 30 seconds to 
support cell lysis; insoluble cell fragments are removed by centrifugation at 4000 x g for 5 
min at room temperature in a desktop centrifuge. Cell lysate (50µl) is added to 100µl 
incubation buffer containing 1 mmol/L inosine-monophosphate (IMP) as substrate, 0.5 
mmol/L NAD as co-substrate, 72 mmol/L sodium dihydrogen-phosphate, and 180 mmol/L 
potassium chloride (pH = 7.5). After adjusting the volume to 180ml with distilled water, the 
samples are incubated at 37°C in a heating block. In presence of NAD, IMPDH converts 
inosine-monophosphate to xanthine 5’-mono-phosphate. In the subsequent high-
performance liquid chromatography (HPLC) assay, the amount of synthesized xanthine 5’-
monophosphate is determined together with the amount of AMP, which serves as an 
internal standard for normalization to the cell count. 
After exactly 2.5 hours of incubation, the reaction is stopped by adding 20µl ice-cold 4mol/L 
perchloric acid. Precipitation of denatured protein is enhanced by incubating the samples at 
-20°C for 10 min. After centrifugation at 13000 rpm for 2 min in a desktop centrifuge, 170µl 
supernatant are transferred to a test tube containing 14µl 2.5 mol/L potassium carbonate 
solution for neutralization. The exact volume of potassium carbonate, required to achieve a 
final pH between pH 6 and pH 7, has to be determined for each lot of 4 mol/L perchloric 
acid and 2.5 mol/L potassium carbonate solution. Prior to HPLC analysis, the samples are 
deep-frozen at -20°C for at least 30 min, thawed, and centrifuged 5 min at 13000 rpm in a 
desktop centrifuge. 
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5.3 HPLC chromatography 
Determination of the amounts of xanthine-monophosphate and adenosine-monophosphate 
is carried out by ion-pair reversed-phase high-performance liquid chromatography on a 
computerized isocratic HPLC system from Shimadzu (Kyoto, Japan) consisting of a system 
controller SCL-10A VP, an HPLC pump LC-10AT VP, an autoinjector SIL-10AF, a column 
oven CTO-10AS VP, and an UV-VIS detector SPD-10A VP, controlled by Shimadzu LC 
Solution data collection software.  
For the assay 6µl of the samples are loaded onto a 250 mm x 3.1 mm Prontosil 120 to 5 ODS 
AQ column (Bischoff Chromatography, Leonberg, Germany). Column oven temperature is 
set to 40°C. Chromatographic separation is achieved using a mobile phase containing 50 
mmol/L potassium-dihydrogen-phosphate, 7 mmol/L tetra-n-butyl-ammonium hydrogen 
sulfate, and 6% (v/v) methanol at a flow rate of 1 mL/min. The analytes are detected at 254-
nm wavelength. Incubation efficacy is verified by including a sample from a healthy 
volunteer as incubation control in each incubation cycle. For calibration, two standards 
containing 500 and 2500 pmol xanthin-monophosphate and adenosin-monophosphate, 
respectively, in 0.4% BSA solution are processed in several independent experiments, and 
repeatedly measured, like the patient specimen: protein denaturation with perchloric acid 
followed by neutralization with potassium carbonate. This calibration curve allows to 
deduct the amount of XMP synthesized during incubation and the amount of AMP in the 
sample. The specific IMPDH activity is then expressed as pmol XMP synthesized per 
second, which is normalized to 1 pmol of AMP [pmol XMP/(pmol AMP s)]. 
6. Summary and conclusion 
Mycophenolic-acid (MPA) is a selective, non-competitive inhibitor of Inosine-
Monophosphate-Dyhydrogenase (IMPDH) leading to the inhibition of the de-novo 
synthesis of guanosine-nucleotides. In human lymphocytes inhibition of IMPDH results in 
altered cellular proliferation with arrest in the S-phase of the cell cycle. Due to the absence of 
a salvage pathway, proliferating activated t-cells are severely affected by the inhibitory 
effects of MPA. 
In patients after renal transplantation, MPA is a well-established part of 
immunosuppressive therapy, applied either as mycophenolate-mofetil (MMF, Cellcept) or 
as mycophenolate-sodium (MPS, Myfortic). MMF is used in prophylaxis of kidney rejection 
for nearly 15 years in daily doses of 2 – 3 g/d. The enteric-coated MPS is available since a 
few years; the recommended daily dose is 1440 mg/d. Both preparations are equipotent, 
when given in equimolar doses. 
In recent years drug monitoring of MPA gained more and more attention proving its 
usefulness in clinical setting. Relevant information could be collected by measuring MPA 
drug exposure by calculating the MPA-Area under the curve (MPA-AUC) with 
pharmacokinetic modeling allowing estimating the degree of immunosuppression. 
In different clinical studies MPA-AUC target concentrations of 30 – 60 µg*h/ml were 
correlated to a low rate of rejections and less occurrence of drug induced side effects. 
Clinically important, MPA metabolism is influenced not only by the choice of 
immunosuppressive medication, but also by renal function and concomitant medication.  
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Recently pharmacodynamic measurement of MPA was introduced into clinical practice. 
Especially with the use of reversed-phase HPLC, it becomes possible to monitor the 
immunosuppressive effect of MPA in its target cell population by quantifying the activity of 
IMPDH. IMPDH activity is inversely correlated to MPA blood concentrations. Maximum 
inhibition of IMPDH activity ranges between 60% and 80% and the reported IC (50) of 
IMPDH activity corresponds to MPA blood levels of 2-3 µ/l. In renal transplant recipients, 
IMPDH shows relevant inter-individual variability. However, pre-transplant IMPDH 
activity was predictive for increased risk of rejection when additional dose reductions of 
MMF were necessary. In a cross-sectional studies better transplant function was associated 
with lower IMPDH-activity and probably the usage of EC-MPS. Pharmacokinetic and 
pharmacodynamic parameters of MPA are influenced by additional immunosuppression. In 
addition, concomitant therapy especially the use of proton-pump inhibitors affects MPA-
levels, whereas an effect of IMPDH-activity, at least in renal transplant recipients could not 
be disclosed. Therefore, it can be concluded, that pharmacokinetic and pharmacodynamic 
measurements of MPA adds relevant information to improve clinical care of renal transplant 
recipients. 
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1. Introduction 
Renal transplantation is the preferred renal replacement therapy for patients with end 
stage renal disease (ESRD) as this modality provides better quality of life, improved 
overall survival, and lower treatment cost than dialysis. Malignancy is a known 
complication among transplant recipients, and is likely to become even more common in 
these patients as donation criteria are extended to allow older donors, the age of patients 
on waiting list is increased, and transplant recipients live longer (Gallagher et al, 2010). 
However still there is a continuous struggle to keep the delicate balance between reducing 
the immunosuppression and maintaining the graft survival. Majority of post-transplant 
morbidity and mortality is related to immunosuppression. Post-transplant patients are 
subjected to high rate of infections, medication nephrotoxicity, cardiovascular disorders, 
and development of malignancies. The life expectancy in kidney transplant patients is 
only half of that in general population. Although cardiovascular diseases are the most 
common cause of death in patients with functioning graft, malignancy is a significant 
cause of mortality. Malignancy is the third most common cause of death in renal 
transplant recipients after cardiovascular events and infections. There is a substantial 
three to five fold increase in the incidence of malignancy after solid organ transplantation 
as compared to the general population. Moreover the cancer incidence is also higher in 
transplant recipients than that seen in dialysis patients (Rama & Grinyó, 2010). As the risk 
of acute rejection and subsequent organ loss diminished due to the introduction of better 
immunosuppressive agents, infection and malignancy incidence has increased. Recently 
the life-threatening infections have also been declining due to the more judicious use of 
immunosuppressive agents and improved treatment regimen for infections. As 
cardiovascular diseases poses the greatest risk to the long-term graft and patient survival, 
efforts are being undertaken to reduce these risks by the use of less atherogenic 
immunosuppressive regimens, aggressive treatment of hyperlipidemia and better blood 
pressure control. Based on these observations it is estimated that malignancy will surpass 
cardiovascular complications as the leading cause of death post-transplant within the next 
2 decades (Buell et al, 2005). 
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There are several factors that lead to development of malignancy among transplant 
recipients. These include impaired immunosurveillance of tumor cells, DNA damage and 
impaired DNA repair mechanism, exposure to oncogenic viruses, and upregulation of 
cytokines that may promote tumor growth such as vascular endothelial growth factor, 
transforming growth factor β1 (TGF-β1), and  interleukin-10. Certain neoplasms have a 
much higher incidence in post-transplant patients such as skin cancers including squamous 
cell carcinoma, basal cell carcinoma, merkel cell cancer, and melanoma, kaposi’s sarcoma, 
lymphoma, carcinoma of oropharynx, anogenital cancer, liver cancer, in-situ carcinoma of 
cervix , renal cell carcinoma, and several sarcomas. In contrast,  solid tumors that are most 
commonly seen in general population such as breast, colorectal, prostate, and invasive 
cervical cancer have only a modest increase in post-transplant patients. The largest study on 
the rate and types of malignancies was on 35,000 first time renal transplant recipients of 
deceased and living donor kidney transplants. As compared to the general population, the 
incidence of tumors was found to be as follows (kasiske et al, 2004):  
 2 fold increase: most common solid tumors in general population such as breast, colon, 
prostate, lung, ovary, stomach, pancreas, and esophagus. 
 3 fold increase: testicular and bladder carcinoma. 
 5 fold increase: melanoma, leukemia, hepatobiliary, cervical, and vulvovaginal tumors. 
 15 fold increase: renal cell carcinoma. 
 20 fold increase: nonmelanoma skin cancer, non-Hodgkins lymphoma(NHL), and 
kaposi’s sarcoma (KS). 
Certain malignancies tend to occur at a higher rate in transplant recipients as compared to 
patients on transplant waiting list (Morath et al, 2004). These include non-melanoma skin 
cancer (2.6 fold), melanoma (2.2 fold), KS (9 fold) NHL (3.3 fold), oral cancer (2.2 fold), and 
renal cell carcinoma (39% higher) (Kasiske et al, 2004). Malignancy development is 2-4 fold 
more common in heart transplant than renal transplant patients as a result of increased 
immunosuppression required in heart transplantation. In general, the post-transplant 
carcinomas tend to behave more aggressively and have a worse outcome. The incidence of 
second primary cancer is similar to that of the first malignancy with an exception of non-
melanoma skin cancer with recurrent Squamous cell carcinoma. Malignancies develop in 15-
20% of transplant recipients after 10 years. After 20 years of immunosuppressive therapy, 
approximately 40% of recipients develop cancer. However the real incidence still could be 
underestimated as follow-up is usually short in many patients (Pita-Fernandez et al, 2009).  
The average latency of malignancy development after transplant is approximately 3-5 years. 
Different tumors have a distinct time interval between transplant and tumor presentation 
(Brennan et al, 2011): 
 Kaposi’s sarcoma : 13-21 months 
 Lymphomas: 32 months. The risk is highest during the first year when the 
immunosuppression is intense and the risk of viral infection is highest. 
 Epithelial carcinomas (including skin): 69 months 
 Anogenital region carcinomas: 84-112 months. The latency is longer in children 
transplant recipients who may develop tumors during adulthood. 
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3. Common malignancies in transplant recipients 
3.1 Skin carcinomas 
Non-melanoma skin cancers such as squamous cell and basal cell carcinomas are common 
after transplant. They account for approximately 37% of all cancers, and can result in 
significant morbidity and mortality rate of 5-8%. As compared to general population, the 
transplant recipients develop these tumors 15-20 years earlier with an average time of 
development of 4-9 years post- transplant. The incidence of these tumors can vary between 
different geographic locations. Risk factors include increase age, male gender, fair skin, HLA 
A11, B27, and DR7, presence of HPV, use of cyclosporine, or Azathioprin, sun exposure, and 
the geographic location. Rapamycin has been reported to potentially decrease the risk of 
developing these tumors after transplant (Comeau et al, 2008). The overall incidence of skin 
cancer rises progressively as transplanted graft longevity increases with a cumulative risk 
increase from 7.5% to 28.6% after 5 years and 15 years respectively. The anatomic 
distribution of these tumors in transplant recipients is similar to the general population. The 
development of skin cancer is also strongly related to the patient’s age and sex at the time of 
the transplantation (Naldi et al, 2000).  
3.1.1 Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) 
Non-melanoma skin cancers are the commonest tumors following solid organ transplant. They 
are reported to occur approximately 8 years after renal transplant in recipients aged 40 years 
or younger, and 3 years post-transplant in recipients 60 years and older. SCC and BCC account 
for more than 90% of these tumors. The risk of SCC is 60-250 times greater than the general 
population whereas the risk of BCC is 10 times higher. Interestingly, SCC is more common 
than BCC in transplant patients which is in contrast to the general population where the ratio 
of BCC:SCC is 4:1. Both tumors generally occur at a younger age, involve multiple sites, 
behave more aggressively, and tend to recur after treatment. The most important risk factors 
are prior exposure to ultraviolet radiation, and for SCC, development of premalignant lesions 
such as Bowen’s disease, premalignant keratosis and warts, and keratoacanthoma. 
3.1.2 Melanoma 
The risk of developing melanoma is 3.6 times greater than in the general population. The 
risk is positively associated with increasing age at transplant, and use of depleting anti-
lymphocyte antibodies. On the other hand, increasing time since transplant, female sex, and 
non-Caucasian race are associated with a reduced risk of melanoma development.  
3.1.3 Merkel cell carcinoma (MCC) 
MCC is an aggressive neuroendocrine carcinoma of skin which has an even more aggressive 
outcome in transplant patients.it is more common in transplant recipients with an average 
of 7 years post-transplant and mean survival of 18 months after diagnosis. Merkel cell 
polyomavirus (MCV) is believed to be a contributing factor. 
3.1.4 Carcinomas of anogenital region 
The incidence of these tumors is 100 fold higher in renal transplant recipients. These tumors 
often present as pigmented maculopapular lesions or warts. They tend to involve multiple 
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of BCC:SCC is 4:1. Both tumors generally occur at a younger age, involve multiple sites, 
behave more aggressively, and tend to recur after treatment. The most important risk factors 
are prior exposure to ultraviolet radiation, and for SCC, development of premalignant lesions 
such as Bowen’s disease, premalignant keratosis and warts, and keratoacanthoma. 
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The risk of developing melanoma is 3.6 times greater than in the general population. The 
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lymphocyte antibodies. On the other hand, increasing time since transplant, female sex, and 
non-Caucasian race are associated with a reduced risk of melanoma development.  
3.1.3 Merkel cell carcinoma (MCC) 
MCC is an aggressive neuroendocrine carcinoma of skin which has an even more aggressive 
outcome in transplant patients.it is more common in transplant recipients with an average 
of 7 years post-transplant and mean survival of 18 months after diagnosis. Merkel cell 
polyomavirus (MCV) is believed to be a contributing factor. 
3.1.4 Carcinomas of anogenital region 
The incidence of these tumors is 100 fold higher in renal transplant recipients. These tumors 
often present as pigmented maculopapular lesions or warts. They tend to involve multiple 
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sites including anus, and or perianal skin, and external genitalia of both sexes. They are 
usually extensive, in particular in women, one third of whom have concurrent cervical 
cancer. 
3.2 SCC of the eye 
The incidence of SCC of the eye is 20 fold higher in transplant recipients than in the general 
population. The incidence is also higher in HIV patients. 
3.3 Urinary tract malignacy 
There is an increased risk of developing tumors of the native urinary tract in patients with 
an exposure to cyclophosphamide, analgesic nephropathy, and nephropathy-induced by 
Chinese herbs (Morath et al, 2004).  
3.3.1 Renal cell carcinoma (RCC) 
The incidence of RCC after renal transplant is increased by more than 15 fold. Primary RCC 
occurs in approximately 3% of the general population, and 4.6% of renal transplant patients. 
The risk is increased in African-Americans, men, older donor age of more than 50 years, 
recipient age at least 65 years, patients with microscopic hematuria, acquired cystic kidney 
disease, analgesic nephropathy, and longer pre-transplant dialysis interval. More than 70 % 
of these tumors arise in native kidneys with only few cases reported in allografts. Once a 
RCC is diagnosed in an allograft, it is crucial to know the origin of the tumor cells whether 
they are of donor or recipient origin. RCC originating from renal allograft can be 
distinguished from RCC of the native kidney. Most RCCs of native kidney present as 
incidental tumors (90%) that are of low-grade, low-stage, and have a good prognosis. Post-
transplant RCCs, on the other hand, are multifocal in 40% of cases, and bilateral in 20%. 
Clear cell carcinoma is the most common subtype, although papillary subtype is seen more 
frequently than in non-transplanted patients. If the RCC develops 6 months after transplant, 
it is assumed to be de novo. Although multiple risk factors have been identified, the exact 
risk factor dependent screening protocol is yet to be determined (Klatte & Marberger, 2011, 
& Boix, et al, 2009, & Tydén et al, 2000). 
3.3.2 Bladder carcinoma 
Among the urologic malignancies that develop after transplant, bladder cancers are 
associated with worse prognosis, aggressive behavior, and high risk of recurrence than the 
general population. Most bladder carcinomas reported among solid organ transplant 
recipients are seen after kidney transplant. Yearly screening for non-glomerular hematuria is 
indicated in patients exposed to prolonged cyclophosphamide therapy due to the increased 
risk of bladder cancer. These patients should undergo cystoscopy as cytology may miss low 
grade lesions.  
3.4 Lung carcinoma 
In comparison to renal and liver transplant recipients, the incidence of lung tumors tends to 
be much higher in heart and lung transplant patients.  
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3.5 Kaposi’s sarcoma (KS) 
The incidence of KS is much higher in renal transplant recipients with a male predilection 
(male:female ratio of 3.3:1). It is caused by Human Herpes virus 8 (HHV-8) and is commonly 
seen in patients of Mediterranean, Arabic, Jewish, Caribbean, or African descent, mostly 
corresponding to the geographic distribution of HHV-8. The choice of immunosuppressive 
agent also plays a role in development of this entity as calcineurin inhibitors are associated 
with a higher risk of developing KS than other immunosuppressive agents. Clinical 
presentation is similar to the classic KS with angiomatous lesions involving the lower 
extremities. Approximately 90% of patients have cutaneous involvement with 10% showing 
visceral involvement which is associated with a worse prognosis. The incidence of visceral 
involvement is lower in renal transplant than in heart or lung transplant recipients. 
3.6 Gastrointestinal (GI) carcinomas 
Approximately 50% of GI malignancies affect the large intestine. Other organs at increased 
risk are liver, esophagus, and stomach (Lutz & Heemann, 2003). Colorectal carcinomas 
occur almost 3 times more frequently in renal transplant than age- and gender- matched 
general population. Significant risk factors include male gender, > 50 years of age, and the 
duration of immunosuppression (Nafar et al, 2009). GI malignancies have poor prognosis. 
Cancer survival by stage is also much worse in transplant recipients. The 5 year survival for 
localized cancer is 74% in transplant patients as compared to 90% in the general population. 
3.6.1 Hepatocellular carcinoma 
Infection with oncogenic hepatitis B and C viruses increases the risk of hepatocellular cancer. 
Transplant recipients with known hepatitis B and C cirrhotic liver disease should have serum 
alpha-fetoprotein (AFP) and hepatic ultrasound screen every 12 months (Kasiske et al, 2010). 
AFP has high specificity (>90%) but low sensitivity (20-60%) for detection of small 
hepatocellular carcinomas. The abdominal ultrasound, on the other hand, is more sensitive 
than serum AFP (80-85%) for detection of small hepatocellular carcinoma (1-5 cms in size). 
Patients with suspicious lesions should undergo contrast-enhanced CT (Brennan et al, 2011). 
3.7 Post-transplant lymphoproliferative disorder (PTLD) 
PTLD is characterized by abnormal proliferation of lymphoid cells with majority 
representing malignant lymphoproliferative lesions. The most recent 2008 WHO 
classification of PTLD stratifies the subgroups into monoclonal or polyclonal. These are 
further subdivided according to their morphologic features and characteristics to 
monomorphic, if cells are homogenous, or polymorphic if cells are heterogenous. (Table 1) 
(Mucha et al, 2010). PTLD varies from polyclonal B cell proliferation with normal 
cytogenetics and no evidence of immunoglobulin gene rearrangement to polyclonal B cell 
proliferation with early malignant transformation associated with clonal cytogenetic 
abnormalities and or immunoglobulin gene rearrangements to monoclonal B cell 
proliferation with malignant cytogenetic abnormalities and immunoglobulin gene 
rearrangements, the latter accounting for about 15% of cases (Nalesnik et al, 1988). 80-90% of 
these PTLDs representing B-cell malignancies are associated with EBV infection. Most 
PTLDs are of recipient origin with only few that are of donor cell origin. The recipient-origin  
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indicated in patients exposed to prolonged cyclophosphamide therapy due to the increased 
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grade lesions.  
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In comparison to renal and liver transplant recipients, the incidence of lung tumors tends to 
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PTLD is characterized by abnormal proliferation of lymphoid cells with majority 
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Early Leions  Plasmacytic Hyperplasia 
 Infectious-mononucleosis like lesions 
Polymorphic PTLD  
Monomorphic PTLD  B Cell Neoplasms 
o Diffuse large B-cell lymphoma 
o Burkitt lymphoma 
o Plasma cell myeloma 
o Plasmacytoma-like lesions 
 T Cell Neoplasms 
o Peripheral T-cell lymphoma, not 
otherwise specified 




Table 1. Pathologic Classification of PTLD (Morgans et al, 2009). 
PTLDs clinically present with a multisystem disease that occurs after an average of 76 
months post-transplant. On the other hand, the donor-origin PTLDs are usually limited to 
the allograft, develop after an average of 5 months, and regress with reduction of 
immunosuppression. Although, most of these disorders are of B-cell origin, however T-cell 
derived lesions are rarely reported. Data obtained from United States Renal Data System 
related to 66,159 renal transplant recipients, reported the development of malignant 
lymphoid proliferation in 1.8% of patients over 10 year follow-up, with 70% representing 
NHL, 14% multiple myeloma, 11% lymphoid leukemias, and 5% Hodgkins lymphoma (HL) 
(Caillard et al, 2006). The incidence was higher in the first year. NHLs in these patients have 
a more aggressive clinical course with more extranodal involvement occurring in 30-70% of 
cases, and worse prognosis. The lymphoproliferative disorders occurring in post-transplant 
behave differently than those in general population. NHL accounts for 65% of lymphomas 
in the general population whereas it accounts for 93% in post-transplant patients. Most of 
these NHLs are large cell lymphomas, majority of B-cell origin. For early detection of these 
disorders, a high level of suspicion is required, and when diagnosed the management 
should be handled by an experienced team to overcome this life-threatening complication 
(Morgans et al, 2009). Although the prognosis varies with clonality and extent of disease, the 
overall survival rate ranges from 25-35%. Mortality with monoclonal malignancies has been 
reported to be as high as 80%. T cell lymphomas in general have an extremely poor 
prognosis. Additional prognostic factors associated with worse outcome are identified for 
PTLD that include the performance status of > 2 as per the Eastern Cooperative Oncology 
Group criteria and more than one site involvement. The International Prognostic Index 
useful in determining prognosis in immunocompetent patients with NHL, is less beneficial 
in this setting. Adverse prognostic indicators include the presence of hypoalbuminemia, and 
involvement of central nervous system (CNS) and bone marrow. Increase mortality rates 
have been associated with a diagnosis within 6 months versus after 6 months from surgery 
(64% versus 54%), increasing age, no surgical intervention (100% versus 55%), allograft plus 
other organ involvement versus allograft involvement alone (64% versus 31%), and multiple 
versus single sites (73% versus 53%) and the risks are additive (Friedberg et al, 2011). 
 




Malignancy can develop in transplant recipients in three different ways (Morath et al, 2004): 
 De novo malignancy occurrence. The risk is approximately 0.2%. 
 Recurrent malignancy in the recipient.  
 Transmission of malignancy from the donor. Despite all efforts to secure a safe organ 
for transplantation, transmission of diseases such as malignancies, and infections may 
occur. Donor transmission of solid cancers is an unlikely event (Pedotti et al, 2004). 
These tumors may represent metastasis from malignancies diagnosed in the donor at 
the time of transplant (Donor-transmitted malignancy) or tumors develop de novo in 
transplanted donor tissue (Donor-derived malignancy). The risk of cancer developing 
in recipients receiving kidney from a donor with known or incidentally discovered 
cancer is 45%. In a population based study by the United Network for Organ Sharing 
analysed 257 donors who donated 650 organs over a period of 33 months (Birkeland & 
Storm, 2002 ), both cadaveric and living-related donors were seen to have a concealed 
malignancy. In general, diagnosis of a malignant tumor in a donor is a contraindication 
for organ donation, except from those with in-situ carcinoma of cervix, low-grade 
cancers of skin, and primary tumors of CNS. CNS tumors may metastasize in less than 
2.3% of cases with only few reports of transmission to recipients (Detry et al, 1997 & 
2000 & Wallace et al, 1996). 
4.1 Risk factors 
Multiple factors are associated with development of de novo malignancy in transplant 
recipients. The risk of oncogenesis after transplantation is related to the types and duration 
of exposure to immunosuppressive therapy. Disruption of both antitumor immune 
surveillance and antiviral activity likely play a role. Chronic antigen stimulation from 
transplanted organs, repeated infections, or transfusion of blood products may overly 
stimulate a partially depressed immune system, resulting in the development of post-
transplant lymphoproliferative disorder (Buell et al, 2005, Chapman and Campistol, 2007). 
4.1.1 Immunosuppression 
There is strong evidence that the intensity of immunosuppression after transplant affects the 
risk of post-transplant malignancy development. This observation is supported by the fact 
that the incidence of malignancy is higher in heart and lung transplant patients who 
routinely require more intense immunosuppression than renal transplant recipients. In 
addition, the risk of development of PTLD is highest in the first year post-transplant when 
the degree of immunosuppression is at its maximum. Episodes of graft rejection in the first 
year post-transplant increase the likelihood of developing a second malignancy most likely 
due to the increased level of immunosuppression required. 
4.1.1.1 Calcineurin inhibitors (CNI) 
Both cyclosporine and tacrolimus have been associated with increased levels of TGF-β that 
might lead to tumor growth since both agents have long been linked to the development of 
post-transplant malignancies including PTLD and solid organ cancers. Some authors suggest 
that tacrolimus is safer than cyclosporine in this regards. In addition, cyclosporine also 
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These tumors may represent metastasis from malignancies diagnosed in the donor at 
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analysed 257 donors who donated 650 organs over a period of 33 months (Birkeland & 
Storm, 2002 ), both cadaveric and living-related donors were seen to have a concealed 
malignancy. In general, diagnosis of a malignant tumor in a donor is a contraindication 
for organ donation, except from those with in-situ carcinoma of cervix, low-grade 
cancers of skin, and primary tumors of CNS. CNS tumors may metastasize in less than 
2.3% of cases with only few reports of transmission to recipients (Detry et al, 1997 & 
2000 & Wallace et al, 1996). 
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Multiple factors are associated with development of de novo malignancy in transplant 
recipients. The risk of oncogenesis after transplantation is related to the types and duration 
of exposure to immunosuppressive therapy. Disruption of both antitumor immune 
surveillance and antiviral activity likely play a role. Chronic antigen stimulation from 
transplanted organs, repeated infections, or transfusion of blood products may overly 
stimulate a partially depressed immune system, resulting in the development of post-
transplant lymphoproliferative disorder (Buell et al, 2005, Chapman and Campistol, 2007). 
4.1.1 Immunosuppression 
There is strong evidence that the intensity of immunosuppression after transplant affects the 
risk of post-transplant malignancy development. This observation is supported by the fact 
that the incidence of malignancy is higher in heart and lung transplant patients who 
routinely require more intense immunosuppression than renal transplant recipients. In 
addition, the risk of development of PTLD is highest in the first year post-transplant when 
the degree of immunosuppression is at its maximum. Episodes of graft rejection in the first 
year post-transplant increase the likelihood of developing a second malignancy most likely 
due to the increased level of immunosuppression required. 
4.1.1.1 Calcineurin inhibitors (CNI) 
Both cyclosporine and tacrolimus have been associated with increased levels of TGF-β that 
might lead to tumor growth since both agents have long been linked to the development of 
post-transplant malignancies including PTLD and solid organ cancers. Some authors suggest 
that tacrolimus is safer than cyclosporine in this regards. In addition, cyclosporine also 
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induces production of VEGF, thus promoting carcinogenesis, and enhances the apoptotic 
effect of taxol and INF-gamma on human gastric and bladder carcinomas (Buell et al, 2005). 
Patients receiving low dose cyclosporine have a lower incidence of malignancy development 
(19.8% versus 32%) in particular skin carcinomas. In animal model, cyclosporine and 
tacrolimus have a direct effect on the tumor cells, promote invasiveness, and facilitate 
metastases. Data suggest that the CNI promote metastatic spread of the pre-existing tumor 
cells rather than convert a non-malignant cell into a cancer cell (Suthanthiran, 2009). 
4.1.1.2 Azathioprin 
Azathioprine is an antimetabolite that has long been recognized as an etiologic agent in the 
development of neoplasia. It is in particular associated with increased incidence of non-
melanoma skin cancer especially SCC. It also may lead to the development of 
myelodysplastic syndrome. Azathioprin has been reported to increase photosensitivity and 
also allows ultraviolet A to directly damage the DNA by intercalating DNA level, inhibiting 
repair splicing, eliciting codon misreads, and development of microsatellite DNA instability 
(Buell et al, 2005 & O’Donovan et al, 2005). 
4.1.1.3 Antilymphocyte therapy 
The use of anti-T-cell therapy (antilymphocyte serum or muromonab-CD3), but not IL-2 
receptor antibodies, has been shown to predispose solid organ transplant recipients to EBV-
associated PTLD. Transplant patients on monoclonal antilymphocyte antibody (anti-CD3) as 
the sole induction agent, show a 72% increase in in the risk of PTLD, however despite this 
relation anti-CD3 has not been found to show any association in the development of other 
solid organ malignancies. Anti-CD52 appears safer with no increased risk of de novo 
malignancy development (Buell et al, 2005). 
4.1.1.4 Sirolimus 
Sirolimus, an inhibitor of the mammalian target of rapamycin (m-TOR), suppresses the growth 
and proliferation of tumors. It has antineoplastic effect mainly due to inhibition of p70 S6K, IL-
10, cyclins, and vascular endothelial growth factors A and C, with direct inhibition of cell 
replication, induction of apoptosis, and inhibition of tumor angiogenesis. Some studies show a 
decreased incidence of malignancy in patients receiving Sirolimus than other 
immunosuppressive therapies. Post-transplant patients treated with Sirolimus appear to have 
a lower incidence of de novo malignancy when compared with a triple immunosuppressive 
regimen treated group (CNI, antimetabolite, and corticosteroids). In addition the use of 
Sirolimus in place of cyclosporine has been associated with complete regression of KS in the 
vast majority of renal transplant recipients (Buell et al, 2005). Newer sirolimus analogues, such 
as temsirolimus, have become a focus in pure oncological research for their antineoplastic 
effects on a variety of malignancies (Kapoor, 2008, & Campistol, 2007). 
4.1.1.5 Mycophenolate Mofetil (MMF) 
MMF impairs lymphocyte function by inhibiting enzyme inosine monophosphate 
dehydrogenase leading to purine biosynthesis block. Several cancers including leukemias 
and some solid tumors produce dramatic elevation of this enzyme. Some studies suggest 
that the risk of malignancy is not increased and even may be even decreased with MMF 
(Rama & Grinyó, 2010 & Brennan et al, 2011). Recent studies show a distinctive 
antineoplastic effect of MMF against colorectal and prostatic carcinomas, and its inhibiting 
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effect on the adhesion of colonic adenocarcinomatous cells to endothelial cells (Eng, 2005, & 
Leckel, 2003). The use of MMF is clearly associated with a distinctive decrease in the 
incidence of post-transplant PTLD (Buell et al, 2005).   
4.1.2 Conventional risk factors 
Exposure to ultraviolet radiation is associated with increased risk of skin cancer. Other 
common risk factors are also associated with development of post-transplant malignancy 
such as advanced age, smoking, and analgesic abuse. History of phenacetin abuse is 
associated with striking increase in urothelial carcinoma. Renal transplant recipients also 
have higher incidence of development of carcinomas in the native kidneys in particular if 
they have been on long term dialysis. The incidence is almost 100 times greater than 
expected and is in part related to ESRD, tubular hyperplasia, cyst formation, and in some 
cases malignant transformation.  
4.1.3 Genetic factors 
Transplant recipients who had history of invasive carcinoma before transplant have a higher 
risk (relative risk 2.38) of developing a second invasive carcinoma post-transplant. Some 
primary renal disorders such as von Hippel-Lindau disease are associated with higher risk 
of developing renal cell carcinoma that behave more aggressively. In addition, patients with 
Wiskott-Aldrich syndrome and Drash syndrome are also associated with an increased risk 
of carcinoma development in particular lymphoma and Wilms tumor.  
4.1.4 Coexisting oncogenic viral infection 
Certain viral infections are associated with increased predisposition of transplant patients to 
development of specific tumors. At least 4 viruses may be cocarcinogenic in transplant 
patients.  
4.1.4.1 EBV 
Most PTLDs are associated with EBV infection. EBV is a gamma herpes virus. It is present 
worldwide and EBV antibodies are seen in almost 90-95% of the population. In 
immunosuppressed patients, EBV infection can lead to cell transformation. Latent 
membrane protein-1 (LMP-1) of EBV has the major role in EBV-associated PTLD 
development as it engages the signaling proteins from tumor-necrosis-factor-receptor-
associated factors (TRAFs) that lead to cell growth and transformation. There is increased 
risk of PTLD among EBV-seronegative recipients of EBV positive donors. The incidence of 
PTLD for EBV seronegative recipients is reported to be 24 times higher than EBV 
seropositive recipients. EBV negative PTLDs present much later (2324 days versus 546 days 
post-transplant), and have a much more virulent behavior (Friedberg et al, 2011). 
4.1.4.2 HHV-8 
All types of KS including classic, endemic, AIDS-related, and post-transplant KS are all 
associated with HHV-8 presence in tumor tissue. There is convincing evidence of 
transmission of HHV-8 from the donor to transplant recipients, with one study showing 
evidence of donor-derived tumor cells transmitted to transplant recipients. HHV-8 is 
necessary but not sufficient for KS development, with transplant related immune  
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effect on the adhesion of colonic adenocarcinomatous cells to endothelial cells (Eng, 2005, & 
Leckel, 2003). The use of MMF is clearly associated with a distinctive decrease in the 
incidence of post-transplant PTLD (Buell et al, 2005).   
4.1.2 Conventional risk factors 
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common risk factors are also associated with development of post-transplant malignancy 
such as advanced age, smoking, and analgesic abuse. History of phenacetin abuse is 
associated with striking increase in urothelial carcinoma. Renal transplant recipients also 
have higher incidence of development of carcinomas in the native kidneys in particular if 
they have been on long term dialysis. The incidence is almost 100 times greater than 
expected and is in part related to ESRD, tubular hyperplasia, cyst formation, and in some 
cases malignant transformation.  
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primary renal disorders such as von Hippel-Lindau disease are associated with higher risk 
of developing renal cell carcinoma that behave more aggressively. In addition, patients with 
Wiskott-Aldrich syndrome and Drash syndrome are also associated with an increased risk 
of carcinoma development in particular lymphoma and Wilms tumor.  
4.1.4 Coexisting oncogenic viral infection 
Certain viral infections are associated with increased predisposition of transplant patients to 
development of specific tumors. At least 4 viruses may be cocarcinogenic in transplant 
patients.  
4.1.4.1 EBV 
Most PTLDs are associated with EBV infection. EBV is a gamma herpes virus. It is present 
worldwide and EBV antibodies are seen in almost 90-95% of the population. In 
immunosuppressed patients, EBV infection can lead to cell transformation. Latent 
membrane protein-1 (LMP-1) of EBV has the major role in EBV-associated PTLD 
development as it engages the signaling proteins from tumor-necrosis-factor-receptor-
associated factors (TRAFs) that lead to cell growth and transformation. There is increased 
risk of PTLD among EBV-seronegative recipients of EBV positive donors. The incidence of 
PTLD for EBV seronegative recipients is reported to be 24 times higher than EBV 
seropositive recipients. EBV negative PTLDs present much later (2324 days versus 546 days 
post-transplant), and have a much more virulent behavior (Friedberg et al, 2011). 
4.1.4.2 HHV-8 
All types of KS including classic, endemic, AIDS-related, and post-transplant KS are all 
associated with HHV-8 presence in tumor tissue. There is convincing evidence of 
transmission of HHV-8 from the donor to transplant recipients, with one study showing 
evidence of donor-derived tumor cells transmitted to transplant recipients. HHV-8 is 
necessary but not sufficient for KS development, with transplant related immune  
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dysfunction being an important contributing cofactor. Pretransplant antibody screening of 
recipients as well as donors in high seroprevalent areas may be useful. However 
seropositivity for HHV-8 is not always associated with increased risk of development of KS. 
Studies from Saudi Arabia show the proportion of patients with antibodies against HHV-8 
is higher among patients who developed KS post-transplant than those who did not. In 
addition the incidence of KS is higher in patients with HHV-8 infection at the time of 
transplant than among those who did not have infection (15-28% versus <1%) (Diociauiti et 
al, 2000, & Cattani et al, 2001, & Regamey et al, 1998). A study from Saudi Arabia revealed 
10 fold higher incidence of KS in Saudi transplant recipients than in Western countries. In 
addition, there was a markedly higher incidence of specific anti-HHV-8 antibodies in 
patients with KS as compared to those without it (92% versus 28%) (Qunibi et al, 1998). 
4.1.4.3 Human papilloma virus (HPV) 
There is an extremely diverse group of HPV subtypes that can be found in various benign, 
premalignant, and malignant skin lesions in transplant recipients. Multiple subtypes can be 
seen in a single lesion. HPV DNA is detected in 65-90% of skin tumors in transplant 
recipients. However a causative role of HPV in development of secondary skin cancers is 
not proven. Interestingly, HPV has been detected in normal hair follicles of transplant 
patients (Boxman et al, 1997, & Berkhout et al, 2000). 
4.1.4.4 Merkel cell virus (MCV) 
MCV is believed to be a contributing factor to MCC.  
4.1.5 Geographic differences 
Literature review shows widely variable relative frequency of the different types of post-
transplant malignancies in different geographic areas. In Saudi Arabia the most common 
tumors in transplant recipients are KS, skin cancers (melanoma being more common in 
children than in adults), anogenital cancers, and lymphomas particularly in children (al-
Sulaiman & al-Khader, 1994). In Japan the most common post-transplant tumors are those of 
digestive tract including stomach, liver, colon, and rectum. On the contrary, the incidence of 
lymphoma and skin tumors in Japan is low. In Australia the risk of skin cancer development is 
the highest, most likely due to the excessive sun exposure of the fair-skinned population. In 
South East Asia the frequency of liver cancer is high where hepatitis B and C infections are 
endemic. In United Kingdom lymphomas, renal cell carcinomas, bronchial cancer, and tumors 
of digestive tract are the most commonly encountered tumors in post-transplant recipients 
(Morath et al, 2004). In South Africa, the incidence of post-transplantation malignancy 
development is reported to be 5.6%, the commonest tumors being PTLD, followed by non-
melanoma skin cancer, KS, gastrointestinal carcinoma, cervical cancer, and vulval cancer 
(Maharaj & Assounga, 2010). The Northern Italy Transplant program studied 3,521 patients 
over a 10 years period in 10 local Transplant centers. The average cancer incidence was 4.9%. 
The commonest tumors were KS, PTLD, renal and skin cancers followed by colorectal, breast, 
gastric, lung, and bladder carcinomas, and mesothelioma (Pedotti et al, 2003). In India, the 
incidence of malignancy after transplant is lower than the Western countries. PTLD is the 
commonest malignancy there especially in the first year followed by oropharyngeal cancer. 
Skin cancer incidence of both melanoma as well as non-melanoma cancer is much lower 
mostly attributed to the high cutaneous melanin content (Joshi and Jha, 2009).  
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4.1.6 Renal transplant tourism 
Despite the international abandonment of commercial organ trafficking, many patients 
continue to travel to different countries to receive commercial transplants. Commercial 
cadaveric renal transplant was compared to domestic cadaveric renal transplant in China. 
The 10 year cumulative cancer incidence of the touring group, primarily of Taiwan origin, 
(21.5%) was significantly higher than the domestic group (6.8%). This might be related to 
older age at transplantation, more depleting antibody induction therapy, and omitted pre-
transplant cancer screening. The graft and patient survival in transplant tourism group is 
inferior as compared to the domestic group. Hepatocellular and urothelial carcinoma were 
the most prevalent malignancies in renal transplant tourism patients from Taiwan when 
compared to Western patients. This can be explained by the high incidence of viral hepatitis 
in Taiwan and the use of Chinese herbal medications. The use of Chines herbal medications 
containing anistolochic acid, which is associated with urothelial carcinoma development, 
facilitates diuresis and is a common practice in ESRD patients who do not accept dialysis. It 
is interesting that transplant tourism is considered to be an independent risk factor for post-
transplant malignancy development (Tsai et al, 2011).  
4.1.7 Blood groups 
Types of blood groups does not seem to be related to increased incidence of cancer 
development (Pedotti et al, 2003). 
4.1.8 Transplant center selection 
Selection of a particular transplant centers does not appear to be related to an increase in  
incidence of cancer development (Pedotti et al, 2003). 
4.1.9 HLA match 
There is a strong influence of HLA matching on graft outcome (Opelz, 2001). However the 
association is indirect and related to the aggressive immunosuppression required for low 
degree HLA matching.  
5. Incidence of post-transplantation malignancy in children 
The pattern of malignancies that occur in pediatrics post-transplant population is different 
from the adult post-transplant patients and the general pediatric population. In a study of 
219 children who underwent renal transplant, 7.3% developed malignancy. The 
cumulative incidence of cancer development was found to be 1.9% at 1 year, 4.0% at 5 
year, 6.9% at 10 years, and 10.2% at 15 years. The 10 years incidence of PTLD was 4.5% 
when the mortality rate was 25%. Other commonly encountered tumors in post-transplant 
children recipients are HL, Burkitt lymphoma, renal papillary carcinoma, thyroid 
papillary carcinoma, recurrent ovarian seminoma, and skin cancer. The occurrence of skin 
cancer is rare in children and usually occurs during early adulthood. Screening and early 
detection of these tumors in children is of great importance. In addition regular screening 
for EBV viral load is recommended for patients at risk for developing PTLD 
(Koukourgianni et al, 2010). 
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6. Transplantation in patients with pre-existing malignancy 
The recurrence rate of malignancy is 22% in patients treated before transplantation and 27% 
in those treated after transplantation. There is however variability in recurrence rate 
according to the type of tumor (Barrett et al, 1993, & Trofe et al, 2004, & Kasiske et al, 2001): 
 0-10%: Localized renal cell carcinoma, cervical, testicular, and thyroid carcinoma, and 
Hodgkins as well as non-Hodgkins lymphoma. 
 11-25%: Wilm’s tumor, and cancer of colon, uterus, prostate, and breast. 
 Over 25%: Advanced renal cell carcinoma, bladder cancer, myeloma, sarcoma, and skin 
cancer including melanoma and non-melanoma skin tumors.  
Patients with low risk tumors such as in-situ carcinoma, low grade bladder carcinoma, and 
basal cell carcinoma should have no waiting period for transplantation. Patients with 
tumors that have a high risk of recurrence such as melanoma, colorectal and breast cancer 
should wait for at least 5 years before translantation. For most other tumors a delay of 2 
years is often considered sufficient (Table 2) (Morath et al, 2004).  
Type of Cancer Recommendation (years) 
Breast cancer > 5 (> 2 for early disease) 
Colorectal cancer > 5 (> 2 for Dukes Stage A or B1) 
Melanoma > 5 (> 2 melanoma in situ) 
Uterine cervical cancer > 2 (> 5 for more advanced cervical cancer) 
Renal cell 
carcinoma/Wilms tumor 
> 2 (> 5 for large cancers; no wait for 
incidental tumor < 5 cm) 
Bladder cancer > 2 
Kaposi sarcoma > 2 
Leukemia > 2 (limited data to make 
recommendation) 
Lung cancer > 2 
Lymphoma > 2 (possibly > 5) 
Prostate cancer > 2 ( possibly less for localized disease) 
Testicular cancer > 2 
Thyroid cancer > 2 
Skin (nonmelanoma) cancer 0-2 (no wait for basal cell carcinoma) 
Liver cancer Unable to give recommendation 
Myeloma Unable to give recommendation 
Table 2. Recommended Wait Time (Years) Based on Type of Cancer Before Listing for 
Transplantation (Kasiske et al, 2001). 
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7. Multiple independent primary cancers or second tumor in transplant 
recipients 
Excluding the non-melanoma skin cancers, the risk of developing a second primary cancer is 
almost the same as the incidence of first cancer. The risk of developing a second primary in 
this group could be related to persistence of environmental risk factors associated with the 
first cancer such as tobacco, genetic factors responsible for development of second primary 
cancer, and individual susceptibility to carcinogens. A study of a network of cohort of 
transplanted patients shows the incidence of second primary cancer development to be 
0.3%. The incidence of developing second primary cancer is 1-5%. Excluding skin cancers, 
transplant patients with first cancer diagnoses should follow regular screening procedures 
and do not appear to require a special program (Taioli et al, 2006). 
Skin cancer is the commonest second malignancy among transplant recipients (Morath et al, 
2004). The North Italy Transplant program reported the prevalence of second primary 
cancer to be 1.7% and development of multiple independent primary cancers arising in the 
same patient to have a prevalence of 3.6% (Pedotti et al, 2003). The risk of developing a 
second non-melanoma skin cancer is high in renal transplant recipients who developed a 
first non-melanoma skin cancer. The risk is, in particular, high of SCC but is also 
substantially increased for BCC. The risk is much lower for SCC in renal transplant 
recipients who present with BCC, however after the diagnosis of first SCC the subsequent 
risk for SCC appears to be the same. The 3 year cumulative risk is approximately 59% of 
non-melanoma skin cancers and 62% of subsequent SCC. The 3 year risk of BCC is 37% and 
the 5 year risk of subsequent BCC is 51%. Renal transplant recipients who develop SCC 
mostly develop SCC as subsequent skin cancer and recipients who have BCC as first 
malignancy mostly develop subsequent BCC. This difference could be related to the 
difference in the lifestyle as the risk of SCC is associated with chronic cumulative sun 
exposure whereas BCC is more associated with intermittent intense sun exposure. Longer 
time between transplantation and development of first SCC is also associated with an 
increased risk of subsequent SCC. The type of maintenance immunosuppression is the most 
important risk factor of subsequent development of SCC. Patients on Azathioprin have an 
approximately 3 times higher risk of subsequent SCC as compared to cyclosporine-based 
regimen. The duration of immunosuppression also influences the development of 
subsequent SCC after the first SCC. Sun exposure is an important risk factor for multiple 
lesions development. Fair skin of patients and light color of the hair and the eyes are 
predictive of multiple SCC development (Euvrard et al, 2006). Male sex is also a risk factor 
for multiple skin cancer development, especially the BCC. In addition, BCC is more 
commonly seen in living-related kidney transplant than the cadaveric kidney transplant 
recipients (Wisgerhof et al, 2010). 
8. Prevention and screening for early detection 
Regular cancer screening is recommended when a patient is considered for renal transplant. 
Screening and early detection of cancers should be incorporated into the pre-transplant 
evaluation of ESRD patients. Screening may also detect premalignant lesions quite early 
allowing for a timely intervention (Kiberd, 2005). The rising age and the prolonged duration 
on transplant waiting list increases patients’ risk of being transplanted with an undetected 
malignancy (Morath et al, 2004). Careful screening should be performed for the recipient as  
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evaluation of ESRD patients. Screening may also detect premalignant lesions quite early 
allowing for a timely intervention (Kiberd, 2005). The rising age and the prolonged duration 
on transplant waiting list increases patients’ risk of being transplanted with an undetected 
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Target Organ or 
Cancer 
Test* Frequency Age of Screening 
Breast Mammography Every 1-2 years > 40 years 







Every 5 years 
 
Every 10 years 
> 50 years 
 
> 50 years 
 
> 50 years 
Prostate gland Digital rectal exam 
PSA 
Annually > 50 years 
Kidney Imaging study† Once All patients 
Bladder Cystoscopy Not routine > 50 years and all high-
risk patients 
Uterine cervix Pap smear 
Pelvic exam 
Every 1-3 years > 20 years or any 
sexually active patient 
Testicle History and physical exam Once All male patients 
Kaposi sarcoma History and physical exam
HHV-8 assay 
Once All patients 
All high-risk patients 
Skin History and physical exam Once All patients 
Melanoma History and physical exam Once All patients 
Liver Imaging study† Once, high risk 
annually 
All patients 
Lung CXR Once All patients 
Lymphoma History and physical exam
EBV assay 
Annually All patients 
Leukemia CBC Annually All patients 
Myeloma Immunoelectropheresis Once > 50 years 
PSA = prostate specific antigen; HHV-8 = human herpes virus 8; CXR = chest x-ray;  
EBV = Epstein-Barr virus; CBC = complete blood count 
*Abnormalities on screening tests may indicate the need for additional tests. For example, suspicious 
lung lesions on the chest x-ray should be followed up with a computed tomography scan. 
†Ultrasound, CT scan, or magnetic resonance imaging scan. 
Table 3. Possible Pretransplant Screening Strategies for the Potential Kidney Transplant 
Recipient (Kasiske et al, 2001). 
well as the donor. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical 
practice guidelines on monitoring and treatment of kidney transplant recipients were 
developed to help practitioners caring for these patients. These guidelines were based on 
evidence and systemic review of treatment trials. A set of recommendations were developed 
 
Malignant Neoplasms in Kidney Transplantation 
 
193 
for screening and risk assessment of renal transplant recipients (Kasiske et al, 2010). Patients 
with failed transplant returning to dialysis have a higher mortality than those on transplant 
waiting list (Cattran & Fenton, 1993).  
The Clinical Practice Guidelines Committee of the American Society of Transplantation 
(AST) has published guidelines for outpatient evaluation of pediatric and adult kidney 
transplant candidates that include recommendations for screening and early detection of 
malignancies. Some of these recommendations are represented in Tables 3 and 4 (Kasiske et 
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8.1 Skin and lip cancer 
Introduction of patient education programs is recommended in particular in countries with 
high incidence of non-melanoma skin carcinoma secondary to high sun exposure. Patients 
should also be educated about their increased risk of such cancers especially if they are fair 
skinned, have high sun exposure level, or have prior history of skin cancer. Patients should 
reduce their sun exposure, perform self-examination, and have an annual skin and lip 
examination by qualified Health care provider. Oral acitretin should be given to patients 
with prior history of skin cancer to prevent development of new malignancy. 
8.2 Non-skin cancer 
The recommendations for transplant patients with moderately increased risk of developing 
non-skin cancer are non-specific. However they reinforce the same recommended screening 
strategies as for the general population. These include pap smear, self-breast examination, 
mammography, and colonoscopy. In addition annual liver ultrasound and α-fetoprotein 
monitoring is also recommended in patients with cirrhosis ((Rama & Grinyó, 2010). 
8.3 PTLD 
Since development of PTLD is related to the degree of immunosuppression, and infection 
with EBV and CMV, prevention largely relies on limiting patient exposure to aggressive 
immunosuppression, and anti-viral prophylaxis. There is a relatively high incidence of 
PTLD reported with introduction of tacrolimus and therefore rapid tapering of tacrolimus 
may limit the development of PTLD (Friedberg et al, 2011). In one review of PTLD in 
children, the incidence of PTLD development was 17% in children who received renal 
allograft with tacrolimus as compared to 4% in children who underwent aggressive tapering 
of tacrolimus (Shapiro et al, 1995). There is higher incidence reported of PTLD among EBV-
seronegative recipients of EBV-seropositive donors that suggests that treatment of early EBV 
infection may decrease subsequent development of PTLD (Holmes et al, 2002 & Funch et al, 
2005). In addition prophylactic antiviral therapy is also associated with a reduced risk of 
PTLD development. The use of prophylactic anti-CMV during the first 3-6 months after 
renal transplant significantly reduces the incidence of PTLD in the first year post-transplant 
but not in the subsequent 5 years (Kasiske et al, 2010, & Opelz et al, 2007).  
8.4 Colorectal carcinoma 
Community-level screening for colorectal carcinomas using fecal occult blood is now a 
standard practice in most developed countries. Studies in the general population have 
shown that the benefits of starting screening at a younger age were little and costly as 
compared to starting at age of 50. However renal transplant patients have an age-shifted 
increase in the risk of colorectal carcinoma and screening at a younger age in this population 
seems therefore justifiable (Wong et al, 2008). 
9. Treatment 
Reduction or cessation of immunosuppression is particulary useful in renal transplant 
recipients as loss of graft secondary to rejection is not a fatal event in this group as 
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compared to the heart, lung, or liver transplant recipients. Immunosuppression reduction 
may lead to spontaneous regression of some tumors such as some cases of PTLD, some 
skin cancers, KS, and donor-derived malignancies. In KS reduction of CNI may be 
particularly important. Despite the association of CNI and cancer development, some 
authors recommend discontinuation of antimetabolite and use of CNI and Prednisone as 
first line approach in transplant recipients with malignancy. This is because rejection is 
less likely to occur with double therapy (CNI and prednisone) than combination of 
antimetabolite and prednisone. An exception to this is the very well matched HLA 
transplant recipients with 0 HLA, B, or DR mismatch, in which the risk of rejection is low 
with the use of antimetabolite in combination with prednisone (Brennan et al, 2011, & 
Bosman and Verpooten, 2007). 
9.1 Skin, non-melanoma carcinomas 
Once a skin lesion is detected there is no evidence of benefits from stopping azathioprin . 
Treatment of these patients requires several strategies including preventive strategy, specific 
treatment, and medical adjunct therapy because these tumors may present with multiple 
lesions, and large areas of skin involvement. Despite this, dedicated surveillance programs 
are lacking for most patients. Surgery remains the mainstay of managing these tumors and it 
may be destructive in large or multiple skin tumors. Studies in immunocompetent patients 
show recurrence in almost 100% of cases with incomplete surgical excision and therefore 
tumors that are not completely excised should be treated by additional methods (Jemec & 
Holm, 2003). 
9.1.1 SCC 
Premalignant lesions can be treated with topical retinoids or in combination with low 
dose systemic retinoids. Although systemic retinoids reduce actinic keratosis and prevent 
development of new dysplastic lesions in transplant patients, the treatment is frequently 
discontinued due to drug adverse events such as mucocutaneous xerosis, pruritis, 
arthralgia, and hyperlipidemia. Once treatment is discontinued, the lesions tend to recur 
rapidly. Superficial cancers can be treated with cryotherapy or electrocautery and 
curettage. More aggressive local therapy is required for invasive SCC as they may have 
metastasis at presentation and are more likely to develop recurrence. These invasive 
tumors need surgical excision with negative margins. Although there are no clear 
established guidelines about margins of SCC excision, Mohs micrographic surgery is 
typically recommended for these high risk tumors especially those seen in cephalic 
location, a diameter of > 2 cms, or rapid growth. Metastasis in a single lymph node is 
considered potentially curable. Adjuvant radiation, systemic chemotherapy, and or 
immunotherapy are not of benefit. Several reports show beneficial effect to immune 
response modifier Imiquimod, however, the safety and efficacy of this agent has not been 
adequately assessed (Brennan et al, 2011).  
9.1.2 BCC 
Development of frequent BCCs should prompt reduction in immunosuppression. The 
management otherwise is similar to that in non-immunocompromised patients. 
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Although management of MCC is similar to that in non-immunocompromised patients, the 
overall prognosis is poorer in transplant patients as compared to the general population 
with 2 year survival of 44% versus 65-75%. Distant metastasis may regress temporarily with 
cyclosporine discontinuation (Brennan et al, 2011). 
9.2 Skin, melanoma 
Multiple strategies are required to treat melanoma including wide local excision with or 
without sentinel lymphadenectomy, and reduction of immunosuppression. 
9.3 KS 
Discontinuation of immunosuppression should be the first line of treatment as majority of 
patients with KS may show complete regression of the lesions. The disappearance of KS by 
reducing immunosuppression is about 17% with mucocutaneous disease and 16% with 
visceral involvement. Substitution of Sirolimus for cyclosporine has also been associated 
with complete regression (Stallone et al, 2005). Patients who do not regress spontaneously 
should be treated the same way as non-immunosuppressed patients are treated. In the 
CONVERT study, a randomized prospective study to evaluate the effect of conversion to 
sirolimus from CNI, displayed a significantly lower malignancy rate (3.8%) at 24 months 
compared with those who continued CNI based therapy (11%). An mTOR-inhibitor CNI-
free regimen should be considered for transplant recipients at high risk for cancer 
development and for those who develop malignancies over the post-transplant course 
(Alberú, 2010, & Schena, 2009). 
9.4 Anogenital carcinomas 
Anogenital Intra-epithelial neoplasia / in-situ carcinomas are treated with laser therapy, 
topical fluorouracil, or electrocautery. Reduction of immunosuppression is beneficial and 
may lead to regression of the in-situ lesions. Invasive carcinomas, on the other hand, require 
wide local excision with inguinal lymphadenectomy for tumors that are >1 mm thick. 
Adjuvant therapy is given to only selected patients. 
9.5 Bladder carcinomas 
9.5.1 Non-muscle invasive bladder carcinoma 
Bacillus Calmette-Guerin is still the only intravesical therapy that has shown a significant 
reduction in recurrence-free and possibly progression-free survival. 
9.5.2 Muscle-invasive bladder tumor 
The mean time between organ transplant and bladder tumor development is 2.8 and 4 years. 
Most patients presenting with muscle-invasive bladder carcinoma have extravesical disease 
or lymphadenopathy at the time of surgery. In general, there has been little to no 
improvement in the survival after radical cystectomy. A reasonable cancer-specific survival 
and renal allograft preservation is achieved after aggressive surgical therapy in only a few 
patients. (Wallerand et al, 2010). 
 
Malignant Neoplasms in Kidney Transplantation 
 
197 
9.6 Other solid organ tumors 
The course of these malignancies is more aggressive than the general population and the 
outcome is mostly determined by the stage of tumor at the time of presentation. Visceral 
malignancies are treated with surgical intervention, chemotherapy, and radiation therapy. If 
chemotherapy is needed, azathioprine should be discontinued to avoid myelosuppression. 
Early invasive and in-situ carcinomas can be cured by surgery. The outcome is poor in 
advanced disease with majority of the patients dying within 1-2 months (Brennan et al, 
2011). 
9.7 Donor-derived tumors 
If the cancer is shown to be of donor origin, reduction of immunosuppression should 
theoretically lead to rejection of the tumor. This has been shown to be effective in PTLD but 
the data is not very supportive in other solid organ tumors. In RCC with no metastatic 
disease, total transplant nephrectomy is curative, however the patient has to go back to 
dialysis. Some authors suggest nephron sparing surgery in non-metastatic RCC that are 
located peripherally and are  < 4 cms in size. Recipients with metastatic RCC should be 
treated with transplant nephrectomy, reduction in immunosuppression, and immune 
therapy (Muruve & Shoskes, 2005). 
9.8 PTLD 
9.8.1 Reduction of immunosuppression 
The most important treatment modality for PTLD is reduction of immunosuppression 
which allows restoration of the natural T-cell mediated immune response against EBV-
infected B cells. The goal by reducing the immunosuppression is to find the correct dose that 
will allow restoration of the patient’s immune response against the PTLD without causing 
rejection of the transplanted organ. Transplant rejection occurs in approximately 39% of 
transplant recipients regardless of whether they respond to treatment or not. The risk of 
rejection also varies with the type of transplanted organ, with highest risk among heart and 
lung transplant recipients. The reduction of immunosuppression has no standard approach 
and it has to be individualized for each patient depending on various characteristics such as 
transplant type, relative risk of transplant rejection, extent and severity of PTLD, and 
selection of immunosuppressive agents. In general, MMF and azathioprine are discontinued 
first and the doses of CNI and steroids are reduced. There are several predictive factors to 
response to reduction of immunosuppression. Interestingly, EBV serostatus does not predict 
response and therefore this modality of treatment should be used for both EBV seronegative 
as well as EBV seropositive patients. Multiple factors are associated with poor response that 
include lactate dehydrogenase level of > 2.5 times the upper limit of normal, bulky disease, 
multiple visceral sites being involved, and organ dysfunction. Patients lacking these features 
show a response rate to reduction of immunosuppression as good as 89% (Morgans et al, 
2009). The vast majority of polyclonal lymphoproliferative lesions and EBV-related 
plasmacytomas show significant improvement or complete resolution by 
immunosuppression reduction. The response is best in patients with early onset disease in 
whom the level if immunosuppression is a major risk factor as compared to patients with 
late onset or extensive disease who are much less likely to benefit. One potential regimen for 
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patients who are severely ill and have extensive disease is to reduce prednisone and 
stopping all other immunosuppressive agents. For patients who are less severely ill and 
have only limited disease, one regimen is to reduce cyclosporine or tacrolimus and 
prednisone by at least 50% and the discontinuation of azathioprine or MMF. If necessary 
another 50% reduction of immunosuppression can be considered. Immunosuppressive 
regimens with the fewest possible toxic effects are desirable for transplant recipients. The 
ELITE-Symphony Study which is the largest prospective study in kidney transplantation 
evaluated the effects of standard dose versus low dose immunosuppression. The primary 
end point of the study was the estimated glomerular filtration rate and the secondary end 
points included acute rejection events and allograft survival. Over 3 years, daclizumab 
induction, MMF, steroids and low-dose tacrolimus proved highly efficacious, without the 
negative effects on renal function commonly reported for standard CNI regimens. (Ekberg 
et al, 2007, 2009). 
9.8.2 Antiviral prophylaxis 
Initially antiviral prophylaxis was used to eradicate EBV from the patient’s system thereby 
preventing reactivation of any latent infection and abnormal cellular proliferation that may 
lead to PTLD. Currently there is no supportive evidence of antiviral therapy efficacy for 
treatment of PTLD. The nucleoside analogues acyclovir and gancyclovir inhibit the 
replication of multiple members of herpes virus family including CMV and herpes simplex 
virus. Although theoretically these medications should be effective against EBV, in vivo they 
are not effective against EBV. These agents need intracellular phosphorylation by a viral-
encoded thymidine kinase which is not expressed in infected latent B cells. One approach to 
overcome this limitation is to use these agents in combination with arginine butyrate which 
induces the lytic phase of EBV gene expression and thus can induce expression of thymidine 
kinase. This may enable gancyclovir to be phosphorylated into its active form. Several 
studies are investigating the efficacy of these 2 agents used in combination in both solid 
organ as well as bone marrow transplant patients with PTLD and have shown moderate 
success (Morgans et al, 2009 & Friedberg et al, 2011).  
9.8.3 Local therapy 
Localized PTLD involving skin or a single GI lesion can be managed by surgery or radiation 
without the use of systemic therapy. This will spare the patient side effects of systemic 
therapy and withdrawal of immunosuppression. Local treatment in conjunction with 
immunosuppression reduction has resulted in very low PTLD-related mortality. Rituximab 
in combination with surgery or radiation has shown some success. Patients requiring 
palliative and emergent therapy for advanced disease can benefit from local field radiation 
therapy (Morgans, 2009). 
9.8.4 Anti-B-cell antibody 
Since most PTLDs are of B-cell origin, the use of medications that target B-cell antigens is 
proven beneficial with a reasonable response rate of 50-80%. In earlier studies the use of 
antiCD21 and antiCD24 has achieved complete response rates of 63% and long-term 
survival of 46%. However, in the past 10 years, more and more emphasis is on the use of 
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antiCD20, the rituximab in the treatment of CD20 positive PTLDs. AntiCD20 binds to B 
cells, induces clearance of cells and destruction by antibody-dependant complement-
mediated apoptosis. It may activate patient’s immune system against EBV-infected B cells 
helping destruction of tumor and preventing its recurrence. These proposed mechanisms of 
action would explain the better efficacy of rituximab in patients with PTLD than the usual 
NHLs. Risk factors for poor response to anti B-cell therapy include late onset PTLD (onset > 
1 years after transplantation), and involvement of CNS and multiple viscera. Rituximab has 
been reported to induce complete remission of PTLD in some patients with solid organ and 
bone marrow transplant. Early treatment with rituximab along with reduction of 
immunosuppression appears to be the evolving standard of care for CD20 positive PTLDs 
(Friedberg et al, 2011). Other anti-B-cell antibodies have not been fully evaluated 
systemically in PTLD. There are newer anti-CD20 antibodies such as tositumomab (anti-
CD20 coupled with radioactive iodine-131), ibitumomab (anti-CD20 with yttrium-90), 
epratuzumab (anti-CD22), and galiximab (antiCD 80) that are currently being investigated 
(Morgans et al, 2009).  
9.8.5 Cytotoxic chemotherapy 
For patients in whom reduction of immunosuppression is ineffective and who have rapidly 
progressive or life-threatening disease, chemotherapy can be used as an alternative or 
additional treatment. Several chemotherapy regimens similar to those used in NHLs are 
offered for treating patients with monoclonal PTLD such as cyclophosphamide with 
prednisone, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), dose-adjusted 
ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), and other new 
regimens. Unfortunately although these chemotherapy agents are highly effective, they are 
associated with serious side-effects that significantly affect patient morbidity and mortality. 
Studies show that using CHOP after reduction of immunosuppression is associated with a 
complete remission rate of 63% and median disease-free survival of 10.5 years. The overall 
response rate of patients to rituximab is 68%. Patient with EBV-positive disease are more 
likely to respond to rituximab and achieve a complete response rate than those with EBV-
negative disease. Patients who received chemotherapy show an overall response rate of 
74%. Several factors limit the use of chemotherapy in PTLD. These  include suboptimal 
performance status, drug-to-drug interaction, high likelihood of infectious complications, 
and dose-limiting organ-dysfunction. Although the overall response rate is somewhat 
higher for chemotherapy, the associated toxic effects are significant. Approximately 50% of 
these patients get hospitalized for infections and about 6% eventually die of complications. 
The debate regarding when to use rituximab as opposed to chemotherapy and how to use 
them in combination is still ongoing with no consensus recommendations (Morgans et al, 
2009 & Friedberg et al, 2011). 
9.8.6 Cellular immunotherapy 
Cellular immunotherapy of PTLD involves reinfusion of T-cells into a recipient targeting the 
EBV-related lymphoma. T-cell targeting is HLA specific and EBV-specific and therefore 
cytotoxic T lymphocytes (CTL) must be HLA-matched to the recipient. Autologous pre-
transplant-harvested CTLs are shown to be effective in reducing the EBV viral loads. More 
recently several tissue banks have been storing EBV-specific CTLs for various HLA types. 
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negative disease. Patients who received chemotherapy show an overall response rate of 
74%. Several factors limit the use of chemotherapy in PTLD. These  include suboptimal 
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higher for chemotherapy, the associated toxic effects are significant. Approximately 50% of 
these patients get hospitalized for infections and about 6% eventually die of complications. 
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EBV-related lymphoma. T-cell targeting is HLA specific and EBV-specific and therefore 
cytotoxic T lymphocytes (CTL) must be HLA-matched to the recipient. Autologous pre-
transplant-harvested CTLs are shown to be effective in reducing the EBV viral loads. More 
recently several tissue banks have been storing EBV-specific CTLs for various HLA types. 
 
Renal Transplantation – Updates and Advances 
 
200 
The overall response rate after these infusions is close to 52% and the results are thought to 
have a better response at 6 months in patients receiving closest HLA-matched CTLs 
(Morgans et al, 2009).  
9.8.7 Retransplant 
Kidney transplant recipients can be treated with complete withdrawal of 
immunosuppression and even removal of transplanted organ as it is not a life-sustaining 
organ unlike heart and lung transplant. Successful treatment of PTLD can result in years of 
continous transplant function. Patients with transplant failure due to PTLD may safely go 
through re-transplantation after 1-2 years. In addition, relapse of PTLD after re-
transplantation only rarely occurs (Morgans et al, 2009). 
10. Conclusion 
Malignancy is a common cause of death after renal transplantation. Early detection and 
treatment of post-transplant malignancies is an important challenge. An even greater 
challenge is to prevent the development of these malignancies. Screening these patients for 
malignancies while they are on the waiting list for transplant and post-transplantation is 
crucial. It is also recommended to use the lowest planned doses of maintenance 
immunosuppressive medications by 2-4 months after transplantation, if there has been no 
acute rejection (Kasiske et al, 2010). The approach in these patients should start with 
preventive measures including minimizing immunosuppression, avoidance of carcinogenic 
factors such as ultraviolet radiation, avoidance of repeated exposure to depleting anti-
lymphocyte antibodies, and screening of donors and recipients for cancer. There is also 
growing interest in the potential antioncogenic characteristics of the immunosuppressive 
agent – mTOR inhibitor. Once malignancy is detected, it should be managed with specific 
therapy. Reducing CNI dose is a good first approach in patients who develop lymphoma, 
skin cancer, or KS. Substitution of CNI for mTOR can lead to complete regression of early, 
small, or low grade KS in renal transplant recipients. Regression of PTLD has also been 
reported with conversion of CNI by mTOR. Long term studies are needed confirm the 
beneficial effects of mTOR in regression of cancer in transplant recipients. 
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1. Introduction 
Approximately 25,000 patients undergo renal transplantation every year worldwide due to 
end-stage renal disease(ESRD). Renal transplantation is expected to lead to a progressive 
correction of the established renal bone disease, and osteonecrosis of the femoral 
head(ONFH) is a common and severe complication in these patients. It induces deformity of 
the hip joint and reduces the quality of life, especially in the young population ranging from 
20 to 50 years old. Total hip replacement is not reasonable in this population due to the finite 
lifespan of implants. Clinical results suggest that free vascularized fibular grafting(FVFG) 
can slow or potentially halt the progression of osteonecrosis, it offers an alternative method 
for preserving the femoral head in younger renal transplant recipients. 
2. Clinical backgroud 
Chronic renal failure(CRF) and end-stage renal disease(ESRD) are associated with many 
disturbances of bone structure and metabolism due to deficiency of calcitriol, hypocalcemia, 
retention of phosphate, metabolic acidosis, secondary hyperparathyroidism. Renal 
transplantation can improve the metabolism disturbances of ESRD, but osseous 
complications like osteoporosis, consequent fracture, bone pain and osteonecrosis are not 
rare. It is reported that up to 40% of renal graft recipients have spontaneous osteoporotic 
pain. A major obstacle to the investigation of renal osteodystrophy in transplant recipients 
has been its unpredictable evolution under the multiple biochemical and hormonal 
influences that regulate mineral metabolism and bone turnover independently. Its course 
after transplantation depends on persisting abnormalities such as hypercalcaemia, 
hypophosphataemia and hypomagnesaemia as well as on the type, dose and duration of 
immunosuppressive medications that are needed to minimize allograft rejection.  
2.1 Morbidity of ONFH in the recipients 
Osteonecrosis of the femoral head (ONFH), an aseptic and ischemic disease, is especially 
common in the transplant recipients. Kubo documented femoral head MRI abnormalities of 
osteonecrosis in 25% of 51 renal allograft recipients; Marston reported 20% of 52 patients and 
11% of 103 hips developed ONFH within 1 year after transplantation; Lopez-Ben reported 4% 
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Osteonecrosis of the femoral head (ONFH), an aseptic and ischemic disease, is especially 
common in the transplant recipients. Kubo documented femoral head MRI abnormalities of 
osteonecrosis in 25% of 51 renal allograft recipients; Marston reported 20% of 52 patients and 
11% of 103 hips developed ONFH within 1 year after transplantation; Lopez-Ben reported 4% 
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of 48 patients and three of 96 hips had ONFH within 6 months after renal transplantation; In 
the study of Lee, ONFH developed in 6.3% of the 237 patients and 4.9% of the 473 femoral 
heads from 8 months to 16 months after renal transplantation. In the report of Children by 
Nishiyama et al, 141 renal transplants were performed in 129 children(72 boys and 57 girls), 
aged from 2 to 17 years. Osteonecrosis occurred in seven patients, in the following sites: the 
femoral head in four children including two bilateral cases: and the femoral condyle in Three 
children, with two bilateral cases. The mean period from transplantation to the diagnosis of 
OHFH was 18 months, 75% appeared more than 9 months after transplantation.  
2.2 Etipathogenesis 
2.2.1 Use of corticosteroids 
High doses of corticosteroids are used after renal transplantation to reduce rejection and 
improve graft survival. They have also been implicated as the major predisposing factor for 
post-transplant bone loss and osteonecrosis, and It takes a few years to develop 
osteonecrosis after the start of corticosteroids therapy. Although corticosteroids therapy 
represents a pathogenetic key factor other immunosuppressive drugs such as cyclosporine, 
tacrolimus, azathioprine and rapamycin clearly contribute to its prevalence and expression 
through their pleiotropic pharmacological effects. These drugs have been shown to increase 
overall bone turnover and/or to stimulate loss of bone mass independently. Long-term 
glucocorticoid administration and possibly cyclosporine treatment may chronically activate 
osteoclasts in spongy and/or cortical bone while osteoblast activity is inhibited, and the 
highest tertiles of cumulative glucocorticoid were significantly associated with BMD loss 
and osteonecrosis. A prospective study using MRI in renal transplant patients showed the 
occurrence of ONFH within several months after the initiation of steroid treatment, and a 
time discrepancy between the occurrence of ONFH and onset of symptom.  
2.2.2 Dose-related risk of osteonecrosis 
Furthermore, an appreciable dose-related risk of osteonecrosis was also found in patients 
receiving long-term steroid therapy. Hirota et al reported the relationship between ONFH 
and the daily dosage of steroid (#16.6 mg in terms of prednisolone) or the highest daily dose 
(#80mg in terms of prednisolone) and concluded that higher steroid dosage per day 
contributed to increasing the frequency of ONFH in renal transplant patients. In a 
retrospective study of the medical records of 750 patients who had received a renal 
transplant during the period of 1968-1995, Lausten showed an 11.2% incidence of 
symptomatic osteonecrosis with high-dose glucocorticoids(cumulative mean dose of 
prednisolone 12.5g at 1 year post-transplant) and 5.1% with low-dose(cumulative mean dose 
of prednisolone average dose 6.5g). This difference in numbers of femoral head necroses 
was highly significant (p < 0.005); The cohort of Kopecky et al showed an osteonecrosis 
incidence of 22%, had a prednisolone equivalent dose of 7±3.25g prednisolone during the 
first 90 days after transplantation; The cohort of Lopez-Ben et al showed an osteonecrosis 
incidence of 4%, had a slightly lower cumulative steroid dosage (2.1g prednisolone at 3 
months after transplantation) compared to previously reported cohorts; Lee et al also found 
a low incidence of ONFH in renal transplantation patients at the time of 1 year post-
transplantation, which seems to be related with low cumulative steroid dosage. There is no 
known threshold dose. In clinical practice, some patients fail to benefit from daily doses as 
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low as 2.5–7.5 mg of prednisone, whereas daily doses >7.5 mg will definitively induce 
osteoporosis and osteonecrosis in the majority of patients.  
2.2.3 Main mechanism 
The mechanism of ONFH after renal transplantation includes: 1. Thrombus due to the 
steroid-induced hypercoagulable state(Hypercoagulability of plasma was found after 3 
months of steroid treatment in previous studies). 2. Reduction of blood flow in 
bone(Femoral head blood flow was 2-3 fold lower after 2 week high dose steroid treatment, 
decreased arterial inflow or increased venous outflow resistance can reduce intraosseous 
blood flow) 3. Osteoporosis of femoral(Steroid can decrease the absorption of calcium from 
intestine and increase its elimination via the kidneys. Direct and indirect effects on PTH 
secretion, changes in bone protein matrix, increased osteoclastic activity, and decreased 
protein synthesis all lead to a reduction in bone mass after renal transplantation, inhaled 
corticosteroids in doses above 1.5 mg/d may be associated with a significant reduction in 
bone density). 4. Metabolism disorder. 5. Fat embolism of femoral head. 6. Rise of 
intraosseous pressure(In the rigid intraosseous compartment, growth of fat cells may cause 
a rise in intraosseous pressure, and thereby compress the thin-walled sinusoids, with a 
subsequent decrease in bone blood flow). 7. Degenerative changes of the hip 
capsule(Degenerative changes in the arteries and arterioles of the capsule of the hip and the 
femoral head have been found in cadavers of renal transplant patients without clinical hip 
symptoms. There was thickening of the intima, gross diminution in the number and calibre 
of the vessels in the arteries of the femoral head and infarcts of subchondral bone).  
2.2.4 Other risk factors  
The type of donor, dialysis duration, acute rejection rate, and postoperative weight gain. 
The age of the graft recipients also matters. An age of less than forty years is a risk factor for 
osteonecrosis of the femoral head. 
2.3 Contradiction during the treatment 
ONFH continues to be a difficult problem to manage, especially in renal transplant 
recipients. Both the patients and surgeons were concerned about changes of renal function 
and survival of the graft. They paid little attention to the hip joint, although early signs of 
osteonecrosis were present. High doses of steroids were used in a continuous manner, 
neglecting the abnormal joint function, which hastened the deterioration of the femoral 
head. ONFH was diagnosed at a mean of 3.5 years after transplantation, it can progress to 
severe osteoarthritis and seriously impair the life quality of transplant recipients. Early hip 
joint symptoms, including progressing hip pain and joint dysfunction, always appear 9 to 19 
months after transplantation, But in most of the clinical cases, severe joint pain and 
irreversible collapse of the femoral head had already developed when the diagnosis was 
established. Furthermore, steroid-induced ONFH following transplantation tends to have 
larger necrotic areas, and bilateral involvement is more common than unilateral 
involvement. the natural history of femoral head osteonecrosis has shown evidence that a 
large majority of clinically diagnosed cases will progress to femoral head collapse. The 
treatment of ONFH depends on the staging and severity of the clinical symptoms. 
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low as 2.5–7.5 mg of prednisone, whereas daily doses >7.5 mg will definitively induce 
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3. Therapy methods 
3.1 Core decompression and THA 
Joint-preserving operations like core decompression cannot arrest the progression of the 
disease effectively. Total hip replacemen(THA)t is also unsuitable for younger patients 
because of their higher activity level and longer remainder of life. So Osteonecrosis of the 
femoral head continues to be a difficult problem to manage, especial in the patient with 
various kinds of renal diseases(such like IgA nephropathy, focal segmental glomerular 
sclerosis, membranous nephropathy, mesangial proliferative glomerulonephritis, crescent 
glomerulonephritis, lupus nephritis, minimal change nephropathy and renal transplantation 
after end-stage renal diseases ). Many patients with renal diseases inevitably lose the ability 
to live independently due to advanced stages of osteoarthritis.  
3.2 FVFG 
FVFG showed favorable outcomes. Compared with core decompression of femoral head, 
FVFG had a significantly lower conversion rate to total hip arthroplasty(stage II and III 
hips), because it can enhance the revascularization of bone tissue and arrest the progression 
of the necrosis. It is also an alternative method for younger patients without severe 
osteoarthritis of the hip joint. 
3.2.1 Advantages of FVFG 
The advantage of FVFG lies in the combination of femoral head decompression(Extensive 
decompression of the femoral head along with removal of necrotic bone theoretically 
interrupts the cycle of increased intraosseous pressure and ischemia and allows for 
revascularization of the femoral head), removal of necrotic bone, introduction of 
osteoinductive cancellous bone(Filling the defect with fresh cancellous bone provides both 
osteoinductive and osteoconductive stimulation of healing), and vascularized cortical bone 
support of the subchondral surface( The vascularized fibula provides a viable cortical bone 
strut to support the subchondral bone from collapse and further enhances the 
revascularization process). This procedure may benefit young patients with more advanced 
osteonecrosis of the femoral head by halting progression of collapse, prolonging reduction 
of symptoms, and postponing total hip replacement.  
3.2.2 Clinical application of FVFG 
With the emergence of microsurgical techniques, Judet et al first treated ONFH with FVFG 
in the late 1970s. The long-term results cover 68 hips in 60 patients with 18 of these classified 
as early failures requiring conversion to THA. The remaining 50 hips were followed on 
average for 18 years. Thirty-five hips scored good or very good, which corresponds to a 52% 
success rate, the data clearly show an increase in good results for patients younger than 40 
years, and an increase in the rate of failures for patients older than 40 years. Specifically, of 
the patients younger than 40 years, 80% had good and very good results, whereas of the 
patients between 40 and 50 years, only 57% had good and very good results. After systemic 
research and long-term clinical study, Urbaniak et al improved the surgical technique. The 
results for 103 consecutive hips(eighty-nine patients) that had been treated with FVFG 
because of symptomatic osteonecrosis of the femoral head were reviewed in a prospective 
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study. total arthroplasty had been performed in thirty-one hips: five (23 per cent) of the 
twenty-two that were in stage III; seventeen (43 per cent) of the forty that were in stage IV; 
and seven (32 per cent) of the twenty-two that were in stage V. Harris hip scores had 
improved at the latest follow-up evaluation, compared with the preoperative values (p < 
0.001). For the stage-II hips, the average score improved from 56 to 80 points; for the stage-
III hips, from 52 to 85 points; for the stage-IV hips, from 41 to 76 points; and for the stage-V 
hips, from 36 to 75 points. 59 percent of the hips did not limit or only slightly limited the 
patient's ability to carry out daily activities, and 62 percent did not limit or only slightly 
limited the patient's ability to work. FVFG had decreased the need for pain medication for 
86 percent of the hips that had not been subsequently treated with an arthroplasty. 
Regardless of whether or not a subsequent arthroplasty was done, 81 per cent of the patients 
(81 per cent of the hips) were satisfied with their decision to have fibular grafting.  
FVFG became widely performed in their clinical activities. Some other clinical research also 
showed good results. Zhang et al treated 56 hips in 48 patients with FVFG and followed 
patients for a mean duration of 16 months. Roughly 69.6% of femoral heads showed 
improvement on radiographs, and the Harris hip scores showed improvement ranging from 
11-13 points. Most patients had full weight-bearing ability and took part in their daily 
activities. Aldridge et al reported an 88% success rate associated with FVFG in the femoral 
heads without collapse and a success rate of 78% with subchondral collapse. The results 
showed that FVFG is the most promising technique because it had satisfactory mid-term 
and long-term outcomes. Fibular grafts have also been proven to be alternative for the post-
collapse stage of ONFH, It is also a worthwhile procedure in patients with postcollapse 
osteonecrosis. 188 patients (224 hips) who had undergone free vascularized fibular grafting, 
between 1989 and 1999, for the treatment of osteonecrosis of the hip that had led to collapse 
of the femoral head but not to arthrosis. The mean preoperative Harris hip score was 54.5 
points, and it increased to 81 points for the patients in whom the surgery succeeded; 63% of 
the patients in that group had a good or excellent result, Patients with postcollapse, 
predegenerative osteonecrosis of the femoral head appear to benefit from FVFG, with good 
overall survival of the joint and significant improvement in the Harris hip score. FVFG is a 
well accepted treatment option for all symptomatic stages of the disease ,with proper patient 
selection, middle and long-term outcomes appear promising. FVFG continues to be a 
primary treatment option to provide relief of symptoms and preserve bone stock, especially 
in the younger patient population.  
3.2.3 Attampts on the renal transplant recipients 
FVFG has been rarely systematically reported in renal transplant recipients, although ONFH 
after renal transplantation is not rare in the clinical work. Recipients with renal insufficiency 
and unstable general conditions cannot withstand the excessive blood loss and traumatic 
stress of a hip operation. Postoperative renal graft dysfunction, severe anemia, electrolyte 
disorder, and infection are life-threatening complications. Therefore, laboratory indices, 
including the HB, WBC, ESR, BUN, SCr, UA, electrolyte, 24 hours urine volume, and urine 
protein quantity, are indispensable. In addition, the CRP and  ESR should also be included 
as a nonspecific marker of the activation of the immune system in order to provide early 
signs of postoperative graft dysfunction and infection. Furthermore, the surgery should be 
rapid and less invasive. The use of toxic renal medicine should be avoided as well. Guo 
report three renal transplant recipients with ONFH who underwent FVFG in the 
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orthopedics department of Shanghai Sixth Poeple’s Hospital. Of the three cases, two cases 
showed radiographic improvement, one case showed radiographic unchanged. All the three 
cases have been living in good health and are satisfied with their joint function. The hip joint 
pain was significantly relieved and joint motion was also improved, The Harris hip score 
elevated 22 points in average, and the Visual Analogue Scale (VAS) was decreased by 37.3 
points. Their quality of life has been greatly improved and the gait can return to normal 
after positive rehabilitation training. The patients were able to walk without aid, even 
engaged in sports. After operation, the patients returned to full activities with a better 
quality of life due to normal joint and kidney function. The follow-up results demonstrated 
that FVFG is safe, effective, and feasible for transplant recipients without serious renal graft 
dysfunction, anemia, or other systemic diseases. However, the safety of the operation 
should also be attributed to proficient surgical technique, meticulous laboratory monitoring, 
and deliberate postoperative supportive treatment. 
3.2.4 Indication discussion 
According to our previous experience, indications for using FVFG to treat ONFH in patients 
after the renal transplantation include: 1) A patient younger than 50 years who is not 
suitable for total hip replacement; 2) Severe hip pain that greatly impairs daily activity; 3) 
Necrosis of the femoral head less than Steinberg stage V (osteoarthritis stage); 4) The 
recipient’s general physical condition is stable without renal graft dysfunction, serious 
anemia, metabolic disorder, or any other systemic diseases; 5) The recipient is active and in 
need of a high quality of life; 6) To take the safety of operation into account, FVFG ought to 
be performed at least one year after transplantation. 
4. Clinical example 
A 39-year-old man who was diagnosed with IgA nephropathy by renal biopsy and 
histopathological examination in January 1998. The disease developed to chronic renal 
failure six years later. The patient was maintained on hemodialysis for 10 months until 
unilateral renal transplantation in May 2005. He received steroid therapy for 18 months after 
the operation. The accumulative dose of corticosteroids was 7.5g (converted to prednisone 
dose). Tacrolimus (FK-506) 15mg per day and MMF 2.0g was also taken each day at the 
same time. He visited our hospital in November 2006 because of severe hip joint pain on the 
left side. The symptom became aggravated quickly, and the patient had to take 0.6mg 
Ibuprofen per day to maintain his daily activities. He was diagnosed with left side ONFH 
upon hip X-ray and MRI (classified as Steinberg stage III, Fig 1 a, b). A physical exam 
revealed a gait abnormality, deep inguinal region pain, positive Thomas sign, and 
Trendelenburg sign on the affected side. A decreased range of motion occurred in abduction 
and flexion. The Harris hip score was 72 points, and the VAS pain score was 80 points. All 
routine laboratory examination results were normal upon admission (shown in Table 1). 
FVFG on the left side was performed uneventfully one week later. The laboratory exam 
showed no significant change, except for a slight elevation of the WBC to 11.2×109/L on 
postoperative day 1. The body temperature rose to 37.9°C. The WBC returned to 8.6×109/L 
on day 3 and 7.4×109/L on day 7 after antibiotic treatment (intravenous Cefuroxime 3.0g 
drip bid for 3 days), and the patient’s temperature also returned to normal. The patient was 
discharged within 2 weeks in good health. No signs of infection or renal graft dysfunction 
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were discovered during the 1 year and 8 months of follow-up. The latest radiograph results 
showed improvement (Fig 1 c). The left joint pain and stiffness were significantly relieved. A 
daily pain-killer was no longer needed. The patient’s gait also returned to normal after 
positive rehabilitation training. He returned to his full activities with a better quality of life 
due to normal joint and kidney function. The Harris hip score rose to 89 points, and the VAS 
pain score decreased to 28 points. 
 
Fig. 1. (a) Preoperative radiograph (b) T1-weighted MRI (c) Radiograph 1 year and 8 months 
after FVFG showed revascularization of the necrosis area. The femoral head did not 
collapse. 
5. References 
[1] A.Y. Plafseychuk, S.Y. Kim and B.C. Park et al., Vascularized compared with 
nonvascularized fibula grafting for the treatment of osteonecrosis of the femoral 
head, J Bone Joint Surg Am 85 (2003), p. 589. 
[2] H. Hedri, M. Cherif and K. Zouaghi et al., Avascular osteonecrosis after renal 
transplantation, Transplant Proc 39 (2007), p. 1036. 
[3] J.M. Aldridge and J.R. Urbaniak, Free vascularized fibular grafting for the treatment of 
osteonecrosis of the femoral head, Tech orthop 23 (2008), p. 44.  
[4] M.E. Steinberg, G.D. Hayken and D.R. Steinberg. A quantitative system for staging 
avascular necrosis, J Bone Joint Surg Br 77 (1995), p. 34. 
[5] H.L Hoeksma, C.H.M. Van den Ende, H.K. Ronday et al., Comparison of the 
responsiveness of the Harris Hip Score with generic measures for hip function in 
osteoarthritis of the hip, Ann Rheum Dis 62 (2003), p. 935. 
[6] Holdgate, S. Asha, J. Craig et al., Comparison of a verbal numeric rating scale with the 
visual analogue scale for the measurement of acute pain, Emerg Med 15 (2003), p. 441 
[7] J.G. Heaf, Bone disease after renal transplantation, Transplantation 75 (2003), p. 315.  
[8] T.R. Mikuls, B.A. Julian and A. Bartolucci et al., Bone mineral density changes within six 
months of renal transplantation, Transplantation 75 (2003), p. 49. 
 
Renal Transplantation – Updates and Advances 
 
210 
orthopedics department of Shanghai Sixth Poeple’s Hospital. Of the three cases, two cases 
showed radiographic improvement, one case showed radiographic unchanged. All the three 
cases have been living in good health and are satisfied with their joint function. The hip joint 
pain was significantly relieved and joint motion was also improved, The Harris hip score 
elevated 22 points in average, and the Visual Analogue Scale (VAS) was decreased by 37.3 
points. Their quality of life has been greatly improved and the gait can return to normal 
after positive rehabilitation training. The patients were able to walk without aid, even 
engaged in sports. After operation, the patients returned to full activities with a better 
quality of life due to normal joint and kidney function. The follow-up results demonstrated 
that FVFG is safe, effective, and feasible for transplant recipients without serious renal graft 
dysfunction, anemia, or other systemic diseases. However, the safety of the operation 
should also be attributed to proficient surgical technique, meticulous laboratory monitoring, 
and deliberate postoperative supportive treatment. 
3.2.4 Indication discussion 
According to our previous experience, indications for using FVFG to treat ONFH in patients 
after the renal transplantation include: 1) A patient younger than 50 years who is not 
suitable for total hip replacement; 2) Severe hip pain that greatly impairs daily activity; 3) 
Necrosis of the femoral head less than Steinberg stage V (osteoarthritis stage); 4) The 
recipient’s general physical condition is stable without renal graft dysfunction, serious 
anemia, metabolic disorder, or any other systemic diseases; 5) The recipient is active and in 
need of a high quality of life; 6) To take the safety of operation into account, FVFG ought to 
be performed at least one year after transplantation. 
4. Clinical example 
A 39-year-old man who was diagnosed with IgA nephropathy by renal biopsy and 
histopathological examination in January 1998. The disease developed to chronic renal 
failure six years later. The patient was maintained on hemodialysis for 10 months until 
unilateral renal transplantation in May 2005. He received steroid therapy for 18 months after 
the operation. The accumulative dose of corticosteroids was 7.5g (converted to prednisone 
dose). Tacrolimus (FK-506) 15mg per day and MMF 2.0g was also taken each day at the 
same time. He visited our hospital in November 2006 because of severe hip joint pain on the 
left side. The symptom became aggravated quickly, and the patient had to take 0.6mg 
Ibuprofen per day to maintain his daily activities. He was diagnosed with left side ONFH 
upon hip X-ray and MRI (classified as Steinberg stage III, Fig 1 a, b). A physical exam 
revealed a gait abnormality, deep inguinal region pain, positive Thomas sign, and 
Trendelenburg sign on the affected side. A decreased range of motion occurred in abduction 
and flexion. The Harris hip score was 72 points, and the VAS pain score was 80 points. All 
routine laboratory examination results were normal upon admission (shown in Table 1). 
FVFG on the left side was performed uneventfully one week later. The laboratory exam 
showed no significant change, except for a slight elevation of the WBC to 11.2×109/L on 
postoperative day 1. The body temperature rose to 37.9°C. The WBC returned to 8.6×109/L 
on day 3 and 7.4×109/L on day 7 after antibiotic treatment (intravenous Cefuroxime 3.0g 
drip bid for 3 days), and the patient’s temperature also returned to normal. The patient was 
discharged within 2 weeks in good health. No signs of infection or renal graft dysfunction 
 
Osteonecrosis of Femoral Head (ONFH) After Renal Transplantation 
 
211 
were discovered during the 1 year and 8 months of follow-up. The latest radiograph results 
showed improvement (Fig 1 c). The left joint pain and stiffness were significantly relieved. A 
daily pain-killer was no longer needed. The patient’s gait also returned to normal after 
positive rehabilitation training. He returned to his full activities with a better quality of life 
due to normal joint and kidney function. The Harris hip score rose to 89 points, and the VAS 
pain score decreased to 28 points. 
 
Fig. 1. (a) Preoperative radiograph (b) T1-weighted MRI (c) Radiograph 1 year and 8 months 
after FVFG showed revascularization of the necrosis area. The femoral head did not 
collapse. 
5. References 
[1] A.Y. Plafseychuk, S.Y. Kim and B.C. Park et al., Vascularized compared with 
nonvascularized fibula grafting for the treatment of osteonecrosis of the femoral 
head, J Bone Joint Surg Am 85 (2003), p. 589. 
[2] H. Hedri, M. Cherif and K. Zouaghi et al., Avascular osteonecrosis after renal 
transplantation, Transplant Proc 39 (2007), p. 1036. 
[3] J.M. Aldridge and J.R. Urbaniak, Free vascularized fibular grafting for the treatment of 
osteonecrosis of the femoral head, Tech orthop 23 (2008), p. 44.  
[4] M.E. Steinberg, G.D. Hayken and D.R. Steinberg. A quantitative system for staging 
avascular necrosis, J Bone Joint Surg Br 77 (1995), p. 34. 
[5] H.L Hoeksma, C.H.M. Van den Ende, H.K. Ronday et al., Comparison of the 
responsiveness of the Harris Hip Score with generic measures for hip function in 
osteoarthritis of the hip, Ann Rheum Dis 62 (2003), p. 935. 
[6] Holdgate, S. Asha, J. Craig et al., Comparison of a verbal numeric rating scale with the 
visual analogue scale for the measurement of acute pain, Emerg Med 15 (2003), p. 441 
[7] J.G. Heaf, Bone disease after renal transplantation, Transplantation 75 (2003), p. 315.  
[8] T.R. Mikuls, B.A. Julian and A. Bartolucci et al., Bone mineral density changes within six 
months of renal transplantation, Transplantation 75 (2003), p. 49. 
 
Renal Transplantation – Updates and Advances 
 
212 
[9] S. Tang, T.M. Chan and S.L. Lui et al., Risk factors for avascular bone necrosis after renal 
transplantation, Transplant Proc 32 (2000), p. 1873. 
[10] W. Drescher, T. Schneider and C. Becker et al., Selective reduction of bone blood flow by 
short-term treatment with high-dose methylprednisolone, An experimental study 
in pigs. J Bone Joint Surg Br 83 (2000), p. 274.  
[11] G.S. Dean, R.C. Kime and R.D. Fitch et al., Treatment of osteonecrosis in the hip of 
pediatric patients by free vascularized fibular graft, Clin Orthop Relat Res 386 (2001), 
p. 106. 
[12] H. Judet and A. Gilbert, Long-term results of free vascularized fibular grafting for 
femoral head necrosis, Clin Orthop Relat Res 386 (2001), p. 114. 
[13] J.R. Urbaniak, P.G. Coogan and E.B. Gunneson et al., Treatment of osteonecrosis of the 
femoral head with free vascularized fibular grafting: A long-term follow-up study 
of one hundred and three hips, J Bone Joint Surg Am 77 (1995), p. 681. 
[14] C.Q. Zhang, B.F. Zeng and Z.Y. Xu, et al., Treatment of femoral head necrosis with free 
vascularized fibular grafting: a preliminary report, J Microsurg 25 (2005), p. 305. 
[15] K.R. Berend, E.B. Gunneson and J.R. Urbaniak, Free vascularized fibular grafting for the 
treatment of postcollapse osteonecrosis of the femoral head, J Bone Joint Surg Am 85 
(2003), p. 987.  
[16] A.M. Cueto-Manzano, L.E. Morales-Buenrostro and L. Gonzalez-Espinoza et al., 
Markers of inflammation before and after renal transplantation, Transplantation 80 
(2005), p. 47.  
[17] C. Reek, S. Conrad and H. Huland, The role of C-reactive protein in graft dysfunction 
after renal transplantation, J Urol 161 (1999), p. 1463. 
[18] Y. J. Guo, D. X. Jin, C.Q. Zhang, et al., Curative Effect and Safety of Vascularized Fibula 
Grafting in Renal Transplant Recipients With Osteonecrosis of the Femoral Head: 
Three Case Reports, J Transplant Proc 41(2009), P. 3731. 
[19] H. Sperschneider, G. Stein, Bone disease after renal transplantation, J Nephrol Dial 
Transplant 18(2003), P.874 
[20] E. Lee, K. Lee, W. Huh, et al., Incidence and radio-uptake patterns of femoral head 
avascular osteonecrosis at 1 year after renal transplantation: a prospective study 
with planar bone scintigraphy, J  Nuclr Med Commun 27(2006), P. 919. 
[21] T. Kubo, S. Yamazo, N. Sugano, et al., Initial MRI findings of non-traumatic 
osteonecrosis of the femoral head in renal allograft recipients. J Magn Reson Imaging 
15(1997), P. 1017. 
[22] S. B. Marston, K. Gillingham, R. F. Bailey, et al., Osteonecrosis of the femoral head after 
solid organ transplantation: a prospective study. J Bone Joint Surg Am 84A (2002), P. 
2145. 
[23] R. Lopez-Ben, T. R. Mikuls, D. S. Moore, et al., Incidence of hip osteonecrosis among 
renal transplantation recipients: a prospective study, J Clin Radiol 59(2004), P. 31. 
[24] G. S. Lausten, T. Lemser, P. K. Jensen, et al., Necrosis of the femoral head after kidney 
transplantation. J Clin Transplant 12(1998), P. 572. 
[25] K. K. Kopecky, E. M. Braunstein, K. D. Brand, et al., Apparent avascular necrosis of the 
hip: appearance and spontaneous resolution of MR findings in renal allograft 
recipients. J Radiol 179(1991), P. 523 
[26] J. Brian. Lipworth, Systemic adverse effects of inhaled corticosteroid therapy: A 
systematic review and meta-analysis, J Arch Intern Med. 159(1999), P. 941 
[27] T. Kubo. H. Tsuji H, T. Yamamoto T, et al., Antithrombin III deficiency in a patient who 
has mulitifocal osteonecrosis. J. Clin Orthop. 378(2000), p. 306 
14 
Pediatric Kidney Transplant in Uropaties 
Cristian Sager, Juan Carlos López, Víctor Durán,  
Carol Burek, Juan Pablo Corbetta and Santiago Weller 
Hospital Nacional de Pediatría Prof. Dr. J. P. Garrahan 
Argentina 
1. Introduction 
It has been long reported that for children with end-stage renal disease (ESRD), renal 
transplant is the treatment of choice (Fine et al., 1978; Gradus & Ettenger, 1982). With this 
approach the lost renal function is reestablished and the pondo-stature, psycho-intellectual 
and social development is not affected (Ferraris & Rodriguez, 2008). 
Hemodialysis or ambulatory peritoneal dialysis are modalities used in the treatment of 
children with ESRD when there is no living donor available or when patients are waiting for 
a cadaver donor (Galvez et al., 2005). However, these patients will eventually present 
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Nevertheless, there exists considerable controversy around the best approach to handle 
these types of patients, since there are no guidelines designed with defined reconstructive 
surgical criteria, optimal surgical procedures or recommendations as to when the best time 
to perform such interventions (Riley et al.,2010). 
2. Etiologies for end stage renal disease – Uropathies 
Among the most frequent etiologies for end stage renal disease are renal hypodysplasia 
(17%), obstructive uropathies (16.9%), focal segmental glomerulosclerosis (9%), 
vesicoureteral reflux (6.3%), renal polycystosis, uremic hemolitic syndrome, Prune belly, 
neurogenic bladder due to neural tube defects, among others (North American Pediatric 
Renal Transplant Cooperative Study (N.A.P.R.T.C.S.), 2007)  
The predominance of one or other etiology is conditioned by the different geographical 
regions. The deterioration of the renal function is not the most common consequence of 
vesicoureteral reflux (VUR), with an estimated risk lower than 1%. There is a direct 
relationship between the degree of VUR and the incidence of the nephropathy (Skoog et 
al, 1987). Up to 35% of renal scarring is congenital, due to dysmorphic renal tissue from 
the gestational stage, especially in high degree VUR. When there is vesicoureteral reflux 
the patient is prone to develop pyelonephritis, and if this occurs during the first months of 
life or in repeated fashion, there are more chances of developing renal scars and 
aggravating the renal function. The incidence of chronic pyelonephritis is within 15 and 
25% of ESRD.  
The term ‘obstructive uropathies’ includes entities such as pyeloureteral stenosis, 
ureterovesical stenosis, obstructive megaureters and prior surgically corrected obstructive 
uropathy remnants. All these uropathies manifest as hydronephrosis or 
ureterohydronephrosis. The obstruction to the urine flow, if not corrected, eventually 
produces irreversible reduction of the function, depending on whether the obstruction is 
bilateral, affects only one kidney or an insufficient one (Podestá & Bertolotti, 2008).  
Posterior urethral valve (PUV) remains the most frequent organic-anatomical obstruction in 
males and it is due to a congenital defect in the development of the membranous urethra. 
This condition can manifest along a spectrum of severity, ranging from disease incompatible 
with postnatal life to conditions that have minimal impact later in life. Chronic obstruction 
of the outlet urinary tract during the critical stage of organogenesis of the urinary system 
exerts a deep impact on the kidneys, ureters and vesical function. Approximately a third of 
the patients with PUV progress to ESRD (López & Durán, 2008).  
In the case of Prune belly syndrome the kidneys may exhibit: ureterohydronephrosis, 
VUR, renal dysplasia, anatomical infravesical obstruction. This syndrome has a broad 
spectrum of affected anatomy with different levels of severity, from incompatibility with 
life to minimally compromised renal function (Woodward & Smith, 1998). Many patients 
require multiple urological surgeries with some cases of irreversible deterioration in the 
renal mass.  
Patients with a neurogenic bladder caused by spinal dysraphism that do not receive 
appropriate treatment can progress to ESRD (De Jong et al., 2008). Spinal dysraphism 
abnormalities mainly include myelomeningocele, lipomeningocele and caudal regression 
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syndrome. All of them generate different types of behavior of the neurogenic bladder and 
particularly affect the renal function (Torre et al., 2011). 
The urodynamic variables that are more involved as risk factors are: detrusor hyperactivity, 
reduced compliance, detrusor-sphincter dyssinergia.  
Medical therapies implemented during the first months of life and sustained by 
anticholinergic drugs and clean intermittent catheterization greatly help to avoid 
compromise or deterioration of the renal function.  
3. Evaluation of the urinary tract 
There is general consensus among the most prominent health care centers that assessment of 
the lower urinary tract before performing a renal transplant is of the utmost importance. If 
alterations are found, they must be corrected before the allograft is implanted. A 
dysfunctional lower urinary tract that has promoted the deterioration of the native kidneys 
represents a risk for the allograft.  
In the first place, a history of baseline pathologies and a thorough physical examination are 
fundamental, since they determine which complementary studies will be needed. It is not 
necessary to have all patients undergo all possible urological studies. For that reason it is 
useful to define beforehand whether ESRD was caused by a nephropathy or by an uropathy. 
If the latter applies, it is necessary to classify patients into two groups: those who did not 
require urinary tract surgery and those who did.  
Overall, for the group of patients who required lower urinary tract surgery most of the 
complementary studies described below will be needed. When the signs and symptoms 
reported by patients or parents are not clear enough, especially with respect to urinary 
incontinence or alterations of the voiding frequency, keeping a voiding diary and a record of 
urinary leakage becomes very useful. 
On occasions, when the history or symptoms of urologic pathology are not defined, we 
must resort to other specialties for further evaluation, such as neurology-neurosurgery, in 
order to search for the etiological diagnosis of certain urinary dysfunctions.  
The physical examination also includes the assessment of the abdominal and pelvic region 
for position of dialysis catheters, intestinal and urinary stomas, either for possible 
reconstructions of the urinary tract or to locate a future allograft implantation. In addition, it 
is necessary to analyze the status and mobility of lower and upper limbs, with the purpose 
of deciding whether intermittent catheterization could be used for bladder voiding, via the 
urethra or via continent stoma. 
Ultrasound scanning is the initial technique of choice in order to detect morphological 
abnormalities. Although it is operator/observer-dependent, it does not present any 
contraindications and it can be repeated as many times as necessary without having 
damaging effects on the patient (Bibiloni, et al., 2008). In ESRD, ultrasound is used in order 
to characterize degree of ureterohydronephrosis, double ureter systems and characteristics 
of the vesical wall. If diuresis exists, ultrasound scanning with full and empty bladder is 
required in order to evaluate if there is post void residual or ureterohydronephrosis 
alterations.  
 
Renal Transplantation – Updates and Advances 214 
Nevertheless, there exists considerable controversy around the best approach to handle 
these types of patients, since there are no guidelines designed with defined reconstructive 
surgical criteria, optimal surgical procedures or recommendations as to when the best time 
to perform such interventions (Riley et al.,2010). 
2. Etiologies for end stage renal disease – Uropathies 
Among the most frequent etiologies for end stage renal disease are renal hypodysplasia 
(17%), obstructive uropathies (16.9%), focal segmental glomerulosclerosis (9%), 
vesicoureteral reflux (6.3%), renal polycystosis, uremic hemolitic syndrome, Prune belly, 
neurogenic bladder due to neural tube defects, among others (North American Pediatric 
Renal Transplant Cooperative Study (N.A.P.R.T.C.S.), 2007)  
The predominance of one or other etiology is conditioned by the different geographical 
regions. The deterioration of the renal function is not the most common consequence of 
vesicoureteral reflux (VUR), with an estimated risk lower than 1%. There is a direct 
relationship between the degree of VUR and the incidence of the nephropathy (Skoog et 
al, 1987). Up to 35% of renal scarring is congenital, due to dysmorphic renal tissue from 
the gestational stage, especially in high degree VUR. When there is vesicoureteral reflux 
the patient is prone to develop pyelonephritis, and if this occurs during the first months of 
life or in repeated fashion, there are more chances of developing renal scars and 
aggravating the renal function. The incidence of chronic pyelonephritis is within 15 and 
25% of ESRD.  
The term ‘obstructive uropathies’ includes entities such as pyeloureteral stenosis, 
ureterovesical stenosis, obstructive megaureters and prior surgically corrected obstructive 
uropathy remnants. All these uropathies manifest as hydronephrosis or 
ureterohydronephrosis. The obstruction to the urine flow, if not corrected, eventually 
produces irreversible reduction of the function, depending on whether the obstruction is 
bilateral, affects only one kidney or an insufficient one (Podestá & Bertolotti, 2008).  
Posterior urethral valve (PUV) remains the most frequent organic-anatomical obstruction in 
males and it is due to a congenital defect in the development of the membranous urethra. 
This condition can manifest along a spectrum of severity, ranging from disease incompatible 
with postnatal life to conditions that have minimal impact later in life. Chronic obstruction 
of the outlet urinary tract during the critical stage of organogenesis of the urinary system 
exerts a deep impact on the kidneys, ureters and vesical function. Approximately a third of 
the patients with PUV progress to ESRD (López & Durán, 2008).  
In the case of Prune belly syndrome the kidneys may exhibit: ureterohydronephrosis, 
VUR, renal dysplasia, anatomical infravesical obstruction. This syndrome has a broad 
spectrum of affected anatomy with different levels of severity, from incompatibility with 
life to minimally compromised renal function (Woodward & Smith, 1998). Many patients 
require multiple urological surgeries with some cases of irreversible deterioration in the 
renal mass.  
Patients with a neurogenic bladder caused by spinal dysraphism that do not receive 
appropriate treatment can progress to ESRD (De Jong et al., 2008). Spinal dysraphism 
abnormalities mainly include myelomeningocele, lipomeningocele and caudal regression 
 
Pediatric Kidney Transplant in Uropaties 215 
syndrome. All of them generate different types of behavior of the neurogenic bladder and 
particularly affect the renal function (Torre et al., 2011). 
The urodynamic variables that are more involved as risk factors are: detrusor hyperactivity, 
reduced compliance, detrusor-sphincter dyssinergia.  
Medical therapies implemented during the first months of life and sustained by 
anticholinergic drugs and clean intermittent catheterization greatly help to avoid 
compromise or deterioration of the renal function.  
3. Evaluation of the urinary tract 
There is general consensus among the most prominent health care centers that assessment of 
the lower urinary tract before performing a renal transplant is of the utmost importance. If 
alterations are found, they must be corrected before the allograft is implanted. A 
dysfunctional lower urinary tract that has promoted the deterioration of the native kidneys 
represents a risk for the allograft.  
In the first place, a history of baseline pathologies and a thorough physical examination are 
fundamental, since they determine which complementary studies will be needed. It is not 
necessary to have all patients undergo all possible urological studies. For that reason it is 
useful to define beforehand whether ESRD was caused by a nephropathy or by an uropathy. 
If the latter applies, it is necessary to classify patients into two groups: those who did not 
require urinary tract surgery and those who did.  
Overall, for the group of patients who required lower urinary tract surgery most of the 
complementary studies described below will be needed. When the signs and symptoms 
reported by patients or parents are not clear enough, especially with respect to urinary 
incontinence or alterations of the voiding frequency, keeping a voiding diary and a record of 
urinary leakage becomes very useful. 
On occasions, when the history or symptoms of urologic pathology are not defined, we 
must resort to other specialties for further evaluation, such as neurology-neurosurgery, in 
order to search for the etiological diagnosis of certain urinary dysfunctions.  
The physical examination also includes the assessment of the abdominal and pelvic region 
for position of dialysis catheters, intestinal and urinary stomas, either for possible 
reconstructions of the urinary tract or to locate a future allograft implantation. In addition, it 
is necessary to analyze the status and mobility of lower and upper limbs, with the purpose 
of deciding whether intermittent catheterization could be used for bladder voiding, via the 
urethra or via continent stoma. 
Ultrasound scanning is the initial technique of choice in order to detect morphological 
abnormalities. Although it is operator/observer-dependent, it does not present any 
contraindications and it can be repeated as many times as necessary without having 
damaging effects on the patient (Bibiloni, et al., 2008). In ESRD, ultrasound is used in order 
to characterize degree of ureterohydronephrosis, double ureter systems and characteristics 
of the vesical wall. If diuresis exists, ultrasound scanning with full and empty bladder is 
required in order to evaluate if there is post void residual or ureterohydronephrosis 
alterations.  
 
Renal Transplantation – Updates and Advances 216 
Voiding cystourethrogram is mandatory, especially in the case of patients with a history of 
urinary infections and lower urinary tract surgeries. It is an irreplaceable method to detect 
vesicoureteral reflux, to show anatomical details of the bladder neck, of the male urethra, 
and to characterize other findings, such as bladder stones and irregularities of the bladder 
wall. This methodology also provides information on voiding pathophysiology. As it is an 
invasive procedure that uses fluoroscopy radiation, it must be carried out by trained 
professionals, so that the method can be optimized.  
Urodynamic studies record the activity of the lower urinary tract in the filling and voiding 
phases of the bladder. The variables recorded, such as volume, bladder pressure, urinary 
leakage pressure, bladder compliance, detrusor muscle stability, coordination of the cycle, 
perineal surface electromyography activity, among others, determine the type of bladder 
dysfunction and help to indicate the most appropriate treatment and to control the 
evolution and therapeutic response (Burek & Sager, 2008). Urodynamic studies are required 
when there is a history of spinal dysraphism and other etiologies of neurogenic bladder, 
posterior urethra valves, lower urinary tract surgeries, urine incontinence, therapy with 
anticholinergic drugs, anatomical alterations as shown in the voiding cystourethrogram and 
high degree of vesicoureteral reflux.   
In the latter case, a video urodynamic study is the preferred method, since it combines the 
benefits of voiding cystourethrography and urodynamic records. This results in a thorough 
anatomic and functional evaluation of the urinary tract. The video urodynamic study 
requires a certain degree of technical complexity and it must be performed by very well-
trained professionals. In the case of some patients, in order to simplify and reduce 
manipulation, the following algorithm can be applied: renovesical ultrasound and video 
urodynamic study ( Cerruto & Artibani, 2006). 
4. Adequate bladder function 
The urinary tract can be described as being “functional” if the storage and voiding phases of 
the bladder function in a coordinated way. In the first phase, the pelvis and ureters must 
void an adequate volume of urine into a bladder or neobladder of low pressure without 
leaks. Competent ureterovesical junctions stop urine from refluxing into the upper urinary 
tract. During the voiding phase, the bladder muscle (detrusor) contracts at regular intervals 
and in a sustained fashion, with relaxation of the outlet urinary tract (bladder neck and 
sphincter) with the purpose of eliminating urine. Many patients cannot achieve normal 
voiding and require clean intermittent catheterization.  
After evaluation is completed we must define whether the lower urinary tract is in good 
condition to receive an implant. The parameters used to define “adequate bladder function” 
are:  
- Absence of signs and symptoms of low urinary tract dysfunction. 
- Absence or scant post void residual urine on renovesical ultrasound. 
- Adequate volume capacity and bladder compliance, stability of the detrusor muscle, 
adequate voiding, no post void residual and no leaks as assessed by urodynamic/video 
urodynamic studies ( Barry, 2004).  
If assessment outcome shows that the lower urinary tract is not in adequate condition to 
receive a new kidney, therapy customized to the particular urologic condition should be 
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indicated and a new evaluation should be carried out prior to transplantation. If 
reconstruction of the lower urinary tract is to be performed, the objective is to achieve a 
functional urinary tract.  
5. Treatments for the lower urinary tract 
5.1 Medical treatments 
The objective of any treatment is to provide a safe mechanism of drainage for those patients 
who have voiding difficulties, by means of clean intermittent catheterization (CIC) and 
pharmacological reduction of storage pressure or non-inhibited contractions with the use of 
anticholinergic drugs.  
CIC is the most significant advancement in the urological care of patients with neurogenic 
dysfunction of the lower urinary tract. This procedure provides adequate voiding and a 
reduced risk of urinary infections; it helps to avoid bladder overdistension; it facilitates 
resolution of the vesicoureteral reflux and favors urinary continence. CIC may be performed 
at any age, on both sexes and at any position and site. It can be indicated in the presence of 
high intravesical pressure, detrusor-sphincter dyssynergia, sphincter hypertonia, high 
residual urine volume and absence of spontaneous voiding. It is fundamental that 
instruction of the procedure be in charge of trained nurses, who will also supervise CIC 
management periodically.  
CIC is a safe, easy and effective way of emptying the bladder with a low rate of 
complications. Although unusual, the most frequent complications are urethral bleeding 
and false passages, and epididymitis. Asymptomatic bacteriuria is observed in 70% of 
patients, but it is not associated to renal scarring; therefore, it is not treated. Antibiotic 
prophylaxis is indicated only at the beginning of CIC to patients with vesicoureteral reflux 
and those who have received a renal transplantation.  
Anticholinergic drugs, mainly oxybutynin, are used for the treatment of hyperreflexia and 
bladder hypertonia. They are widely used in pediatric settings; they are of acceptable 
tolerance and they have proved to provide a beneficial therapeutic effect. For those patients 
who do not tolerate oxybutynin, tolterodine can be used. It is more selective; it has fewer 
adverse effects, but does not seem to have more efficacy. Other even more selective drugs, 
such as darifenacin, are also being used lately in the pediatric population.  
The selective alpha-adrenergic blockade is a therapeutic alternative in cases of dysfunctional 
voiding of different etiologies. It facilitates the release of infravesical outflow obstruction. 
Doxazosin is one of the most commonly used drugs (Austin et al., 1999) Biofeedback 
therapy, mainly used with patients with non-neurogenic bladder dysfunction, contributes to 
educating, relaxing the perineum region and improving the dynamics of the detrusor-neck-
sphincter unit. 
5.2 Surgical treatment  
5.2.1 Reconstruction of the urinary tract in children 
The aim of the surgical intervention/s is to reestablish a new system that can protect the 
renal function and achieve adequate urine volume at low pressure, avoid urinary infections 
and lead to continence.  
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trained professionals. In the case of some patients, in order to simplify and reduce 
manipulation, the following algorithm can be applied: renovesical ultrasound and video 
urodynamic study ( Cerruto & Artibani, 2006). 
4. Adequate bladder function 
The urinary tract can be described as being “functional” if the storage and voiding phases of 
the bladder function in a coordinated way. In the first phase, the pelvis and ureters must 
void an adequate volume of urine into a bladder or neobladder of low pressure without 
leaks. Competent ureterovesical junctions stop urine from refluxing into the upper urinary 
tract. During the voiding phase, the bladder muscle (detrusor) contracts at regular intervals 
and in a sustained fashion, with relaxation of the outlet urinary tract (bladder neck and 
sphincter) with the purpose of eliminating urine. Many patients cannot achieve normal 
voiding and require clean intermittent catheterization.  
After evaluation is completed we must define whether the lower urinary tract is in good 
condition to receive an implant. The parameters used to define “adequate bladder function” 
are:  
- Absence of signs and symptoms of low urinary tract dysfunction. 
- Absence or scant post void residual urine on renovesical ultrasound. 
- Adequate volume capacity and bladder compliance, stability of the detrusor muscle, 
adequate voiding, no post void residual and no leaks as assessed by urodynamic/video 
urodynamic studies ( Barry, 2004).  
If assessment outcome shows that the lower urinary tract is not in adequate condition to 
receive a new kidney, therapy customized to the particular urologic condition should be 
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indicated and a new evaluation should be carried out prior to transplantation. If 
reconstruction of the lower urinary tract is to be performed, the objective is to achieve a 
functional urinary tract.  
5. Treatments for the lower urinary tract 
5.1 Medical treatments 
The objective of any treatment is to provide a safe mechanism of drainage for those patients 
who have voiding difficulties, by means of clean intermittent catheterization (CIC) and 
pharmacological reduction of storage pressure or non-inhibited contractions with the use of 
anticholinergic drugs.  
CIC is the most significant advancement in the urological care of patients with neurogenic 
dysfunction of the lower urinary tract. This procedure provides adequate voiding and a 
reduced risk of urinary infections; it helps to avoid bladder overdistension; it facilitates 
resolution of the vesicoureteral reflux and favors urinary continence. CIC may be performed 
at any age, on both sexes and at any position and site. It can be indicated in the presence of 
high intravesical pressure, detrusor-sphincter dyssynergia, sphincter hypertonia, high 
residual urine volume and absence of spontaneous voiding. It is fundamental that 
instruction of the procedure be in charge of trained nurses, who will also supervise CIC 
management periodically.  
CIC is a safe, easy and effective way of emptying the bladder with a low rate of 
complications. Although unusual, the most frequent complications are urethral bleeding 
and false passages, and epididymitis. Asymptomatic bacteriuria is observed in 70% of 
patients, but it is not associated to renal scarring; therefore, it is not treated. Antibiotic 
prophylaxis is indicated only at the beginning of CIC to patients with vesicoureteral reflux 
and those who have received a renal transplantation.  
Anticholinergic drugs, mainly oxybutynin, are used for the treatment of hyperreflexia and 
bladder hypertonia. They are widely used in pediatric settings; they are of acceptable 
tolerance and they have proved to provide a beneficial therapeutic effect. For those patients 
who do not tolerate oxybutynin, tolterodine can be used. It is more selective; it has fewer 
adverse effects, but does not seem to have more efficacy. Other even more selective drugs, 
such as darifenacin, are also being used lately in the pediatric population.  
The selective alpha-adrenergic blockade is a therapeutic alternative in cases of dysfunctional 
voiding of different etiologies. It facilitates the release of infravesical outflow obstruction. 
Doxazosin is one of the most commonly used drugs (Austin et al., 1999) Biofeedback 
therapy, mainly used with patients with non-neurogenic bladder dysfunction, contributes to 
educating, relaxing the perineum region and improving the dynamics of the detrusor-neck-
sphincter unit. 
5.2 Surgical treatment  
5.2.1 Reconstruction of the urinary tract in children 
The aim of the surgical intervention/s is to reestablish a new system that can protect the 
renal function and achieve adequate urine volume at low pressure, avoid urinary infections 
and lead to continence.  
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At present, most of the reconstructive procedures are performed in order to correct 
anomalies of the native urinary tract refractory to medical treatment. Children with bladder 
and sphincter dysfunction represent a big challenge and most patients who require 
reconstructive procedures have myelodysplasia as etiology for the neurogenic bladder.  
The pathophysiological ways that lead to dysfunction of the excretory system are manifold; 
therefore, the evaluation of reconstruction should be meticulous and individualized. In 
addition to technical surgical matters, in questions of evolution and outcome it is important 
to consider the commitment of the patient and the family in the monitoring and post-
surgery care. When a reconstruction of the lower urinary tract is considered, the aim is to 
achieve the characteristics of a functional urinary tract.  
In general, vesicoureteral reflux is secondary to bladder dysfunction. In other etiologies, 
such as Prune belly syndrome and posterior urethra valves, the reflux can be primary and 
secondary. In the case of secondary reflux of low degree in patients that will undergo 
bladder augmentation, it is not necessary to correct the reflux, since after the augmentation, 
this type of reflux may resolve without the need for reimplantation. If the reservoir has 
adequate low pressure volume, reimplantation is not necessary. However, some surgeons 
prefer correction of the reflux, since they state that bacteiruria can unfold episodes of 
pyelonephritis.  
Furthermore, when thinking of reimplanting dilated ureters, it should be taken into account 
that sometimes they have fibrous walls, and tunnelization and aggressive remodeling can 
lead to ureterovesical obstruction. For patients suffering from ESRD with vesicoureteral 
reflux and ureterohydronephrosis, pre-transplant nephroureterectomy can be beneficial. If 
ureteral dilation comes first and the patient requires bladder augmentation, ureteral 
segments can be used for the reconstruction.  
The urothelium is exempt from complications that are inherent to intestinal segments 
(Nahas et al, 2004, Hitchcock, 1994). In this case, an extraperitoneal approach is taken: 
lumbotomy incision for the nephrectomy of the dysplastic kidney and mobilization of the 
dilated ureter and suprapubic incision for bladder augmentation. This approach is beneficial 
in that it avoids the risks of peritoneal adhesions, and it should be considered in the case of 
ventriculoperitoneal diversions and of patients who are still under ambulatory peritoneal 
dialysis (Bellinger, 1993; Dewan et al., 1994; Reinber et al., 1995; Wolf & Turzan, 1993). 
Ureterocystoplasty that is laparoscopically assisted has been used since a few years ago. No 
serious complications have been reported with the use of this procedure, although the need 
for reaugmentation has been informed to a high degree in the case of native bladders with 
severely reduced compliance. It is thought that the best candidates to receive 
ureterocystoplasty have moderately reduced compliance (> 20 ml/cmh2o) and available 
ureter of a diameter greater than 15 mm to be used in the reconstruction (Husmann et al., 
2004) 
When it is not possible to obtain urothelial tissue for bladder augmentation, segments from 
the digestive tube are used: from the stomach, now hardly ever used, to bowel segments. 
The native bladder is preserved and, for a better anastomosis to the bowel segment, a 
sagittal incision is performed in order to divide it in two valves. The intestinal segment is 
open along its antimesenteric border in order to detubularize it and reconfigure it into 
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spherical shape thus achieving maximum volume per given surface area, blunting of 
intestinal contraction, and improving overall compliance and distensibility.  
In many health care centers, ileal segments are chosen to perform colocystoplasty (Nahas et 
al., 2007), whereas at Hospital de Pediatría Prof. Dr. J. P. Garrahan and since several years 
ago, sigmoid colon segments without specific bowel preparation have been the segments of 
choice. No significant infection complications have been observed postoperatively. We have 
adopted the colon because of its proximity to the native bladder; it has a low rate of 
metabolic complications and no technical complications. 
It is necessary to train the patient and their family in the postoperative care of the 
colocystoplasty. This consists of clean intermittent catheterization, daily vesical washes and 
periodical visits to the urologist, because there is a certain risk of complications, such as 
symptomatic urinary infections, lithiasis, perforations and tumoral neoformations.  
Once a bladder or reservoir with adequate volume and low pressure is obtained, it is 
essential to resolve the urinary incontinence. One of the greatest technical challenges that 
the urologist surgeon faces in the reconstruction of the vesical neck is to be able to provide 
adequate outlet resistance. Especially in the case of the neurogenic bladder due to spinal 
dysraphism, bladder outlet is generally incompetent. There are many surgical options that 
include adjustments of the neck and proximal urethra thanks to the aponeurosis slings, 
creation of valve mechanisms, endoscopic injection of artificial volume-formation agents 
and artificial urinary sphincter.  
Several techniques that increase outlet resistance may also deteriorate the detrusor status, 
reducing its compliance or generating instability. These events will occur depending on the 
baseline pathology. Therefore, previous urodynamic evaluations carried out and a strict 
follow-up post-reconstruction and post-transplantation are the golden rule. The final option 
will undoubtedly be customized according to the baseline disease, the goals of the patients 
and technical limitations of medical nature.  
It is reasonable to say that clean intermittent catheterization may have been the most 
significant contribution in terms of reconstruction of lower urinary tract functions. The 
potential need or absence of need for CIC in every reconstruction should always be 
considered, and both patients and family must be updated as to the objectives of 
reconstruction as well as the importance of adapting themselves to long term CIC regimens 
in a strict way. In most cases, the CIC procedure will be needed and patients must learn 
about it and accept CIC before reconstruction.  
When the urethra is inaccessible, sensitive or carries irreparable obstructions, a tubular 
system with continence mechanism is built with the purpose of facilitating the access to the 
bladder or the reservoir. The Mitrofanoff principle (1980) solved this dilemma, thanks to the 
creation of a conduit, being the cecal appendix the most commonly used, reimplanted in the 
submucosal bladder tunnel at one extreme and converted into a catheterizable stoma at the 
other extreme, in the abdominal wall. When the bladder is full, optimal coaptation is 
achieved avoiding urine leakage. If it is not possible to use the cecal appendix, other tubular 
structures can be used, for instance the ureter, the Fallopian tubes or the reconfigured small 
intestine (Monti). It should be taken into account that complications that are not so 
infrequent, such as conduit stenosis, mucous prolapse and false passages, may occur. 
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At present, most of the reconstructive procedures are performed in order to correct 
anomalies of the native urinary tract refractory to medical treatment. Children with bladder 
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Furthermore, when thinking of reimplanting dilated ureters, it should be taken into account 
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ureteral dilation comes first and the patient requires bladder augmentation, ureteral 
segments can be used for the reconstruction.  
The urothelium is exempt from complications that are inherent to intestinal segments 
(Nahas et al, 2004, Hitchcock, 1994). In this case, an extraperitoneal approach is taken: 
lumbotomy incision for the nephrectomy of the dysplastic kidney and mobilization of the 
dilated ureter and suprapubic incision for bladder augmentation. This approach is beneficial 
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ventriculoperitoneal diversions and of patients who are still under ambulatory peritoneal 
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serious complications have been reported with the use of this procedure, although the need 
for reaugmentation has been informed to a high degree in the case of native bladders with 
severely reduced compliance. It is thought that the best candidates to receive 
ureterocystoplasty have moderately reduced compliance (> 20 ml/cmh2o) and available 
ureter of a diameter greater than 15 mm to be used in the reconstruction (Husmann et al., 
2004) 
When it is not possible to obtain urothelial tissue for bladder augmentation, segments from 
the digestive tube are used: from the stomach, now hardly ever used, to bowel segments. 
The native bladder is preserved and, for a better anastomosis to the bowel segment, a 
sagittal incision is performed in order to divide it in two valves. The intestinal segment is 
open along its antimesenteric border in order to detubularize it and reconfigure it into 
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spherical shape thus achieving maximum volume per given surface area, blunting of 
intestinal contraction, and improving overall compliance and distensibility.  
In many health care centers, ileal segments are chosen to perform colocystoplasty (Nahas et 
al., 2007), whereas at Hospital de Pediatría Prof. Dr. J. P. Garrahan and since several years 
ago, sigmoid colon segments without specific bowel preparation have been the segments of 
choice. No significant infection complications have been observed postoperatively. We have 
adopted the colon because of its proximity to the native bladder; it has a low rate of 
metabolic complications and no technical complications. 
It is necessary to train the patient and their family in the postoperative care of the 
colocystoplasty. This consists of clean intermittent catheterization, daily vesical washes and 
periodical visits to the urologist, because there is a certain risk of complications, such as 
symptomatic urinary infections, lithiasis, perforations and tumoral neoformations.  
Once a bladder or reservoir with adequate volume and low pressure is obtained, it is 
essential to resolve the urinary incontinence. One of the greatest technical challenges that 
the urologist surgeon faces in the reconstruction of the vesical neck is to be able to provide 
adequate outlet resistance. Especially in the case of the neurogenic bladder due to spinal 
dysraphism, bladder outlet is generally incompetent. There are many surgical options that 
include adjustments of the neck and proximal urethra thanks to the aponeurosis slings, 
creation of valve mechanisms, endoscopic injection of artificial volume-formation agents 
and artificial urinary sphincter.  
Several techniques that increase outlet resistance may also deteriorate the detrusor status, 
reducing its compliance or generating instability. These events will occur depending on the 
baseline pathology. Therefore, previous urodynamic evaluations carried out and a strict 
follow-up post-reconstruction and post-transplantation are the golden rule. The final option 
will undoubtedly be customized according to the baseline disease, the goals of the patients 
and technical limitations of medical nature.  
It is reasonable to say that clean intermittent catheterization may have been the most 
significant contribution in terms of reconstruction of lower urinary tract functions. The 
potential need or absence of need for CIC in every reconstruction should always be 
considered, and both patients and family must be updated as to the objectives of 
reconstruction as well as the importance of adapting themselves to long term CIC regimens 
in a strict way. In most cases, the CIC procedure will be needed and patients must learn 
about it and accept CIC before reconstruction.  
When the urethra is inaccessible, sensitive or carries irreparable obstructions, a tubular 
system with continence mechanism is built with the purpose of facilitating the access to the 
bladder or the reservoir. The Mitrofanoff principle (1980) solved this dilemma, thanks to the 
creation of a conduit, being the cecal appendix the most commonly used, reimplanted in the 
submucosal bladder tunnel at one extreme and converted into a catheterizable stoma at the 
other extreme, in the abdominal wall. When the bladder is full, optimal coaptation is 
achieved avoiding urine leakage. If it is not possible to use the cecal appendix, other tubular 
structures can be used, for instance the ureter, the Fallopian tubes or the reconfigured small 
intestine (Monti). It should be taken into account that complications that are not so 
infrequent, such as conduit stenosis, mucous prolapse and false passages, may occur. 
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5.3 Defunctionalized urinary tract: dry bladder 
Anuric children who are awaiting for a kidney transplantation deserve special attention. 
Patients without a relevant history of urologic disorders, in general patients with 
nephropathies, have a high probability of recovering the normal functional bladder 
parameters after the renal transplant, since their bladder has simply defunctionalized due to 
lack of diuresis. Thus, this alteration is reversible. 
On the other hand, patients with a history of neurogenic bladder or posterior urethra valves 
have a few chances of recovering, with the artificial bladder cycling or after the renal 
transplant, the adequate features of a functional urinary reservoir. In such cases, due to the 
chronic status of the baseline disease, the bladder walls suffer an important deposit of 
collagen connective tissue, with the subsequent reduction or lack of bladder compliance to 
accommodate increasing volumes of urine. Therefore, the urodynamic alterations are 
irreversible without an appropriate treatment after the renal transplant.  
Pre-transplant augmentation cystoplasty in anuric children can represent a problem if it is 
not appropriately controlled. The cumulus of intestinal mucus is the main enemy to 
manage. The lack of regular cycles/washes leads to the appearance of urinary infections, 
mucus plugs, development of lithiasis and risk of intestinal perforations. Three to four daily 
washouts with distilled water are recommended with the aim of achieving augmentation 
distension and eliminating the mucus. It is important to emphasize that the washout liquid 
must not contain mineral salts in order to avoid precipitates with intestinal mucus, which is 
an important factor involved in the lithogenesis. Finally, the urodynamic evaluation must be 
repeated prior to renal transplantation. 
5.4 Timing of reconstruction of the lower urinary tract 
The reconstruction of the lower urinary tract may be performed before, during or after 
kidney transplantation. Many authors claim that reconstruction must be done before 
transplantation (Ali-El-Dei et al., 2004; Nahas et al., 2004) on the assumption that the 
uropathy is directly responsible for ESRD and must be corrected; furthermore, as post-
transplant immunosuppression is far away in time from reconstruction, it will not affect the 
plastic procedures of the surgery (Fontaine et al., 1998).  
In general the reconstruction of the lower urinary tract before the renal transplantation is 
preferred, since in this way the complications related to the reimplanted ureter that could 
lead to the loss of the graft are reduced (Taghizadeh et al., 2007). It is worth considering that 
in already augmented bladders the surgery of the renal transplant may become technically 
more complex because of the special care needed to avoid damaging the vascular pedicle of 
the cystoplasty during reimplantation, with the consequent risk of cystoplasty necrosis 
(MacInerny et al., 1995). 
The lower urinary tract reconstruction performed simultaneously with renal transplantation 
has the main disadvantage of interference in the process of tissue remodeling after bladder 
augmentation, generated by steroid-based immunosuppression, which would increase 
tissue fragility. This would promote complications, such as perforations and urinary 
infections. The manipulation of bowel segments a short time prior to kidney implantation 
would lead to infection complications related to the allograft. Nevertheless, there exist 
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specific situations in which some patients would benefit from such an approach. That is the 
case of patients who at the moment of the transplant surgery present important 
vesicoureteral reflux to the native kidneys and a bladder with low capacity and high 
pressure. Then it would be advisable to consider nephroureterectomy of the native kidneys 
and the use of urothelium segments of dilated ureters for ureterocystoplasty immediately 
before the placement of the graft. In this way, the reconstruction of the lower urinary tract is 
resolved with adequate tissues, with a low rate of infection complications for the graft.  
The reconstruction of the lower urinary tract after the renal transplantation may be performed 
when the renal function is stable and immunosuppression has been reduced, in order not to 
interfere with the postoperative remodeling processes. The main advantage of this approach is 
that the lower urinary tract is reconstructed 'only' when the infection complications appear, 
which are related to the difficulties in urinary voiding. That is why it has been suggested that 
continent apendicovesicostomy of the Mitrofanoff type should be performed before renal 
transplantation, and augmentation cystoplasty, after the renal transplant, if necessary. Several 
reports describe acceptable outcomes in terms of complications, survival of the graft and the 
receptor, compared to the patients that have been operated on before renal transplantation 
(Sheldon et al., 1994; Thomalla, 1990; Nahas et al., 1997).  
However, there is evidence that lower urinary tract reconstructions post renal transplant 
may trigger a high incidence of complications (Barisi et al., 2002), including episodes of 
pyelonephritis. Another disadvantage of this approach is that the time needed to reduce the 
immunosuppression doses exposes the graft and urinary tract to risky situations, where the 
patient requires a quick surgical solution to a transplant that may be deteriorating but it is 
not possible yet to reduce the immunosuppression drug doses.  
Our team adheres to Taghizadeh, who concludes that augmentation cystoplasty ‘before’ the 
renal transplant is preferable, because the incidence of complications related to the 
transplanted ureter and loss of graft is reduced.  
6. Renal transplant – Surgical technique – Anesthetic questions 
A main part of the preparation of the living donor’s kidney is done in situ by the surgical 
team of the donor. In general, the cadaveric donor’s kidney requires major manipulation in 
order to be able to be implanted, in a procedure called bench surgery, where the dissections 
of perirenal tissues are performed, technical procedures are applied in order to prepare the 
blood vessels to be anastomosed and the kidney is irrigated with specific solutions.  
By means of Gibson technique or paramedian cut, the incision extends from the costal 
border to the pubis and into the retroperitoneal space of the iliac fossa. The choice of one 
side, right or left, over the other is determined by the availability of the left or right kidney, 
localization of peritoneal dialysis catheter, stomas and available vascular access. 
Anastomosis between renal artery and vein is performed with primitive ileac artery and 
vein or hypogastric ones, and sometimes inferior vena cava and aorta, in a terminal-lateral 
fashion, with continuous polypropylene sutures 7/0. The procedure is performed by a 
cardiovascular surgeon. 
In the case of small patients, weighing less than 15 kilograms, a transperitoneal approach is 
preferred, using midline incision, from the xyfoid appendix to the pubis, with release and 
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specific situations in which some patients would benefit from such an approach. That is the 
case of patients who at the moment of the transplant surgery present important 
vesicoureteral reflux to the native kidneys and a bladder with low capacity and high 
pressure. Then it would be advisable to consider nephroureterectomy of the native kidneys 
and the use of urothelium segments of dilated ureters for ureterocystoplasty immediately 
before the placement of the graft. In this way, the reconstruction of the lower urinary tract is 
resolved with adequate tissues, with a low rate of infection complications for the graft.  
The reconstruction of the lower urinary tract after the renal transplantation may be performed 
when the renal function is stable and immunosuppression has been reduced, in order not to 
interfere with the postoperative remodeling processes. The main advantage of this approach is 
that the lower urinary tract is reconstructed 'only' when the infection complications appear, 
which are related to the difficulties in urinary voiding. That is why it has been suggested that 
continent apendicovesicostomy of the Mitrofanoff type should be performed before renal 
transplantation, and augmentation cystoplasty, after the renal transplant, if necessary. Several 
reports describe acceptable outcomes in terms of complications, survival of the graft and the 
receptor, compared to the patients that have been operated on before renal transplantation 
(Sheldon et al., 1994; Thomalla, 1990; Nahas et al., 1997).  
However, there is evidence that lower urinary tract reconstructions post renal transplant 
may trigger a high incidence of complications (Barisi et al., 2002), including episodes of 
pyelonephritis. Another disadvantage of this approach is that the time needed to reduce the 
immunosuppression doses exposes the graft and urinary tract to risky situations, where the 
patient requires a quick surgical solution to a transplant that may be deteriorating but it is 
not possible yet to reduce the immunosuppression drug doses.  
Our team adheres to Taghizadeh, who concludes that augmentation cystoplasty ‘before’ the 
renal transplant is preferable, because the incidence of complications related to the 
transplanted ureter and loss of graft is reduced.  
6. Renal transplant – Surgical technique – Anesthetic questions 
A main part of the preparation of the living donor’s kidney is done in situ by the surgical 
team of the donor. In general, the cadaveric donor’s kidney requires major manipulation in 
order to be able to be implanted, in a procedure called bench surgery, where the dissections 
of perirenal tissues are performed, technical procedures are applied in order to prepare the 
blood vessels to be anastomosed and the kidney is irrigated with specific solutions.  
By means of Gibson technique or paramedian cut, the incision extends from the costal 
border to the pubis and into the retroperitoneal space of the iliac fossa. The choice of one 
side, right or left, over the other is determined by the availability of the left or right kidney, 
localization of peritoneal dialysis catheter, stomas and available vascular access. 
Anastomosis between renal artery and vein is performed with primitive ileac artery and 
vein or hypogastric ones, and sometimes inferior vena cava and aorta, in a terminal-lateral 
fashion, with continuous polypropylene sutures 7/0. The procedure is performed by a 
cardiovascular surgeon. 
In the case of small patients, weighing less than 15 kilograms, a transperitoneal approach is 
preferred, using midline incision, from the xyfoid appendix to the pubis, with release and 
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dissection of aorta and inferior vena cava. Anastomosis is also done in these vessels using 
continuous polypropylene sutures 7/0 (Madeiros-Domingo et al., 2005). 
Prior to declamping of the vessels for blood reperfusion of the graft, it is essential to maintain 
central venous pressure between 15 to 20 cmh2o, with the use of hematic, colloidal and 
crystalloid products. When reperfusion is done, the graft can sequester up to 300 ml of liquid 
volume; that is why it is important to keep substantial reposition of liquids post-clamping.  
If the size of the organ is considerable in relation to the recipient, it may displace de liver 
and diaphragm upwards, making breathing and venous return difficult due to obstruction 
of the inferior vena cava  (Madeiros-Domingo et al., 2005). 
On the contrary, when the kidneys to be transplanted are small or shorter than 6 cm, they 
can be implanted in unit fashion, with anastomosis of the distal extreme to the aorta and 
inferior vena cava of the recipient vessels in a terminal-lateral way, as a segment interposed 
with proximal and distal anastomosis (Madeiros-Domingo et al., 2005). 
Uretero-neo-cystostomy (ureterovesical reimplantation) is performed using extravesical 
Lich-Gregoire antireflux ureteroneocystostomy method (Lich Jr. et al., 1961). Some groups 
use intravesical reimplants, according to Politano-Leadbetter technique (Politano, 1958), and 
it is performed by a urologic surgeon. The former is preferred, since it is fast, does not 
require extra cystostomy or big ureteral length.  
In most cases in our series, and when it was possible, the ureter was reimplanted into the 
native bladder. When the ureteric reimplantation wass difficult or the ureter caliber small, a 
double J (pig tail) catheter was used and it is removed 6 weeks following transplantation. 
For the rest of the patients, a K33-like catheter was used up to the renal pelvis of the graft, 
with an exit site other than the incision site and it was removed 5-7 days after the surgical 
procedure. The systematic use of a ureteral tutor for all recipients has reduced the incidence 
of ureteral complications ( Pleass et al. 1995). 
In the case of patients with bladder augmentation, the ureteroneocystostomy technique is 
the same, although special attention should be taken not to interfere in the continent 
diversion site (Mitrofanoff) in order to avoid urine leakage.  
In all recipients, in order to guarantee a complete drainage of the bladder, vesical drainage 
through the urethra or by way of continent appendicovesicostomy (Mitrofanoff procedure) 
was established for 7 days, and drainage of the perirenal space was performed.  
7. Modifications of the lower urinary tract after the renal transplantation 
After re-evaluation during follow-up, there are cases in which for different reasons, such as 
course of the baseline pathology, alterations in the bladder behavior due to reconstructive 
procedures, inadequate management and care after reconstruction, among others, there 
appears a need for another reconstruction of the urinary tract in order to keep the features of 
a "functional urinary tract.” Thus, on some occasions bladder re-augmentations, continent 
apendicovesicostomies of the Mitrofanoff type or procedures in the neck and/or proximal 
urethra must be performed so as to treat urinary incontinence. There is approximately 3% of 
cases described in the literature that needed procedures in the lower urinary tract after renal 
transplantation, although they had undergone evaluation and surgeries previously to the 
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transplantation (Sager et al., 2011). This evidences that although we may think that 
everything that was done was enough, in surgical terms, the nephro-urologic follow-up 
show us that evaluation and follow-up are fundamental and many times it is necessary to 
do adjustments in order to protect the allograft.  
8. Graft survival 
Extensive bibliography shows that renal transplantation can be indicated safely in the case 
of patients with lower urinary tract reconstructions, achieving acceptable survival and 
function of the graft. The results are comparable to the ones obtained for patients with 
normal urinary tract (Franc-Guimond & Gonzalez, 2004; Capizzi et al., 2004).  
At Hospital Nacional de Pediatría Prof. Dr. J. P. Garrahan, 156 renal transplants have been 
performed up to date on children with uropathies, 38 of which received reconstructions of 
the dysfunctional urinary tract. No significant differences have been found between the 
latter and those patients that had no lower urinary tract reconstructions regarding survival 
of the graft or levels of creatininemia at year 1 and 5 after transplantation (Sager et al., 2011). 
In general terms, the actuarial global functional survival rate after the first year 
postoperatively was higher than 93%, and at year 5 it was between 75% and 85% (Figure 1) 
 
Fig. 1. Actuarial allograft survival in patients with uropathies. Group A: Patients without 
surgeries in lower urinary tract; Group B: Patients who underwent surgeries in lower 
urinary tract and preserved adequate bladder function; Group C: Patients who underwent 
surgeries in lower urinary tract due to inadequate bladder function. 
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9. Complications 
9.1 Vascular complications 
Vascular thrombosis is the third cause of loss of the graft in children according to the 
NAPRTCS (North American Pediatric Renal Transplant Cooperative Study), with an 
incidence of 11.6% (Benfield, 2003). When the receptor is very young and has a low weight, 
the risk increases because of the reduced diameter in the vascular structures. 
Vascular thrombosis, especially venous thrombosis, may occur immediately and up to 90 
days post-transplantation. It is a devastating complication, since besides the graft loss, it 
may unleash rupture of the graft capsule, major hematomas, massive hemorrhage, 
thromboembolic events and sepsis.  
Arterial thrombosis is the most feared, since it invariably conditions the loss of the graft and 
subsequent nephrectomy. In children its incidence is 6% (Singh et al., 1997). 
The causes of vascular thrombosis are intimal dissection, atherosclerosis, immunological 
factors and hypercoagulable state. Furthermore, high doses of cyclosporine or 
antilymphocyte globulin, systemic lupus erythematosus, antiphospholipid syndrome, and 
deficiency of protein C and S are involved.  
Arterial stenosis, with an estimated frequency of occurrence between 2% and 10% can 
appear during the post-transplant period or many years later, and it is localized at the site of 
anastomosis or distal to it. Immunological and mechanical factors generate a hyperplasic 
response of the intima. Arterial stenosis manifests as out of control arterial hypertension and 
deterioration of the function of the graft. This entity forces physicians to perform procedures 
such as transluminal percutaneous angioplasty with or without endovascular prosthesis or 
vascular bypass.  
Other vascular complications that are less frequent but not less severe are arteriovenous 
fistulas and perigraft hematomas or ureterovesical joint hematomas on the reimplantation 
site; the latter are also resolved surgically.  
9.2 Urologic complications 
Forced immunosuppression and complexity of the reconstructed urinary tract facilitate the 
appearance of different complications. By far, the most frequent bacteria infection in patients 
with a renal transplantation is the urinary tract infection (UTI) (Abbott et al., 2001; Karakayali 
et al., 2001). The incidence of UTI varies significantly across the literature: from 6% to 86% after 
renal transplantation. This variation responds to the different criteria in defining what UTI 
involves, the methods of urine collection and type of antibiotic prophylaxis, among others.  
The possible impact of UTI increases mortality and morbidity rates due to infection itself, 
and the potential effects on the processes of acute and chronic rejection. UTI episodes occur 
especially in the first postoperative stage, when the patient is hospitalized. A great 
percentage of UTI occurs between 6-12 months after the implant.  
Numerous risk factors for UTI are involved in renal transplantation; among the most 
important are the patients with a reconstructed lower urinary tract. The major causes are: 
anatomical conditions, characteristics of the intestinal mucus, vesicoureteral reflux and 
immunosuppression. Most of these patients who are under a clean intermittent 
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catheterization program present with asymptomatic chronic bacteriuria. Reports have 
shown that this event has no effect on the survival of the graft (Warhom et al., 1999; Hatch et 
al., 2001). However, some authors believe that when pyelonephritis and recurrent episodes 
of asymptomatic UTI appear, the function of the graft is at risk, with the subsequent 
possibility of extirpation (Mendizabal et al., 2005; Alfrey et al., 1997). Other authors claim 
that recipients of the renal transplant with repeated UTI episodes show deterioration of the 
graft function, although its survival does not differ from the survival rate of the general 
population (Sullivan et al., 2003; Surange et al., 2003).    
In some reports, instituting an aggressive treatment for UTI at an early stage post-transplant 
is recommended, since UTI may trigger acute rejection (Sullivan et al., 2003); other reports, 
however, suggest that intensive treatment in the case of asymptomatic UTI may favor the 
development of resistant bacteria strains. In our center, the approach followed consists of 
using as antibiotic prophylaxis trimetropin/sulfametoxazol even in the presence of positive 
urocultures in asymptomatic patients, without alteration of the function of the graft. 
Intensive antibiotic therapy is reserved for those patients with symptomatic UTI, worsening 
of the renal function or the presence of aggressive germs such as pseudomonas aeruginosa 
or those related with lithogenesis, like proteus mirabilis.  
In our case report we showed that 25% of patients with renal transplantation and 
reconstructed urinary tract presented low UTI; 42.5% presented high UTI, and two patients 
developed sepsis of urologic cause; one of them with graft loss. Due to the detection of more 
episodes of UTI in this subgroup, vesicoureteral reflux was more frequently diagnosed 
(25%) compared to the subgroup of patients with uropathies without reconstructions, where 
reflux was observed in only 1% of the group (Sager et al., 2011). 
Vesicoureteral reflux to the graft, especially of high grade, which is associated to 
symptomatic UTI, is generally treated first with endoscopic approach. Different materials 
are used as endoscopic bulking agents in ureterovesical junction: the most common one is 
dextranomer/hyaluronic acid. Many times the endoscopic technique becomes difficult 
because the bladder has undergone previous surgery or augmentation, and the opening of 
the urethral meatus may not always be located. In cases of neurogenic bladders with 
vesicoureteral reflux to the graft and failure of the bulking agents, as the urinary tract has 
already been reconstructed, open ureterovesical reimplantation is very frequently done.  
If intermediate or low grade vesicoureteral reflux to the graft is detected under 
ureterohydronephrosis study and there are no UTI leaks nearby and the renal function is 
preserved, a vigilant attitude under antibiotic prophylaxis is taken before resorting to 
surgical techniques to resolve the reflux, provided the urodynamic studies do not show 
significant alterations.  
Ureterovesical stenosis may have an incidence between 2% and 4%. Different procedures 
can be required in order to reestablish the adequate urinary flow, such as pig tail catheters 
via percutaneous nephrostomy and posterior ureterovesical reimplant. Ureteral fistulas are 
produced by ischemic necrosis of the distal ureter, as a consequence of vascular lesion 
during donor nephrectomy. Hematoma of the ureterovesical juncture, urinary fistulas and 
necrosis of the distal ureter (2 to 4%) are directly associated as causative agents of 
ureterovesical stenosis and require in all cases open exploration (Sager et al., 2011). 
Perirenal collections are another frequent surgical complication with an incidence of 
approximately 49% (Pollak, et al., 1988). Lymphoceles cause several collections and are  
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generated by the cumulus of lymphatic liquid in the retroperitoneum, due to the dissection 
and binding of lymphatic vessels at the moment of forming the vascular pouch. Their 
occurrence has been associated to the use of Sirolimus (Giessing & Budde, 2003). Some 
lymphoceles may grow until displacing or comprising the reimplanted ureter, generating 
ureterohydronephrosis extrinsic to the implant. If the lymphocele grows progressively or is 
persistent, it may be treated by means of external percutaneous drainage or with 
laparoscopic exploration and marsupialization.  
Transplants    
n  
Group A  
68  
Group B  
48  
Group C  
40  
Complications      n(%)           
Vascular:           
   Arterial Stenosis  4(6)  2(4.2)  -  
   Arterial Thrombosis  2(3)  2(4.2)  -  
   Venous Thrombosis  1(1.5)  2(4.2)  1(2.5)  
   Arteriovenous Fistula  1(1.5)  -  -  
   Hematoma  1(1.5)  -  1(2.5)  
            
Urologic:           
   Ureterovesical Junction Hematoma  -  1(2)  -  
   Ureterovesical Stenosis  2(2.9)  2(4.2)  1(2.5)  
   Vesicoureteral Reflux (>grade II)  1(1.5)  1(2.1)  10(25)  
   Urinary Fistula - Ureteral Necrosis  2(2,9)  2(4.2)  1(2.5)  
   Renal Pelvis Necrosis  -  -  1(2.5)  
   Lymphocele  5(7.5)  2(4.2)  -  
   Vesical Lithiasis  -  -  2(5)  
   Retained drainage in surgical site  1(1.5)  -  -  
  Urinary Infections:     -  -  
       -Lower:  6(9)  3(6.2)  10(25)  
       -Upper:  8(12)  11(23.1)  17(42.5)  
   Sepsis of urologic origin  -  -  2(5)  
   Urinous Peritonitis  -  -  1(2.5)  
   Infection of surgical wound  1(1.5)  2(4.2)  6(15)  
   Abdominal wall abscess  -  -  2(5)  
   Urine Incontinence  -  -  1(2.5)  
Total n(%) 35(51.5)  30(63)  53(132) 
References: Group A: Patients without lower urinary tract; Group B: Patients that required surgery in 
lower urinary tract and preserved adequate bladder function; Group C: Patients that needed surgery in 
lower urinary tract due to inadequate function.  
Table 1. Vascular and Urologic Post Renal Transplant Complications in Patients with 
Uropathies. 
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Other causes of perirenal collections include: hematomas, urinomas and sera cumuli, all of 
which are not resolved unless surgical intervention is performed. 
Other urologic complications in decreasing order of presentation are: surgical wound 
infections, wall abscess, vesical lithiasis and urinous peritonitis due to colocystoplasty 
perforation.  
Recently, colocystoplasty neoformations –infrequent but of poor prognosis- have been 
reported as appearing several years after bladder reconstruction-augmentation. The exact 
etiopathogenic mechanism for these neoformations is unknown, but the possible 
explanations include: increased nitrosamines at the vesicointestinal anastomosis site; 
influence of disguised and chronic urinary infections, among others. At a histological level, 
the neoformations may be adenocarcynomas, urothelial tumors located in the native 
bladder, in the bowel segment or at the vesicointestinal anastomosis site, and in general they 
exert a very aggressive effect (Bono Ariño, et al., 2001). This poses a serious ethical-medical 
dilemma, since so far the established modality widely embraced has been the re-
functionalization of the lower urinary tract by means of intestinal segments in patients that 
will surely be put under immunosuppression regimens. Up to date, the only weapon to 
protect this complex subgroup of patients is a strict clinical, ultrasound and endoscopic 
follow-up, especially when hematuria is present.  
In our case report we describe the following complications and interventions post renal 
transplant (Tables 1 and 2). 




Group A  
68  
Group B  
48  
Group C  
40  
Vascular Interventions          
   Angioplasty  2  -  -  
   Bypass  1  2  -  
   Fistula embolization  1  -  -  
            
Urologic Interventions          
   Sigmoid vesical augmentation  1  -  2  
   Mitrofanoff  1  1  1  
   Mitrofanoff reoperation  -  1  2  
   Aponeurotic sling  -  -  1  
   Closure of bladder neck  -  -  1  
   Ureterovesical reimplant due to:           
      - vesicoureteral reflux  1  -  -  
      -Stenosis  2  1  1  
      -Fistula  2  2  1 
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bladder, in the bowel segment or at the vesicointestinal anastomosis site, and in general they 
exert a very aggressive effect (Bono Ariño, et al., 2001). This poses a serious ethical-medical 
dilemma, since so far the established modality widely embraced has been the re-
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Group A  
68  
Group B  
48  
Group C  
40  
Vascular Interventions          
   Angioplasty  2  -  -  
   Bypass  1  2  -  
   Fistula embolization  1  -  -  
            
Urologic Interventions          
   Sigmoid vesical augmentation  1  -  2  
   Mitrofanoff  1  1  1  
   Mitrofanoff reoperation  -  1  2  
   Aponeurotic sling  -  -  1  
   Closure of bladder neck  -  -  1  
   Ureterovesical reimplant due to:           
      - vesicoureteral reflux  1  -  -  
      -Stenosis  2  1  1  
      -Fistula  2  2  1 
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Transplants  
n  
Group A  
68  
Group B  
48  
Group C  
40  
   Nephroureterectomy of native kidney  3  -  2  
   Drainage-punction of lymphocele  4  1  -  
   Drainage-punction of abscess-hematoma  2  -  2  
   Nephrostomy  3  1  3  
   Cystoscopy  2  -  -  
   Placement of pig tail catheter  2  1  3  
   Injection of substances due to vesicoureteral 
reflux  
-  -  1  
   Injection of substances due to urine incontinence -  -  1  
   Nephrectomy of the graft  5  2  4  
   Parcial Ureterectomy  -  2     
   Ureterostomy  -  -  2  
   Endoscopic Cystolitotomy  -  -  1  
   Open Cystolitotomy  -  -  1  
References: Group A: Patients without lower urinary tract; Group B: Patients that required surgery in 
lower urinary tract and preserved adequate bladder function; Group C: Patients that needed surgery in 
lower urinary tract due to inadequate function.  
Table 2. Vascular and Urologic Post Renal Transplant Interventions. 
11. Graft loss 
There are different causes of graft dysfunction, such as renal rejection and nephrotoxicity 
due to cyclosporine, tacrolimus and vascular problems. The vascular thromboses that are 
more associated to graft loss are venous thromboses. Urologic causes have infrequent 
relation to the renal graft loss, but recurrent urinary infections, such as pyelonephritis 
generate lymphocyte and intratubular neutrophilus deposits. As a consequence, but not 
exclusively due to pyelonephritis, the normal functional renal tissue is replaced by 
interstitial fibrosis and tubular atrophy (IF/TA). 
Even though the patients who have received a kidney transplantation and have corrected or 
reconstructed urinary tracts are subjected to an important incidence of urologic 
complications, the main cause for graft loss in our series was the presence of vascular events 
(Sager, et al., 2011). 
12. Survival and quality of life 
Survival rates at years 1 and 5 post-transplantation are 98.8% and 94.2%, respectively. In our 
series, 8 out of 150 patients died due to cardiovascular causes, lymphoproliferative disease 
and non urologic sepsis (Sager et al., 2011). 
In other studies, 100% of transplanted patients with over 10 years of follow-up reported that 
they feel they have good or excellent health status; 94% stated that their health status does 
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not interfere with their family and social life; 90% of them study or work; 70% have an active 
sexual life, and absence from their work or study places was in general minimal (Ferraris & 
Rodriguez, 2008). 
The success of this type of therapy also depends on “the patients’s adherence to treatment.” 
Lack of adherence is the most important risk factor for the development of chronic allograft 
nephropathy (CAN) and sub-clinical rejection. The critical period is when the adolescent 
goes from dialysis to the post-transplant phase, when the responsibilities as to being alert, 
managing care and decision-making increase.  
13. Follow-up 
Strict follow-up is essential in order to carry out a continuous assessment of the following 
aspects: function of the graft and drainage to the lower tract; function of the lower urinary 
tract; record of the urinary volume and frequency voided by means of voiding records; need 
for contrasting studies, such as cystourethrography and urodynamic studies.  
It is necessary to monitor compliance with medication therapy, for instance, anticholinergic 
drugs; compliance with daily bladder washes in the case of those who have undergone 
bladder augmentation, and the correct use of catheters for those who need catheterization 
via Mitrofanoff or urethra.  
It is likewise important to bear in mind that many patients and parents gradually lose 
interest in the urologic follow-up after the renal transplant. Thus, physicians should 
emphasize how essential monitoring is since the first consultation, so that parents, 
patients and medical caregivers become committed to a thorough and long-term follow-
up program.  
14. Conclusions 
Along the time, it has been demonstrated that the renal transplant is the best option for 
children with end stage renal disease. At present these children can benefit from this type of 
therapy provided the functions of the dysfunctional lower urinary tract are corrected, either 
by means of medical and/or surgical treatment. Otherwise, the bladder dysfunction that is 
not corrected will negatively affect the function of the graft.  
Among the most frequent etiologies for ESRD we can find renal dysplasia, obstructive 
uropathies, focal and segment glomerulosclerosis, nephropathy due to vesicoureteral reflux, 
renal polycystosis, hemolytic uremic syndrome, Prune belly, neurogenic bladder due to 
neural tube defects, and other conditions. All of them must be exhaustively evaluated so 
that it can be determined whether the lower urinary tract is in optimal condition to receive a 
renal implant, following the principle of "functional urinary tract." This term refers to the 
condition that a lower urinary tract should be a reservoir with adequate volume, low 
intravesical pressure and continence, and correct and complete urine voiding.  
For those cases that do not meet these criteria, different treatments are offered in order to 
provide a safe mechanism of drainage when voiding difficulties are present, via clean 
intermittent catheterization and pharmacologic reduction of filling pressure or contractions 
that are not inhibited, with the use of anticholinergic drugs.  
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When the objectives cannot be reached in spite of applying medical treatments, the option is 
surgical intervention for reconstruction of the urinary tract. Here the possibility of using 
urothelial tissues should be considered, since these patients usually have high grades of 
vesicoureteral reflux or obstructive ureterohydronephrosis. When it is not possible to obtain 
urothelial tissue to perform bladder augmentation, segments of the digestive tube can be 
used, either from the small or the large bowel, according to the criterion of each health care 
center.  
Favorable long term outcomes have been reported on patients who underwent renal 
transplantations with reconstruction of the urinary tract; however, there is considerable 
controversy around which is the best way to manage these patients, since there are no 
guidelines with defined criteria for reconstructive surgeries, optimal surgical procedures, or 
even recommendations as to when is the best time to do them.  
Our team adheres to Taghizadeh, whose report claims that augmentation cystoplasty before 
renal transplant is preferable, as the incidence of complications and graft loss is reduced, 
especially in relation to lesions of the transplanted ureter.  
It has also been agreed that renal transplantation can be indicated in a safe way to patients 
with lower urinary tract reconstructions, with acceptable survival and function of the graft. 
Results are comparable to those obtained in the case of patients with normal urinary tract. 
Nevertheless, it is undeniable that forced immunosuppression and the complexity of the 
reconstructed urinary tract favor the appearance of complications, especially infections 
related to the urinary tract. Potentially, this would promote the increase of morbidity and 
mortality rates and it would attempt against the implant. However, urologic causes have an 
infrequent relationship with the loss of the renal graft. 
In the case of these complex and heterogeneous patients, it is essential to provide a careful 
and individualized evaluation of the lower urinary tract prior to transplantation and a 
strict postoperative follow-up in order to diminish and control possible urological 
complications. Since at present there are no sound guidelines or protocols for the 
management of pediatric patients with dysfunctional lower urinary tract and end stage 
renal disease, it is necessary to design randomized multicenter studies in order to achieve 
better results on morbidity. 
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